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Abstract 
The interaction of type 1 and 2 IFNs with neutrophils in JSLE 
Sophie Lindsay Irwin 
Introduction: Juvenile-onset Systemic Lupus Erythematosus (JSLE) is a multisystem 
autoimmune disease characterised by an increase in nuclear autoantigens and subsequent 
increased production in autoantibodies. Neutrophil function and apoptosis is dysregulated in 
JSLE, and thus neutrophils are thought to be an important factor in JSLE pathogenesis. Type 
1 and 2 interferons (IFNs) have been shown to be increased in SLE and JSLE serum, and an 
IFN and granulocyte genetic signature within JSLE patients has indicated a potential 
interaction of IFNs and neutrophils within JSLE. However, specific mechanisms of IFNs on 
neutrophil apoptosis and function within JSLE is yet to be elucidated. 
Aim: To investigate the interaction of IFNs with neutrophil function, apoptosis and signalling 
pathways, with specific focus on how these interactions may change in an inflammatory 
disease such as JSLE.  
Methods: Neutrophils were isolated from whole blood from healthy adult volunteers and 
children with and without JSLE. Neutrophils were left naïve or primed with TNFα or IFNs, and 
subsequently stimulated with IFNs and other stimulants. Phagocytosis, apoptosis, activation 
states and receptor expression were analysed using flow cytometry. Intracellular signalling 
proteins were analysed using Western blotting. Chemotaxis was analysed using a transwell 
assay in the presence or absence of chemokines. NETosis was analysed using confocal 
microscopy and DNA quantification.  
Results: An in vitro model was developed to investigate the role of IFNs on a range of key 
neutrophil functions. IFNs were shown to have little effect on specific aspects of chemotaxis, 
phagocytosis and NETosis of healthy volunteer neutrophils. IFNs were shown to be anti-
apoptotic towards naïve neutrophils from healthy adult volunteers but could either lose this 
ability or induce apoptosis when neutrophils were primed with TNFα. The anti-apoptotic 
effect observed was via reduced cleavage of caspase 3 but not through the stability of MCL1. 
Patient serum (including paediatric control) activated neutrophils from healthy adult 
volunteers, but this had no significant effect on neutrophil apoptosis downstream. Priming 
with TNFα reduced IFNAR1 expression on neutrophils from healthy adult volunteers but did 
not change the expression of other IFN receptor chains. There was no difference in IFN 
receptor chain expression on neutrophils from JSLE patients compared to paediatric controls. 
Following priming with TNFα, there was a reduction of STAT3 phosphorylation and an 
increase in STAT1 phosphorylation in neutrophils from healthy adult volunteers.  
Conclusion: IFNs have an important influence on neutrophil apoptosis. In primed neutrophils, 
lower concentrations of IFNs lose their anti-apoptotic ability and can induce apoptosis at high 
concentrations. This may reflect what is happening at sites of inflammation in active patients. 
Drug treatment may help to reduce this potentially IFN-related increase in neutrophil 
apoptosis in JSLE patients. Patients with inactive JSLE disease, likely due to their medication, 
had similar rates of apoptosis to matched controls. Activation of healthy adult neutrophils 
reduced the expression of IFNAR1 alone, which may contribute to the differential IFN induced 
phosphorylation of anti-apoptotic STAT3 and pro-apoptotic STAT1. This manipulation of the 
IFN signalling pathway through TNFα priming (and therefore through activation of 
neutrophils in inflammatory diseases) may contribute to the dual IFN effect on apoptosis, 
with STAT1 possibly involved in increased neutrophil apoptosis in JSLE. Inhibition of STAT1 
may therefore be therapeutically beneficial in JSLE. 
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Chapter 1: Literature Review  
1.1. What is lupus? 
Systemic Lupus Erythematosus, or SLE, is a multisystem autoimmune disease with a wide 
range of clinical and immunological manifestations (1). On a cellular level, SLE is characterized 
by hyperactive B cells, and subsequent autoantibody production directed against nuclear 
autoantigens (2). It has been demonstrated that T lymphocytes play a role in autoantibody 
formation (3). It is unclear what causes SLE or how the disease progresses. However, it is 
thought that there are hormonal, genetic and environmental factors contributing to the 
pathogenesis of SLE (4-6). 
Juvenile-onset SLE (JSLE), in which onset of lupus occurs before 18 years of age, is rarer than 
adult-onset SLE and is generally more severe than its adult counterpart, both at diagnosis 
and over the disease course (7). The spectrum of disease differs between JSLE and adult-
onset SLE, with children having more active renal, neuropsychiatric and haematological 
disease and increased associated disease activity and organ damage (7). Up to 20% of SLE 
patients develop the disease in childhood and thus JSLE produces an important research area 
to be investigated (8). 
1.1.1. The UK JSLE Cohort Study 
The United Kingdom (UK) JSLE Study Group is a collaborative group of paediatric 
rheumatologists, nephrologists, and other specialities including basic scientists from multiple 
centres, which was started in 2006, and is led by the University of Liverpool, based at Alder 
Hey Children’s Foundation NHS Trust. The UK JSLE Cohort Study aims is to bring together a 
comprehensive team of experts to investigate the ‘clinical characteristics and 
immunopathology of JSLE’, which includes a database of clinical and demographic data, and 
a biobank of blood products and urine (https://www.liverpool.ac.uk/translational-
medicine/research/ukjsle/about/).  
The majority of adult SLE and JSLE patients are female, with approximately 85% overall of the 
UK JSLE Cohort Study being girls (9). The median age at diagnosis within the Cohort is 12.6 
years, and the median time from onset of symptoms to diagnosis is 3.2 months (9). Male JSLE 
patients are generally younger at disease presentation than females (9). Although the 
majority of JSLE patients in the UK JSLE Cohort Study are Caucasian (approximately 50%), 
there is a significant incidence of JSLE in non-Caucasian populations, including of black African 
and Asian ethnic origin (9). Non-Caucasian patients tend to be younger than Caucasian 
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patients, and there is a tendency of increased nephritis at presentation in Chinese, Black 
African and mixed ethnicity patients (9). Some 40% of patients have a family history of 
autoimmune disease, with 15% of families having lupus (9). In a multicentre analysis, which 
included adult-onset SLE and the UK JSLE Cohort Study patients, although females 
represented the majority of cases, this gender ratio in favour of females was less evident in 
the younger patient populations (10). There is a higher proportion of males with JSLE than 
with adult-onset SLE, with younger children (and those over the age of 60) having the lowest 
male-to -female ratio (10). Older patients tended to be Caucasian, and a higher proportion 
of Asian patients were found in JSLE patient population (10).  
1.1.2. Epidemiology of SLE 
Childhood-onset SLE is a rare condition with an incidence of 6-30 per 100,000 children per 
year (11), with some 15-20% of patients with SLE having disease onset in childhood. The 
incidence of SLE has been shown to depend on many demographic factors such as geography, 
gender, age and ethnicity (12). In general, the incidence of SLE is more prevalent in females 
which ranged from 2:1 to 15:1, depending on population studied (12). SLE in females peaks 
around the third to seventh decades of life, whereas SLE in males peak around the fifth to 
seventh decades of life (12).  
1.1.3. Clinical symptoms of JSLE 
The American College of Rheumatology (ACR) has devised a set of 11 criteria for SLE 
classification, whereby at least four are required to diagnose SLE (13, 14). Some of the most 
common features in JSLE using the ACR criteria are renal, neuropsychiatric, immunogenic and 
hematologic features, as well as non-erosive arthritis and malar rash (13, 14). Hematologic 
features include lymphopenia, leukopenia, haemolytic anaemia and thrombocytopenia (13, 
14). The immunological characteristics include: anti-double stranded deoxynucleic acid 
(dsDNA), anti-Smith (Sm) and anti-phospholipid antibodies (12, 13). The paediatric British 
Isles Lupus Assessment Group (pBILAG)-2004 disease activity score is made up of specific 
domains which describe the organ involvement which may be affected by JSLE, and which 
can be assessed by a series of questions and clinical assessments assigned to each of these 
organs (15). These scores assess whether JSLE disease was active (assigned an A or B), 
improving (assigned a C), inactive but with previous involvement (assigned a D) or inactive 
with no previous disease involvement (assigned an E) at time of assessment (15). These letter 
classifications can have numerical assignments, and these numerical assignments are totalled 
to create an overall pBILAG score (15). Overall, active disease may be defined as a patient 
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having an A or B in any organ domain, whereas inactive disease may be defined as a patient 
having a D or E in all organ domains (16). 
Other organ system involvement and damage can involve: ophthalmic (ocular cataract and 
retinal change), neurological, pulmonary (including hypertension, fibrosis, and pulmonary 
infarction), cardiac (including cardiomyopathy), vascular (including venous thrombosis) 
gastrointestinal (including gastrointestinal infarction), muscoskeletal (including muscular 
atrophy), cutaneous (including alopecia) and diabetes (13, 14, 17). 
In comparing UK JSLE Cohort Study patients to a population of adult SLE patients looked after 
in a large, tertiary referral centre, there were no significant clinical differences in the 
prevalence of rash or photosensitivity (10). JSLE patients tended to have more alopecia and 
oral rashes, whereas adults were more likely to have arthritis and serositis, although there 
was a reduction in serositis in the mature age group (10). JSLE patients had significantly more 
lupus nephritis than any other group, and a trend that JSLE patients had more neurological 
disease (10). Lymphopenia became more common with age, whereas thrombocytopenia and 
haemolytic anaemia were both more prevalent in JSLE (10). Cardiovascular events were more 
common and had longer duration in adult-onset SLE than in JSLE and additionally, mortality 
was higher in adult-onset SLE than in JSLE (10). A diagram summarising an overview of the 
systems affected is shown in Figure 1.1. 
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Figure 1.1. Organ systems affected by JSLE and their manifestations. Although not a 
comprehensive list for systems or symptoms, this illustrative figure denotes each symptom 
classified by organ system (neurological = red, mucocutaneous = green, ophthalmic = dark 
blue, renal = orange, gastrointestinal = purple, musculoskeletal = pink, vasculitis = light blue, 
and cardio and respiratory = black). Whether these symptoms are improving, or worsening 
will contribute to pBILAG classification. (Human body outline = 
http://humananatomychart.us/anatomy-human-body-diagram/anatomy-human-body-
diagram-printable-human-body-outline-174/). 
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1.1.4. Aetiology of JSLE 
SLE is characterised by many clinical characteristics but also cellular components. Clinically, 
as noted these can involve many organ systems, which include articular, skin, pleuro-
pulmonary, gastrointestinal and renal findings (18). On a cellular level, increased gamma (γ)-
globulins, anaemia, anti-nuclear antibodies (ANA), anti-dsDNA and anti-histone antibodies 
can be detected, which can help in the diagnosis of JSLE (18). Although SLE can affect 
individuals of any age, as a group, the UK JSLE Study Group focus specifically on the 
pathogenesis of JSLE, and as such, the majority of this thesis will have this patient group as 
the focus of investigation.  
Within the UK JSLE Cohort Study, 98% of JSLE patients were positive for ANA (9). Compared 
to UK adult patients, JSLE patients had more anti-dsDNA, anti-ribonucleoprotein (RNP) and 
anti-Sm autoantibodies, and low complement component (C)3 was more common (10). Anti-
nuclear autoantibodies can help diagnostically and they also can indicate or predict SLE 
activity (19). Microarray technology has been used to analyse such autoantibodies which 
were found to be higher in JSLE than healthy controls, and include commonly used antibodies 
such as those directed against dsDNA, histones and RNP (19). Recently, it was also shown 
that that autoantibodies against other factors are increased in JSLE such as B-cell activating 
factor (BAFF) (19). BAFF is a member of the tumour necrosis factor (TNF) family and in 
particular stimulates the growth of B cells (20). BAFF autoantibodies, in particular, have been 
shown to be associated with active disease, emphasising the importance of autoantibodies 
and autoantigens in the development of JSLE (19). Autoantibodies such as those directed 
against dsDNA and histone H1 have been shown to be higher in patients with lupus nephritis, 
indicating a role of autoantibodies in the development of particular organ damage (19). 
Therefore, the role of autoantibodies, and investigation into the processes that contribute to 
autoantibody development, such as dysregulated apoptosis, is important for understanding 
the development of JSLE. 
1.1.5. Genetics of JSLE 
Both adult-onset SLE and JSLE have important genetic as well as environmentally-induced 
factors underpinning their disease pathogenesis. Studies have shown that certain genetic 
variants and polymorphisms may contribute to JSLE pathogenesis or predispose patients to 
the development of the disease (21-27), as discussed in detail below. A genetic variant of the 
oestrogen receptor 1 was found to significantly more frequent in JSLE patients than healthy 
controls, which may be associated with the high percentage of female patients (9, 21). 
Interestingly, within an adult cohort of SLE patients, there is a higher frequency of an 
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oestrogen receptor 2 allele, suggesting that age of onset may rely on different genetic causes 
(21).  
Dysregulation of the immune system is important in the development of JSLE. Of interest is 
the role of the inflammasome (28, 29). It has been shown that genes that may be important 
in inflammasome assembly are differently distributed between JSLE patients and controls, 
and specific genes, such as interleukin (IL)-1B gene, are significantly associated with JSLE (22, 
23). It was found that there were various differences in polymorphisms in genotype, 
haplotype and alleles in the IL-4 gene and a haplotype polymorphism association within the 
IL-6 gene in JSLE patients compared to controls (23, 24). Interleukins (ILs) are a large family 
of cytokines that can act in a paracrine or autocrine way, and can modulate cellular growth, 
differentiation and activation during immune responses (30). Other gene polymorphisms 
such as the -28C/G polymorphism in the chemokine regulated on activation, normal T cell 
expressed and secreted (RANTES) promoter is more frequent in JSLE patients, and patients 
with the C/G or G/G genotypes at RANTES –28 had a higher presence of JSLE markers such as 
ANA, and lower levels of C3 (26, 31). These data indicate that the dysregulated immune 
response found in JSLE, is due, in part at least to genetic variants. This theory is supported by 
other studies, including investigation of the A allele of a PD1 gene polymorphism which has 
been found to be more frequent in JSLE than healthy controls (25). It was also shown that a 
G/G genotype and a G allele in the PD1 gene were significantly less frequent in JSLE than 
healthy controls, suggesting that there can be a variety of genetic differences in just one gene 
that can contribute to JSLE, highlighting the complexity of this disease (25). Programmed cell 
death 1 (PDCD1 or PD1) which the PD1 gene can encode, is involved in central and peripheral 
tolerance and acts as an inhibitory immune receptor which can modulate self-reactive T cells 
(25, 32). Therefore, the decrease intolerance, and possible over activation of the immune 
system in JSLE may be partly genetic.  
Other genes have been found to have variants that are more associated with JSLE in certain 
ethnic populations. In a Mexican population of JSLE patients, the protein tyrosine 
phosphatase, non-receptor type 22 (PTPN22) 1858 C/T genotype and the PTPN221858 T 
allele was more frequent in JSLE patients than controls (27). This suggests that, within a 
Mexican population at least, there are specific components within signalling pathways that 
are genetically altered within JSLE, and this is contributing, with the genetic variants 
suggested above, to an altered immune response within JSLE, which may be true of other 
JSLE populations.  
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1.2. Immune system 
1.2.1. Overview 
The immune system is made up of multiple cell-types and tissues. The cells are grouped into 
those of the innate and adaptive immune systems (33). The different types of immune cells 
can be individually distinguished by their morphology including shape and size of the nuclei, 
pattern of granules and cluster of differentiation (CD) markers.  
 The cells of the innate immune system comprise of neutrophils, macrophages, natural killer 
(NK) cells, mast cells and dendritic cells (33). The main purpose of the innate immunity is to 
act as the body’s ‘first line of defence’ against infection and injury. The adaptive immune 
system is more specific; T and B cells ‘memorise’ specific antigens of pathogens or foreign 
factors, and are thus able to target these in a very swift, direct and precise manner. However, 
previous infection of these ‘recognised’ pathogens is required to produce this adaptive 
immune system memory. B-cells produce antibodies that recognise invading microbes, and 
can rapidly remove the microbe if it has previously invaded. The adaptive immune system  
can be activated by the innate immune system via cytokines or antigens of invading 
pathogens and is particularly useful if the innate immune system is unable to effectively deal 
with and/or remove any pathogens (33).  
Antigens are molecules that can induce an immune response (33). An invading organism 
express antigens on their surface that the immune system can recognise as foreign through 
interaction with antibodies or receptors. Host cells also express antigens and generally, these 
are not immunogenic. However, within autoimmunity, host antigens can elicit an immune 
response without the presence of an invading pathogen; these are termed autoantigens (33). 
Cytokines are small molecules that are secreted by all immune cells in response to a certain 
stimulus (33). They can have an effect on the cell that produces them (known as an autocrine 
effect) and are important in cell-to-cell signalling. Cytokines are involved in cell growth, 
differentiation, chemotaxis, activation and cytotoxicity. Different cytokines may have similar 
biological roles, whereas other cytokines may have opposing effects on cells, depending on 
the environment or stimulus (33). The action of cytokines may vary considerably depending 
upon their concentration and that of other cytokines present in the general or specific 
cytokine milieu, the cells producing them, and the cells they are influencing. 
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1.2.2. Innate immune system 
The innate immune system is usually the first line of defence when pathogens infect the body 
(34). Although quick to respond, the innate immune system has quite a generic role, and 
cannot adapt to attack specific pathogens, or contribute to long term immunity (34).  
1.2.2.1. Neutrophils 
Neutrophils are the most abundant circulating leukocyte and are involved in early 
inflammatory reactions (34, 35). The cytoplasm contains granules that are filled with 
enzymes and microbicidal substances, and thus are termed ‘granulocytes’ (34). Immature 
neutrophils are produced in the bone marrow and mature in the presence of granulocyte 
colony stimulating factor (GCSF), a process termed granulopoiesis (34, 35). Standardly, adults 
will have 1x1011 circulating neutrophils, which, although can live between a few hours and a 
few days, it has been suggested that neutrophils have a typical half-life of 6-8hrs (34, 36). At 
sites of infection, neutrophils will migrate into the tissue, and function through phagocytosis 
or neutrophil extracellular traps (NET)osis to remove invading pathogens (34, 37, 38). The 
function of neutrophils is described in greater detail in Section 1.3. 
1.2.2.2. Low density granulocytes 
Low density granulocytes were first described in 1986, which were initially termed ‘low 
buoyant density granulocytes’ (39, 40). These granulocytes were found typically in the PBMC 
layer of fractioned adult SLE blood, and correlated with disease activity (39, 40). Within a 
study by Bennett et al., microarray analysis detected a high expression of neutrophil genes 
within the PBMC layer of fractioned JSLE patient blood, and was thought that these genes 
were from immature neutrophils present in this PBMC layer (40, 41). A negative selection 
technique by Denny et al., was developed to purify the low density neutrophils, which the 
group termed Low density granulocytes (LDGs), and it was shown that LDGs were present in 
the PBMC fraction of all SLE patients (40, 42).  
LDGs have been observed to have less segmented nuclei than normal density neutrophils, 
with hetero- and euchromatin delineated, and various granulocytes observed in the 
cytoplasm (40). Surface marker wise, LDGs express high CD15, and low CD14, which can 
distinguish the LDGs from CD14 high and CD15 low monocytes (40). LDGs also express the 
mature granulocyte markers CD10 and CD16, but only express the immature granulocyte 
marker CD33 weakly, suggesting LDGs aren’t simply immature granulocytes and are a sub 
type of mature granulocytes (40). In comparison to healthy control neutrophils, both LDGs 
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and autologous lupus neutrophils have an activated phenotype; this was shown through the 
upregulation of CD66b and CD11b (40).  
LDGs have increased ability to form NETs compared to control/normal density neutrophils 
(40). Additionally, LDGs have a decreased phagocytosis function, which may be contributing 
to the increased NETosis seen (40).  
1.2.3. Cytokines and their role in the innate and adaptive immune system          
Cytokines are small proteins that are used to signal between cells and influence different 
functions such as growth, chemotaxis, activation and can regulate the immune system as a 
whole (33). Immune cytokines can be grouped depending on which cell type produces it or 
its function. However, cytokines are not exclusively produced by immune cells, and can have 
effects on cells of different lineages (43-45). ILs are produced by leukocytes, monokines are 
produced by myeloid cells, lymphokines are produced by lymphocytes, chemokines are 
involved in cell migration and IFNs protected against invading viruses, and are able to activate 
cells and modulate immunity (for details on IFNs, see 1.5) (33). 
Lymphokines are lymphocyte growth factors, which include IL-2, IL-3 and IL4 (33). IL-2 is 
made by T cells and functions as a T cell growth factor. IL-3 has an important role in 
haematopoiesis, IL-4 is produced by Th2 and mast cells, and has a role in growth and 
differentiation for Th2 and B cells (33). IL-5, which like IL-4 is produced by Th2 and mast cells, 
is involved in B cell activation and IgA production (33). IL-10, another cytokine produced by 
Th2 cells, induces the response of Th2 cells (33).  
Monokines have been indicated to be critical to immune defence and inflammation functions 
(33). IL-1, TNFα and IL-6 can activate lymphocytes, phagocytes and the vascular endothelium 
(33). IL-8 is also a chemokine, as it is chemotactic for neutrophils (33). IL-12 can activate NK 
cells to produce IFNγ (33).  
 Chemokines are small specialist cytokines that are produced by many cells in response to 
either invading pathogen or physical damage to the tissue (33). They can activate and cause 
migration of cells that express the appropriate receptors to the site of infection or damage, 
and are involved in the migration of leukocytes into the tissue (33). Chemokines are divided 
into two groups; CC chemokines (proteins with two adjacent cysteines near the amino 
terminus) attract monocytes, and CXC (proteins with two amino terminal cysteines separated 
by another amino acid) can attract polymononuclear cells such as neutrophils (31, 33).  
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Other cytokines, which don’t come under the classifications above, include colony 
stimulating factors, that influence the development, differentiation and expansion of 
myeloid cells (33). Granulocyte macrophage stimulating factor (GMCSF) induces the 
differentiation of myeloid cells into both monocyte and granulocyte cells, whereas GCSF and 
macrophage colony stimulating factor (MCSF) differentiate myeloid cells into either 
granulocyte or monocyte cells respectively (33). TGFβ is involved in the inhibition of B and T 
cell growth, TNFβ is deemed cytotoxic (33). 
1.2.4. The complement system 
The complement system was first defined in the 1890s, where it was shown that factors aided 
bacteria killing by heat stable antibodies found in the serum (46). The complement system 
encompasses more than 30 different proteins that are either present within the blood or are 
associated with membranes (46). Once the complement system is activated, a cascade of 
enzyme reactions leads cleavage of some glycoproteins (or complement components, 
classified by ‘C’ and a number) into active fragments (for example, C3 is cleaved into C3a and 
C3b), which then can activate components downstream (33). This leads to the lysis of 
invading pathogens, or at least some protection against such pathogens (33). It has been 
shown that the complement system has a role in both the innate and adaptive immune 
systems (46). 
The complement system involves three pathways; the alternative, the classical and the lectin, 
which all involve C3 (46). The alternative pathway is activated by carbohydrates, lipids and 
proteins found on foreign surfaces which certain complement proteins are associated with 
specific pathogens (33, 46). The classical pathway is activated by the formation of immune 
complexes to invading pathogens or other foreign antigens through which antibodies are 
bound to either an antigen or the invading pathogen (33, 46). The lectin pathway is initiated 
by the binding of mannose binding lectin (MBL) or ficolin to carbohydrates on pathogen 
surfaces (46). MBL and ficolin create complexes in the serum with MBL-associated proteins 
(MASP); MASP1 has been shown to cleave C2m and thus is thought to help enhance 
complement activation (46). 
Complement proteins have been shown to have roles in many cell signalling and processes 
(46). The major functions of the complement system include: an initiation of the acute 
inflammation through the activation of mast cells (which involves C3a and C5a); attraction of 
neutrophils through chemotaxis to the site of infection (which involves C5a); enhanced 
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attachment of the pathogen to the phagocyte (which involves C3a); and finally killing of the 
pathogen activating lysis (which involves C9) (33). 
1.3. Neutrophil functions 
The specific focus of this thesis is the investigation of neutrophils and their function in 
relation to JSLE, and the following sections describe the functions of neutrophils that may be 
important in JSLE pathogenesis. Key characteristics of neutrophils include their role in: 
chemotaxis, phagocytosis, NETosis, and apoptosis, which will be considered further below. 
1.3.1. Neutrophil Chemotaxis 
Neutrophils migrate by a process called chemotaxis (depicted in Figure 1.2) by which they 
move towards host or bacterial chemokines (chemotactic cytokines; see Table 1.1) or 
chemoattractants. These chemoattractants/chemokines have a hierarchy on neutrophil 
migration, which is dependent on the strength of the chemotactic signal and this has been 
particularly seen with IL-8 (which can be released from macrophages and epithelial cells) and 
N-formyl-methionyl-leucyl-phenylalanine (fMLP) (a bacterial product) (47-50). This hierarchy 
helps neutrophils to migrate through the vasculature endothelium to the general site of 
inflammation created by other leukocytes such as macrophages via chemokines such as IL-8, 
and then migrate specifically to the site of invading infections via chemoattractants such as 
fMLP (47). This suggests an importance of a range of chemokines in promoting migration of 
neutrophil to the appropriate site of infection, and both bacterial- and host-originated 
chemokines are needed to attract neutrophils. 
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Table 1.1. Most common neutrophil chemoattractants.  
Chemoattractant Intracellular 
pathway 
Reference 
fMLP p38/MAPK (47) 
IL-8 PI3K/PKB (47, 51) 
C5a PI3K/PKB (51, 52) 
Growth-regulated oncogene 
(GRO)α/β/γ 
PI3K/PKB* (53-55) 
Leukotriene B4 PI3K/PKB* (56-58) 
IFNγ PI3K/PKB*, # (59, 60) 
*most likely signalling pathway. 
#IFNγ chemotactic ability on neutrophils found in mice. 
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There are two pathways that are activated in chemotaxis, the PI3K/protein kinase B (PKB) 
and p38/MAPK pathways, and which of these is specifically activated is dependent on the 
chemokine present (47). Chemoattractants such as fMLP function through the p38/MAPK 
pathway, and the intermediary chemokines function through the PI3K/PKB pathway (47). 
Additionally, fMLP has been indicated to signal through the PI3K/PKB pathway although no 
published data suggests IL-8 signals through p38/MAPK (55). Neutrophils preferentially 
migrate to end target chemoattractants (chemoattractants that attract neutrophils to the 
precise area of infection) such as fMLP compared to intermediary ones (chemoattractants 
that attract neutrophils to the general area of infection) such as IL-8 (47); this may be due to 
the observed inhibitory effect of fMLP on the PI3K/PKB pathway, which was independent of 
the IL-8 receptor (47). This suggests that IL-8 from other cells will attract neutrophils, but 
once in close enough proximity, the neutrophils will switch pathways, and migrate specifically 
to fMLP – producing bacteria and not accumulate unnecessarily with host cells within the 
general site of infection.  
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Figure 1.2. Mechanism of neutrophil chemotaxis. Neutrophils migrate from the vasculature 
to the general site of infection via chemotaxis towards IL-8. Neutrophils then migrate 
sepcifically to the invading pathogen (red outline) within the tissue via chemotaxis along a 
gradient of concentration of fMLP. The vascular eptithelial cells are in red, and in regards to 
the neutrophils, the cytoplasm is in light purple, the plasma membrane is in pink, the nucleus 
is in purple, and granules are in yellow. 
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1.3.2. Phagocytosis function 
Neutrophils eliminate pathogens and cell debris by phagocytosis (Section 1.2.2.1) (Figure 
1.3). Neutrophils recognise foreign particles through receptors (such as Fcγ receptors and 
complement receptors (61)); once the receptors are activated, particles are internalised and 
degradation pathways within the neutrophil are triggered to degrade the particles (38). 
Neutrophils are able to phagocytise opsonised (a process by which particular are coated with 
immune complexes that bind to immune cell receptors) and non-opsonised particles. Fc 
receptors and β2 integrins are the main opsonisation receptors on neutrophils, and bind to 
Ig and complement-coated particles (38). Of note, the process of opsonisation occurs when 
a pathogen or foreign molecule is coated by particular molecules, such as C3b and antibodies 
such as IgG, to allow the pathogen to be phagocytosed more easily (33).  
Fcγ receptors are the most characterised in regards to phagocytic internalisation, and require 
phosphorylation of tyrosine residues (38). These phosphorylated tyrosines allow for docking 
of proteins with src homology 2 (SH2) domains such as Syk, which has been deemed essential 
for IgG-opsonised particle phagocytosis (38). These activate phosphoinositide kinases and 
PLC, which again are required for phagocytosis (38). This pathway induces the polymerisation 
of actin and thus the membrane of the phagocytosing cell is reconfigured, which then enables 
the host cell to engulf particles (38). Endomembranes are delivered to the particle to form a 
phagosomal cup (38).  
The phagosome, a vesicle that is formed around the engulfed phagocyte, is matured from 
the phagosomal cup, by which it obtains necessary complexes to kill and dispose of the 
particles (38). These include microbicidal enzymes, vacuolar ATPases and nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase (38). The phagosome is made up through 
the fusion of secondary vesicles and granules, which contain microbial peptides and 
proteolytic enzymes (38). Granules include primary, which contains myeloperoxidase (MPO), 
secondary which contain lactoferrin, tertiary which contain gelatinase, and secondary 
vesicles which contain albumin, and express alkaline phosphatase on the membrane (38). 
Changes in cytosolic calcium are required for granule secretion and fusion in neutrophils in 
the process of phagocytosis (38).  
Neutrophils generate reactive oxygen species upon activation, which are generated by 
NADPH oxidase (38). Assembly occurs during ingestion of particles and a superoxide anion is 
created, which can be converted to hydrogen peroxide and hypochlorous acid, which can act 
as effective antimicrobial agents (38).  
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Within neutrophils, by using compounds such as phosphatidylinositol-specific phospholipase 
C (PI-PLC), specific roles of each phagocytosis receptor can be investigated. PI-PLC can 
specifically affect the phagocytic receptor FcγIIIb, but not other phagocytic receptors, such 
as FcγII (62). Priming is the process by which cytokines can pre-determine or enhance certain 
processes immune cells conduct or change the state of activation of these cells. When primed 
(where neutrophils are pre-treated to become activated or have an altered function to that 
of naïve neutrophils) neutrophils from healthy volunteers were shown to have an increased 
respiratory burst when incubated with immune complexes in vitro (62). However, depletion 
of the FcγIIIb receptor on these healthy volunteer neutrophils reduced the primed 
neutrophils’ respiratory burst but did not significantly reduce neutrophil related bacterial 
killing of heat-inactivated serum-opsonised Staphylococcus aureus (S. aureus), nor neutrophil 
phagocytosis of serum-opsonised, propidium iodide-stained S. aureus in vitro (62). 
Additionally, depletion of the FcγIIIb receptor did not have any effect on the phagocytosis of 
non-opsonised or serum-opsonised latex particles, but did reduce the phagocytosis of IgG-
coated beads, showing that FcγIIIb has a major role in phagocytosis of IgG coated particles 
(62). Depletion of the FcγIIIb receptor did not have any effect on the activation of the 
respiratory burst during phagocytosis of non-opsonised or serum-opsonised latex particles, 
but did reduce the respiratory burst during phagocytosis of IgG-coated beads (62). Blocking 
of the FcγII and the FcγIIIb receptor had a slight and equal delay on activation of the 
respiratory burst when neutrophils were phagocytising un opsonised and serum opsonised 
latex beads, whereas blocking the FcγII and the FcγIIIb receptor decreased respiratory burst, 
with blocking the FcγIIIb receptor more so than the FcγII receptor (62). 
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Figure 1.3. General mechanism of neutrophil phagocytosis. Neutrophils detect pathogens 
(red outline) and foreign particles through various receptors (such as Fcγ receptors and β2 
integrins, depicted as ‘phagocytic receptor’), engulf them and kill them using various 
enzymes within a phagosome (shown in blue). The cytoplasm is in light purple, the plasma 
membrane is in pink, the nucleus is in purple, and granules are in yellow. 
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1.3.3. NETosis function 
NETosis has been described as a form of cell death that lead to the formation of neutrophil 
extracellular traps (NETs) by which chromatin and associated proteins are released into the 
extracellular space to trap and kill bacteria (Figure 1.4) (37, 63). NETs are released from 
activated neutrophils, and when stimulated with cytokines or products such as IL-8, probal 
myristate acetate (PMA) or LPS, the neutrophils became flat and their membranes protruded 
(37). NETs, which when measured can form large threads up to 50nm long, contained 
proteins from primary granules, such as neutrophil elastase (NE), cathepsin G and MPO, and 
proteins from secondary and tertiary granules such as lactoferrin and gelatinase (37). 
Additionally, DNA is the main structural component of NETs, which can be dismantled using 
DNase (37). Using confocal microscopy, antibody staining of NETing neutrophils (upon 
stimulation with PMA, IL-8 or LPS) demonstrates that histones H1, H2A, H2B, H3 and H4 are 
also part of the NET structure (37). NETs can associate with both gram-negative and gram-
positive bacteria, which are thought to be ‘trapped’ in the NETs (37). Proteases and 
neutrophil elastase within the NETs target bacterial virulence factors, and therefore NETs can 
attack bacteria once trapped (37). NETs material, which included granule proteins and 
histones are required for bactericidal activity (37). 
The mechanism of action of NETs has been studied extensively in the mouse model. This has 
allowed exploration of underlying mechanisms through in vivo studies and mouse knockout 
models. These can provide some insight into the possible processes of NETosis taking place 
in humans in an in vivo environment. NETs induced by S. aureus in exteriorised mouse skin 
can be visualised as sheets of extracellular DNA (64). The NETs formed are extravascular and 
induced by systemic and not localised infection. This migration into tissue may enhance DNA 
release, and prevent NETs spreading through the blood and causing damage (64). NET 
material, specifically histones and neutrophil elastase, is released upon injection of S. aureus 
and Streptococcus pyogenes (S. pyogenes), whilst histone stained areas expanded akin to the 
spread of extracellular DNA also observed, indicating that the observed reaction was NET 
production (64). Injection of dead bacteria into the model also induced NET formation, 
indicating that neutrophil recognition of bacteria material is sufficient to induce NETosis (64). 
Using mouse knockouts, toll-like receptor (TLR)2 and C3 have been shown to be important in 
regulating NET formation, although neither alone was sufficient to induce NETs in isolation 
(64). NETing neutrophils have been shown to be viable and have an intact chemotactic 
function, and still be able to phagocytose (64).  
19 
 
Of note, NADPH oxidase is required for NETosis to occur in pulmonary aspergillosis and once 
committed to NETosis, neutrophils are not then able to undergo any apoptosis (65). This was 
shown by the de-condensation of chromatin (a hallmark of NETosis) in contrast to chromatin 
condensation (a hallmark of apoptosis; Section 1.3.4) and the absence of cleaved caspase 3 
(the apoptosis effector protein; Section 1.3.4) (65). HMGB1 can induce NETosis through a 
TLR4 dependent manner (66). This is likely to be important in the context of JSLE, as it has 
been shown that HMGB1 is up-regulated in JSLE plasma (67, 68). This increase in HMGB1 may 
increase NETosis in JSLE, a function that may contribute to JSLE pathogenesis.  
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Figure 1.4. Diagram depicting the process of NETosis. Neutrophils release chromatin, which 
contains DNA, histones and granule proteins, which can trap and kill invading pathogens (red 
outline). The cytoplasm is in light purple, the plasma membrane is in pink, the nucleus and 
nuclear material is in purple, and granules are in yellow. 
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1.3.4. Neutrophil Apoptosis 
Apoptosis was first characterised in 1972 by J.F. Kerr (69). Apoptosis is the process of 
programmed cell death (depicted in Figure 1.5), and a natural phenomenon and integral to 
the cell cycle. Many animal models, cell lines and in vitro experimentation of isolated human 
or animal cells have been used to investigate apoptosis. 
Apoptosis is integral to many processes within the body. During embryogenesis, apoptosis 
has been sure to have a role in organ shape development, and helps structure fingers and 
toes (70). Additionally, it has been shown that both the nervous system and the immune 
system arise through overproduction of cells; cells which don’t fully develop into 
differentiated nerve or immune cells undergo apoptosis to maintain homeostasis (70). Within 
adults, cell production and differentiation from stem cells for the majority of cell types is 
constant; apoptosis of cells is required to maintain the balance of cell populations (70). 
Additionally, apoptosis is required to remove old or damaged cells (70).  
Dysregulated apoptosis is associated with many diseases. For example, increased apoptosis 
has been associated with diseases such as Acquired Immune Deficiency Syndrome (AIDs), 
neurodegenerative diseases and some autoimmune diseases such as Graft Versus Host 
Disease (GVHD)  (70). Decreased or inhibited apoptosis has been shown in other diseases, 
such as cancer and importantly for this thesis, SLE and JSLE (70-72). 
 Using electron microscopy of both human and animal cells, apoptosis has been characterised 
by the formation of apoptotic bodies, via the condensation of chromatin and membrane 
blebbing, which forms apoptotic bodies (69). The apoptotic bodies are then taken up 
phagocytic cells, and then are broken down in phagosomes (69). There are two main 
pathways within apoptosis, the extrinsic pathway and the intrinsic pathway, and the 
signalling pathways controlling the apoptotic process take place via the cleavage of certain 
caspases from inactive procaspases (73). 
The intrinsic pathway within apoptosis depends on the release of cytochrome C from the 
mitochondria (74). This release of cytochrome c from the mitochondria into the cytoplasm 
the result of the interaction of apoptotic protein Bax with the mitochondria, resulting in a 
pore formation in the outer membrane (75). Once released, the cytochrome C interacts with 
apoptotic protease activating factor 1 (Apaf1) and ATP to form an apoptosome (74). This 
apoptosome recruits and subsequently cleaves procaspase 9, resulting in the release of the 
active caspase 9 (74). Caspase 9 subsequently cleaves procaspase 3, resulting in the release 
of active apoptotic effector caspase, caspase 3, which induces apoptosis (74).  
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The extrinsic pathway within apoptosis is dependent on the interaction of a death ligand, 
such as Fas, to an associated death receptor (73). This binding leads to the recruitment of 
Fas-associated protein with a death domain (FADD) to the receptor; FADD interacts with 
procaspase 8 and procaspase 10 through the interaction death effector domains (DED) on 
both components, creating death inducing signal complex (DISC) (73). The DISC formation 
cleaves procaspase 8 and active caspase 8 subsequently cleaves procaspase 3, resulting in 
the release of active apoptotic effector caspase, caspase 3, which induces apoptosis (76). 
The fine balance in pro- and apoptotic proteins that regulate apoptosis. In addition to the 
pro-apoptosis proteins, caspases and p53 described above, there are many anti-apoptotic 
proteins involved in the apoptosis signalling, an important one being B cell lymphoma (BCL)2. 
BCL2 can inhibit the release of cytochrome c from mitochondria, inhibiting subsequent 
apoptosis (73). Neutrophils typically do not have BCL2, but rather the delay in apoptosis in 
neutrophils is via the stability of myeloid cell leukaemia (MCL)1, another member of the BCL2 
family (77). Other anti-apoptotic such as members of the inhibitors of apoptosis proteins 
(IAP) family including cellular (c)IAP1, cIAP2 and x-linked (x)IAP are found in neutrophils (78). 
These can inhibit apoptosis by inhibiting cleaved caspases, such as caspase 3, 7 and 9 (79). 
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Figure 1.5. Mechanisms controlling apoptosis. The extrinsic pathway, through receptors on 
the plasma membrane, and the intrinsic pathway, via the release of cytochrome c from the 
mitochondria, and the FADD independent pathway, via genotoxic stress and p53, induce 
apoptosis through the cleavage of caspases. MCL1 and IAPs can inhibit apoptosis at various 
stages of apoptosis by interacting and inhibiting various apoptotic proteins and factors. 
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1.3.5. Neutrophil priming 
Priming of neutrophils encompasses an exposure to a priming agent, which modulates an 
enhanced activation and/or function by subsequent stimuli (80). It has been thought that 
priming of neutrophils is important in host defence, but also associated with certain diseases, 
whereby priming is linked to disease severity or activity (80). 
It is known that certain cytokines, such as TNFα and GMCSF, are known to prime neutrophil 
function such as respiratory burst (81), and this priming can lead to activated neutrophils, a 
phenotype commonly found in inflammatory diseases such as SLE (82, 83). Through priming, 
TNFα and GMCSF can influence the expression of proteins in neutrophils (84), and this may 
influence how other cytokines influence neutrophil function.  
TNFα and GMCSF can prime healthy volunteer neutrophils to undergo a respiratory burst in 
vitro via the upregulation of p47 phosphorylation and TNFα priming can elevate the effect of 
other signalling pathways such as fMLP on the respiratory burst (85-88).     
GMCSF has also been shown to enhance TLR2 expression and subsequent TLR2-mediated IL-
8 responses in healthy volunteer neutrophils in vitro (89). Along with TNFα and GMCSF, IFNγ 
can also prime neutrophils; priming neutrophils in vitro from healthy volunteer and 
malignant melanoma patients with GMCSF, TNFα and IFNγ increases the neutrophil cytokine 
production of IL-1β, IL-6 and TNFα upon subsequent opsonized zymosan stimulation (90). 
These same processes resulting in the priming of neutrophils may be important in the 
pathogenesis of SLE and JSLE. Ex vivo, it has been shown that TLR2 is increased in CD4+ T cells 
in patients with SLE compared to healthy controls, which enhance immune reactivity, and 
TLR2 is required for autoantibody production and development of renal disease in a lupus 
mouse model (91, 92). Thus, activated neutrophils in JSLE may have increased TLR2 
expression, which may contribute to dysregulated neutrophil function. Increased numbers of 
activated neutrophils can be seen in SLE. This activated neutrophil phenotype may contribute 
to the increased cytokine production observed in SLE, and thus may have a contributory role 
to the development of a pro-inflammatory environment in these patients (93, 94). 
Published data has demonstrated that ex vivo neutrophils from individuals with SLE are more 
activated than neutrophils from healthy individuals (83). Neutrophils from individuals with 
JSLE may also demonstrate increased neutrophil activation in comparison to neutrophils 
from healthy individuals. To investigate the role of priming of neutrophils in the 
aetiopathogenesis of JSLE, an experimental model would need to use both naïve and 
activated neutrophils. To measure neutrophil priming, which models neutrophil activation, 
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particular protein markers of neutrophil activation/priming can be analysed using flow 
cytometry. Upon in vitro priming of neutrophils, activation markers undergo changes in 
expression. For example, expression of CD11b is typically increased, and CD62L is typically 
decreased. Priming agents such as TNFα can initiate these changes, which can additionally 
influence the downstream expression and activation of other proteins in the relevant 
signalling pathways (85, 86, 95, 96). Of note, CD11b is an integrin that forms part of the Mac-
1, an integrin receptor, also known as CC chemokine receptor (CCR)3 and is involved in 
functions such as chemotaxis and phagocytosis (97-100). CD62L (L-Selectin) is an adhesion 
molecule that can mediate leukocyte rolling (i.e. migration within the blood) (101). It is 
apparent that in vitro, and probably in vivo priming and subsequent activation of neutrophils 
may influence downstream neutrophil function, and other signalling pathways via changes in 
expression or activation of certain membrane or intracellular proteins. This altered function, 
which may include dysregulated apoptosis and pro-inflammatory cytokine production, may 
contribute to the pathogenesis of JSLE.   
 
1.4. Immune system in autoimmune diseases 
Autoimmunity occurs when an individual’s immune system becomes highly activated 
towards self-antigens (autoantigens) and as a consequence the surrounding tissue becomes 
injured (34). One organ can become affected (organ-specific, such as type 1 diabetes), or 
multiple organs can become affected (systemic, such as SLE). Autoimmune diseases are 
characterised by immune complexes, auto reactive T cells and circulating autoantibodies. 
Autoantigens are ever present in autoimmune disease and amplify and sustain immune 
responses which cause the disease to be chronic. However, clinical and pathological features 
can differ and diseases are characterised by the dominant autoimmune features (34). 
1.4.1. Immune system in autoimmune diseases other than JSLE  
There is a fine signalling balance between the innate and adaptive immune systems, by which 
the innate system immediately attacks any pathogens, and also signals to the adaptive 
immune system, which can have a delayed response (102). DCs are important in this link 
between innate and adaptive immune system as they are critical in promoting primary T and 
B cell responses to invading pathogens (102). T cells that are reactive to autoantigens, and 
such are named self-reactive T cells are usually removed in the thymus, although some are 
found in the periphery (102). These cells are usually dealt with through mechanisms, such 
downregulation of self and non-self-antigens by CD4+ cells containing the IL-2 receptor α 
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chains, so that they are tolerated and therefore do not react with host cells and so avoid 
triggering an immune response (102, 103). However, intercurrent infections and up-
regulated stimulation of antigen presenting cells can break this tolerance and can prime the 
activation of self-reactive T cells which may lead to autoimmunity (102). 
Macrophages can also contribute to the development of autoimmunity, through production 
of such cytokines such as TNFα, IL-1 and IL-6, and chemokines such as CCL5, CXCL9 and 
CXCL10, which can promote recruitment of Th1 cells and NK cells to the site (104). 
Neutrophils can produce NETs (see 1.3.3) which contain histones, DNA and HMGB1, that may 
contribute to autoimmunity underlying diseases such as JSLE and rheumatoid arthritis  (RA) 
(104) (Section 1.5.3.2 and Section 3.1). 
In the example of type 1 diabetes, T cells attack insulin producing pancreatic beta cells, and 
it has been suggested that TLR-mediated innate immune responses can contribute to 
diabetes induction in mice and that CD4+ and CD8+ T cells also promote further inflammation 
in this tissue (102, 104). Innate immune cells such as γδ T cells, macrophages and neutrophils 
may play an essential role in the pathogenesis of type 1 diabetes, through the production of 
cytokines that promote β-cell apoptosis, (which leads to the loss of β-cell and reduction in 
insulin production) and increase the recruitment of the T cells that destroy remaining β-cells 
(104). Diabetic ketoacidosis may trigger an inflammatory response, as it may increase the 
levels of CXCL8, IL-1β and TNFα (105). Additionally, M1 macrophages can initiate pancreatic 
β cell death, via the production of ROS, and can also activate T cells within diabetes (104). It 
was suggested that number of neutrophils are reduced in the blood of patients with type 1 
diabetes (106). Increased recruitment of neutrophils noted in the pancreatic tissue in 
neonatal non-obese diabetic (NOD) mice may explain reduced circulating neutrophils found 
in diabetic patients (106, 107). Increased neutrophil infiltration into the pancreas may 
contribute to β-cell destruction, and subsequent diabetic development.  
Within the example of RA, environmental factors may be a cause of molecular changes to 
proteins, and a breakdown of immune self-tolerance (104). These factors can also lead to 
autoantibody development towards citrullinated protein antigens (108). Many cells are 
involved in the pathogenesis of RA, including T and B cells, neutrophils and fibroblasts (104). 
As they are usually the first at the site of inflammation, neutrophils may play a role in tissue 
damage and initiate inflammation in RA, as neutrophil depletion in animal models could block 
joint inflammation and swelling in RA (104). Neutrophils are abundant in synovial fluid in 
active RA and can release high concentrations of oxidants such as ROS, cytokines such as 
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TNFα and granules containing proteases and myeloperoxidases into the synovial fluid or 
directly on cartilage surfaces (104). NETs are increased in peripheral blood and synovial fluid 
in RA patients compared to healthy individuals (peripheral blood) and patients with 
osteoarthritis (synovial fluid) respectively, and are a source of the citrullinated proteins that 
act as antigens, such as vimentin, and it has been shown that RA serum auto-antibodies can 
cause RA and control neutrophils to undergo NETosis (108).  
Within a model of experimental autoimmune encephalomyelitis (EAE), an animal modal of 
multiple sclerosis, CD4+ T cells mediate the progression of the disease (102). Activation of 
innate immune cells via microbial TLR ligands was deem critical for priming of CD4+ T cells 
and progression of EAE (102). Induction of EAE requires signalling through myeloid 
differentiation primary response 88 (MyD88) (102). Myeloid DCs (mDCs) were also shown to 
induce the expansion of IL-17 producing CD4+ T cells within EAE (102). pDCs however were 
found in central nervous system (CNS) and prevent mDC-induced pro-inflammatory CD4+ T 
cells responses via IL-17 and IFNγ (102). Additionally CD8α- mDCs can suppress myelin-
specific T cell function, and therefore the severity of EAE by producing anti-inflammatory IL-
10 (102).  
1.4.2. Immune system in adult onset SLE and JSLE 
The role of the immune system in SLE is highly diverse and involves many aspects. It is 
typically characterised by the development of autoantigens directed against nuclear 
autoantigens, and the loss of tolerance by other cells to these autoantigens (109). Exposure 
to antigens activates T and B cells and their subsequent proliferation (109). B cells produce 
autoantibodies that can contribute to tissue injury and can take up autoantigens which then 
allow exposure of more autoantigens to auto-reactive T cells (109). It is of particular note 
that the main mechanism of interest for B cells in particular is through the interaction of 
autoantigens and TLRs (109). Therefore, unpicking the immune system in regards to SLE and 
JSLE pathogenesis is fundamental to understanding the disease, and finding potential 
therapeutic targets. 
1.4.3. Role of neutrophils in adult onset SLE and JSLE 
Within healthy individuals, neutrophils mature in the bone marrow, and once mature are 
released into the blood stream (104). Neutrophils then migrate to the tissues to perform 
immune functions; once complete and with no further stimulus, they undergo apoptosis and 
are cleared by macrophages to maintain homeostasis (104). This death and clearance is 
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efferocytosis, and its decreased function, and decreased clearance of neutrophil apoptotic 
debris, may contribute to autoimmunity such as SLE (104).  
Dysregulated neutrophil apoptosis clearance has been shown to be particularly heightened 
in both SLE and JSLE and have been indicated as sources of autoantigens such as dsDNA, 
again through the exposure of chromatin (71, 72, 110). As there is indication that neutrophils 
are a source of autoantigens due to being particularly both NETotic and apoptotic in JSLE, 
neutrophils are potentially fundamental to JSLE (111). 
Phagocytosis, and in particular neutrophil phagocytosis, has been shown to be reduced in 
SLE and JSLE (112-115). The decreased phagocytosis function of neutrophils and other 
immune cells such as macrophages may contribute to the reduced clearance of the increased 
neutrophil apoptotic debris (112, 113, 115). This indicates that dysregulated phagocytosis 
may also be an important contributor to the build-up of autoantigens that may be coming 
from apoptotic material. 
Neutrophil migration, or chemotaxis, is an important function within immune responses. 
However, it has been indicated that neutrophil chemotaxis is dysregulated in SLE and JSLE 
(112, 116, 117). Many demographical and clinical aspects have been shown to contribute to 
dysregulated chemotaxis in SLE and JSLE; however, consensus of published data showed that 
neutrophil chemotaxis is generally reduced in SLE and JSLE, although one study suggests an 
increase in chemokines in SLE patient plasma (112, 116-118). This may result in accumulation 
of neutrophils at sites of inflammation and cause tissue damage that contributes to JSLE 
pathogenesis. 
1.5. Interferons and SLE 
IFNs are cytokines, categorised into 3 groups; type 1 encompasses the biggest group and 
includes IFNα and IFNβ, type 2 includes IFNγ only, and type 3 includes IFNλ only (120). The 
initial role for type 1 IFNs in particular involves antiviral effects, and type 2 expands on this, 
and can have roles in development of host protection against pathogens, and anti-tumour 
immune response and can also amplify antiviral activity by IFNα or IFNβ (121). Type 3 IFNs 
can modulate Th1 and Th2 responses in the form of IL-13 and IFNγ secretion (122). 
IFNα is one of the main type 1 IFNs and is produced by activated pDCs upon interaction with 
other cells, such as neutrophils (123). Specifically, autoantigens such as dsDNA and 
mitochondrial (mt)DNA expressed by neutrophils can activate pDCs, and these then can 
29 
 
produce an increased amount of IFNα (123). IFNα has been correlated with SLE severity and 
increases T cell activation and B cell activation and survival (124-126).  
IFNβ is an early response cytokine after viral infections, as shown through the increase of its 
messenger ribonucleic acid (mRNA), and has been shown to be important for positive 
feedback loop for the expression of IFNα in mouse fibroblasts (127). Both pDCs and myeloid 
DCs produce IFNβ upon activation through TLRs (128).  
IFNγ is the only type 2 interferon, and is structurally different from the type 1 interferons and 
signals through a different receptor (129). Many cells produce IFNγ, including T cells, which 
are involved in adaptive immune response, and NK cells, which are involved in early 
responses (129). IFNγ production is controlled by cytokines, of note IL-12 and IL-18 and 
negative regulators of IFNγ include IL-4 and TGFβ (129). 
1.5.1. JAK/STAT pathway  
The Janus kinase (JAK)/ signal transducers and activation of transcription proteins (STAT) 
pathway regulates a host of processes (including cell proliferation, migration and apoptosis) 
and is the principal pathway for a wide variety of cytokines (130-133). The JAK family 
comprises of four proteins, JAK1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (130). The JAKs range 
from 120kDa to 140kDa in size, and comprise seven conserved  JAK homology (JH) domains 
(134). Two carboxyl-terminal JH regions contain a kinase and pseudo kinase domain, whereby 
activation is through phosphorylation of tyrosines within an inactivation loop (134). Four 
amino-terminal JH regions contains four point one, ezrin, radixin, moesin (FERM) domain that 
associates with receptors via the proline-rich, membrane-proximal box1/box2 domain on the 
receptors. An SH2 related domain lies between the psuedokinase and FERM domains, 
although the function remains unknown (134). The structure is depicted in Figure 1.6.  
 
 The STAT family comprises of seven proteins; STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b 
and STAT6 (135). STATs range from 750 to 900 amino acids in size, STATs have a similar 
structure consisting of a amino-terminal domain, coiled-coil domain, a DNA binding domain, 
a linker domain, an SH2 domain, a phosphotyrosyl tail segment (whereby a tyrosine is 
phosphorylated upon STAT activation), and with the exception of two STAT isoforms, STAT1β 
and STAT4β, have a transactivation domain (134, 136). The amino terminal, approximately 
125 residues, is implicated to be involved in homodimers of inactive STAT dimers, and is 
important in cooperative binding to DNA (see below) (134). The coiled-coil domain, 
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consisting of approximately residues 135-315, creates a large hydrophilic surface that binds 
regulators (134). The DNA binding domain, consisting of residues 320-480, contains a β-barrel 
immunoglobulin fold that can bind to the gamma interferon activation site (GAS) family of 
enhancers (which STAT1 dimers bind) (134). The corresponding domain in STAT1/STAT2 
heterodimers is yet to be determined (134). The adjacent residues, 480-580, is the linker 
domain and maintains the right conformation between the DNA-binding and dimerization 
domains (134). The SH2 domain (consisting of residues  575-680) is the most conserved 
domain, and the tyrosine activation domain (at approximately residue 700) is situated 
directly adjacent to the SH2 domain (134). Lastly, the carboxyl terminal, which differs 
between STATs, contains the transactivation domain (134). Within resting cells, STATs form 
inactive homodimers, and remain in the cytoplasm (134). Activation of the STATs is via an 
initial activation and phosphorylation of the JAK proteins, and as such phosphorylation of the 
STATs and their subsequent dimerization (136). Activated dimers translocate to the nucleus 
and bind to specific gene sequences (134); STAT1 homodimers via IFNγ stimulations bind to 
GAS family of enhancers, whereas type 1 IFN stimulation results in STAT1/STAT2 
heterodimers which form interferon stimulated gene factor (ISGF)-3 with interferon 
regulatory factor (IRF)-9 and bind to the ISRE family of enhancers (134). 
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Figure 1.6. Depiction of the structures of JAK (A) and STAT (B) families (by Schindler et al. 
(134)). The JAK structure constitutes JH domains, which create a FERM domain, a SH2-related 
domain (“SH2”), a pseudo kinase domain (ψKi) and a kinase domain (Ki). The STAT structure 
contains an amino-terminal domain (NH2), a coiled-coil domain, a DNA-binding domain 
(DBD), a linker domain (Lk), an SH2 domain, a phosphotyrosyl tail segment/tyrosine 
activation domain (Y) and a transcriptional activation domain (TAD).  
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The dimerization of STAT1 in particular is via the phosphorylated tyrosine within the SH2 
domain and interaction of alanine in position 77 (137). Additionally, substitution of alanine 
to phenylalanine at position 77 leads to dimerization of unphosphorylated STAT1 in a 
conformation entitled ‘anti-parallel’ (137). The parallel conformation arises through the 
stabilisation of SH2-phophtryosine interactions, and tyrosine-phosphorylated STAT1 dimers 
are able to switch between anti-parallel and parallel conformations (137). pSTATs then 
translocate to the nucleus to activate transcription of target genes, the target being 
dependent on cytokine stimulus and the specific STAT (136). Cooperative DNA binding is the 
principle of switching between occupied and non-occupied promotor states, and STAT1 
cooperative binding is important in recruiting gamma interferon activation factor (GAF) to 
gene promotors, and subsequent IFN gene expression (137). Mutations within the N domain 
(i.e. substitution of alanine to phenylalanine at position 77 within a mouse model) disrupts 
IFNγ-related STAT1-cooperative DNA-binding, and can lead to increase in bacterial infections 
such as Listeria monocytogenes within mouse macrophages (137).  
In vitro, STAT1 has been shown to be pro-apoptotic in a variety of cells, including A431, Hela 
and HT29 and published data have shown that this can be via the up regulation of Fas and 
Fas ligand (FasL) expression or through expression of caspase 1 (138, 139). STAT2 was shown 
to be particularly important in antitumor effects of type 1 IFNs (140). STAT3 is considered 
anti-apoptotic, and has been shown to induce type 1 and 2 IFN mediated anti-apoptosis in 
neutrophils (141). STAT4 is important in the differentiation and proliferation of Th1 cells 
(142). STAT5 was shown to be involved in suppression of the tumour protein, p53, and 
enhanced Mouse double minute 2 homolog (MDM2), and thus may be important in 
regulating apoptosis and contribute to cell survival (143) STAT6 is involved in the induction 
of regulatory T (Treg) cells, and Th2 immunity promotion (144, 145). 
Ligands such as IFNs activate the signalling pathway by initially dimerising the receptor 
subunits, such as IFNα receptor (IFNAR) and IFNγ receptor (IFNGR), these receptors are then 
able to phosphorylate JAK tyrosine kinases, which associate with the receptor (see Figure 1.6) 
(146-149). Different JAK kinases associate with different receptors, as JAK1 and JAK2 are 
shown to be phosphorylated by IFNγ, whereas JAK1 and Tyk2 are phosphorylated by IFNα, 
contributing to the dynamic signalling of the JAK/STAT pathway (148, 150). STATs can 
associate with the receptor and can be phosphorylated on the SH2 domain by the JAK kinases 
(149, 151). Again, different STATs associate with different JAKs and receptors, such as STAT2 
with IFNα receptor allowing for multiple cytokines to exert different effects (149). 
Phosphorylated STATs can dimerise through their SH2 domains and the phosphorylated sites 
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and are able to enter the nucleus via importin alpha 5 and 7 pathway, and bind to specific 
regulatory sequences to activate or repress the transcription of target genes (151-153). The 
JAK/STAT pathway is involved in neutrophil apoptosis and up-regulates apoptosis genes in 
JSLE. 
1.5.1.1. STAT3  
Within healthy volunteer neutrophils, in an in vitro setting, it was shown that 1000U/ml 
GMCSF can induce the JAK/STAT pathway, via JAK2 and STAT3, as shown by an 
electrophoretic mobility shift assay (EMSA) (154). This in vitro STAT3 phosphorylation by 
GMCSF was shown to reduce the level of neutrophil apoptosis, an observation also seen in 
JSLE-serum activated neutrophils (110, 154). In vitro STAT3 depletion by an antisense 
oligonucleotide increased the level of apoptosis after GMCSF stimulation, indicating an 
important STAT3 role in GMCSF delayed apoptosis (154).  
MCL1 protein and mRNA was also increased upon GMCSF treatment, and it was confirmed 
in vitro that GMCSF delayed healthy volunteer neutrophil apoptosis via increased MCL1 
stability (77, 154). These studies highlight a potential mechanism by which the GMCSF delays 
apoptosis via the phosphorylation of STAT3 and an increased stability of MCL1. Additionally, 
it has been shown in vitro that IFNs can be anti-apoptotic in healthy volunteer neutrophils, 
which is through the phosphorylation of STAT3 and up-regulation of cIAP2 (141). IFNs may 
delay apoptosis, particularly in the neutrophils of healthy individuals, and this may be via the 
phosphorylation of STAT3 and leading to increased stability of MCL1. In JSLE neutrophils, 
however, STAT3 may be down regulated, and its potential effect on MCL1 and delayed 
apoptosis may be reduced.  
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Figure 1.7. The JAK/STAT pathway. IFNs bind to the IFN receptor, which allows for 
dimerization. JAKs associate with the receptor and phosphorylate each other. This then leads 
to the phosphorylation of STAT1, which transports to the nucleus and up-regulates IFN-
inducible genes.  
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1.5.1.2. Interplay of STATs within IFN signalling 
The effect of IFN signalling depends on the phosphorylation and interaction of STATs with 
each other and downstream components, which results in a variety of different processes. It 
has been shown that IFN signalling can lead to augmented TLR signalling within macrophages, 
through the activation of STAT1 (155). Interestingly, within STAT1 deficient macrophages, 
IFNγ and IFNβ can suppress TLR signalling, through the reduction of activated NFκB and 
subsequent production of cytokines such at TNFα and IL-12. This correlated with sustained 
phosphorylation of STAT3 (155), suggesting a switch in IFN/STAT signalling. Additionally, it 
has been shown that in the absence of STAT1, IFNγ can activate STAT3 via SRC-family kinases 
within mouse embryo fibroblasts (MEFs) (156). STAT1 and STAT3 have similar structures and 
activation domains, and this leads to STAT1 and 3 activating overlapping but distinct genes; 
this explains how, in STAT1-null MEFs, STAT3 drives the expression of STAT1 genes (156). 
Contextually, this may be important in regards to apoptosis; STAT1 has been shown to be 
pro-apoptotic, and STAT3 has been shown to be anti-apoptotic (138, 141). STAT2, which is 
usually associated with type 1 IFN signalling, has been identified to be part of the IFNγ 
pathway, and can inhibit STAT1, but not STAT3, in multiple pathways (157). The study by Ho 
et al. suggest that this STAT2 related STAT1 inhibition may allow for a shift towards STAT3 
related signalling, and therefore may be important in IFN-related apoptosis signalling (157). 
Additionally, STAT1 mediated cytokine function depends on ‘free’ STAT1 and that although 
STAT1 is present in excess compared to STAT2, IFN stimulation increases STAT1:STAT2 dimers 
(157), and therefore likely to be regulating the amount of activated STAT1 signalling. These 
dynamics may be dysregulated within SLE and JSLE, in particular in regards to JSLE apoptosis.  
1.5.1.3. SOCSs 
Suppressors of cytokine signalling (SOCS) proteins were shown to be STAT target genes that 
can antagonise STAT activation, resulting in a negative feedback loop (134). SOCS1, SOCS2 
and SOCS3 can inhibit the IFNγ/STAT1, IL-12/STAT4, IL-4/STAT6. GH/STAT5 and IL-6/STAT3 
pathways (134). 
Understanding of the mechanisms of SOCS proteins have been derived from SOCS1 and 3, 
which have overlapping functions but some unique differences (158). Both SOCS1 and 3 can 
block JAK/STAT signalling through inhibition of JAK enzyme; SOCS1 and SOCS3 interact with 
the phosphotyrosine found in  in the JAK catalytic loop and has also been shown to interact  
phosphotyrosine residues on the IFNα receptor 1 chain  (IFNAR1) and IFNγ receptor 1 chain 
(IFNGR1) (158).  
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Kinase inhibitory region (KIR) of SOCS 1 and 3 (a 12 amino acid domain located on the amino 
terminal, adjacent to the SH2) is required for inhibition of JAK kinase activity (158). It was 
shown to work as a pseudo-substrate, and blocking the catalytic cleft of the JAK to prevent 
further enzymic activity (158). The SOCS family is typically defined by a 40 amino acid SOCS 
box motif, which is generally located at the carboxyl terminus (158). The SOCS box consists 
of three α helices which are attached to an E3 ubiquitin ligase complex (158). Within this 
region, the SOCS box also contains an E1 ubiquitin-activating enzyme, and an E2 ubiquitin-
conjugating enzyme, which contribute to the polyubiquitination and proteasomal 
degradation of  the proteins which SOCS bind to (158). The SOCS box of SOCS1 has been 
shown to ubiquitinate targets such as JAK2, signalling for degradation (158). The induction of 
SOCS protein expression by cytokine stimulation has been implicated to be STAT dependent 
(158). Cytokine stimulation rapidly induces SOCS1 and SOCS3 expression and both are 
degraded upon termination of said signalling,  suggesting that the half-life  SOCS protein is 
tightly regulated (158).  
1.5.2. Interferon receptors 
IFNs signal through receptors on membrane surfaces to activate the JAK/STAT pathway. The 
type 1 IFNs signal through the IFNα receptor (IFNAR). However, it has been shown that the 
potencies and effects of this binding and signal vary between IFNs (159, 160). Type 2 IFNs 
signal similarly through the IFNγ receptor (IFNGR) (161, 162). Both receptors consist of two 
distinct chains, and the expression and dimerization of these chains are important in how the 
signalling pathway is activated (146, 147). In particular, it has been shown that the IFNGR 
chains have differential expression on different immune cell lines, and this differentiation can 
contribute to whether IFNγ induces a signalling cascade to induce cell proliferation or 
apoptosis in isolated healthy volunteer T cells and the T cell line (161, 162). 
1.5.3. Roles of IFNs on neutrophil function in JSLE 
Although this is covered in in subsequent chapters in more detail (see Chapter 3 and 4), it is 
of note that the IFNs have each been shown to have significant effects on neutrophil 
apoptosis, NETosis, chemotaxis and phagocytosis, which all of have been indicated to be 
dysregulated in SLE, and therefore could be possible contributors to the pathogenesis of both 
SLE and JSLE (71, 72, 112, 116, 117, 163).  
1.5.3.1. IFNs and Apoptosis in JSLE 
IFNs have been shown to be both pro- and anti-apoptotic in vitro, and this is dependent on 
the signalling pathway, whereby STAT1 is pro-apoptotic, and STAT3 is anti-apoptotic (138, 
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141, 164-166). This may also depend on the activation state of neutrophils. Neutrophils have 
been shown to be activated in SLE, and probably also JSLE patient neutrophils (83). Cytokines 
such as GMCSF, TNFα and IFNγ can prime/activate neutrophils in vitro and this can alter the 
signalling pathways, both extracellular and intracellular protein expressions, and neutrophil 
function (81, 85, 86, 90, 95, 167-169). Thus, it is likely that the probable activation of JSLE 
patient neutrophils may account for the up regulation of the pro-apoptotic proteins shown 
within JSLE patients neutrophils in vitro (170). It is also possible that IFNs are involved in the 
up-regulation of neutrophil apoptosis within JSLE due to their role in pro-apoptosis, and the 
high IFN genetic signature and high IFN serum levels found within SLE and JSLE patients (41, 
68, 72, 171-174) (Section 1.4.2).  
1.5.3.2. IFNs and NETosis in JSLE 
It has been suggested that IFNs prime neutrophils to undergo NETosis in vitro (175). However, 
it is important to note that it is likely that NETosis is more important for the increase in IFNα 
production from pDCs found in JSLE patients and in vitro in particular. This may contribute in 
turn to the increased IFNα concentration measured within JSLE serum, would could lead to 
more neutrophils being primed for NETosis, creating a positive feedback loop (68, 172, 175, 
176). It would therefore be of importance to investigate the role of IFNs on NETosis, either 
as priming agents or whether they stimulate NETosis in naïve or TNFα-primed neutrophils. 
1.5.3.3. IFNs and chemotaxis in JSLE 
IFNs have been shown to have an influence on chemotaxis, although this can be differential 
depending on IFN and cell type. In vitro, IFNβ was shown to reduce healthy volunteer PMBC 
migration towards chemokines RANTES, macrophage inflammatory protein (MIP)1α and 
monocyte chemoattractant protein (MCP)1, and in particular can reduce healthy volunteer T 
cell chemotaxis (177, 178). Alternatively, in vitro, IFNγ can up-regulate healthy volunteer 
neutrophil chemotaxis through the upregulation of CCR1 and CCR3, which recognise 
chemokines such as MCP3 and RANTES, however, IFNγ had no effect on healthy adult T cell 
chemotaxis in vitro (178-182). It is suggested that IFNγ in particular has an influence on 
neutrophil chemotaxis, and it would be of interest to investigate the role of IFNs on 
neutrophil chemotaxis, and how this may relate to dysregulated neutrophil chemotaxis seen 
in SLE, and possibly in JSLE (116, 117). 
1.5.3.4. IFNs and phagocytosis in JSLE 
IFNs can affect phagocytosis. However, this effect can be differential depending on the type 
of IFN, the targeted immune cell, the phagocytic pathway being followed, and the particle 
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being phagocytosed. For example, within mouse peritoneal macrophages, IFNs have a 
differential effect on phagocytosis in vitro; IFNα/β can increase the phagocytosis of 
Escherichia coli (E.coli), whereas IFNγ reduced this phagocytosis (183). Both IFNα and IFNγ 
have been shown to up-regulate neutrophil phagocytosis of S. aureus in vitro (184). Of note, 
many receptors are involved in phagocytosis, and in vivo administration of IFNγ in healthy 
volunteers has been shown to influence receptors such as the FcγRI on healthy volunteer 
neutrophils ex vivo, which in turn may have an effect on phagocytosis in vitro (185). Thus, 
IFNs may be involved in the dysregulated neutrophil phagocytosis seen in JSLE (112).  
1.5.4. Implications of IFN/JAK/STAT pathway in JSLE  
1.5.4.1. IFN expression and SLE/JSLE 
It has previously been shown that there was both an increase in type 1 and 2 IFNs in the 
serum of SLE patients, and a recent study has shown that IFNγ was increased in SLE serum 
(171, 186). In recent years, it has been shown that IFNα is increased in JSLE serum (68, 172) 
and it may be that IFNγ is also raised in JSLE. 
Both adult-onset SLE and JSLE are characterised by an increased granulocyte and IFN gene 
signature (a set of genes deemed associated with granulocytes or stimulated by IFNs), with 
distant type 1 IFN genes and distinct type 2 IFN genes elevated in SLE patients (41, 174) 
suggesting an interaction between raised IFNs within the serum and neutrophils contribute 
to the pathogenesis of JSLE. Increased granulocyte genes within JSLE PBMCs includes 
defensin alpha 3 (defa3), which has antibacterial functions, and eosinophil derived neurotoxin 
(41). IFN associated genes that were found upregulated in JSLE PBMCs included  genes that 
code for Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), IRF-7b and 
inferferon stimulated gene (ISG)-15 (41). Additionally, IFNAR may have an important role in 
the increased type 1 IFN signature expression seen in JSLE (41, 187).   Of note, healthy 
neutrophils stimulated with JSLE serum had dysregulated genes found in both the TLR and 
IFN pathways, which include an increase in irf-7, and stat1, and a decrease in  apoptotic 
peptidase activating factor (apaf1); over half of these genes correlated with that of JSLE 
neutrophils (163). It also been shown that there were variations of IFN scores within adult 
SLE patients, ranging from absent to strong, and strength of expression IFN genes could 
correlate with disease activity, and biomarkers such as dsDNA (174). Importantly, although 
there were genes that were more associated with either type 1 or type 2 IFN stimulation, 
there were genes that were up regulated by both type 1 or type 2 IFNs within SLE (174). This 
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suggests that not only do the IFNs have a genetic role in SLE pathogenesis; it is likely that SLE 
and JSLE pathogenesis develop through a combination of IFNs and not just one type alone.  
It should be of note that there is an IFN ‘high’ signature (increased expression of IFN-related 
genes) and an IFN ‘low’ signature (no increase in expression of IFN-related genes) within SLE, 
whereby in the IFN low signature patients have similar gene expression to that of control 
patients (188). Within this study, it was showed that the IFN high signature associated more 
with African-American ancestry and a high level of dsDNA and low complement levels (188). 
The IFN high signature patients also had more active disease, and therefore IFN genes are 
likely to be important in SLE pathogenesis (188). Certain analytes within the serum are 
differentially expressed between SLE and control patients; for example, chemokine CCL20 
and fibroblast growth factor (FGF)2 are down regulated in SLE regardless of IFN signature, 
whereas cytokines IL-5, IL-6, and IL-15 are up-regulated in SLE regardless of IFN signature 
(188). Additionally, certain analytes correlated more with IFN high than IFN low patients; for 
example, CCL2, CXCL9, CXCL11 and IL-18 were significantly up-regulated in high IFN patients, 
but not low IFN patient, compared to healthy controls, they were significantly up regulated 
compared to IFN low patients also (188). Many IFN-regulated analytes correlated with 
disease activity and anti-dsDNA antibodies (188). Many of these analytes were chemokines, 
and suggests not only that the patients are undergoing a chemokine ‘storm’ induced by IFNs, 
but also that there was a chemokine gene score that correlated with disease activity (188). 
Certain chemokines, such as CXCL11 and CCL3 were significantly increased in patients with 
renal disease compared to those without (188). Interestingly, CXCL8/IL-8 (a neutrophil 
chemokine) was negatively correlated with active haematological involvement (188). This 
may correlate with the neutropenia commonly found in SLE patients (189). This study 
highlights a role of IFN signature within SLE; inducing certain chemokines that: a) can act as 
biomarkers and b) may lead to recruitment of leukocytes to tissues and organs and become 
involved in disease activity. However, the study also highlights that, although IFNs seem to 
be important in SLE, a subset of patients have IFN signatures similar to healthy controls, and 
therefore IFNs are not the sole cause of SLE pathogenesis, and other cytokines and factors 
must be investigated.  
Within a longitudinal study, there was indication of increased IFNα activity in serum of SLE 
patients precedes their official diagnosis, and elevation of this activity correlates with 
autoantibodies, and has been shown to follow accumulation of autoantibodies (190). IFNγ, 
and its associated mediators was also found to be up-regulated in patient serum before SLE 
was fully evident , and correlates with IFNα activity (190). Additionally, IFNγ, and type 2 IFN 
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mediator, IFNγ induced protein (IP)10, were up regulated prior to accumulation of 
autoantibodies and IFNα activity (190). It was also suggested that type 2 IFN mediators and 
accumulation of autoantibodies can predict SLE classification, and also contribute to the 
increased IFNα activity seen (190). Thus, this indicates an importance of both types of IFNs 
in the initial development of SLE and highlights not only a potential biomarker of SLE 
pathogenies, it highlights that IFNs and any signalling pathway and mediators are important 
therapeutic targets.  
1.5.4.2. STAT1 expression and SLE/JSLE 
Studies have strongly indicated an important role of STAT1 in increased apoptosis. 
Overexpression of STAT1 in lung cancer cells increased the rate of apoptosis upon IFNγ 
induction in vitro (191). IFNγ can induce STAT1 activation subsequent to apoptosis in HeLa 
cells in vitro (138). Cycloheximide, an apoptosis inducer (192), can increase IFN-induced 
STAT1 mRNA expression in healthy volunteer peripheral blood mononuclear cells (PBMCs) in 
vitro (193) indicating a link between STAT1 and any potential increase in apoptosis within 
PBMCs. An increase in STAT1 activation maybe a pivotal factor in any possible IFN induced 
neutrophil apoptosis within JSLE is part of the IFN/JAK/STAT pathway, it may be the link 
between IFNs and neutrophil apoptosis (72).  
Data has shown that STAT1 mRNA and protein expression was increased in PBMCs by IFNα 
and IFNγ in vitro (193). These studies show that IFNs in particular are able to induce increased 
STAT1 mRNA and protein expression in PMBCs, so this indicates that it is likely that the factors 
found in the serum may be causing an increase in STAT1 expression within JSLE neutrophils, 
rather than a genetic factor (193). So, it would be important to know if IFNs or other pro-
inflammatory factors, such as TNFα, are shown to up-regulate STAT1 in any inflammatory 
conditions, especially adult-onset SLE and JSLE.  
Coincidently, increased STAT1 expression occurs in both RA and adult-onset SLE PBMCs (194, 
195). In RA, IFNs and TNFα up regulate STAT1 expression in healthy volunteer and RA PBMCs 
in vitro (195). IFNγ increase the proportion of phosphorylated (p)STAT1 in RA monocytes 
compared to healthy controls in vitro, and lead to an increase in IFN inducible genes (195). In 
this model, an increase in both STAT1 and pSTAT1 in PBMCs in adult-onset SLE compared to 
healthy volunteer neutrophils ex vivo, and IFNγ was able to effectively phosphorylate more 
STAT1 in SLE PBMCs than in healthy controls in vitro (194). This up-regulation of STAT1 in SLE 
PBMCs positively correlated with dsDNA levels, indicating a link between STAT1 and disease 
activity (194). It is possible that in inflammatory diseases, such as RA and adult-onset SLE, 
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cytokines such as TNFα in RA, and IFNs in adult-onset SLE, and possible JSLE, cause an 
increase in STAT1, as indicated by these studies. Thus, in JSLE, the increase in IFNs in the 
serum is not only increasing the expression of STAT1, but also increasing the phosphorylation 
of STAT1. As such, in JSLE, STAT1 is the prominent downstream protein from IFN stimulation 
in neutrophils, and this may result in the observed increase in neutrophil apoptosis (72).  
STAT1 has also been implicated in the mouse model of lupus nephritis, in which the 
expression of both STAT1 and pSTAT1 were higher in cells lupus nephritis mice compared to 
healthy control mice ex vivo (196). A high level of STAT1 is present in the mesangial cells of 
lupus nephritis in a mice model, and both IFNγ and IFNα were able to phosphorylate STAT1 
in these cells in vitro, albeit IFNα less so than IFNγ (196). This phosphorylation was inhibited 
by AG490 in vitro, a JAK2 and JAK3 inhibitor (details found here: 
https://www.tocris.com/products/ag-490_0414), indicating a IFN/JAK role in STAT1 
phosphorylation (196). Interestingly, an increase in the suppressor of cytokine signalling 
(SOCS)1 and 3 mRNA and SOCS3 protein occurs in the kidney tissue of lupus nephritis mice 
compared to healthy controls (196). This mouse model indicates an important potential link 
between IFNs, STAT1 and lupus nephritis pathogenesis. These studies indicate that STAT1 
pathway seems to be paramount in SLE and lupus nephritis pathogenesis. Additionally, the 
STAT1 function pro-apoptosis highlights its potential to become a therapeutic target in SLE 
and JSLE patients. Inhibition of the STAT1 pathway may dampen disease progression through 
a particular reduction in the otherwise increased neutrophil apoptosis, that has been 
hypothesised to contribute to the autoantigens that are characteristic of SLE and JSLE.  
1.5.4.3. Inhibition of the JAK/STAT pathway 
JAK inhibitors have been used to inhibit the JAK/STAT pathway and have been used in lupus 
mouse models to treat SLE and specifically lupus nephritis (197, 198). CP-690,550 (tofacitinib) 
is a JAK inhibitor that can reduce proteinuria and prevent glomerular and tubular lesions in 
mice with lupus nephritis and SLE prone mice (197, 198). Tofacitinib can decrease anti-dsDNA 
levels, complement and IgG glomerular deposits, and macrophage and T cell infiltration into 
the glomeruli (197, 198). Tofacitinib could also reduce the number of effector/memory T cells 
and activated T cells in spleens of lupus prone mice (197). Importantly, tofacitinib inhibited 
the expression of a range of STAT genes (STAT1, STAT2, STAT3, STAT4 and STAT5a) in mice 
with lupus nephritis (198). Additionally, tofacitinib significantly reduced gene expressions of 
IL-6, IL-2 and IFNα in kidneys of lupus prone mice, and reduced IFNγ gene expression within 
whole blood, although this was not significant (197). IFN-induced genes encoding for 
interferon-induced transmembrane proteins (ifitm2 and ifitm3), interferon-induced protein 
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with tetratricopeptide repeats 3 (ifit3) , 2'-5' oligoadenylate synthetase 1A (oas1a) and 
interferon stimulated gene 15 (isig-15) were supressed in splenic T cells in tofacitinib treated 
mice (197). Tofacitinib also reduced systemic circulating cytokines, with a significant 
reduction in IFNα, TNFα and IL-17 levels. Thus, within SLE, and particularly in regard to lupus 
nephritis, inhibiting the JAK/STAT pathway reduces many inflammatory markers and 
cytokines that contribute to SLE development. This shows that the JAK/STAT pathway is 
important in SLE and targeting different components may be of therapeutic benefit. 
JAK inhibitors have differential effects on neutrophil functions (199). Tofacitinib, and another 
JAK inhibitor, baricitinib (a JAK1/JAK2 inhibitor) (both inhibitors are used to treat RA: see 
https://www.nice.org.uk/guidance/ta480 and https://www.nice.org.uk/guidance/ta466 for 
details) were shown to reduce both the IFNγ and GMCSF induced a delay in apoptosis in 
neutrophils from healthy volunteers at 20hrs in vitro (199). Both JAK inhibitors reduced 
GMCSF-induced STAT3 phosphorylation and IFNγ-induced STAT1 phosphorylation in 
neutrophils from healthy volunteers in vitro (199). In vitro, both inhibitors reduced random 
RA neutrophil chemotaxis and baricitinib decreased RA neutrophil chemotaxis towards IL-8, 
although chemotaxis towards fMLP was not affected (199). Additionally, neither IL-8 nor 
fMLP induced STAT1 or STAT3 phosphorylation in vitro (199). Neither inhibitor reduced the 
production of ROS by RA neutrophils in response to fMLP in vitro, however ROS was increased 
in RA neutrophils incubated with tofacitinib and stimulated with PMA and both inhibitors 
increased ROS in GMCSF primed RA neutrophils in vitro (199). This study shows the JAK/STAT 
pathway is important in a variety of neutrophil functions, particularly in regards to the 
inflammatory disease RA, and in particular, its inhibition leads to an altered apoptosis effect 
in regards to GMCSF and IFNγ. Thus, within this thesis, it would be of upmost importance to 
investigate if IFNs influence apoptosis in particular through the JAK/STAT pathway, and 
whether the inhibition of the pathway may alter the increased apoptosis seen in JSLE patients 
and therefore offers potential as a therapeutic target.  
However, although JAK inhibitors are well established for inhibiting the JAK/STAT pathway, 
it was shown that many STATs are inhibited at the gene level in the kidney of a mouse model 
of lupus nephritis by using JAK inhibitors and both STAT1 and STAT3 phosphorylation can be 
inhibited by using JAK inhibitors in stimulated healthy volunteer neutrophils in vitro (198, 
199). As STAT1 and STAT3 are important in IFN-related apoptosis, and importantly have 
opposite effects on this process, in order to differentiate IFN related effects on apoptosis, 
more specific inhibitors than JAK inhibitors are required (138, 141). Briefly, two inhibitors 
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haven been indicated to inhibit STAT1, fludarabine phosphate and S1495, and will be used as 
STAT1 inhibited in this study (200-202). Their roles are discussed later within this thesis. 
 
1.6. Summary 
Neutrophils are important in both health and disease. Within SLE and JSLE, the dysregulation 
of their life cycle and functions may be linked to auto-antigen exposure. Reduced neutrophil 
chemotaxis in these diseases may lead to their accumulation in tissues which may lead to 
organ damage such as that associated with lupus nephritis. Both the neutrophil and IFN-
related gene signatures are upregulated in JSLE, indicating a potential interaction between 
IFNs and neutrophils that may contribute to SLE pathogenesis. Importantly, increased IFN 
protein concentrations have been detected in the serum of individuals with SLE and JSLE, 
supporting the hypothesis that IFNs are important in the disease processes underpinning SLE 
and JSLE. IFNs have been shown to prime neutrophils to undergo NETosis, which in turns 
stimulates pDCs to increase IFNα production. This may in turn contribute to the increased 
IFNα protein level found in JSLE patients and prime more neutrophils to undergo NETosis. 
Neutrophil chemotaxis and phagocytosis have also been shown to be dysregulated in JSLE, 
and IFNs have been implicated to alter these functions, particularly through influencing 
neutrophil receptor expression. IFNs signal via the JAK/STAT pathway, and different 
members of the STAT family have differential effects on apoptosis. Apoptosis is increased 
and dysregulated in JSLE patients and may lead to increased autoantigen exposure. STAT1 in 
particular has been shown to be increased in SLE and may induce a pro-apoptotic signal. The 
effect of inhibition of STAT1 activity on downstream signalling effects on apoptosis may 
highlight it as a potential therapeutic target within JSLE patients.  
 
1.7. Hypothesis 
The interaction of IFNs and neutrophils in JSLE contributes to disease pathogenesis. This may 
be via the influence of IFNs on neutrophil function and apoptosis, due to changes in the IFN 
signalling pathway.  
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1.8. Aims and objectives 
Overall Aim: To investigate the interaction of IFN sub-types with neutrophils, and how IFNs 
can influence neutrophil function and apoptosis in the context of JSLE. 
Aim 1: To investigate the effect of IFNs on chemotaxis, phagocytosis and NETosis in 
combination with other factors. 
 Objective 1: Using transwells and manual counting using a haemocytometer and light 
microscopy, measure the rate of a) naïve healthy adult neutrophil migration towards 
IFNs and known neutrophil chemoattractants, IL-8 and fMLP; and b) IFN-primed 
healthy adult neutrophils towards known neutrophil chemoattractants, IL-8 and 
fMLP. 
 Objective 2: Using flow cytometry, measure the rate of healthy adult neutrophil 
phagocytosis of E.coli bioparticles after IFN priming. 
 Objective 3: Using confocal microscopy and DNA quantification (via Quant-iT™ 
PicoGreen™ dsDNA assay kit), measure NETosis after a) IFN-priming and subsequent 
LPS stimulation of healthy adult neutrophils and b) stimulation of IFNs on naïve and 
TNFα-primed healthy adult neutrophils. 
Aim 2: To investigate the role of IFNs on neutrophil apoptosis. 
 Objective 1: Using flow cytometry, quantify the rate of apoptosis on naïve and TNFα-
primed healthy adult neutrophils following a 6hr incubation with a high 
concentration of IFNs. 
 Objective 2: Using flow cytometry, quantify the rate of apoptosis on naïve and TNFα-
primed healthy adult neutrophils following a 6hr incubation with IFNs, and measure 
the downstream expression of anti-apoptotic MCL1 (at 6hrs) and caspase 3 (at 20hrs) 
using Western blotting. 
 Objective 3: Using flow cytometry, quantify the rate of apoptosis on naïve and 
patient sera-primed healthy adult neutrophils following a 6hr incubation with a lower 
concentration IFNs. 
 Objective 4: Using flow cytometry, quantify the rate of apoptosis on paediatric 
control patient and JSLE patient neutrophils following a 6hr incubation with a lower 
concentration IFNs. 
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Aim 3: To investigate the IFN signalling pathway in naïve and primed neutrophils and its 
relation to apoptosis.  
 Objective 1: Using flow cytometry, measure the IFN receptor expression on naïve and 
TNFα-primed healthy adult neutrophils. 
 Objective 2: Using flow cytometry, measure the IFN receptor expression on 
paediatric control and JSLE patient neutrophils. 
 Objective 3: Using Western blotting, measure the relative expression of pSTAT1 and 
pSTAT3 in naïve and TNFα-primed  healthy adult neutrophils. 
 Objective 4: Using both flow cytometry and Western blotting, measure the ability of 
fludarabine phosphate and S1459 to reduce pSTAT1/β actin expression ratio (and 
therefore possibly inhibiting pSTAT1) within healthy adult neutrophils and their 
effect on the rate of neutrophil apoptosis.  
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Chapter 2: Technical methods 
2. Part A. Ethics, recruitment and patient data 
2.1. Patient Cohort 
Clinical data and bio-samples used in studies included in this thesis were collected within the 
appropriate regulatory approvals of ‘UK JSLE Cohort Study and Repository’, which started in 
2006. The aim of this study is to investigate the ‘clinical characteristics and immunopathology 
of JSLE’. The study is co-ordinated by the University of Liverpool and collects data and 
samples from 21 centres throughout the UK. Demographic and clinical data are obtained 
during routine clinical appointments using standardised data collection sheets that are then 
uploaded onto a secure, central database managed by the University of Liverpool. In addition 
to this, whole blood DNA, serum, plasma and urine are collected for analysis and/or biobank 
storage from multiple sites. Specifically, whole blood samples for the isolation of immune 
cells are collected from patients attending the Department of Rheumatology at Alder Hey 
Children’s NHS Foundation Trust, Liverpool, UK. These samples are collected generally on the 
National Institute for Health Research (NIHR) Alder Hey Clinical Research Facility for 
Experimental Medicine and processed in the University of Liverpool laboratories within the 
‘Institute in the Park’, Alder Hey Children’s NHS Foundation Trust. Additionally, paediatric 
and adult healthy control samples are collected for comparison within the overarching 
regulatory permissions for the study. As of August 2017, when the laboratory work on this 
thesis was completed, 659 JSLE patients and 610 paediatric control patients have been 
recruited to the study. 
 
2.2. Ethics 
This study formed part of the UK JSLE Cohort Study & Repository that received full ethical 
approval by the North West - Liverpool East Research Ethics Committee (REC: 6/Q1502/77) 
(Appendix A1). The study is sponsored by Alder Hey Children’s NHS Foundation Trust. Written 
informed patient/parental assent/consent was obtained in accordance with the Declaration 
of Helsinki (203). The study protocol stipulates that informed consent is required from 
patients/carers, and consent/assent from patients as appropriate. Information sheets are 
required for the patient and families, who have as much time as required to consider whether 
they wish to participate in the study (Appendix B3). The information sheet was explained by 
an appropriate health professional that was able to answer any questions the child or family 
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had. Consent included access to patients’ medical records, permission to approach patients 
in regard to other research and recording an email address for the parent/patient in order 
for contact for any appropriate follow up. Where English is not a family’s native language, an 
interpreter was provided to facilitate complete understanding of what the study entailed. 
Each patient recruited was allocated a study number to allow for anonymity of the patient, 
and the recording of each patient records, including clinical and demographic data and the 
number was locked on a site away from the database. The study number was used on all data 
collection and databases for the study. Paper forms for data collection were stored in a 
locked filling cabinet after being entered onto the study database. Patient identifiable data 
were not stored on the electronic database. The database was password protected. 
Healthy adults were recruited from staff in the Department of Women’s and Children’s 
Health, University of Liverpool, following informed consent (Appendix B3) under regulatory 
approval from the University of Liverpool research ethics committee (Appendix A2).  
 
2.3. Recruitment 
2.3.1. Inclusion/exclusion criteria 
All JSLE patients fulfilled four of more of the revised ACR classification criteria underpinning 
their diagnosis of SLE before the age of seventeen (Appendix B1) (14). Paediatric non-
inflammatory controls were defined as children investigated for non-inflammatory 
musculoskeletal symptoms or attending for elective surgery where no inter-current infection 
was present. All paediatric patients were recruited from outpatient clinics and inpatient 
wards at Alder Hey Children’s NHS Foundation Trust. Clinical data and laboratory results were 
blinded to all investigators until final experiments were completed. Healthy adult volunteers 
aged over 18 from The University of Liverpool were recruited on the basis of deeming 
themselves healthy. 
2.3.2. Consent 
All patients and adult volunteers were approached by either a research nurse/consultant 
(patients) or Good Clinical Practice (CGP) trained professional (adult volunteers) and 
presented with an information sheet about the study at time of approach (Appendix B3). 
Patients and families and adult donors were given time to process the information and were 
able to participate/not participate/withdraw without explanation at any time. Written 
patient assent and written parental consent was obtained for those under 16 years of age, 
48 
 
and written consent was obtained for those over 16 where appropriate (Appendix B3). All 
documentation was retained in a secure manner within the clinical sites (e.g. Alder Hey 
Children’s NHS Foundation Trust) and anonymised data were held at the University of 
Liverpool, in accordance with regulatory permissions.  
 
2.4. Clinical data and disease activity 
Clinical data, using comprehensive paper-based data collection forms (Appendix B1), were 
recorded by the clinician and/or research nurse during routine clinical appointments. These 
were anonymised, given the patient’s unique study number, and then transferred to be 
uploaded and stored on the UK JSLE Cohort Study database. Data forms are standardised for 
use across all the 21 centres, so a standardised data set was collected (Appendix B1). Baseline 
forms were submitted at first diagnosis, along with clinical data forms for each hospital visit 
and an annual review was submitted each year (Appendix B1).  
The forms aimed to obtain comprehensive review of many important clinical and 
demographic aspects. These include; age, ethnicity and family history of SLE and/or 
autoimmune disorders (Appendix B2). Clinically, the ACR classification form was used to 
assess and confirm the diagnosis of JSLE (meeting four or more ACR criteria) (Appendix B1) 
(13, 14). The Systemic Lupus International Collaborating Clinics (SLICC) damage index was 
used to determine the extent of disease damage (Appendix B1) (17). An annual review was 
conducted, which consisted assessment of a range of clinical biomarkers and blood tests, a 
review of disease activity and damage, and specific review of organ domains (Appendix B1). 
The paediatric adaptation of the British Isles Lupus Assessment Group (pBILAG) disease 
activity score was conducted at each appointment, which scores the severity of disease 
activity within each organ domain (Appendix B1) (9, 15, 204). The pBILAG has been adapted 
from the adult version of the scoring assessment to improve validity of the assessment in the 
paediatric population (9, 15, 204). The pBILAG is collected and submitted to the cohort 
database anonymously which is then used to calculate the pBILAG scores (9). At every 
appointment, the pBILAG is analysed by organ domain, which encompasses a series of 
questions to determine whether organ disease had improved or worsened. A rating is 
assigned to each organ domain based on how the questions are answered. A pBILAG score 
of A or B is deemed to reflect active disease in any given organ domain (such as renal or 
haematological; see Figure 1.1/Section 1.1.3), a score of C is deemed improving disease 
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activity in any given organ domain, a score of D is deemed inactive disease in any given organ 
domain; a score of E is deemed no previous disease involvement in that organ domain and is 
also deemed inactive disease. Overall inactive disease is defined as no A or B in any organ 
domain and overall active disease is defined as an A or B in any organ domain. However, 
within Chapter 4 (Section 4.4.2.3), JSLE patient sera were selected based on overall inactive 
disease and active disease in specific organ domains; renal and haematological domains. This 
was to fully investigate how sera from patients with active JSLE disease in different domains 
may influence neutrophil apoptosis. 
 
2. Part B. Laboratory methods 
Appendix C provides specific details of all laboratory reagents (Appendix C1) and equipment 
(Appendix C2) used in these assays.  
 
2.5. Neutrophil isolation 
Neutrophils were obtained by separating cells from whole blood using Polymorph Prep (Alere 
Ltd, UK) or HetaSep (Stemcell, UK) and Histopaque-1077 (Sigma, UK). These solutions 
separate blood cells using density gradients, either in a one-step approach (Polymorph Prep) 
or a two-step approach (HetaSep and Histopaque-1077). Neutrophils were drawn off, 
washed and any remaining red blood cells (RBCs) were lysed using ammonium chloride 
solution. Both protocols are described in more detail below (Sections 2.5.1 and 2.5.2). 
2.5.1. Polymorph Prep 
Initial neutrophil isolations were conducted using Polymorph Prep solution. Blood was 
layered onto an equal volume of Polymorph Prep and centrifuged at 1800 RPM for 30mins, 
with the brake off. This spin allows RBCs to separate from the white blood cells through 
sedimentation. The neutrophils also separate from the PBMCs via the gradient of the 
Polymorph Prep (Figure 2.1) (http://www.axis-shield-density-gradient-
media.com/Polymorphprep%20package%20insert%202017.pdf). 
The PBMCs and neutrophils were removed using a Pasteur pipette, taking care that other 
layers were not disrupted when removing them. The neutrophils were washed in Roswell 
Park Memorial Institute (RPMI) 1640 media with L-glutamine (Lonza, Switzerland/SLS, UK; 
subsequently known as ‘media’) and centrifuged at 2000 RPM for 10mins to pellet the cells. 
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The supernatant was discarded, and the cells were suspended in the residue. Neutrophils 
were re-suspended in 1ml of media and 9ml of ammonium chloride lysis buffer (155mM 
ammonium chloride [Sigma-Aldrich, UK], 10mM potassium bicarbonate [Sigma-Aldrich, UK], 
127μM EDTA [Fisher, UK]) added to lyse any remaining RBCs, and the tube inverted several 
times, and incubated for 3mins at room temperature. The neutrophils were centrifuged at 
2000 RPM for 5mins to pellet, and the supernatant decanted. The neutrophils were 
suspended in 1ml of media and purity was checked using flow cytometry or a Romanowsky 
stain (Section 2.5.1.1). An acceptable purity was defined as ≥95%. 10µl of the neutrophil 
suspension was removed and placed on haemocytometer to count.  
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Figure 2.1. Separation of blood cells using Polymorph Prep and centrifugation. Blood was 
layered onto the Polymorph Prep, and centrifugation allowed separation of blood cells 
dependent on weight and the density gradient of the Polymorph Prep. Thus, the denser RBCs 
sink to the bottom and the intermediate neutrophils separate from the less dense PBMCs. 
This leaves the plasma layer at the top containing other blood substances. 
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2.5.1.1. Romanowsky stain 
100µl (~1x105 cells) of neutrophils were centrifuged onto a microscope slide. The slide was 
centrifuged at 500xg for 5mins and left to air dry. The slide was placed in, in sequence, 
solution A (fixing solution, HD supplies, UK) for 30secs, solution B (acid dye, HD supplies, UK) 
for 20secs and solution C (base dye, HD supplies, UK) for 20secs, tapping on blue laboratory 
paper between dyes. Excess liquid was rinsed off and tapped dry on paper, taking care not 
to dislodge neutrophils. The slide was left to dry and neutrophils were analysed under the 
light microscope (Figure 2.2). 
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Figure 2.2. Romanowsky stain of healthy adult control population of neutrophils. 
Neutrophils were isolated using HetaSep and Histopaque-1077 method (below) and stained 
with Romanowsky stain. Picture taken at x20 objective on Evos inverted light microscope 
(ThermoFisherScientific, UK). Dark purple stain highlights the nucleus of the cell: cells with 
multilobular nuclei (main proportion of cell in image) are neutrophils (green arrow) and cells 
with lobular nuclei are PBMCs (red arrow). Light purple indicates the cytoplasm.  
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2.5.1.2. Limitations of the Polymorph Prep isolation method  
A limitation of the Polymorph Prep isolation method was the final purity of the neutrophils. 
Although >95% purity was achievable, separating the RBCs and the PBMCs from the 
neutrophils in one stage using this isolation proved to cause inconsistency in the purity of the 
population of neutrophils. This was a particular problem with patient samples, in which 
particular the RBCs did not separate from the neutrophils properly and thus removing 
neutrophils without disrupting the RBCs was problematic. With adult healthy controls, the 
separation space between PBMCs and neutrophils was small, and PBMC layer was often 
indistinct and cause a cloudy like consistency, and thus decreasing the separation space 
further. Thus, PBMC contamination within the neutrophils was frequently higher than 
acceptable, with neutrophil populations with ≥5% PMBCs deemed a significant PBMC 
contamination and would need to be excluded. For example, PBMC significant contamination 
of neutrophil samples could affect protein analysis, protein constitution and stimulation 
experiments thereby limiting the reliability of data from such samples. 
2.5.2. HetaSep and Histopaque-1077 
The HetaSep and Histopaque-1077 method is a well-recognised and improved alternative 
way of isolating neutrophils. Specifically, the majority of the RBCs were removed in the first 
step, allowing the second step to separate mainly neutrophils from PBMCs. This helped 
particularly with patient samples in which the RBC layer did not always separate well. This 
method was therefore used throughout this thesis.  
 Whole blood was mixed with HetaSep at a ratio of 5:1 of blood:HetaSep. The suspension was 
left for approximately 30mins at room temperature to separate until the RBC layer and the 
leukocyte-rich plasma layer were equal (Figure 2.3). The leukocyte-rich plasma was drawn 
off and washed with 4x volume of phosphate buffered saline (PBS) (Sigma—Aldrich, UK; 
Fisher, UK). Leukocytes were centrifuged at 200xg for 10mins and suspended in 1ml of media. 
Suspension was layered onto 2ml of Histopaque-1077, taking care not to mix suspension and 
Histopaque-1077, and centrifuged at 2000 RPM for 20mins to separate the leukocytes into 
neutrophils and PBMCs (Figure 2.3). PBMCs and supernatant were removed using a Pasteur 
pipette, and neutrophils were suspended in 1ml of media. 9ml of ammonium chloride was 
added to neutrophil suspension and incubated for 3mins at room temperature to remove 
any remaining RBCs, inverting for the first 90 seconds. The neutrophils were centrifuged at 
2000 RPM for 5mins, the supernatant decanted completely and the neutrophils were 
suspended in 1ml media with or without 10% foetal bovine serum (FBS) (Life Technologies, 
UK). An aliquot of neutrophils was diluted 1:10 to be counted using a haemocytometer, and 
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purity was checked either by flow cytometry (neutrophils were diluted 1:20 to a total volume 
of 200μl) or Turk’s stain (neutrophils were diluted 1:10; Section 2.5.2.1). Neutrophils were 
initially suspended at 1x106 in media with 10% FBS unless stated otherwise. 
2.5.2.1. Turk’s stain 
Turk’s stain was used to check purity of samples. 0.01% crystal violet (Sigma-Aldrich, UK) was 
mixed with 3% acetic acid (P&R Lab Supplies, UK) and 97% double distilled water, totalling 
100 ml. 10µl of the final 1ml neutrophil suspension was mixed with 90µl of Turk’s stain and 
10µl was analysed on haemocytometer to check purity. This purity was defined by analysing 
the cells seen by the shape of the stained nuclei, neutrophils have granular nuclei and PBMCs 
have rounded nuclei, and determining the percentage of neutrophils seen. A population of 
~95% neutrophils or higher was deemed a sufficient purity. 
2.5.2.2. HetaSep and Histopaque-1077 optimisations 
When possible, HetaSep was warmed to room temperature to optimise RBC sediment rate. 
Originally, media w/10% FBS was used in all stages. However, the manufacturers Sigma-
Aldrich (http://www.sigmaaldrich.com/technical-documents/articles/biofiles/histopaque-
troubleshooting-guide.html) suggest FBS can affect the Histopaque-1077 gradient and 
therefore subsequent final isolated neutrophil count. Thus, media w/10% FBS was used at 
the last stage only, once neutrophils were isolated from the PBMCs, and ready to be counted 
and checked for purity. All reagents worked most effectively when at room temperature. 
Thus, Histopaque-1077 and media were aliquoted, and PBS removed from the fridge 
immediately after the blood sample was obtained. Once the ammonium chloride lysis buffer 
was added to the neutrophils, the tube was inverted for the first 90secs to prevent 
neutrophils from settling and increasing lysis of RBCs.  
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Figure 2.3. Separation of blood cells using HetaSep and Histopaque-1077. The majority of 
RBCs were sedimented by weight through a density gradient using HetaSep, leaving a 
leukocyte-rich plasma. The leukocytes were separated using Histopaque-1077, again using a 
density gradient to separate by weight.  
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2.6. Flow cytometry principle 
Flow cytometry is a technique that is used to sort cells dependent on the properties detected 
on the cell membrane. Antibodies containing fluorophores bind to specific receptors or 
markers on the membrane that can determine whether the cell is a certain type (e.g. CD16 
antibody for neutrophils) or undergoing a certain process (e.g. annexin V fluorescein 
isothiocyanate (FITC) for apoptosis). The cells are suspended in a liquid stream and are 
individually processed through the flow cytometer. The fluorophores are excited by a laser 
and are detected by different fluorescent channels (e.g. fluorescence channel 1 (FL1), etc.) 
depending on the wavelength: for example, FITC is detected at the 495nm wavelength in the 
FL1 channel. The size and shape of the cells can also be measured by analysing the forward 
scatter (FS) (size of cells) and side scatter (SS) (granularity of cells) of the lasers, which allow 
for selecting the right cell type to be analysed and checking the purity of the cell suspension. 
The percentage of cells that express the fluorophores, and hence express the marker, can be 
analysed using dot blots, and the amount of the marker per cell can be presented using 
histograms (Figure 2.4).  
A key advantage of flow cytometry as a technique is that it is a quantitative method. 
However, flow cytometry equipment is expensive to buy and maintain, and requires 
extensive training. Flow cytometers are also prone to blockages and breakdowns that require 
time and specialist engineers to resolve. Incompetency, through lack of training, therefore, 
can result in not only breakage of the equipment but result in unreliable or inconsistent data. 
Through training, prior knowledge of how a flow cytometer works, how to set up an assay 
that produces reliable, quality data, and how to use flow cytometry analytical packages is 
required to save time, resources and minimise equipment malfunction. Other pitfalls of this 
technology include the requirement of cells being in suspension and lack of ability to conduct 
a comprehensive analysis of the distribution of intracellular proteins. This requires 
permeabilization, which would require confocal microscopy to analyse.  
2.6.1. IFN dose response and subsequent time course 
An IFN (PeproTech, UK) dose response (1, 5 and 10ng/ml) was conducted for each IFN 
subtype, whereby apoptosis was measured at 6hrs and 20hrs. No significant difference was 
seen in the rate apoptosis of at both time intervals between concentrations of IFNα, nor IFNγ; 
however, a concentration of 10ng/ml of IFNβ resulted in greater apoptosis than at the lower 
concentrations of IFNβ (6hrs: unstimulated = 14.5%, 1ng/ml = 15.5%, 5ng/ml = 13.0%, 
10ng/ml = 10.0%, n=1; 20hrs: unstimulated = 74.9% 1ng/ml= 82.9%, 5ng/ml = 82.4%, 10ng/ml 
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= 76.8%, n=1) (Figure 2.5). Therefore, subsequently neutrophils were simulated with 10ng/ml 
for each of the IFN subtypes and 5ng/ml GMCSF (R&D Systems, UK) for 6hrs and 20hrs in 96 
well plates at 37°C, 5% CO2, 1x105 neutrophils per condition. Apoptosis was analysed as 
below (Section 2.6.2) using both Beckman Coulter F500 and Guava EasyCyte flow cytometers 
and results analysed on FlowJo (v.10, USA). 
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A  
B C  
 
Figure 2.4. Depiction of the flow cytometry procedure and an example dot plot and 
histogram following flow cytometry analysis. Neutrophils were isolated from healthy adult 
donors and were stained with antibodies containing fluorophores. Neutrophils were 
processed through the flow cytometer and excited by a laser (shown in A). The fluorescence 
was detected by channels depending on wavelength (A), and dot blots (B, analysing the FS 
on X axis and SS on the Y axis) and histograms were produced (C). Within B, neutrophils were 
primed with TNFα for 30mins, and stained with CD11b. Unstained neutrophils (red peak), 
isotype control (blue peak) were used to set the protocol and the peak moves to the right 
when the neutrophils were positively stained (for example TNFα-primed neutrophils = purple 
peak).  
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Figure 2.5. Apoptosis of healthy adult neutrophils at 6hrs and 20hrs in response to different 
doses of IFNs. Neutrophils were isolated from healthy adult donors and were stimulated with 
1, 5 and 10ng/ml IFNα, IFNγ or IFNβ, and 5ng/ml GMCSF for 6 and 20hrs. Apoptosis was 
measured at 6hrs (Figure A) and 20hrs (Figure B) respectively. Other than IFNβ, where 
10ng/ml had a different effect (where it particularly delayed apoptosis at 6hrs) to other 
concentrations, there was no significant difference demonstrated between doses of IFNα or 
IFNγ. Therefore, 10ng/ml IFNs were subsequently used. 
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2.6.2. Annexin V FITC and PI staining  
During early apoptosis, phosphatidylserines (PS) are expressed on the cell surface. Annexin 
V is able to bind to PS, and the subsequent fluorescence indicates that cells are undergoing 
apoptosis. During late stage apoptosis, annexin V is able to bind to cytosolic PS and propidium 
iodide (PI) is able to enter the cell and bind to DNA. PI is typically used to detect necrotic cells 
and in combination, annexin and PI are able to differentiate necrotic, apoptotic and viable 
cells within a heterogeneous population.  
2.6.2.1. Original apoptosis staining assay 
Neutrophils were lifted from the plate and placed in 5.4ml flow cytometry tubes for staining. 
The neutrophils were centrifuged at 1500 RPM for 5mins. The supernatant was decanted, 
being careful to not disrupt the pellet, and 1ml of Hanks' balanced salt solution (HBSS) 
(Sigma-Aldrich, UK) was added. The plate was centrifuged at 1500 RPM for 5mins. The 
supernatant was decanted, being careful not to disrupt the pellet, and the neutrophils were 
suspended in 100µl of HBSS. Annexin V FITC (Sigma-Aldrich, UK) was added a 1:100 and the 
tubes were incubated at 4°C for 15mins. 900μl of HBSS and 1:1000 PI (Sigma-Aldrich, UK) 
were added and the tubes were incubated at room temperature in the dark for 5mins. The 
tubes were centrifuged at 1500 RPM for 5mins, the supernatant was decanted and 600µl of 
HBSS was added and mixing the suspension well. Each sample was run using a pre-set annexin 
V FITC/PI program on the Beckman Coulter F500 (Beckman Coulter, UK), whereby events 
were allowed to reach up to 10,000 events. Analysis was conducted using the Beckman 
Coulter flow cytometry analysis software, Kaluza (v.1.3, USA). 
2.6.2.2. Optimised apoptosis staining assay 
Neutrophils were centrifuged at 1800 RPM for 5mins. The supernatant was decanted, being 
careful to not disrupt the pellet, and 100µl of HBSS was added. If not already in a 96 well 
plate, the neutrophils were transferred to one. The plate was centrifuged at 1500 RPM for 
5mins. The supernatant was pipetted out, being careful not to disrupt the pellet, and the 
neutrophils were suspended in 100µl of HBSS. Annexin V FITC was added a 1:100 and the 
plate was incubated at 4°C for 15mins. PI was added at 1:1000 and the plate was incubated 
at room temperature in the dark for 2mins. 100µl of HBSS was added, and suspension was 
mixed well. Each sample was run using a pre-set annexin V FITC/PI program on the Beckman 
Coulter F500, or Guava EasyCyte (Merck Millipore), whereby events were allowed to reach 
up to 10,000 events. Analysis was conducted using flow cytometry analysis software, Kaluza 
or FlowJo (Figure 2.6).  
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Figure 2.6. Annexin V FITC and PI staining of unstimulated neutrophils after 6hrs. 
Neutrophils were isolated from healthy volunteers and incubated for 6hrs. Neutrophils were 
stained with annexin V FITC and PI and the percentage of staining was analysed using flow 
cytometry. Cells in quadrant Q8 (bottom left) did not stain for annexin V FITC or PI, and thus 
were considered viable. Cells in quadrant Q7 (bottom right were stained for annexin V FITC 
only and were considered apoptotic. Cells in quadrant Q5 (top left) were stained for PI only 
and were considered necrotic. Cells in quadrant Q6 (top right) were stained for both annexin 
V FITC and PI and were considered secondary necrotic.  
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2.6.3. Activation assays 
Flow cytometry assays were developed to analyse activation markers CD11b and CD62L on 
neutrophils. When primed for activation, CD11b expression has been shown to increase, and 
CD62L to decrease (95). TNFα can prime neutrophils to become activated, and this priming 
can be detected by analysing the expression markers CD11b and CD62L in naïve and TNFα-
primed neutrophils (169). TNFα priming of neutrophils was used to model activated 
neutrophils that are found in inflammatory diseases, and which are found in SLE patients 
(83). Specific methods can be found in Chapters 4 and 5. 
2.6.4. IFN receptor analysis 
Flow cytometry assays were developed to analyse the individual IFN receptor chains (IFNAR1, 
IFNAR2, IFNGR1 and IFNGR2). IFNs signal through receptors on membrane surfaces to 
activate the JAK/STAT pathway. Specifically, it has been shown that IFNGR chain expression 
is differentiated depending on immune cell line and environment, and this contributes to 
whether IFNγ induces cell proliferation or apoptosis. (161). Thus, IFN receptor analysis was 
an important signalling element to investigate in relation to neutrophil apoptosis in JSLE. 
Specific methods can be found in Chapters 4 and 5. 
2.6.5. Phagocytosis assay 
Flow cytometry was used to analyse the phagocytic ability of neutrophils. Phagocytosis is a 
major function of neutrophils, and it thought to be dysregulated in JSLE (112, 115). PHrodo 
Red E. coli bioparticles, which fluoresce when phagocytosed by neutrophils, were incubated 
with neutrophils pre-treated with the different IFN subtypes, and phagocytosis was 
measured by fluorescence by flow cytometry. Specific methods can be found in Chapter 3.  
 
2.7. Protein Analysis 
Neutrophils were stimulated, and various intracellular proteins were extracted and analysed 
to understand the IFN signalling pathway further, and to supplement flow cytometry data 
already analysed. Protein concentration was analysed using a Pierce assay where 
appropriate, normalised and protein expression was analysed using Western blotting. 
2.7.1. Protein extraction  
Neutrophils were lifted from suspension and centrifuged at 1800 RPM for 5mins. The 
supernatant was poured off and the pellet washed in 100µl of media. The neutrophils were 
centrifuged at 1800 RPM, the supernatant was poured off and again washed in 100µl of 
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media. The neutrophils were then centrifuged at 8000 RPM for 5mins, or 1000g for 3-5mins. 
25µl lysis buffer (89% sodium dodecyl sulphate (SDS) buffer [10% glycerol (BDH, UK), 125mM 
Tris buffer (pH 6.8, Fisher, UK), 3% SDS (BioRAD, UK) 0.2% bromophenol blue (Sigma-Aldrich, 
UK)], 10% dithiothreitol (DTT) (Sigma-Aldrich), 1% 100X protease and phosphoprotease 
inhibitor cocktail (ThermoFisherScientific, UK)) was added per 5x105 cells, except for cells for 
MCL1, where 25µl per 2x106 cells was added, and the samples heated for 3mins at 100°C 
vortexed every 60 secs to homogenise the samples. 
2.7.2. Pierce assay 
 The Pierce assay measures protein concentration by light absorptions in reference to a 
standard curve of known protein concentrations. 
A stock of fresh lysis buffer was made to use as the diluent for the assay (see above). 
Standards of between 62.5µg/ml and 2000µg/ml bovine serum albumin (BSA) (Sigma-
Aldrich, UK) were made using a serial dilution, and placed at 4°C until needed. Protein 
samples were heated at 100°C for 3mins, and vortexed every 60secs to homogenise the 
samples. Aliquots of samples were diluted at 1:2 or 1:3 and stored at 4°C until needed. 20ml 
of Pierce 660nm protein assay reagent (ThermoFisherScientific, UK) was mixed with 1g of 
ionic detergent compatibility reagent (ThermoFisherScientific, UK) and was shaken until the 
powder was dissolved. The tubes were well covered with parafilm (StarLab, UK) and foil 
(Sainsbury’s, UK) and kept stored at 4°C until needed.  
10µl of standards and samples were aliquoted in duplicate in a 96 well plate and 150µl of 
Pierce 660nm protein assay reagent was added to each well. The plate was shaken for 60secs 
at room temperature and then incubated at room temperature for 5mins. The plate was read 
at 660nm on a Varioskan Flash plate reader (ThermoFisherScientific, UK). A standard curve 
was produced using absorptions of standards at known concentrations, and the equation of 
the curve was calculated (e.g. for shown example in Figure 2.7, absorbance = 0.0002(protein 
concentration) + 0.138, R² = 0.9943) (Figure 2.7). 
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Figure 2.7. Pierce 660nm Assay standard curve. BSA was diluted at 2000µg/ml, and serial 
dilutions achieved other standards using protein lysis buffer (1500µg/ml, 1000µg/ml, 
750µg/ml, 500µg/ml, 250µg/ml, 125µg/ml, 62.5µg/ml, and protein lysis buffer as 
0µg/ml/blank). Standards and samples were loaded in duplicate into a 96 well plate, and the 
Pierce 660nm assay reagent was loaded. The plate was read, and the standard curve was 
plotted using average absorbance against the known standards.  
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2.7.3. Western Blot 
Western blot is the technique by which proteins are detected and can be semi-quantified by 
the size of the protein and specific probing of antibodies. Proteins are reduced and denatured 
to their primary structure and SDS applies a negative charge to these proteins. Once placed 
into a polyacrylamide gel, proteins can be separated by molecular weight. An electrical field 
is induced in the gel, and proteins migrate towards a positive charge, with smaller proteins 
migrating further than larger proteins. Proteins are transferred to a membrane, and this 
membrane is incubated with antibodies grown against specific proteins (primary antibodies). 
Antibodies with broader specificities, bound with a fluorescent molecule (such as horse 
radish peroxidase [HRP]; secondary antibodies) are incubated with the membrane to bind to 
the primary antibodies. Chemiluminescent reagents are placed onto the membrane which 
allow fluorescent molecules to omit light, which allows proteins of interest to be detected 
and analysed. The Western blot process is depicted in Figure 2.8. Western blotting is cheaper 
than other techniques, and it is possible to analyse multiple proteins on one membrane. 
However, it is laborious, time consuming and semi-quantitative.  
Assay optimisation is often required; optimum antibody dilutions and incubation protocols 
can vary depending on protein lysate and the protein of interest. Low expressed proteins 
may require higher concentrations of antibodies, and longer incubation with the antibodies. 
This increase in incubation time can cause increased background noise, which may then 
require different incubation conditions. For long incubations with antibodies, incubations at 
4°C and appropriate washes in Tris base saline + (0.1%) tween 20 (TBST) after each antibody 
incubation can improve this. Time and voltage use for the sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) may need to differ depending on the size of 
protein of interest. Longer electrophoresis time, increased voltage or use of a gel with a lower 
polyacrylamide percentage can separate larger proteins better than standard protocols. 
However, this can result in loss of the proteins with the lowest molecular weights, so careful 
consideration of what proteins are to be analysed on the same gel is required.  
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Figure 2.8. Detection of proteins of interest using Western blotting. Proteins were extracted 
and lysed to become their primary structures with a negative charge. Proteins were 
separated by electrophoresis and transferred to a membrane. The membrane was incubated 
with primary and secondary antibodies, and chemiluminescent reagents allows the 
secondary antibody fluorescent molecule to omit light. This allowed for protein detection, 
visualisation and analysis using specialist equipment and software. 
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2.7.3.1. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
15μl of sample was loaded into a 12% min-PROTEAN TGX precast protein gel (BioRAD, UK) 
placed in Western blot tank (BioRAD) surrounded in running buffer (3.5mM SDS, 192mM 
glycine, 25mM Tris base). 4μl of Precision Plus Protein™ WesternC™ standards ladder 
(BioRAD, UK) was loaded and an electrical current was applied to separate the proteins 
according to molecular weight. Standardly, the SDS-PAGE was run at 160 volts for 45mins, 
unless otherwise stated.  
2.7.3.2. Transfer  
The gel was removed from the plastic cassette and cut according to size of membrane and 
proteins being probed (e.g. if both pSTAT3 [79/86 kDa] and β actin [42 kDa] were being 
probed, the gel was cut just above 50kDa). The gel was placed on a PVDF membrane within 
Trans-Blot Turbo Mini PVDF transfer packs (BioRAD, UK), and the proteins transferred to be 
analysed by antibody blotting. The BioRAD TransBlot achieved this by creating a ‘sandwich’ 
with filter paper, the gel and membrane, the filter paper and membrane already having been 
pre-soaked in transfer buffer. The sandwich was placed in the TransBlot apparatus (BioRAD), 
and a mixed molecular weight pre-programmed protocol (1.3 ampere, 25 volts, 7mins) was 
applied to transfer the proteins from the gel to the membrane. 
2.7.3.3. Blotting 
The membranes were blocked in 5% milk (Marvel semi-skimmed milk, Sainsbury’s, UK) in 
TBST (1mM Tris base, 15mM sodium chloride, 0.1% tween 20) for 1hr at room temperature, 
with gentle agitation. Any excess block was washed off using TBST, shaking 2x for 30secs.  
Primary antibodies were diluted in 5% (w/v) milk TBST as per indicated by company data 
sheet (Table 2.1), and incubated with the membrane, either using plastic bags or plastic 
boats. The membranes were agitated at room temperature for 1hr or 4°C overnight to allow 
antibodies to bind. Primary antibodies were washed in TBST, initially 2x 30secs                                                                                                                                                                                                                                                            
to wash off excess, 2x 5mins to wash off intermediate unspecific binding and background 
noise, and 1x 15mins to wash off tightly bound unspecific binding and background noise.  
Secondary antibodies with chemiluminescent probe HRP were diluted in 5% milk TBST as per 
indicated by company data sheet (Table 2.1) and incubated with the membrane. The 
membranes were agitated at room temperature for 1hr to allow the binding to the secondary 
antibody. The antibody was washed off as with the primary antibody.  
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2.7.3.4. Imaging and analysis 
WesternSure® PREMIUM chemiluminescent substrate (LI-COR, UK) was applied to the 
membrane and left to incubate at room temperature for 5mins. Multiple images were taken 
by the scanner and the densitometry was calculated by drawing round the bands using 
software Image Studio Digits V.3.1 (Figure 2.9). Ratios were then calculated by dividing the 
protein of interest densitometry by a control protein densitometry.  
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Figure 2.9. Western blot analysis of procaspase 3 and caspase 3 after 20hrs IFN incubation. 
An example Western blot showing neutrophils stimulated with 5ng/ml GMCSF, 10ng/ml 
IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 20hrs. The protein was extracted and lysed into its 
primary structure with a negative charge. Proteins were loaded into a gel, according to 
condition (naïve, GMCSF stimulated, and stimulated with each IFN subtype) and separated 
based on molecular weight via electrical current towards a positive charge. The proteins were 
transferred to a membrane, cut around 50kDA and unwanted proteins blocked with 5% milk, 
and probed with caspase 3 antibody and its associated secondary antibody (Table 2.1). The 
expression of proteins was detected through the fluorescence of the secondary antibody 
through reaction with a chemiluminescent reagent. The caspase 3 antibody was stripped, re-
blocked, and the membrane re-probed with β actin primary antibody, probed with its 
associated secondary antibody, and protein was detected through the fluorescence of the 
secondary antibody through reaction with a chemiluminescent reagent (not shown). 
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Table 2.1. Electrophoresis time course and antibody dilutions for western blots.   
Protein of 
interest 
Electrophoresis 
Primary 
antibody 
type and 
dilution 
Manufacturer 
Secondary 
antibody 
type and 
dilution 
Manufacturer 
pSTAT1 
160 volts; 
60mins 
rabbit; 
1:1000 
Cell Signalling 
(USA) New 
England 
Biolabs (UK 
goat; 
1:1000 
R&D Systems, 
UK 
pSTAT3 
160 volts; 
60mins 
mouse; 
1:1000 
Cell Signalling 
(USA) New 
England 
Biolabs (UK 
goat; 
1:1000 
R&D Systems, 
UK 
STAT3 
160 volts; 
60mins 
rabbit; 
1:1000 
Cell Signalling 
(USA) New 
England 
Biolabs (UK 
goat; 
1:1000 
R&D Systems, 
UK 
MCL1 
160 volts; 
45mins 
rabbit; 
1:1000 
Cell Signalling 
(USA) New 
England 
Biolabs (UK 
goat; 
1:1000 
R&D Systems, 
UK 
caspase 3 
160 volts; 
45mins 
rabbit; 
1:1000 
Cell Signalling 
(USA) New 
England 
Biolabs (UK 
goat; 
1:1000 
R&D Systems, 
UK 
β actin 
Dependent on 
protein of 
interest above 
mouse; 
1:5000 
Abcam, UK 
goat; 
1:1000 
R&D Systems, 
UK 
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2.8. Chemotaxis assay 
Chemotaxis assays, or Boyden Chamber Assays, are used to measure the random and 
directed migration of neutrophils (Figure 2.10). Neutrophils were plated within inserts that 
contain pores within the membrane. These pores expose neutrophils to media and 
stimulants (including chemoattractant fMLP and chemokine IL-8) and allow for migration of 
the neutrophils from the insert into the well underneath. After an incubation period, any 
migrated neutrophils are suspended within the media in the wells, and an aliquot from each 
well is removed to be counted using a haemocytometer.  
These assays were quick, simple and relatively cheap, and allowed for data to be quickly 
acquired. However, the plates needed to be pre-coated with polyHEMA at least 24 hours 
before. Counting of neutrophils was conducted manually using a haemocytometer; this 
method is not as accurate as other methods such as automated cell counting and can 
introduce operator bias. Effort was made to consistently add the same number of neutrophils 
to the inserts for each experiment (1x106 neutrophils/200µl); however, after pre-treatment 
with IFNs, there was some neutrophil loss from centrifugation. Therefore, for these 
experiments, neutrophils in each condition were normalised to the lowest concentration of 
neutrophils for each donor. This was to try to minimise any variation in the trend of migration 
between priming conditions due to differences in number of neutrophils seeded.  
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.  
Figure 2.10. Neutrophil migration through pores into lower well containing chemokines. 
Neutrophils were either primed or left unstimulated and suspended up to 1x106/200µl media 
w/10% FBS to be placed in a hanging insert. Neutrophils underwent migration, either 
directed or random into the well below and counted after 90mins. 
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2.9. NETosis assay 
Confocal microscopy and DNA quantification was used to analyse NETosis in response to IFN 
priming or IFN stimulation. Isolated Neutrophils (Section 2.5.2) settle onto coverslips, 
stimulated, and mounted onto microscope slides. The mounting medium contains 4', 6-
diamidino-2-phenylindole (DAPI), which stains DNA, which can be visualised using confocal 
microscopy; NETs are detected through the exposure of DNA fibres. Additionally, DNA is 
cleaved into the supernatant using a nuclease, and the concentration can be measured via 
fluorescence using a PicoGreen reagent.  
2.9.1. Confocal microscopy principle 
Confocal microscopy uses lasers to stimulate florescent emission from fluorophore bound 
antibodies, which can be detected by a computer. Cells are fixed onto microscope cover slips 
using formaldehyde, permeabilised and blocked in Tris base saline (TBS) containing 2% BSA. 
The cells are subsequently stained for specific proteins using antibodies attached to 
fluorophores, and also stained with DAPI, a commonly used DNA stain. The coverslips are 
mounted (in this case using a mounting medium containing DAPI) and left to set. As with flow 
cytometry, the fluorophores on the antibodies are excited by a laser, and are detected by 
computer depending on the wavelength, and all proteins can be visualised individually, and 
can be merged to create a comprehensive image (Figure 2.11).  
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Figure 2.11. Diagram depicting confocal microscopy function. Samples were fixed, stained 
with DAPI, and mounted onto microscope slides. Fluorophores were stimulated with a laser 
and emissions were detected on a computer. Multiple emissions can be analysed and merged 
to create a comprehensive image.  
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2.9.2. DNA quantification analysis 
DNA is a major component of NETs (37). Therefore, to complement the confocal images, and 
give a consistently quantifiable analysis, DNA concentration can be measured in the 
supernatants from neutrophils analysed for NETs. Specific methods are described in chapter 
3. 
 
2.10. Statistical analysis 
Statistical analyses were conducted using GraphPad Prism 6. Non-parametric tests were 
conducted for all analyses due to the low sample sizes (majority n=5, one control analysis 
n=6), and thus does not make assumption about the samples being normally distributed. 
Paired analyses were used for the majority of statistical tests, as multiple conditions were 
conducted on dependent/related samples. One-tailed Wilcoxon matched-pairs signed rank 
test was used for activation assays (two related conditions for each marker), where it is 
established in that CD11b increases upon activation, and CD62L decreases upon TNFα 
priming, and thus the direction of observations were already known (169). The Friedman test 
was conducted for experiments on related sample with more than two conditions, with a 
post hoc Dunn’s multiple comparison test to specify which condition is significantly different 
and to correct for multiple comparisons. A Kruskal-Wallis test was conducted to compare 
between paediatric control and JSLE neutrophil conditions when analyzing the IFN receptor, 
activation marker and apoptosis data, which compared multiple conditions between two 
independent sample sets (e.g. unstimulated paediatric control neutrophils vs unstimulated 
JSLE neutrophils) with a post hoc Dunn’s multiple comparison test to specify which condition 
is significantly different and correct for multiple comparisons. 
 
2.11. Summary 
Here, it was shown how patients with JSLE were identified, diagnosed, and phenotypically 
determined samples acquired through processes governed by appropriate regulatory 
approvals. Anonymised patient data, including demographics and clinical data were also 
collected and stored, in accordance with regulatory approvals, which were analysed to 
accompany experimental data where appropriate. Major experimental processes and 
background theory is discussed, allowing for specific methods and any optimisations to be 
outlined in results chapters. Appropriate statistical analysis was selected and described, 
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based on experimental data output, following consultation of a statistician at the 
Department of Biostatistics, University of Liverpool.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
Chapter 3: The role of IFNs in neutrophil functions 
in JSLE 
3.1. Introduction 
 Neutrophils are among the first immune cells to defend against infection and therefore 
many of their functions are essential in killing invading pathogens, dysregulation in these 
functions can lead to inflammatory disease. Neutrophils and IFNs have been indicated to be 
important in JSLE pathogenesis (Section 1.5). The concentration of IFNs has been shown to 
be increased in the serum of patients with SLE and JSLE, and there is a pronounced 
granulocyte and IFN signature found in JSLE patients (Section 1.5.4.1). It thus seems possible 
that any neutrophil functions that may be dysregulated in JSLE may be influenced by IFNs 
(41, 68, 171, 172). Here, it was investigated whether IFNs influence neutrophil phagocytosis, 
chemotaxis and NETosis, which have been shown to be dysregulated in SLE and JSLE (112, 
116-118) (Sections 1.3, 1.4.3, 1.5.3).  
Chemotaxis is the process by which neutrophils migrate towards certain stimuli, such as 
chemokines and bacterial products. It has been shown that these stimuli have an attracting 
hierarchy, which allows neutrophils to be finely directed to the site of infection (47). It has 
been suggested that other cytokines, such as TNFα and GMCSF, can influence neutrophil 
chemotaxis, and thus that the neutrophil environment is very important for this process (205, 
206). Importantly, it has been demonstrated that IFNγ can influence expression of chemokine 
receptors on neutrophils, and thus IFNs may have an influential role in neutrophil chemotaxis 
in JSLE (179). 
Within a North American population of SLE patients, neutrophils reduced random migration 
and directed migration towards C5a compared to healthy controls (116). Chemotactic activity 
within SLE serum was also reduced compared to that of healthy controls, and the level of 
dsDNA negatively correlated with chemotactic activity (117). The reduced chemotactic 
activity was found in patients who were younger at onset of disease and onset of renal 
involvement, and these patients tended to have increased incidence of infection (117). 
However, another study in a Taiwanese population of JSLE patients found that infection, 
disease activity or medication had no influence on chemotaxis, although there was a 
suggestion that neutrophil chemotaxis was reduced (112). Thus, the pro-inflammatory 
environment within SLE patients, which includes infection, medication and disease activity, 
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may reduce neutrophil chemotaxis. However, this effect may be very dependent on ethnicity 
and age of onset of SLE.  
In contrast to the above studies, growth regulated oncogene (GRO)α, a neutrophil 
chemokine, has been shown to be higher in a Chinese population of SLE patients than in 
healthy controls, and thus suggesting increased chemotaxis in these patients, highlighting 
that ethnicity may be important in how chemotaxis is dysregulated in SLE (118). Interestingly, 
there were no observed differences in IL-8 plasma levels between SLE and healthy control 
patients (118). This is interesting as IL-8 is a potent neutrophil chemokine, and thus it is 
thought that blood levels of IL-8 would correlate with the degree of dysregulated chemotaxis 
already outlined (116, 117, 207). Other cytokines, such as IP-10, RANTES, monokine induced-
by-γ-IFN (MIG) and MCP1, which have chemotactic properties, were shown to be higher in 
SLE patient plasma than healthy control patients (118). MCP1 and IL-8 plasma concentrations 
correlated with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores in SLE 
patients, and plasma concentrations of IP-10 and IL-8 correlated with SLEDAI scores of SLE 
patients with renal involvement (118). This elevation in chemokine concentration, and thus 
possible increase in neutrophil chemotaxis within SLE, contradicts other published studies 
that found a reduced chemotactic activity within SLE patients (116-118). 
Although it has been shown in adults with SLE that a history of infection reduces neutrophil’s 
phagocytic ability compared to patients without infection, this isn’t the case in JSLE. A history 
of infection does not influence neutrophil phagocytosis in JSLE patients compared to 
neutrophils of healthy control patients (112, 115). Of interest, neutrophil phagocytosis in JSLE 
patients is also not affected by medication or disease activity (112). Interestingly, in a 
previous study, only the phagocytosis of salmonella by JSLE neutrophils is reduced, whilst the 
phagocytosis of E.coli and S.aureus is comparable to healthy control neutrophils (112). 
Phagocytosis may be affected by the presence of autoantigens, as demonstrated by the fact 
that 38% of adult SLE patients positive for anti-Sjögren's syndrome type B (SSB)/La antibodies 
had reduced levels of neutrophil phagocytosis (115, 189). Thus, the ability of neutrophils to 
phagocytose may be affected by many factors, which may include expression of 
autoantigens, and the type of bacteria undergoing phagocytosis. 
IFNs have been shown to have an effect on phagocytosis, although this effect is dependent 
on the sub-type of IFN, the immune cell type and the bacteria being phagocytised. IFNα and 
IFNβ both can increase the attachment and phagocytosis of non-opsonised and opsonised 
E.coli by mouse peritoneal macrophages, whereas IFNγ reduces these functions (183). 
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Additionally, both IFNα and IFNβ increase both the Fc receptor mediated and C3b receptor 
mediated phagocytosis of opsonised sheep erythrocytes, by mouse peritoneal macrophages, 
whereas IFNγ only slightly reduces these types of phagocytosis (183). Another study showed 
IFNα and IFNγ up-regulate neutrophil phagocytosis of S. aureus, and additionally IFNα 
stimulated bacterial killing by the neutrophils (184). IFNs may have a role on neutrophil 
phagocytosis, but this may be very dependent on the receptors that mediate the process and 
the type of infection that neutrophils are responding to. 
NETosis is a unique type of death in which the neutrophils release their contents to trap 
bacteria (neutrophil extracellular traps, or NETs) – Section 1.3.3. It has been shown that there 
is an increase of NETosis in adult-onset SLE and this leads to increased expression of 
autoantigens in the form of exposed chromatin and DNA material, which strongly suggests 
that NETs are important in SLE development (208). Similar to the clearance of apoptotic 
debris, NET clearance is dysregulated in SLE patients via the inhibition of DNase 1 within the 
serum, which then may allow autoantigens to persist and thus lead to organ damage such as 
lupus nephritis (208).  
Anti-RNP has been shown to induce NETs in JSLE neutrophils, which resulted in increased 
secretion of leucine leucine (LL)37 and HMGB1 which localised with globular structures in 
NETs from SLE patients (163). LL37 is the only human cathelicidin-derived antimicrobial 
peptide and can be produced by epithelial cells and neutrophils (209, 210). LL37 activates 
immune cells by increasing the secretion of cytokines and chemokines from a variety of cells 
(210). LL37 can also enhance innate immune cell responses through multiple pathways (210). 
HMGB1 is a nuclear protein that acts as a DNA chaperone, and if HMGB1 is released, it can 
stimulate cytokine production through the NFκB pathway (211). Supernatants from JSLE 
neutrophils cultured with anti-RNP antibodies were able to induce pDC activation, resulting 
in IFNα production (163). It was shown that TLR7 is needed for NETosis in response to anti-
RNP (163). IFNα up-regulated TLR7, and anti-RNP IgG was able to induce NETosis in IFNα-
primed healthy neutrophils. The supernatants from these cells were able to activate pDCs in 
a DNA-dependent manner (163). IFNα and IFNγ have been indicated to prime neutrophils for 
NETosis, and NETing neutrophils in turn have been indicated to promote IFNα production 
from pDCs in JSLE (163, 175). This creates a positive feedback loop which may increase the 
autoantigens produced by NETs (212). Although IFNs are unlikely to induce NETs on their 
own, they seem to be important in priming neutrophils to produce NETs.  
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3.1.1. Summary 
Cytokines are important in regulating many important neutrophil functions. There is no clear 
evidence that IFNs are directly involved in neutrophil chemotaxis, NETosis or neutrophil 
phagocytosis in the pathogenesis of JSLE. However, the increased level of IFNs in JSLE and 
SLE sera and the pronounced granulocyte and IFN signature found in JSLE patients suggests 
some potential and important interaction, and thus IFNs may have some direct or indirect 
role in these functions. It has been shown that priming neutrophils with exposure to IFN does 
influence neutrophil functions, as seen in JSLE, and thus may contribute to JSLE pathogenesis. 
 
3.2. Chapter hypothesis 
There is an increase of IFNs within the serum of patients with adult-onset SLE and JSLE and 
an increased IFN and neutrophil signature in JSLE PBMCs, suggesting an interaction of IFNs 
and neutrophils within JSLE pathogenesis. IFNs may have a role in dysregulated neutrophil 
function that contributes to JSLE pathogenesis. 
 
3.3. Aims and Objectives 
Aim: To investigate the effect of IFNs on chemotaxis, phagocytosis and NETosis in 
combination with other factors. 
 Objective 1: Using transwells and manual counting using a haemocytometer and light 
microscopy, measure the rate of a) naïve healthy adult neutrophil migration towards 
IFNs and known neutrophil chemoattractants, IL-8 and fMLP; and b) IFN-primed 
healthy adult neutrophils towards known neutrophil chemoattractants, IL-8 and 
fMLP. 
 Objective 2: Using flow cytometry, measure the rate of healthy adult neutrophil 
phagocytosis of E.coli bioparticles after IFN priming. 
 Objective 3: Using confocal microscopy and DNA quantification (via Quant-iT™ 
PicoGreen™ dsDNA assay kit), measure NETosis after a) IFN-priming and subsequent 
LPS stimulation of healthy adult neutrophils and b) stimulation of IFNs on naïve and 
TNFα-primed healthy adult neutrophils. 
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3.4. Methods 
3.4.1. Chemotaxis assays 
3.4.1.1. Plate coating  
12mg/ml of Poly (2-hydroxyethyl methacrylate) (polyHEMA) (Sigma-Aldrich, UK) was diluted 
in warmed ethanol (Chemistry Department, University of Liverpool, UK) and 400µl was used 
to coat wells of a 24 well plate. The ethanol was allowed to evaporate in a 37°C incubator for 
24 hours. The plates were used immediately or stored at room temperature. 
3.4.1.2. The effect of IFNs on neutrophil migration 
PolyHEMA coated plates were washed with media 2-3 times to remove any remaining 
ethanol. 800µl of media w/10% FBS was added to the wells. Chemokines (100ng/ml IL-8 
[PeproTech, UK] and 10nM fMLP [Sigma-Aldrich, UK] as positive controls) or 10ng/ml IFNα, 
10ng/ml IFNγ or 10ng/ml IFNβ were added to the wells. Polyethylene terephthalate (PET) 
hanging inserts with 3.0 µm pore size (Merck Millipore, UK) were added on top of wells, and 
were left to soak in the media for at least 10mins.  
Neutrophils were isolated from healthy adults as described in the technical methods chapter 
(Section 2.5.2). Neutrophils were either primed with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml 
IFNβ for 30mins before chemotaxis analysis (Section 3.4.1.3) or left unstimulated and 
immediately analysed for chemotaxis. Neutrophils were suspended at up to 1x106/200µl and 
200µl of neutrophil suspension was added to each insert. The plate was incubated at 37°C, 
5% CO2 for 90mins to allow migration to occur. The inserts were lifted out and the media in 
the wells was mixed by pipetting to make sure the neutrophils were evenly suspended. A 
10µl aliquot was removed and counted on a haemocytometer. The count was then 
extrapolated to calculate the number of neutrophils per 800µl, which represents the number 
of migrated neutrophils.  
3.4.1.3. IFN priming of neutrophils for chemotaxis analysis 
Neutrophils were isolated from healthy adults as described in the technical methods chapter 
(Section 2.5.2). Neutrophils were aliquoted into four Falcon tubes at 3-4x106 per Falcon (3-
4mls). One aliquot of neutrophils was left unstimulated, and 10ng/ml IFNα, 10ng/ml IFNγ or 
10ng/ml IFNβ were added to the other three aliquots. The neutrophils were placed on a 
rocker at 37°C, 5% CO2 for 30mins. The neutrophils were centrifuged at 1500 RPM for 5mins, 
washed in 1ml media w/10% FBS and centrifuged at 1500 RPM for 5mins. The supernatant 
was decanted, and any remaining was removed using a pipette. 400-600µl of media was 
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added to the neutrophil pellet and neutrophils were recounted to account for any loss in 
neutrophils during centrifugation. Neutrophils in each condition were normalised to the 
lowest concentration of neutrophils for each donor (4.8x105-1x106/200µl), and chemotaxis 
assay was conducted as described above (Section 3.4.1.2). 
3.4.2. Phagocytosis assay 
Neutrophils were isolated from healthy adults (Section 2.5.2). 1ml of extra blood was also 
taken from each healthy volunteer and centrifuged at 2000 RPM for 10mins to obtain 
autologous serum. Neutrophils were plated in a 96 well plate at 1.5x105/150μl per condition, 
with one extra well empty for the ‘bioparticles only’ condition. Either 10ng/ml IFNα, 10ng/ml 
IFNγ or 10ng/ml IFNβ were subsequently added to neutrophils and incubated for 30mins at 
37°C, 5% CO2. PHrodo Red E. coli bioparticles (Life Technologies, UK) were initially suspended 
in 2ml of HBSS/20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 
7.4, Sigma-Aldrich, UK), vortexed and subsequently diluted further: 4.5µl of bioparticles plus 
55.5µl of buffer per condition. For treatment conditions, in which bioparticles needed to be 
opsonised, 60µl of bioparticles was suspended in 15µl of autologous serum (which equates 
to 10% serum in final assay set up) and left for at least 15mins at room temperature. 
Neutrophils were centrifuged at 1800 RPM for 5mins, and the supernatant was decanted. 
For each ‘treatment’ condition (including unstimulated cells), 75µl of media was added to the 
neutrophils, plus 75µl of bioparticles/serum. For cells only, 150µl of media was added. For 
bioparticles only, cells + bioparticles, and no serum conditions, 90µl media plus 60µl 
bioparticles (in buffer only) were added to the neutrophils. The neutrophils were incubated 
at 37°C, 5% CO2 for 10mins, and centrifuged at 1800 RPM for 3mins. The supernatant was 
decanted and 200µl of HBSS/20mM was added. Neutrophils were transferred to tubes and 
run on a pre-programmed phagocytosis protocol on the Guava EasyCyte. Percentage of 
bioparticles phagocytosed was analysed using FlowJo.   
 
3.4.3. NETosis assays 
3.4.3.1. Cytokine priming and stimulation for NETosis assay 
Neutrophils were isolated and suspended as protocol (Section 2.5.2) and suspended at 
1x106/ml in media w/2% FBS. Neutrophils were plated at 2x105 in 2x24 well plates, one with 
sterile cover slips (for confocal microscopy) and one without (for DNA quantification). 500μl 
of media w/2% FBS was added, for a final neutrophil concentration of 2x105/500μl.  
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Neutrophils were left to settle on coverslips for 30mins at 37°C, 5% CO2. Neutrophils were 
left unstimulated or primed with 1μg/ml TNFα (PeproTech, UK), 10ng/ml IFNα, 10ng/ml IFNγ 
or 10ng/ml IFNβ for 30mins at 37°C, 5% CO2. Naïve neutrophils were stimulated with 320nM 
PMA (Sigma-Aldrich, UK), 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ, TNFα-primed 
neutrophils were stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ and IFN 
primed neutrophils were stimulated with 1μg/ml of LPS (Sigma-Aldrich, UK). Neutrophils 
were incubated at 37°C, 5% CO2 for 3hrs, and then processed for confocal and DNA 
quantification analysis.  
3.4.3.2. Confocal analysis 
Medium was removed, and coverslips were washed twice with 300μl PBS. 300μl 4% 
formaldehyde (Sigma-Aldrich, UK) was added to coverslips for 10mins at RT to fix the 
neutrophils. The 4% formaldehyde was removed and coverslips were washed twice with 
300μl PBS. Coverslips were mounted onto microscope slides using Prolong Gold Antifade 
Reagent with DAPI (Molecular Probes by Life Technologies, UK). Slides were wrapped in foil 
and left to dry at RT for at minimum overnight, or until ready to analyse. Analysis was carried 
out using a DM2500 confocal microscope (Leica, UK) with a pre-programmed protocol on 
Leica Application Suite, Advanced Fluorescence, whereby 5-6 images were taken per 
condition. 
3.4.3.3. Quantification of NETs from confocal microscopy 
Quantification of NETs from confocal images was trialled. From all the images taken during 
the confocal analysis, a representative sample of confocal images was produced. This 
included an image from each donor (n=5) for each condition (n=13) which in total was 65 
images to be analysed for each user. To help define NETosis as visualised using confocal 
microscopy, an example of a viable neutrophil (no NETosis) and a NETing neutrophil was 
provided. Three independent operators calculated the percentage of NETs in each image, 
using the calculation:  
% 𝑜𝑓 𝑁𝐸𝑇𝑠 = (
𝑁𝑜𝑓𝑁𝐸𝑇𝑖𝑛𝑔 𝑛𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙𝑠
𝑁𝑜𝑓𝑁𝐸𝑇𝑖𝑛𝑔 𝑛𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙𝑠 + 𝑛𝑜. 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑛𝑢𝑒𝑡𝑟𝑜𝑝ℎ𝑖𝑙𝑠
) 𝑋100 
From each operators’ image analysis, an average percentage for each condition across the 
five donors was calculated per operator; these three operator averages were plotted for each 
condition and analysed for inter-operator variability. 
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3.4.3.4. DNA quantification analysis 
After stimulation and incubation of neutrophils, DNA was cleaved into the supernatant, 
which was centrifuged to remove cellular debris. The DNA concentration was measured by a 
plate reader using fluorescence from Quant-iT™ PicoGreen™ reagent and comparison to a 
standard curve.  
250 micro (m)Units of micrococcal nuclease (Sigma-Aldrich, UK) was added to the neutrophil 
culture with 5μl of 0.1M of calcium chloride (Sigma-Aldrich, UK) to cleave NET material. The 
neutrophils were incubated for 10mins at 37°C, 5% CO2. 5mM EDTA was added to terminate 
the enzyme digestion, and the supernatant was centrifuged at 200xg for 8mins to remove 
remaining cells. Care was taken to avoid disrupting any cellular pellet and the supernatant 
was stored at -80°C until analysis. 
The NET material was analysed using Quant-iT™ PicoGreen™ dsDNA Assay Kit 
(Invitrogen/ThermoFisherScientific, UK). λDNA was diluted to 2000ng/ml, 200ng/ml, 
20ng/ml and 2ng/ml in 1x Tris EDTA (TE) buffer, and 100μl of both standards and samples 
were loaded into a black, flat-bottomed 96 well plate, with 1xTE buffer used as a blank. 100μl 
of 1x Quant-iT™ PicoGreen™ was added to all samples and standards and the plate was 
incubated at room temperature for 4mins. The fluorescence was measured at 485nm 
excitation and 535nm emission on a TECAN GENios Plus plate reader (Tecan, UK).  
A standard curve was generated, plotting standards against absorbance, and the 
concentration of each sample was extrapolated from the line of best fit equation using the 
average of the absorbance obtained (Figure 3.1). 
3.4.4. Statistical analysis 
Statistical analyses undertaken for data arising from these assays were analysed using 
Friedman’s test with Dunn’s post hoc multiple comparison test in GraphPad Prism 6. For 
detailed justification, Section 2.10. 
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Figure 3.1. Quant-iT™ PicoGreen™ dsDNA Assay Kit standard curve. λDNA was diluted at 
200ng/ml, and dilutions using 1xTE buffer and PicoGreen was conducted to achieved other 
standards. Standards and samples were loaded in dulicate into a 96 well plate, and the 
Quant-iT™ PicoGreen™ reagent was loaded. The plate was read, and the standard curve was 
plotted using average absorbance against the known standards. 
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3.5. Results 
3.5.1 Investigating the effect of IFNs as ‘neutrophil chemokines’ 
The first neutrophil function to be investigated was chemotaxis. Although there was no 
significant published evidence to confirm the role of IFNs as chemokines for neutrophils, this 
function was investigated to confirm or disprove this role.  
Compared to random migration occurring in control conditions (media w/10% FBS only; 
1.7x105 ± 0.3x105 n=5), both IL-8 (2.7x105 ± 0.4x105 n=5) and fMLP (3.5x105 ± 0.8x105, n=5, 
p=0.020) (Figure 3.2) were shown to increase the migration of neutrophils in this model, this 
being more pronounced with fMLP-induced migration (see Figure 3.2). These data correlate 
well with the published literature (47) and indicate the model was working effectively. 
Notably, none of the IFN subtypes demonstrated any additional effect on neutrophil 
migration (IFNα = 1.7x105 ± 0.2x105; IFNγ = 1.6x105 ± 0.3x105; IFNβ = 1.8x105 ± 0.2x105; n=5) 
compared to the neutrophil random migration occurring in controlled conditions.  
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Figure 3.2. Neutrophil chemotaxis towards media (random migration) and 
chemokines/cytokines after 90mins. Plates were coated with PolyHEMA and media w/10% 
FBS was added, and was left un-supplemented, or supplemented with 100ng/ml IL-8, 10nM 
fMLP, or 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ. Inserts were left to soak for 10mins. 
Neutrophils were isolated from healthy adult donors and were plated in inserts and left to 
migrate for 90mins. Neutrophils were suspended in wells, counted and calculated as number 
of neutrophils/800μl. fMLP significantly attracted neutrophils compared to random 
migration (*, n=5, p=0.020), and IL-8 has increased migration compared to random migration, 
although this was not significant (n=5, p=0.14). None of the IFN subtypes had any 
demonstrable chemokine effect on neutrophils.  
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3.5.2. Investigating the effect of IFN priming on neutrophil chemotaxis 
Based on published data (179, 205, 206), the next step was to investigate whether IFN 
priming could affect random neutrophil migration (towards control medium) or directed 
migration (towards IL-8 and fMLP) neutrophil chemotaxis. Chemotactic conditions were 
therefore replicated as above (Section 3.5.1) with the addition of a 30mins pre-treatment of 
the neutrophils with each of the IFN subtypes.  
With naïve (un-primed) neutrophils, both IL-8 and fMLP were shown to have an increased 
migration effect compared to control media alone, although in these experiments this was 
not shown to be statistically significant (media w/FBS = 1.2x105 ± 0.5x105, n=5; IL-8 = 4.0x105 
± 1.0x105, p=0.22, n=5; fMLP = 3.4x105 ± 0.8x105, p=0.93, n=5) (see Figure 3.3).  
IFNα priming (Section 3.4.1.2) had no demonstrable additional influence over random or 
directed migration compared to naïve neutrophils (IFNα primed neutrophils: media w/FBS = 
0.8x105 ± 0.4x105; IL-8 = 2.4x105 ± 0.5x105; fMLP = 2.9x105 ± 0.6x105; n=5) (Figure 3.3). IFNγ 
priming also had no additional demonstrable influence over random or directed migration 
compared to naïve neutrophils (IFNγ primed neutrophils: media w/FBS = 1.1x105 ± 0.8x105; 
IL-8 = 3.8x105 ± 1.3x105 fMLP = 3.0x105 ± 0.8x105, n=5) (Figure 3.3). Finally, IFNβ also had no 
demonstrable additional effect on random or directed migration compared to naïve 
neutrophils (IFNβ primed neutrophils: media w/FBS = 0.8x105 ± 0.3x105; IL-8 = 2.2x105 ± 
0.6x10%; fMLP = 2.1x105 ± 0.4x105, n=5) (Figure 3.3). Thus, these experiments demonstrated 
that IFN priming had little effect on chemotaxis. 
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Figure 3.3. Neutrophil chemotaxis towards media (random migration) and known 
neutrophil chemokines (IL-8 and fMLP) following priming with 10ng/ml IFNα, 10ng/ml 
IFNγ, or 10ng/ml IFNβ for 30mins. Plates were coated with polyHEMA and media w/10%FBS 
was added to the wells. Media was left un-supplemented or supplemented with 100ng/ml 
IL-8 or 10nM fMLP. Inserts were added and left to soak for 10mins. Neutrophils were isolated 
from healthy adult donors and were left naïve or were primed with 10ng/ml IFNα, 10ng/ml 
IFNγ or 10ng/ml IFNβ for 30mins, then plated into the inserts and left to migrate for 90mins. 
Neutrophils were suspended in wells, counted and calculated as number of 
neutrophils/800μl (n=5). IL-8 and fMLP had an increased migration effect. None of the IFN 
subtypes showed a demonstrably significant effect on either random or migrated 
chemotaxis.  
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3.5.3. Investigating the IFN priming effect on phagocytosis 
The next neutrophil function assay to be investigated was phagocytosis. It has been shown 
previously that neutrophil phagocytosis is significantly reduced in both SLE and JSLE patients 
(112, 115) (Section 1.4.3). Thus, it may be that the high levels of IFNs found in the sera of 
patients with SLE and JSLE are involved in this reduced phagocytosis (68, 112, 115, 171, 172). 
For these reasons, IFN primed neutrophils were investigated on their subsequent 
phagocytosis capability.  
Overall, compared to naïve neutrophils (analysed as fluorescence within the neutrophil 
population; 66.6 ± 10.2%, n=4) the data showed there was no demonstrable priming effect 
of any of the IFN subtypes on neutrophil phagocytosis of E. coli bioparticles (IFNα 68.2 ± 9.4%, 
IFNγ 64.7 ± 10.8%; IFNβ 67.8 ± 10.0%, n=4)(Figure 3.4). It was notable that there was great 
variation in phagocytosis in neutrophils between donors (n=4) (Figure 3.4). Therefore, IFNs 
do not affect neutrophil phagocytosis of E.coli bioparticles. 
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Figure 3.4. Healthy adult neutrophil phagocytosis of E.coli bioparticles after priming with 
10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 30mins. Neutrophils were isolated from 
healthy adult donors and were either left naïve or primed with 10ng/ml IFNα, 10ng/ml IFNγ 
or 10ng/ml IFNβ for 30mins, and subsequently stimulated with E.coli bioparticles for 10mins. 
The percentage of neutrophil phagocytosis of E. coli bioparticles was analysed using flow 
cytometry (n=4). 
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3.5.4. Investigating the effect of IFN subtypes on NETosis 
The next function of neutrophils to be investigated was NETosis, which has been shown to 
potentially be important in the pathogenesis of SLE and JSLE (176, 208, 212) (Section 1.5.3.2). 
To do this, a series of experiments were performed. These included determining the effects 
of stimulation by each of the IFN subtypes on both naïve and TNFα-primed neutrophils. 
Additionally, the effect of LPS stimulation on IFN-primed neutrophils was investigated. LPS is 
a bacterial product and has been shown to induce NETosis in canines (213, 214). LPS was 
therefore used to try model NETosis during infections. Together, these experiments were 
undertaken to determine if, and in what way, the IFN subtypes may either together or 
individually have a role in NETosis. 
3.5.4.1. Investigating the role of IFN subtypes on NETosis using confocal microscopy 
Initially, a confocal analysis was conducted to investigate how the different IFN subtypes 
effect NETosis, either through stimulation or priming. Firstly, neutrophils isolated from 
healthy adult donors were left to settle on coverslips for 1hr, and then either unstimulated 
or stimulated with 320nM PMA and incubated for 3hrs, and subsequently fixed and stained 
with DAPI within mounting media before being assessed using confocal microscopy. As 
expected, there were minimal NETs demonstrated in the unstimulated conditions (9.7 ± 
7.3%; average of three operators’ analysis, Sections 3.4.3.3 and 3.5.4.2) (Figure 3.5, Figure 
3.10 and Appendix E, Figure 1) whilst NETs were clearly induced on stimulation with PMA 
53.6 ± 26.6%; average of three operators’ analysis, Sections 3.4.3.3 and 3.5.4.2) (Figure 3.5, 
Figure 3.10 and Appendix E, Figure 2). These results confirmed that the assay was working as 
expected.  
 
 
94 
 
 
Figure 3.5. NET visualisation at 4hrs of unstimulated healthy adult neutrophils or healthy 
adult neutrophils stimulated with 320nM PMA, as shown by DAPI staining. Neutrophils 
were isolated from healthy adult donors (n=5) and were left to settle on coverslips for 1hr. 
Neutrophils were unstimulated or stimulated with 320nM PMA, and incubated for 3hrs, and 
subsequently fixed and stained with DAPI within mounting media. Each image is 
representative of 5 images taken for each donor. Unstimulated neutrophils did not undergo 
NETosis. However, PMA, was shown to be a strong inducer of NETosis.  
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As the assay has been confirmed to work as expected as shown above, the next stage was to 
investigate how IFN stimulation effects NETosis in naïve neutrophils. Naïve neutrophils were 
stimulated for three hours by adding fixed concentrations of each of the IFN subtypes, 
namely: 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ, and subsequently fixed and stained 
with DAPI within mounting media before being assessed using confocal microscopy. IFNα-
stimulated neutrophils did demonstrate evidence of DNA release as seen by confocal 
microscopy (IFNα = 26.3 ± 2.7%, IFNγ = 12.2 ± 1.4%, IFNβ = 14.6 ± 2.2%; average of three 
operators’ analysis, Sections 3.4.3.3 and 3.5.4.2) (Figure 3.6, Figure 3.10 and Appendix E, 
Figures 3-5), compared to naïve, unstimulated neutrophils (9.7 ± 7.3%; average of three 
operators’ analysis; Sections 3.4.3.3 and 3.5.4.2) (Figure 3.6, and Appendix E, Figure 1) 
indicating evidence of NETosis. However, this was limited and not seen in all images (Figure 
3.6 and Appendix E, Figures 1, 3-5), so whilst some induction occurred, this was modest and 
less striking than that occurring with PMA, and therefore it remains inconclusive whether 
IFNs have a true effect on NETosis in naïve neutrophils. 
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Figure 3.6. NET visualisation at 4hrs of naïve, unstimulated healthy adult neutrophils, or 
healthy adult neutrophils stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ, as 
shown by DAPI staining. Neutrophils were isolated from healthy adult donors (n=5) and were 
left to settle on cover slips for 1hr. Neutrophils left unstimulated or were stimulated with 
10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 3hrs, and subsequently fixed and stained 
with DAPI within mounting media. Each image is representative of 5-6 images taken for each 
donor. IFN-stimulated neutrophils did undergo DNA release and thus did undergo NETosis in 
naïve neutrophils, although this was limited, and not seen in all images. 
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The next set of experiments explored the effect of TNFα-priming on NETosis (without any 
further neutrophil stimulation) and the effect of the different IFN subtypes on NETosis in 
TNFα-primed neutrophils, as assessed by confocal microscopy (Figure 3.7). Neutrophils were 
primed with 1µg/ml TNFα and were left unstimulated or stimulated with 10ng/ml IFNα, 
10ng/ml IFNγ or 10ng/ml IFNβ for 3 hours. These data gave a suggestion of increased NETosis 
in TNFα-primed neutrophils (17.3 ± 1.5%; average of three operators’ analysis; Sections 
3.4.3.3 and 3.5.4.2) (Figure 3.7, Figure 3.10 and Appendix E, Figure 1) compared to that of 
naïve, unstimulated neutrophils (9.7 ± 7.3%; average of three operators’ analysis; Sections 
3.4.3.3 and 3.5.4.2) (Figure 3.7, Figure 3.10 and Appendix E, Figure 6), as shown through some 
DNA release on the confocal images. Those healthy neutrophils primed with TNFα and then 
stimulated with IFNγ and IFNβ, but not IFNα, did demonstrate evidence of DNA release as 
seen by confocal microscopy indicating evidence of NETosis did give an indication of some 
NET formation (IFNα = 12.6 ± 1.4%, IFNγ = 23.9 ± 5.2%, IFNβ = 30.9 ± 11.4%; average of three 
operators’ analysis, Sections 3.4.3.3 and 3.5.4.2) (Figure 3.7, Figure 3.10 and Appendix E, 
Figures 7-9). However, this was limited and not seen in all images (Figure 3.7 and Appendix 
E, Figures 7-9) and was therefore modest and less striking than that occurring with PMA. 
Therefore, it remains inconclusive whether either TNFα-priming or IFN stimulation on these 
primed neutrophils have a true effect on NETosis, although according to the operator analysis 
(Section 3.5.4.2). 
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Figure 3.7. NET visualisation at 4hrs of naïve, unstimulated healthy adult neutrophils, 
TNFα-primed, unstimulated healthy adult neutrophils and TNFα-primed, healthy adult 
neutrophils stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ, as shown by 
DAPI staining. Neutrophils were isolated from healthy adult donors (n=5) and were left to 
settle on cover slips for 30mins. Neutrophils were left naïve or primed with 1μg/ml TNFα for 
30mins, and stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 3hrs. 
Neutrophils were fixed and stained with DAPI within mounting media. Each image is 
representative of 5-6 images taken for each donor. IFN stimulated neutrophils did undergo 
DNA release and thus did undergo NETosis in TNFα-primed neutrophils, although this was 
limited, and not seen in all images. 
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Lastly, it was important to investigate whether priming with the different IFN subtypes has 
an effect on NETosis. Therefore, healthy adult neutrophils were left naïve, or primed with 
10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ, subsequently stimulated with 1µg/ml LPS, and 
assessed for NETosis using confocal microscopy. LPS stimulation of naïve neutrophils did not 
result in DNA release and therefore did not induce any NETs (15.1 ± 4.5%; average of three 
operators’ analysis; Sections 3.4.3.3 and 3.5.4.2) (Figure 3.8, Figure 3.10 and Appendix E, 
Figure 10). LPS stimulation of IFNα-primed neutrophils (but not IFNγ or IFNβ), however did 
demonstrate evidence of DNA release as seen by confocal microscopy indicating evidence of 
NETosis formation (IFNα = 21.5 ± 7.1%, IFNγ = 13.3 ± 3.9%, IFNβ = 16.3 ± 6.3%; average of 2-
three operators’ analysis, Sections 3.4.3.3 and 3.5.4.2) (Figure 3.8, Figure 3.10 and Appendix 
E, Figures 11-13). However, this was limited and not seen in all images (Figure 3.8 and 
Appendix E, Figure 11-13) and was therefore modest and less striking than that occurring 
with PMA. Therefore, it remains inconclusive whether priming with any of the IFN subtypes 
has a true effect on NETosis. 
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Figure 3.8. NET visualisation at 4hrs of naïve, unstimulated healthy adult neutrophils, naïve 
healthy adult neutrophils stimulated with 1µg/ml of LPS, or healthy adult neutrophils 
primed with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ and stimulated with 1µg/ml of 
LPS, as shown by DAPI staining. Neutrophils were isolated from healthy adult donors (n=5) 
and were left to settle on cover slips for 30mins. Neutrophils were left naïve or primed with 
10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 30mins and stimulated with 1µg/ml LPS for 
3hrs. They were subsequently fixed and stained with DAPI within mounting media. Each 
image is representative of 5-6 images taken for each donor. LPS-stimulated, IFN-primed 
neutrophils did release DNA and thus did undergo NETosis, although this was limited, and 
not seen in all images. Additionally, no differences in NETosis were seen upon priming with 
the different IFN subtypes. 
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It should be noted that NETs were not always visualised in all images for each of the set of 
experiments described above. It was evident that there was a great deal of variability 
between donors in the ability of their healthy neutrophils to undergo NETosis in each of the 
various sets of experimental conditions explored, irrespective of whether they were being 
primed or stimulated or left without either taking place (unstimulated, naïve). Many factors 
such as donor medical history and demographics may have contributed to this. An example 
set of images is shown in Figure 3.9, in which for a given set of conditions, all of the images 
associated with each of the five donors is shown. They show intra-donor and inter-donor 
variability in the demonstration of NETosis between images. Typical or illustrative examples 
have been given in the sets of experiments above. For all image sets, please see Appendix E.  
Another methodological challenge noted during these experiments was that clumping of 
neutrophils occurred within the visualised images taken. This made categorising (for some 
images) what was a NET and what was a viable neutrophil difficult to determine. It was 
recognised therefore that this introduces a potential level of subjectivity to this method of 
assessment of the effect of the IFN subtypes on healthy neutrophil NETosis. Whilst this can 
be overcome in part by inter-observer assessment of all the images by a second or more 
investigator (Section 3.5.4.2, Figure 3.10), the extent and number of images needing to be 
assessed make this very difficult in practical terms for a large study. These images highlight 
an unavoidable inconsistency in NETosis visualisation both within and between donors, 
which makes making firm conclusions of findings difficult. In view of this difficulty in analysing 
consistently the level of NETosis in these images using confocal microscopy, a quantifying 
analytical approach was undertaken to determine if this gave a more objective assessment 
(Section 3.5.4.2; Figure 3.10). 
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Figure 3.9. NET visualisation at 4hrs of healthy adult neutrophils, primed with TNFα-
primed, stimulated with IFNγ and stained with DAPI. Neutrophils were isolated from healthy 
adult donors (n=5) and were left to settle on cover slips for 30mins. Neutrophils were primed 
with 1µg/ml TNFα for 30mins and stimulated with 10ng/ml IFNγ for 3hrs. They were 
subsequently fixed and stained with DAPI within mounting media. 5-6 images were taken per 
donor. 
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3.5.4.2. Quantification of NETs from confocal microscopy 
Although estimation of the relative extent of NETosis taking place under different 
experimental conditions can indicate major differences between groups, assessment by 
confocal microscopy, as illustrated and discussed above (Section 3.5.4.1) is a subjective 
method dependent largely upon operator interpretation of fixed 2D images. The 
differentiation between a viable neutrophil from a neutrophil undergoing NETosis may 
therefore be dependent in part upon individual operator experience, expertise and their 
interpretation of any image. This is likely to introduce significant variability into an estimate 
of NETosis using this method, compounded by the inter-donor variability effect also 
previously noted above. There are no published data on inter-operator reliability of confocal 
microscopy as a method to estimate neutrophil NETosis. In order to gain insight into inter-
operator variability using this method, three independent operators were asked to estimate 
the extent of NETosis taking place. They were asked to do this using the equation to estimate 
the percentage of NETosis taking place in each of the images (Section 3.4.3.3), using the same 
set of confocal microscopy images. Each operator was blinded from the other operators’ 
estimates. Prior to carrying out their assessments, each were given instruction and examples 
of images of viable neutrophils and of NETs., Each of the three operators calculated a 
percentage of NETs within each of the five images (five separate donors) presented for each 
condition (five percentages/condition/operator). For each condition, an average percentage 
from the five images was calculated for each operator (one average 
percentage/condition/operator); these three operator averages was plotted for each 
condition and analysed for inter-operator variability (Figure 3.10).  
It was shown that although some conditions there was reasonable inter-observer consistency 
in percentage NETosis estimates (e.g. all three IFN subtype stimulated naïve neutrophils). 
However, for some conditions (e.g. PMA and LPS stimulated neutrophils), there was marked 
inconsistency, particularly in regards to PMA and LPS stimulated neutrophils (Figure 3.10). 
Additionally, one operator found analysing what was a viable neutrophil and what was a 
NETing neutrophil difficult due to neutrophil clumping (PMA stimulation and IFNβ priming 
plus LPS stimulation had no percentage calculated and were omitted for this operator). Due 
to the difficulty and subjectivity of quantifying the percentages of NETs in the confocal 
images, another, more quantifiable assay, was therefore needed to supplement the 
important information and contribution that the confocal images could make to these 
assessments 
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Figure 3.10. NET quantification analysis of confocal microscopy images by three 
independent operators. One confocal image from each donor (n=5) was selected for each 
experimental condition undertaken and were assessed by each of the operators to determine 
the extent (percentage) NETosis present. Results were compiled for analysis. Scoring rules 
was established and each operator was instructed to count the both number of viable and 
number of NETing neutrophils and calculate the percentage of NETs within the population 
seen in each image. Each operator’s percentages were averaged for each condition, and this 
was graphically presented above. Of note, one operator found the PMA and IFNβ-primed, 
LPS-stimulated images too difficult to quantify accurately, and thus no percentages were 
calculated for these from this operator.  
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3.5.4.3. Investigating the role of IFNs on NETosis-related DNA release 
In order to seek to overcome the subjective nature of confocal microscopy assessment of 
NETosis, and the inter-observer variability of this approach (due to clumping of the cells 
within certain conditions making it difficult to analyse), an alternative strategy was explored. 
DNA is a major component of NETs, and is released into neutrophil culture upon NETosis 
induction (37). Therefore, investigation into whether quantification of DNA release could 
rigorously quantify NETosis within this study was explored. The amount of DNA released 
during the process of NETosis was quantified from supernatants processed from neutrophil 
cultures (Section 3.4.3.1 and 3.4.3.4) using Quant-iT™ PicoGreen™ dsDNA Assay Kit (Section 
3.4.3.4).  
Using the experimental conditions previously carried out (Sections 3.4.3.1. and 3.4.3.4), the 
quantity of DNA released within supernatants was measured and compared. Of note, 
although effort was made to collect matched supernatants to the confocal analysis 
conditions, one confocal analysis repeat did not have a matched supernatant to be analysed. 
PMA increased neutrophil DNA released into the supernatant compared to naïve 
unstimulated neutrophils, and this was presumed to relate to the amount of NETs formed 
(PMA-induced: 438 ± 120 ng/ml versus unstimulated: 91 ± 16 ng/ml, n=5) (see Figure 3.11). 
No other experimental conditions used in this study (Section 3.4.3.1) with or without each of 
the IFN subtype stimulating or priming the neutrophils, demonstrated any clear increase in 
DNA release compared to the unstimulated controls (naïve neutrophils: IFNα = 77 ± 14 ng/ml, 
IFNγ = 81 ± 6 ng/ml, IFNβ =79 ± 7 ng/ml, n=5; TNFα-primed neutrophils: unstimulated = 84 ± 
9 ng/ml, IFNα = 72 ± 12 ng/ml, IFNγ = 80 ± 8 ng/ml, IFNβ =110 ± 18 ng/ml, n=5; IFN primed 
neutrophils with LPS stimulation: naïve = 180 ± 97 ng/ml, IFNα = 71 ± 8 ng/ml, IFNγ = 80 ± 9 
ng/ml, IFNβ =98 ± 34 ng/ml, n=5) (Figure 3.11).  
These data alone would indicate that, except for PMA, NETs were not actually formed in 
these conditions. The increase in release of DNA into the matched supernatant by NETosis-
positive control PMA indicates that the DNA quantification technique was working. 
Therefore, it is likely that although confocal microscopy did show that some NETs were 
produced visually, any differences seen in the confocal images may be superficial, and that 
IFNs may not have a big role in NETosis. The number of cells used in the NETosis assay was 
used limited, and an increase in cell number may improve the number of NETs visualised and 
increase the rate of DNA released into the supernatant (below). Additionally, many confocal 
images did not show NETs in each donor; NETs may be present but not seen in the images 
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taken. Therefore, a more accurate and inclusive analysis may be more reflective of the role 
of IFNs on NETosis than the confocal analysis used here.  
It is of note that DNA quantification did allow for more rigorous and consistent analysis of a 
NET material and eliminated operator subjectivity that was a major problem in quantifying 
NETs from confocal images. However, the method of assessing the amount or relative extent 
of NETosis by quantifying the amount of DNA in the supernatant may not be appropriate. 
This may be due to DNA concentrations within supernatants isolated from neutrophil 
cultures was below the sensitivity of the DNA quantification kit, possibly partly due to 
potential DNA loss during the supernatant processing. Additionally, any DNA detected may 
not be exclusively from NETs. Therefore, other techniques, including ROS analysis and 
additional staining of confocal slides for release of NET-associated proteins, such as MPO and 
NE, may strengthen this analytical approach and confirm that, contrary to published 
literature, no differences are seen in NETosis upon IFN stimulation (175).  
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Figure 3.11. Quantification of DNA released by neutrophils at 4hs after cytokine priming 
and stimulation. Neutrophils were isolated healthy adult donors (n=5) and left to settle on 
coverslips for 30mins. Neutrophils were left unstimulated or primed with 1μg/ml TNFα or 
10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 30mins, subsequently stimulated with 
10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ (naïve and TNFα-primed neutrophils) or 1µg/ml 
LPS (IFN primed neutrophils) for 3hrs, and the DNA was cleaved using nuclease. Supernatants 
were lifted and any remaining cells were removed by centrifugation. Supernatants were 
analysed for DNA using Quant-iT™ PicoGreen™ dsDNA Assay Kit (n=4-5). PMA stimulated 
neutrophils released DNA, which correlates well with confocal images. However, no other 
experimental conditions resulted in an overall measurable increase in the amount of DNA 
released. 
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3.6. Discussion  
IFNs are anti-viral cytokines that have been found to influence many immune functions, 
including neutrophils (Section 1.5). Neutrophil function is dysregulated in SLE and JSLE, and 
thus factors influencing neutrophil function and how they are dysregulated is an important 
mechanism to understand in order to improve the understanding of the processes and 
pathways underpinning the pathogenesis of JSLE (112, 115-117, 176, 208) (Sections 1.3, 
1.4.3). It has been noted already that some IFN subtypes are increased in the sera of patients 
with SLE and JSLE. In addition, there is an increased IFN and neutrophil gene signature in JSLE 
PBMCs (Section 1.5.4.1). This chapter therefore sought to explore the potential role that each 
of the IFN subtypes may have on influencing some key roles and function of neutrophils (41).  
3.6.1. IFNs and neutrophil chemotaxis 
Experiments presented here confirmed that both IL-8 and fMLP are strong chemoattractants 
for neutrophils, in line with other published literature (47, 205, 206) (Section 3.5.1). However, 
in contrast, it was shown that each of the IFN subtypes did not demonstrate a chemokine 
role in the model of chemotaxis studied here (Figure 3.3, Section 3.5.2). An alternative in 
vitro model may have been able to elucidate a specific function, but of note, as no published 
literature has been found to suggest otherwise, it is likely that none of the IFN subtypes have 
a key role directly as a chemokine for neutrophils. Additionally, priming with all three IFN 
subtypes did not have any effect on random or IL-8 and fMLP directed chemotaxis.  
However, it is known that some of the IFN subtypes have been shown to affect other types 
of cell migration. A study by Stüve et al that demonstrated increased PBMCs migration 
towards chemokines RANTES, macrophage inflammatory protein 1 α (MIP1α) and MCP1 
(177) showed that 2hrs pre-treatment with IFNβ, plus addition of IFNβ to PBMC suspension 
before migration commencement, resulted in a reduction of migration compared to 
unstimulated PBMCs (177). This reduction of migration is likely due to the IFNβ related 
inhibition of the matrix metallopeptidase (MMP)9 mRNA expression and protein secretion, 
which would be otherwise enhanced in the presence of chemokines such as MCP1 (177). 
MMP9 is a matrix metalloproteinase which facilitates T lymphocyte migration across 
extracellular matrix likely through the interaction with fibronectin (178). This process was 
confirmed in another study by the same group, which showed that T cells migrated via the 
degradation of fibronectin (178).  IFNβ reduced T cell migration and reduced MM9 activity 
(178). The study concluded that T cells migrate through interaction of MMP9 and fibronectin, 
and IFNβ reduces migration by dysregulating this interaction (178).  
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IFNγ has been shown in other studies to up-regulate neutrophil chemotaxis through the up-
regulation of receptors CCR1 and CCR3, whereas in T lymphocytes, IFNγ has no effect on 
chemotaxis (178, 179). In contrast to the experimental conditions conducted in this present 
study, the incubation time of the neutrophils with the three IFN subtypes is different in this 
published study; neutrophils were primed for 6hrs with IFNγ before a 60mins migration assay 
(179). Time of exposure may therefore be a key factor. It is also possible that the chemokines 
used here to analyse the effect of directly induced migration may affect the results obtained. 
Although IL-8 and fMLP are potent and effective neutrophil chemokines, they are not the 
only neutrophil chemokines known (Section 1.5.3.3). It may be that the IFN subtypes up- or 
down-regulate other chemokine or chemoattractant receptors and that they may be more 
influential on chemotaxis and be key chemokines not used in this study. This is supported by 
a study that showed IFNγ not only up-regulated CCR1, CCR3 (both interact with MCPs and 
RANTES) and the MIP1α receptor on neutrophils, but also induced an increase in neutrophil 
migration towards MCP3, MIP1α, MIP5 and RANTES (179-182). As previously indicated, IFNβ 
reduced MMP9 in PBMCs, and also reduced migration of these cells towards RANTES, MIP1α 
and MCP1 (177).  
It should be noted that in the chemotaxis assays, IFN priming resulted in a reduced and thus 
limited number of cells. This is due to loss of cells initially when lifting from the plate (through 
neutrophil adhesion to the wells, which were difficult to remove) and through subsequent 
centrifugation during washing steps. However, the cells were re-counted and each donor set 
was standardised to the lowest neutrophil concentration to minimise any effect this 
experimental issue may have on subsequent results. Additionally, a haemocytometer was 
used, and although it is not the most reproducible method of counting, every effort was 
made to keep counting as accurate as possible.  
In conclusion, in this model of neutrophil chemotaxis and experimental conditions 
investigated, there was no evidence to support the role of any of the IFN subtypes in having 
a direct effect or post stimulation effect on neutrophil chemotaxis investigate. They may 
however have a role in neutrophil migration under the direction of other chemokines not 
studied here.  
3.6.2. IFNs and neutrophil phagocytosis 
It has been established that neutrophil phagocytosis is dysregulated in JSLE and that there 
are various factors that affect phagocytosis (112, 115, 189) (Sections 1.3.2 and 1.4.3). IFN 
subtypes have previously been shown to affect phagocytosis in various ways. However, this 
110 
 
effect is dependent upon a variety of factors, including type of immune cell, type of bacteria 
and the receptors used to undergo phagocytosis (183, 184). 
In this study, it was shown that IFN priming using any of the IFN subtypes had no overall 
effect on neutrophil phagocytosis of E.coli bioparticles, although there was a large donor 
variation in the results obtained. This is interesting as it has been suggested that IFNs can up-
regulate the neutrophil phagocytosis of S. aureus bacteria and in particular IFNγ can up-
regulate phagocytosis of S.aureus bioparticles (184, 185). This suggests that the mechanism 
of action of IFNs on phagocytosis is reliant on the cell types and bacteria being studied. The 
importance in the type of bacteria or particle being phagocytised has previously been noted. 
IFNα increases macrophage phagocytosis of both E.coli and erythrocytes, whereas IFNγ only 
decreases macrophage phagocytosis of E.coli (183). Additionally, the differential effect of 
IFNγ on phagocytosis is dependent on the type of immune cell being used; IFNγ up-regulates 
neutrophil phagocytosis but down-regulates macrophage phagocytosis (183, 184).  
It is of note that LDGs have reduced phagocytosis compared to normal density neutrophils 
(Section 1.2.2.2). It was observed that SLE and JSLE patients have increased LDGs, which 
correlate with disease activity; therefore these LDGs may be contributing to any reduced 
phagocytosis seen in SLE and JSLE. Therefore, it would be of interest to investigate the role 
of IFNs on LDG phagocytosis, which may result in a different observation than shown within 
this thesis.  
In summary, although there is some indication from mouse studies that IFNγ may have a role 
in the reduced phagocytosis seen in JSLE, this was not supported for the role of any of the 
IFN subtypes in specifically reducing neutrophil phagocytosis by data arising from this present 
study (112, 115, 183) (Section 3.5.3). Most previous literature indicates an IFN-induced 
increase in phagocytosis and receptors in healthy immune cells (184, 185). Previous literature 
suggests that generally, immune cell phagocytosis increases in the presence of IFNs (183-
185, 215). Therefore, as IFNs are increased in JSLE, decreased phagocytosis noted in JSLE is 
unlikely due to be directly under the influence of IFN involvement (41, 68, 112, 113, 115, 171, 
172). However, further investigation would be beneficial to fully elucidate IFNs influence on 
JSLE neutrophil phagocytosis, with an additional investigation of IFNs on LDG phagocytosis.  
3.6.3. IFNs and NETosis 
NETosis has been shown to be up-regulated in both SLE and JSLE patients (163, 208) (Section 
1.4.3). It has been proposed that IFNs have a role in increased NET formation through 
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priming, and NETing neutrophils in turn have been indicated to promote IFNα production 
from pDCs in JSLE (163, 175).  
In this study, using confocal microscopy, the results showed that unstimulated neutrophils 
did not undergo NETosis, and IFN stimulated neutrophils had minimal subsequent NET 
formation irrespective of IFN subtype (Section 3.5.4). Priming of neutrophils with TNFα 
caused a slight increase in NET production, with IFN stimulation on occasion having an 
additional increasing effect with each of the IFN subtypes; however, this effect varied 
between donors (Section 3.5.4). IFN priming also slightly induced more NET formation when 
LPS stimulation was used. However, again this varied between donors. Additionally, LPS on 
its own had no effect on NETosis compared to unstimulated naïve neutrophils, suggesting 
priming with cytokines is an important step in NETosis (Section 3.5.4). This suggestion that 
IFN priming may increase NETosis following subsequent stimulation correlates well with 
published data (175). However, it was shown that IFN stimulation alone is not enough and 
that IFN priming with additional subsequent stimuli are needed to induce NETosis (163, 175). 
It is noted that the staining for confocal microscopy as conducted in these experiments only 
targeted DAPI. Thus, although the ‘NETs’ seen were likely to be neutrophil DNA material, 
quantification of the images could be very subjective. Additionally, there was a great deal of 
intra and inter donor variation between images and thus may be too inconsistent to fully 
conclude analysis. DNA quantification was used as an additional method in an attempt to 
provide a quantitative measure of NETosis (Section 3.4.3.4). The DNA quantification method 
showed that only PMA, the positive control, induced a quantifiable increase in DNA release 
from NETs, albeit that this also was the only experimental condition that consistently showed 
NETs in the confocal images (Sections 3.5.4.1, 3.5.4.3). All the other conditions did not have 
any quantifiable additional DNA compared to unstimulated neutrophils. This correlates 
somewhat with the confocal images, that although generally there was not huge overall 
induction of NETs in any condition other than PMA, some images did show some increase in 
NETosis, through release of DNA. However, this increase in DNA release in some donors was 
not detected by the DNA quantification (Section 3.5.4.3). This may be due to the 
concentration of the DNA in the supernatants was below the sensitivity of the DNA 
quantification kit, or the DNA was lost in the supernatant processing.  
Although these data do not show any significant involvement of IFN or its various subtypes 
in NETosis, either as stimulants or priming agents, a published study indicated a IFN priming 
role (175). It is likely that the high level of IFNs within JSLE serum may be priming neutrophils 
112 
 
to undergo NETosis upon stimulus from infections (163, 175). JSLE neutrophils have also been 
suggested to have dysregulated signalling pathways (particularly shown through the 
increased pro-apoptotic proteins, and decreased anti-apoptotic proteins) and thus their 
intracellular components may cause the JSLE neutrophils to become more susceptible to 
induced NETosis than the healthy adult neutrophils used in this study (170).  
Additionally, literature has stated that LDGs have enhanced ability to undergo NETosis 
compared to normal density neutrophils (40) (Section 1.2.2.2). These LDGs may contribute 
more so to any increased NETosis seen with SLE and JSLE patients, and therefore priming or 
stimulating LDGs with IFNs may result in more NETs than what is observed here. Investigation 
of IFNs and LDG NETosis may be paramount in future work. 
Of note, effort was made within this study to quantify the number of NETs seen in the 
confocal images by multiple operators within the laboratory. This post hoc analysis was 
conducted so that some quantification comparison could be used to: a) accurately and 
statistically compare the conditions observed and b) to compare the confocal images to the 
DNA assays conducted. However, this quantification method from confocal images was very 
limited in that categorising viable and NETing neutrophils from confocal images was very 
subjective between operators. This limitation was particularly problematic in images that 
contained clumps of neutrophils; there was a difficulty in concluding what proportion of the 
clump was viable neutrophils and what portion was NET material.  
Quantification of confocal images can be conducted using computer software. This requires 
programming the software to differentiate between viable and NETing neutrophils and 
remove viable cell fluorescence from the analysis to give an accurate NET fluorescence 
measurement. However, this method may not have been possible in the more problematic 
clumps of neutrophils seen in the confocal images as NETs and viable neutrophils were not 
easily distinguishable from each other. However, a study has successfully used ImageJ in 
another way to quantify NETs; the area of Sytox green, which detects extracellular DNA, was 
measured and normalised to the mean area of PKH26, which detects all neutrophils (216). 
This may be a more sensitive way to distinguish NETs and viable neutrophils and allow for a 
more rigorous and objective quantification through ImageJ. Automated/computational 
quantification of microscopy images have been also been reported (217). The study used a 
series of images that contain DNA and histone fluorescent labelling, and manually label NET 
regions (217). This allows for a model to be produced that can be applied to other images to 
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estimate the area of NETs (217). This automation correlated well with human labelling, and 
thus may be useful to use in future experiments (217).  
It should be noted that the scoring system used for analysing NETs on confocal images in this 
study has been used successfully by another group (218). The group added LL37 and NE 
staining, which visualised NETs more clearly and thus allowed more consistent quantification 
than was possible in this study (218). Thus, the images, and scoring, showed here may be 
improved using additional NET-associated protein staining. This additional staining may be 
particularly beneficial in regards to images containing clumps where distinguishing viable 
cells from NETs was difficult; the additional staining may improve the quality of the images, 
which may improve ease of scoring and allow for more consistent quantification of the 
images.  
Measuring certain components of NET material using quantitative methods (such as 
fluorescent emission using a plate reader) could be another useful way to accurately and 
objectively analyse NET release. Although DNA was quantifiably measured from neutrophil 
supernatants, a question of the kit’s sensitivity did arise; there were some images that 
showed an increase in NET material in the form of DNA in some of the conditions, and this 
was not obviously detected in the supernatant by the DNA quantification assay. Thus, other 
components may be easier to retain a large enough quantity in the supernatant processing, 
and thus easier to quantify (maybe by more sensitive assays), such as the release of proteins 
associated with NETs, such as histones, MPO and NE.  
 
3.7. Summary  
Functionally, in this study, the IFN subtypes demonstrated little influence on neutrophil 
chemotaxis and phagocytosis, although this may be due to many factors including the choice 
of chemokines and bacteria used in this study. However, from these data, it seems that if 
IFNs do have a role, especially with phagocytosis, it does not explain the marked 
dysregulation of phagocytosis seen in JSLE. This study suggested that IFNs have a priming role 
on NETosis but showed no marked NET-inducing role in naïve or TNFα-primed neutrophils. 
The role of IFN may be purely priming and that it may be other factors such as pathogens 
having a greater role in inducing NETosis. 
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Chapter 4: The role IFNs in neutrophil apoptosis in 
JSLE 
4.1. Introduction  
Apoptosis, the process of programmed cell death, is a crucial physiological function, and is 
important in the resolution of inflammation (73). It takes place through the cleavage of 
caspases, with active caspase 3 (cleaved from the inactive caspase 3 during apoptosis) being 
the ultimate apoptotic effector protein (73) (Section 1.3.4). However, the observed increase 
in neutrophil apoptosis and subsequent dysregulation of clearance of apoptotic debris is 
thought to contribute to JSLE pathogenesis, leading to the increased production of 
autoantigens directed against nuclear material (72, 110, 113) (Section 1.1.4). 
The increase in neutrophil apoptosis within JSLE may be due to both environmental factors 
and intrinsic signalling factors (72, 170). SLE neutrophils have been shown to be activated 
through the up-regulation of activation marker CD11b, which may be a result of the pro-
inflammatory environment, and activation studies have shown this can alter activation and 
expression of intrinsic signalling proteins, such as increased activation of ERK and p38 MAPK 
proteins, and increase expression of IL-1 receptor (R)a and pro-IL-1β within neutrophils (83-
85). There is an imbalance of apoptotic factors within the serum of JSLE patients, with an 
increase concentration of pro-apoptotic factors such as Fas and TRAIL, and decrease of anti-
apoptotic factors such as GMCSF (72). It has also been shown that JSLE neutrophils express 
increased mRNA of pro-apoptotic proteins such as caspase 7, 8 and 9 and a decrease in anti-
apoptotic proteins such as IAP1 and 2 and xIAP (170).  
IFNs are important cytokines in innate immunity and are released in response to viral 
infection (Section 1.5). Type 1 and 2 IFNs, including IFNα and IFNβ, and IFNγ respectively, 
have been shown to be increased in serum from adults with SLE (171) (Section 1.5). However, 
to date, within the serum of individuals with JSLE, only IFNα was has been shown to be 
elevated (68, 172) (Section 1.5). Genome wide studies have described a granulocyte and IFN 
genetic signature, with increased expression of genes associated with neutrophils and the 
IFN signalling pathway, within PBMCs isolated from JSLE patients, (41). Therefore, this 
indicates a potential interaction between IFNs and neutrophils in JSLE. Type 1 and 2 IFNs have 
a pro- and anti-apoptotic effect, which can depend on cell type (138, 141, 164, 165, 219). 
IFNs signal through the JAK/STAT pathway, as shown in Figure 1.7 (Section 1.5.1). This is 
dependent on the downstream signalling pathway, whereby STAT1 is pro-apoptotic and 
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STAT3 is anti-apoptotic (138, 141, 164, 165, 219). It is possible that within JSLE, different IFN 
subtypes differentially effect the induction of anti-apoptotic effect through STAT3, or a pro-
apoptotic effect via STAT1 (Section 1.5.1). 
 TNFα has been shown to prime neutrophil functions and this priming activates neutrophils, 
which reflects of that of neutrophils in SLE (81-83). Through priming, TNFα can also alter the 
expression of proteins in neutrophils (84). Therefore, to fully investigate IFNs effect on 
apoptosis, TNFα priming of neutrophils can be used to model that of JSLE neutrophils and 
elucidate whether activation of neutrophils is an important step that leads to increased 
apoptosis in JSLE. 
GMCSF has been shown to reduce neutrophil apoptosis induced by JSLE serum, and the 
GMCSF anti-apoptotic mechanism is through the stability of MCL1, which inhibits the pro-
apoptotic Bak dimerization and activity (72, 77, 110, 220). Of note, GMCSF has been shown 
to also reduce the activation of pro-apoptotic proteins caspase 3, caspase 7 and caspase 8 
within healthy neutrophils incubated with JSLE serum (110). Therefore, in this study, GMCSF 
is used as a positive control for a reduction in apoptosis in JSLE, and its downstream effect 
on anti-apoptotic MCL1.  
4.1.1. Summary 
Neutrophils are more apoptotic in JSLE. This may be due to both a pro-inflammatory and 
apoptotic environment which activates neutrophils, and a potential up-regulation of intrinsic 
pro-apoptotic proteins compared to healthy neutrophils. Type 1 and 2 IFNs are both 
increased in SLE serum and in particular IFNα concentrations are increased in JSLE serum. 
The increased IFN and granulocyte genetic signatures present in JSLE indicates a potential 
interaction. Thus, further understanding on whether the IFN subtypes may be involved in 
regulating increased neutrophil apoptosis is required, which could indicate a potentially 
relevant signalling pathway in JSLE pathogenesis and therefore a potential therapeutic 
target.  
 
4.2. Chapter hypothesis 
Type 1 and Type 2 IFNs have both a pro- and anti-apoptotic effect, and this is dependent on 
differential activation of the JAK/STAT pathway (discussed in Chapter 5). This differential 
apoptotic effect may be due to activation of neutrophils by either priming agents such as 
TNFα or the pro-inflammatory environment found in SLE and JSLE patients. It is therefore 
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hypothesised that one or more IFNs may have an anti-apoptotic effect on naïve/healthy 
neutrophils and a pro-apoptotic effect on primed or JSLE neutrophils.     
  
4.3. Chapter aim and objectives 
Aim: To investigate the role of IFNs on neutrophil apoptosis. 
 Objective 1: Using flow cytometry, quantify the rate of apoptosis on naïve and TNFα-
primed healthy adult neutrophils following a 6hr incubation with a high 
concentration of IFNs. 
 Objective 2: Using flow cytometry, quantify the rate of apoptosis on naïve and TNFα-
primed healthy adult neutrophils following a 6hr incubation with a lower 
concentration IFNs, and measure the downstream expression of anti-apoptotic MCL1 
(at 6hrs) and caspase 3 (at 20hrs) using Western blotting. 
 Objective 3: Using flow cytometry, quantify the rate of apoptosis on naïve and 
patient sera-primed healthy adult neutrophils following a 6hr incubation with a lower 
concentration IFNs. 
 Objective 4: Using flow cytometry, quantify the rate of apoptosis on paediatric 
control patient and JSLE patient neutrophils following a 6hr incubation with a lower 
concentration IFNs. 
 
4.4 Methods 
4.4.1. Flow cytometry analysis 
4.4.1.1. Neutrophil priming and stimulation with a high concentration of IFNs 
Neutrophils were isolated from healthy adults (Section 2.5.2) Neutrophils were either 
unstimulated or primed with 1µg/ml TNFα for 30mins at 37°C, 5% CO2, 5x105 neutrophils per 
condition. Neutrophils were either analysed for evidence of their activation (Section 4.4.2.6) 
and/or subsequently stimulated for 6hrs with 10µg/ml IFNα, 1µg/ml, IFNγ or 1µg/ml IFNβ for 
6hrs at 37°C, 5% CO2, using 5x105 neutrophils per condition. Apoptosis was analysed (Section 
2.6.2.2) and results analysed on Kaluza. 
4.4.1.2. Lower concentrations of IFNs on naïve neutrophils at 6hrs and 20hrs 
117 
 
An IFN dose response was conducted (Section 2.6.2.1) for each of the IFN subtypes, whereby 
only 10ng/ml IFNβ had any differential effect on apoptosis compared to other doses of IFNβ; 
there were no differences in the rate of apoptosis with each of the different doses of IFNα or 
IFNγ investigated, and thus a concentration of 10ng/ml for each of the IFN subtypes was 
chosen. Neutrophils were isolated from healthy adults (Section 2.5.2) and were either 
unstimulated or incubated for 6hrs with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 
6hrs and 20hrs at 37°C, 5% CO2, using 1x105 neutrophils per condition. Apoptosis was 
analysed (Section 2.6.2.2) and results analysed on FlowJo. 
4.4.1.3. Lower concentrations of IFNs on TNFα-primed neutrophils 
Neutrophils were isolated from healthy adults (Section 2.5.2) and were either unstimulated 
or primed with 1µg/ml TNFα for 30mins at 37°C, 5% CO2, 1x105 neutrophils per condition. 
Neutrophils were analysed for activation (Section 4.4.2.7) and subsequently incubated for 
6hrs with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs at 37°C, 5% CO2, using 1x105 
neutrophils per condition. Apoptosis was analysed (Section 2.6.2.2) and results analysed on 
FlowJo.  
4.4.2.3. Patient sera selection 
The patients’ pBILAG score (Sections 1.1.3 and 2.4) at the time of sample collection was used 
to select serum samples from JSLE patients with active or inactive disease. Samples were 
characterised as inactive, active in the renal domain or active in the haematological domain 
of pBILAG – Section 2.4. Inactive JSLE sera were selected based on having a score of D or E in 
all organ domains of the pBILAG with a resulting overall pBILAG score of 0. JSLE sera that 
were active in the haematological domain were chosen based on an A or B in the 
haematological domain of the pBILAG, with an overall pBILAG score of >6. JSLE sera that were 
active in the renal domain were chosen based on an A or B in the renal domain of the pBILAG, 
an overall pBILAG score of >6. Sera from patients who were dually active in the 
haematological and renal domains were not selected due to overlap and thus may affect 
result analysis. Demographics were analysed; the age at sampling and gender were analysed 
first to select approximately aged matched and gender matched paediatric control patient 
sera. Other demographic variables analysed included: duration of disease, ethnicity, family 
history, medication and clinical biomarkers such as dsDNA, C3 and erythrocyte sediment rate 
(ESR). 
 
4.4.2.4. Lower concentrations of IFNs on patient sera-primed neutrophils 
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JSLE patient sera samples were selected based on clinical conditions at sampling (Section 
4.4.2.3 and Section 2.4), and paediatric control patient were selected from age- and gender-
matched patients (Section 4.4.2.3 and Section 2.4). Neutrophils were isolated from healthy 
adults (Section 2.5.2) and were either incubated in 10% FBS or primed with 10% patient sera 
for 30mins at 37°C, 5% CO2, 9x104 per condition. Neutrophils were either analysed for 
activation (Section 4.4.2.7) or subsequently stimulated with 5ng/ml of GMCSF, 10ng/ml IFNα, 
10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs at 37°C, 5% CO2. Apoptosis was analysed (Section 
2.6.2.2) and results analysed on FlowJo.  
4.4.2.5. IFN effect on apoptosis in paediatric control and JSLE patient neutrophils 
Neutrophils were isolated from healthy adults (Section 2.5.2) and were unstimulated or 
stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs at 37°C, 5% CO2, using 
1x105 neutrophils per condition. Apoptosis was analysed (Section 2.6.2.2) and results 
analysed on FlowJo. Demographic information was also analysed, including age at sampling, 
disease duration, ethnicity, family history, medication and clinical markers such as dsDNA, C3 
and ESR. 
4.4.2.6. Activation assay for high concentrations of IFNs 
Initially, we aimed to analyse the effect of a high, saturating concentration of IFNs on naïve 
and TNFα-primed neutrophils. An initial dose response of 1, 5 and 10µg/ml TNFα (data not 
shown), showed no significant difference in concentrations on the priming of neutrophils 
after 30mins. Subsequently, neutrophils were isolated from healthy adults (Section 2.5.2) 
and were either unstimulated or treated with 1µg/ml TNFα for 30mins at 37°C, 5% CO2, using 
1x106 neutrophils per condition. Neutrophils were centrifuged at 1800 RPM for 5mins, and 
the supernatant was poured off. Neutrophils were washed in 1ml PBS/0.5% BSA (Sigma-
Aldrich, UK), and centrifuged at 1500 RPM for 5mins. Neutrophils were suspended in residue, 
and stained with 100ng/ml CD11b (eBioscience, UK), 2.5μg/ml CD62L (eBioscience, UK), 
100ng/ml phycoerythrin (PE) isotype control (Beckman Coulter, UK) and 2.5μg/ml 
allophycocyanin (APC) isotype control (Beckman Coulter, UK). Neutrophils were incubated at 
4°C in the dark for 30mins, and then centrifuged at 1500 RPM for 5mins. The supernatant 
was poured off and neutrophils were suspended in 600µl PBS/0.5% BSA, and samples run 
through the flow cytometer using pre-programmed activation assay. Data were analysed 
using Kaluza. 
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4.4.2.7. Activation assay for lower concentrations of IFNs 
As the activation assay above did not consistently show an increase in CD11b upon TNFα 
priming, a new activation assay was set up to analyses the activation of neutrophils before 
stimulation with a lower concentration of IFNs. This lower concentration was more akin to 
cytokine stimulation published in other studies (77, 110, 221).  
Neutrophils were isolated from healthy adults (section 2.5.2). Neutrophils were treated with 
1µg/ml TNFα for 30mins at 37°C, 5% CO2, using 1x105 neutrophils per condition or 10µl of a 
patient serum for 30mins at 37°C, 5% CO2, 9x104 neutrophils per condition. The plate was 
centrifuged at 1800 RPM for 5mins, and the supernatant was decanted. Neutrophils were 
washed in 100μl of PBS/0.5% BSA, and the plate was centrifuged at 1500 RPM for 5mins. The 
supernatant was decanted and 100μl of PBS/0.5% BSA was added. PE and APC isotype 
controls (eBioscience, UK), and CD11b and CD62L were added individually to unstimulated 
neutrophils to a final concentration of 1μg/ml. Dual stain CD11b and CD62L were added to 
unstimulated and TNFα-stimulated neutrophils at a final concentration of 1μg/ml. 
Neutrophils were incubated at 4°C for 30mins, and the plate centrifuged at 1500 RPM for 
5mins. The supernatant was decanted and 200μl PBS/0.5% BSA was added. The neutrophils 
were transferred to 5.4ml flow cytometry tubes and run through Guava EasyCyte, using a 
pre-set protocol.  
4.4.2.8. Activation assay for patient neutrophils  
Neutrophils were isolated from paediatric control and JSLE patients (Section 2.5.2) and 
seeded at 1x105. The plate was centrifuged at 1800 RPM for 5mins, and the supernatant 
decanted. Neutrophils were washed in 100μl of PBS/0.5% BSA, and the plate was centrifuged 
at 1500 RPM for 5mins. The supernatant was decanted and 100μl of PBS/0.5% BSA was 
added. PE and APC isotype controls, and CD11b and CD62L were added individually to 
unstimulated neutrophils to a final concentration of 1μg/ml. Dual stain CD11b and CD62L 
were added to unstimulated and TNFα-primed neutrophils at a final concentration of 1μg/ml. 
Neutrophils were incubated at 4°C for 30mins, and the plate centrifuged at 1500 RPM for 
5mins. The supernatant was decanted and 200μl PBS/0.5% BSA was added. The neutrophils 
were transferred to 5.4ml flow cytometry tubes and run through Guava EasyCyte, using a 
pre-set protocol. 
4.4.2. Western blot analysis 
Neutrophils were isolated from healthy adults (Section 2.5.2) and seeded at 5x105 – 2x106 
per condition. Neutrophils were stimulated with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ 
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or 10ng/ml IFNβ for 6hrs or 20hrs 37°C, 5% CO2. Proteins were extracted and analysed for 
MCL1 (6hrs IFN stimulation) and caspase 3 (20hrs IFN stimulation) using Western blotting 
(Section 2.7). 
4.4.3. Statistical analysis 
The raw data obtained from the experiments carried out here were analysed in GraphPad 
Prism 6. Friedman’s test with Dunn’s post hoc multiple comparison tests were conducted for 
analysis of the majority of data sets, to analyse between multiple paired conditions within a 
sample set. One-tailed Wilcoxon matched-pairs signed rank test was used for analysis of 
activation marker expression. Kruskal-Wallis test with a post hoc Dunn’s multiple comparison 
test was conducted for analysis of comparing multiple comparisons between JSLE and 
paediatric control patient data sets. For full justification, see Section 2.10. 
 
4.5. Results 
4.5.1. Optimisation of the apoptosis assay 
Initial experiments were conducted to optimise the neutrophil apoptosis assays. Using the 
assay outlined previously (Section 2.6.7.1), preliminary experiments of rates of apoptosis 
showed variability at 4hrs and a higher than anticipated rate at 6hrs (see Figure 4.1, A). 
GMCSF did not always reduce apoptosis, and the observed reductions were variable. The 
event rates achieved on the flow cytometer were inconsistent and often too low to analyse, 
and thus optimisation of the assay was needed.  
It was found that plating/incubating neutrophils and staining the neutrophils in a 96 well 
plate increased the rate of cells going through the flow cytometer compared to using a 24 
well plate to incubate cells and staining in flow cytometry tubes. The PI stain incubation was 
reduced to 2mins, as 5mins was deemed excessive due to the swift rate it was able to stain 
the neutrophils. The last centrifugation that was originally 1500 RPM for 5mins was omitted 
to reduce the amount of assay-induced apoptosis before the flow cytometry analysis and to 
retain an appropriate yield of as many viable neutrophils as possible (Figure 4.1, B). These 
steps improved the quality of the data set, via event rate and viability of cells, and the data 
was more consistent with that of published data. 
An IFN dose response on inducing apoptosis was conducted, using doses of: 5 and 10μg/ml 
IFNα, 1, 5 and 10μg/ml IFNγ and 1 and 5μg/ml IFNβ. The dose response showed that 10μg/ml 
IFNα had the greatest reducing effect on apoptosis (data not shown), whilst little differences 
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were seen in the various doses of IFNγ and IFNβ. It was therefore agreed that 10μg/ml of 
IFNα, 1μg/ml IFNγ or 1μg/ml of IFNβ were the most appropriate concentrations to maximise 
the effect seen (Figure 4.1, C and D). Thus, subsequent experiments were conducted using 
these concentrations. 
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Figure 4.1. Apoptosis analysis of healthy adult neutrophils at 6hrs. Neutrophils were 
isolated from healthy adult donors and were left unstimulated or stimulated with a dose 
response of IFNs and incubated for 6hrs. Unstimulated neutrophils were stained with 
Annexin V FITC and PI using the original protocol and measured using Beckman Coulter F500 
and analysed using Kaluza software (A) or stained with optimised protocol and measured 
using Guava EasyCyte and analysed using FlowJo software (B). The initial apoptosis 
experiments had inconsistent results, and as shown, had abnormally increased annexin V 
FITC staining (dot blot A, quadrant E4, 47.7% annexin V FITC staining), indicating increased 
apoptosis. With the optimised apoptosis assay, the annexin V FITC was reduced (dot blot B, 
quadrant Q7, 23% annexin V FITC staining), indicating less apoptosis, which is more 
consistent with published data. A dose response of IFNγ and IFNβ were conducted (C and D 
respectively), and apoptosis was measured at 6hrs using Beckman Coulter F500 and this 
showed little differences in IFNγ and IFNβ dose responses and thus 1μg/ml was used in 
subsequent experiments.
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4.5.2. Activation assay optimisations 
It has previously been shown that TNFα, amongst other cytokines, is a potent neutrophil 
priming agent (81, 84, 85, 90, 167) (Section 1.3.5). It has been demonstrated that in 
individuals with SLE, neutrophils are activated and this may be true of neutrophils in 
individuals with JSLE (83) (Section 1.3.5). Therefore, neutrophil activation, through TNFα 
priming, was used to model neutrophils that may be present in inflammatory conditions such 
as those occurring in JSLE patients. This model was used frequently in this study, as an 
activated neutrophil phenotype was considered important in the investigation of how the 
different IFN subtypes may subsequently affect JSLE neutrophil apoptosis. However, it is 
notable that data need to be carefully analysed an interpreted in this scenario, as TNFα can 
have both pro- and anti-apoptotic effects on neutrophils (23). 
An activation assay was therefore set up on the Beckman Coulter F500 flow cytometer, and 
a dose response of 1, 5 and 10μg/ml TNFα was investigated. A 1:100 – 1:1000 dilution of 
CD11b, and a 1:40 dilution of CD62L were used to stain cells within the flow cytometry tubes. 
Little difference was observed in the activation effects of the different TNFα concentrations 
(data not shown), and thus a TNFα concentration of 1μg/ml was used in subsequent 
experiments. Although an increase in CD11b was not consistently seen, a significant decrease 
in CD62L was seen following stimulation with TNFα (Figure 4.2) (see also Section 4.5.3.1 for 
actual results of assays). This was therefore used to analyse initial TNFα-induced priming for 
subsequent incubation of neutrophils with the high concentration of IFNs.  
Another activation assay was developed in order to analyse both CD11b and CD62L in a more 
rigorous and consistent way using the Guava EasyCyte. Additionally, neutrophils were 
stimulated and stained in a 96 well plate to improve cell viability, event count and quality of 
staining. Neutrophils were primed with 1μg/ml TNFα and stained with 1:100 diluted CD11b 
and CD62L. Comparative isotype controls were used to confirm specific binding. There was 
an increase in CD11b and decrease in CD62L in TNFα-primed neutrophils compared to 
unstimulated neutrophils, confirming activation (Figure 4.3). This assay was used for all 
activation assays using the lower concentration of IFNs.  
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Figure 4.2. TNFα priming of healthy adult neutrophils resulted in a reduction in expression 
of CD62L, assessed using the Beckman coulter flow cytometry assay. Neutrophils were 
isolated from healthy adult donors and were left naïve or primed with 1μg/ml TNFα for 
30mins. Neutrophils were stained with CD62L antibody and the relative expression via 
geometric mean of CD62L was measured using flow cytometry. A reduction of CD62L 
expression after priming with TNFα (red) was noted compared to unstimulated neutrophils 
(green peak) indicating successful neutrophil priming. 
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Figure 4.3. TNFα priming of healthy adult neutrophils resulted in neutrophil activation, 
assessed using the Guava EasyCyte flow cytometry assay. Neutrophils were isolated from 
healthy adult donors and were left naïve or primed with 1μg/ml TNFα for 30mins. 
Neutrophils were stained with CD11b and CD62L antibodies and the relative expression 
assessed by determining the geometric mean expression for CD11b (A) and CD62L (B) using 
flow cytometry. An increase in CD11b expression (purple, Figure A) and a decrease in CD62L 
expression (purple, Figure B) compared to unstimulated neutrophils (green, both figures) 
confirms neutrophil activation. Isotype controls (blue, both figures) and unstained 
neutrophils (red, both figures) were used to confirm specific binding.  
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4.5.3. Investigating the rate of neutrophil apoptosis in naïve and primed 
healthy adult neutrophils following incubation with a high concentration of 
IFNs 
Published data suggests that IFNs have both an anti- and pro- apoptotic function (138, 141) 
(Section 1.5.3.1), and thus this dual function may be dependent on the activation state of 
neutrophils. Therefore, the effect of a high concentration of IFNs on apoptosis in naïve and 
primed neutrophils was investigated. 
4.5.3.1. The effect of TNFα on neutrophil priming 
The first objective was to confirm that TNFα was able to prime neutrophils, which is shown 
here through the shedding of CD62L. Initial 30 min priming of healthy adult control 
neutrophils with 1µg/ml of TNFα showed significant reduction in CD62L (1.61 ± 0.3, n=5, 
p=0.031) compared to unstimulated neutrophils (11.4 ± 1.4, n=5) (Figure 4.4). This confirmed 
neutrophil priming for subsequent incubation of these neutrophils with the different IFNs.  
4.5.3.2. The effect of a high concentration of IFNs on naïve and primed neutrophil 
apoptosis 
Naïve and primed neutrophils were stimulated with 10µg/ml of IFNα and 1µg/ml of IFNγ and 
IFNβ for 6hrs, and apoptosis was measured (section 2.6.2.2). In naïve neutrophils, IFNα (6.6 
± 1 .2%, n=5) and IFNγ (10.8 ± 1.9%, n=5) both reduced apoptosis in compared to 
unstimulated neutrophils (22.0 ± 3.2%, n=5) although the reduction was not statistically 
significant (p>0.5), whereas IFNβ had no demonstrable effect (20.3 ± 5.1%, n=5) (Figure 4.5). 
However, in primed neutrophils, IFNα (48.9 ± 4.8%, n=5), IFNγ (43.1 ± 3.0%, n=5) and IFNβ 
(39.4 ± 3.2%, n=5) all induced apoptosis compared to unstimulated naïve neutrophils (22.0 ± 
3.2%, n=5) although these differences did not meet statistical significance (p>0.05) (Figure 
4.5). This increase in neutrophil apoptosis was not due to TNFα in the neutrophil suspension 
as priming with TNFα had no effect on apoptosis in unstimulated neutrophils (26.4 ± 4.3%, 
n=5) (Figure 4.5).  
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Figure 4.4. Neutrophils were isolated from healthy adult donors and were left naïve or were 
with 1μg/ml TNFα for 30mins. Neutrophils were stained with CD62L antibodies and the 
relative expression via geometric mean of CD62L was measured using flow cytometry. 
Neutrophils were deemed primed when CD62L was shed, as measured by the geometric 
mean (n=5, p=0.031).  
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Figure 4.5. Apoptosis analysis of naïve and 1μg/ml TNFα-primed adult healthy neutrophils 
after 6hr incubation with 10μg/ml IFNα, 1μg/ml IFNγ or 1μg/ml IFNβ. Neutrophils were 
isolated from healthy adult donors and were left naïve (blue) or were primed with 1μg/ml 
TNFα for 30mins (red), and subsequently stimulated for with 10μg/ml IFNα, 1μg/ml IFNγ or 
1μg/ml IFNβ for 6hrs. Neutrophils were stained with annexin V FITC and PI, and the 
percentage of apoptosis was measured using flow cytometry (n=5). 
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4.5.4. Investigating the role of lower concentration of IFNs on apoptosis in 
naïve and primed neutrophil at 6hr and 20hrs 
Following on the observations that high concentrations of IFNs have a dual effect on 
neutrophil apoptosis depending on whether the neutrophils are naïve or primed (Section 
4.5.3), the next objective was to investigate how a lower concentration of (10ng/ml) IFNs 
(which are more typically used in in vitro models (77, 110)) affected neutrophil apoptosis. An 
initial investigation of IFNs at 6hrs and at 20hrs was aimed to explore any effect on either the 
immediate or prolonged neutrophil lifespan. 
Healthy adult neutrophils were stimulated with lower concentrations of IFNs (10ng/ml) and 
GMCSF (5ng/ml) for 6 and 20hrs, and apoptosis was measured (Section 2.6.2.2). At 6hrs it 
was shown that compared to unstimulated neutrophils (17.4 ± 5.0%, n=5), both IFNγ (10.4 ± 
3.8%, n=5, p=0.037) and positive control GMCSF (5.4 ± 1.2%, n=5, p=0.0013) significantly 
reduced the level of apoptosis (Figure 4.6A). There was a suggestion that IFNα (14.7 ± 3.9%, 
n=5) and IFNβ (14.0 ± 4.2%, n=5) had some reducing effect on apoptosis at 6hrs, however 
this difference was not statistically significant (p>0.5). This reducing effect on apoptosis was 
also seen at 20hrs, where compared to unstimulated neutrophils (74.1 ± 4.1%, n=5), IFNα 
(62.1 ± 3.4%, n=5), IFNγ (61.8 ± 6.3%, n=5) and IFNβ (63.4 ± 4.5%, n=5) had a smaller reduction 
in the level of apoptosis but GMCSF significantly reduced the level of apoptosis (53.2 ± 3.5%, 
n=5, p=0.0055) (Figure 4.6B). These data suggest that the optimal effect of IFNs on neutrophil 
apoptosis is at 6hrs rather than at 20hrs. 
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Figure 4.6. Apoptosis analysis of healthy adult neutrophils after 6hr and 20hr incubations 
with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ. Neutrophils were 
isolated from healthy adult donors and were left unstimulated or were stimulated with 
5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs (A) or 20hrs (B). 
Neutrophils were stained with annexin V FITC and PI, and the percentage of apoptosis was 
measured using flow cytometry. GMCSF and IFNγ significantly reduced apoptosis at 6hrs (A) 
(GMCSF – **, n=5, p=0.0013; IFNγ - *, n=5, p=0.037) and GMCSF, significantly reduced 
apoptosis at 20hrs (B) (**, n=5, p=0.0055). 
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4.5.5. Downstream apoptosis signalling pathway analysis at 6hrs and 
20hrs 
In view of both the pro- and anti-apoptotic effects seen in IFN-stimulated neutrophils, it is 
important to investigate the influence of the different IFNs on stability of anti-apoptotic 
MCL1 and cleavage of pro-apoptotic caspase 3 from procaspase 3. As a control, GMCSF was 
used, which has been shown to reduce apoptosis through the stability of MCL1 (77) (Section 
1.3.4). 
Downstream proteins important in apoptosis were measured by Western blotting (Section 
2.7). MCL1 was measured after 6hrs 10ng/ml IFNα 10ng/ml IFNγ 10ng/ml IFNβ and 5ng/ml 
GMCSF incubation and procaspase 3/caspase 3 was measured after 20hrs 10ng/ml IFNα, 
10ng/ml IFNγ, 10ng/ml IFNβ and 5ng/ml GMCSF incubation.  
At 6hrs, only GMCSF stabilised MCL1 expression in neutrophils (1.4 ± 0.6, n=5) compared to 
unstimulated neutrophils (0.6 ± 0.2, n=5, p=0.29) (Figure 4.7). This suggests that compared 
to unstimulated neutrophils, the IFN subtypes each had little effect on MCL1 stability (IFNα 
= 0.6 ± 0.1, n=5; IFNγ = 1.2 ± 0.75, n=5; IFNβ = 0.6 ± 0.2, n=5) (Figure 4.7). Thus, using flow 
cytometry, overall, the results show that although IFNs may have an anti-apoptotic effect at 
both a high and lower concentration (Figures 4.5 and 4.6), it is unlikely to be through MCL1 
stability (Figure 4.7).  
At 20hrs, neutrophils stimulated with all cytokines had a higher procaspase 3/caspase 3 
expression ratio (GMCSF = 5.6 ± 2.6, IFNα = 2.4 ± 0.6, IFNγ = 4.4 ± 0.9, IFNβ 3.1 ± 0.9, n=5) 
compared to unstimulated neutrophils (1.0 ± 0.3, n=5) indicating reduced cleavage of caspase 
3 (Figure 4.8). However, only the difference induced by IFNγ was statistically significant (n=5, 
p=0.0013) (Figure 4.8). This reduced caspase 3 cleavage generally at 20hrs reflects the 
reduction in apoptosis at this time point (see Figure 4.6B). It indicates that the IFN subtypes, 
specifically IFNγ, may reduce apoptosis through the reduction of cleaved caspase 3. 
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Figure 4.7. The expression ratio of MCL1/Β actin in healthy adult neutrophils after 6hr 
incubation with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ. Neutrophils 
were isolated from healthy adult donors and were left unstimulated or were stimulated with 
5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ respectively for 6hrs. Proteins 
were extracted, and the MCL1/Β actin expression ratios were measured using Western 
blotting. Analysis showed that GMCSF stabilises MCL1, whereas the different IFN subtypes 
had little effect (n=5).  
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Figure 4.8. The expression ratio of procaspase 3/caspase 3 in healthy adult neutrophils 
from after 20hr incubation with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml 
IFNβ. Neutrophils were isolated from healthy adult donors and were left unstimulated, or 
were stimulated with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 20hrs. 
Proteins were extracted, and procaspase 3/ caspase 3 expression ratios were measured using 
Western blotting. Analysis showed a decrease in caspase 3 cleavage (shown by a high 
procaspase 3/caspase 3 ratio) in all conditions. IFNγ significantly reduced the cleavage of 
caspase 3 (*, n=5, p=0.0013). The outlier within the GMCSF condition, although seems 
extreme, may be due to the variability of Western blotting protocol, although there were no 
obvious discrepancies within the raw data of that particular experiment compared to other 
blots. 
134 
 
4.5.6. Investigation of the effect of lower concentrations of IFNs on naïve 
and primed neutrophil apoptosis 
From data using a lower concentration of IFNs on apoptosis (Section 4.5.4), an important 
objective was to investigate how the different subtypes of IFNs (at 10ng/ml) effects apoptosis 
in naïve and primed neutrophils from healthy adults compared to that of the higher 
concentrations (1-10µg/ml, Section 4.5.3).       
The activation state of healthy adult control neutrophils was tested by measuring the 
expression of CD11b and CD62L on the neutrophil surface using flow cytometry after 30mins 
priming with 1µg/ml TNFα. There was a significant increase in CD11b (1779.8 ± 163.3 vs 
1128.8 ± 83.5, n=5, p=0.031) and a significant decrease in CD62L (92.6 ± 13.4 vs 460.0 ± 87.0, 
n=5, p=0.031) in TNFα-primed neutrophils compared to unstimulated neutrophils 
respectively, confirming neutrophil activation (Figure 4.9). 
Naïve and TNFα-primed neutrophils were subsequently stimulated with 10ng/ml, IFNα 
10ng/ml, IFNγ, 10ng/ml IFNβ and 5ng/ml GMCSF for 6hrs. Compared to naïve unstimulated 
neutrophils (25.3 ± 6.7%, n=5), IFNα (19.8 ± 6.5%, n=5), IFNγ (13.4 ± 4.9%. n=5) and IFNβ (17.9 
± 5.7%, n=5) all reduced apoptosis in naïve neutrophils (Figure 4.10), although these 
differences were not statistically significant. GMCSF significantly reduced the level of 
apoptosis occurring (6.9 ± 1.3%, n=5, p=0.026). This effect was abrogated in TNFα-primed 
neutrophils (IFNα = 21.7 ± 2.1%, IFNγ = 23.66 ± 4.4%, IFNβ = 27.4 ± 1.3%, n=5), although these 
differences were not statistically significant (Figure 4.10). 
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Figure 4.9. CD11b and CD62L expression analysis of healthy adult neutrophils primed with 
1µg/ml TNFα for 30mins. Neutrophils were isolated from healthy adult donors and were left 
naïve or were primed with 1µg/ml TNFα for 30mins. Neutrophils were stained with 
antibodies to CD11b (A) or CD62L (B) and the relative expression via geometric mean was 
measured using flow cytometry. Increase in CD11b and decrease in CD62L after TNFα priming 
confirms neutrophil activation (*, n=5, p=0.031). 
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Figure 4.10. Apoptosis analysis of naïve and 1μg/ml TNFα-primed adult healthy neutrophils 
after 6hrs incubation with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ. Neutrophils were 
isolated from healthy adult donors and were left naïve (blue) or were primed with 1μg/ml 
TNFα for 30mins (red), and subsequently stimulated with 5ng/ml GMCSF, 10ng/ml IFNα, 
10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs. Neutrophils were stained with annexin V FITC and PI, 
and the percentage of apoptosis was measured using flow cytometry. GMCSF significantly 
reduced apoptosis in naïve neutrophils compared to naïve unstimulated neutrophils (*, n=5, 
p=0.026). IFNs reduced apoptosis in naïve neutrophils, and this effect was abrogated in 
primed neutrophils (n=5). 
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4.5.7. Investigating the role of IFNs on adult neutrophil apoptosis in the 
presence of patient sera 
Following on from investigating the role of IFNs on apoptosis TNFα-primed neutrophils 
(which was a good, but simplistic in vitro model; Sections 4.5.3 -4.5.6), the next stage was to 
investigate how the complex JSLE environment affects IFN-related neutrophil apoptosis. 
Published data demonstrate that JSLE serum can increase the rate of neutrophil apoptosis 
and this increase may be due to the imbalance of apoptotic factors shown within the JSLE 
serum (72, 110) (Sections 1.4.3, 1.5.3.1, 4.1). It has been shown that adult-onset SLE 
neutrophils are more active than neutrophils from healthy adults, and that the serum may 
contain factors that cause this increase in activation (83) (Section 1.3.5). The following 
experiments aimed to investigate the influence of paediatric control and JSLE patient sera 
on: a) the activation state of healthy neutrophils; b) the subsequent influence on neutrophil 
apoptosis; and c) the influence on IFN-mediated apoptotic effect. 
4.5.7.1. Patient sera selections 
Patient sera were selected from the UK JSLE Cohort Study biobank based on their disease 
activity status, as determined by the patients’ pBILAG a time of sample collection. Samples 
were selected that were deemed inactive, active in the renal domain and active in the 
haematological domain of pBILAGs, (Section 4.4.2.3). In addition, age- and gender- matched 
paediatric control sera were also selected. Demographics, medication and laboratory 
variables were recorded (Table 4.1).  
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Table 4.1. Clinical and demographic information of individuals providing serum for 
experimental analysis at time of blood collection.  
Variables Active 
Haematological 
pBILAGa (n=3) 
Active Renal 
pBILAGa (n=5) 
Inactive pBILAGa 
(n=5) 
Control (n=5) 
Ageb  13.6 [13.1-15.3] 16.6 [11.9-18.0] 15.5 [12.2-18.0] 15.0 [14.8 – 15.4] 
Duration of disease 
(months)b 
25 [4-109] 13 [0-24] 18 [7-43] - 
Femalec 2 (66.6) 5 (100) 4 (80) 4 (80) 
Total pBILAG scored 9 [7-10] 9 [8-13] 0 - 
Ethnicity     
 White British - 3 (60) 4 (80) 4 (80) 
 Any other White 
background 
- 1 (20) - - 
 Bangladeshi 1 (20) - - - 
 Pakistani 1 (20) - 1 (20) - 
 Chinese - 1 (20) - - 
 Latin American - - - 1 (20) 
 Other 1 (20) - - - 
Family history      
  Autoimmune diseases - 3 3 - 
  Other 1 1 1 2 
  None 2 2 1 3 
Medicatione     
 Steroids 2 5 2 - 
 DMARDs 3 5 5 - 
 Other 2 4 2 1 
dsDNA (IU/L) 0  0  0 [0-7] - 
C3 (g/L) 1.13 [0.95-1.36] 1.07 [0.65-1.32] 1.11 [1.03-1.33] - 
ESR (mm/h) 1 [1-4] 2 [1-23] 8 [2-16] - 
Data are expressed as median and interquartile range [square brackets] or as total numbers 
with percentages (round brackets). 
pBILAG. Paediatric British Isles Lupus Assessment Group; DMARDs, disease-modifying anti-
rheumatic drugs; dsDNA, anti-double stranded DNA antibody; C3, complement component 
3; ESR, erythrocyte sedimentation rate. 
aClassification of patients into active disease in haematological domain (scored A/B), active 
disease in the renal domain (scored A/B) and inactive disease in all domains (D/E) was 
determined using the pBILAG. 
bAge and disease duration at time of serum sample collection.  
cGender of patients. 
dTotal pBILAG score determined by the numeric scoring of disease classifications of the organ 
domains. 
eMedication taken at time of serum sample collection. 
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4.5.7.2. The effect of JSLE patient and paediatric control sera on neutrophil 
activation 
Neutrophils from healthy adult neutrophils were incubated in media/10% FBS or primed with 
10% patient sera (Section 4.5.5.1) for 30mins and neutrophil activation was then analysed. 
Compared to FBS treated neutrophils, sera from paediatric control patients increased the 
expression of CD11b (1308 ± 161 vs 1025 ± 124, n=5) and significantly decreased the 
expression of CD62L (235 ± 96 vs 780 ± 95 n=5, p=0.031), indicating neutrophils were primed 
for activation (Figure 4.11). Compared to FBS treated neutrophils, sera from JSLE patients 
with inactive disease in all pBILAG domains significantly increased the expression of CD11b 
(1326 ± 120 vs 1025 ± 124, n=5, p=0.031) and significantly decreased the expression of CD62L 
(247 ± 65 vs 780 ± 95, n=5, p=0.031) indicating neutrophils were primed (Figure 4.12). 
Compared to FBS treated neutrophils, sera from JSLE patients with active disease in the renal 
pBILAG domain significantly increased the expression of CD11b (1414 ± 298 vs 1138 ± 214, 
n=5, p=0.031) significantly decreased the expression of CD62L (172 ± 48 vs 494 ± 56, n=5, 
p=0.031), indicating neutrophils were primed (Figure 4.13). Compared to FBS incubated 
neutrophils, sera from JSLE patients with active disease in the haematological pBILAG domain 
had no statistically significant effect on the expression of either activation markers (CD11b = 
961 ± 171.2 vs 978 ± 217, CD62L = 576 ± 216.6 vs 822 ± 167, n=3), indicating that these 
neutrophils were not primed, although this may be due to low sample numbers of sera used 
(n=3 only available at time of assay being undertaken) (Figure 4.14). 
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Figure 4.11. CD11b and CD62L expression analysis on neutrophils from healthy adult 
donors after 30mins priming with sera from paediatric control patients. Neutrophils were 
isolated from healthy adult donors and left naïve or were primed with sera from paediatric 
control patients. The neutrophils were stained with CD11b (A) and CD62L (B) and the relative 
expression via the geometric mean was measured using flow cytometry. An increase in 
CD11b (n=5; p>0.05) and a significant decrease in CD62L after serum pre-treatment (*, n=5, 
p=0.031), confirming neutrophil activation by sera from paediatric control patients  
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Figure 4.12. CD11b and CD62L expression analysis on neutrophils from healthy adults after 
30mins priming with sera from JSLE patients with inactive disease in all pBILAG domains. 
Neutrophils were isolated from healthy adult donors and were left naïve or were primed with 
sera from JSLE patients with inactive disease in all pBILAG domains. The neutrophils were 
stained with CD11b (A) and CD62L (B) and the relative expression via the geometric mean 
was measured using flow cytometry. Increase in CD11b (*, n=5, p=0.031) and a significant 
decrease in CD62L after serum pre-treatment (*, n=5, p=0.031) confirming neutrophil 
activation by sera from patients with inactive JSLE. 
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Figure 4.13. CD11b and CD62L expression analysis on neutrophils from healthy adults after 
30mins priming with sera from JSLE patients with active disease activity in the renal pBILAG 
domain. Neutrophils were isolated from healthy adult donors and were left naïve or were 
primed with sera from JSLE patients with active disease in the renal pBILAG domain. The 
neutrophils were stained with CD11b (A) and CD62L (B) and the relative expression via the 
geometric mean was measured using flow cytometry. Increase in CD11b (*, n=5, p=0.031) 
and a significant decrease in CD62L after serum pre-treatment (*, n=5, p=0.031) confirming 
activation by sera from patients with renal active JSLE. 
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Figure 4.14. CD11b and CD62L expression analysis on neutrophils from healthy adults after 
30mins priming with sera from JSLE patients with active disease in the haematological 
pBILAG domain. Neutrophils were isolated from healthy adult donors and were left naïve or 
were primed with sera from JSLE patients with active disease in the haematological pBILAG 
domain. The neutrophils were stained with CD11b and CD62L and the relative expression via 
the geometric mean was measured using flow cytometry (n=3). 
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4.5.7.3. Effect of JSLE patient and paediatric control patient sera on neutrophil 
apoptosis 
JSLE neutrophils are more apoptotic than control neutrophils, and it has been shown that 
JSLE serum can increase neutrophil apoptosis (72, 110) (Section 4.1). In Section 4.5.5.2, both 
JSLE and paediatric control sera activated healthy neutrophils. In Section 4.5.4.3, it was 
demonstrated that the activation of neutrophils can abrogate the anti-apoptotic potential of 
IFNs and GMCSF, and a high IFN concentration can result in an increase in neutrophil 
apoptosis, as seen in Section 4.5.3.2. Therefore, the effect of each of the IFN subtypes on 
neutrophil apoptosis occurring as a result of treatment with patient sera was therefore 
investigated, with FBS treated neutrophils as a comparison. 
Neutrophils were primed as above with control patient sera, each of the three patient sera 
as stated above (Section 4.4.5.2) or FBS and incubated for 6hrs with 10ng/ml of all three IFN 
subtypes or 5ng/ml of GMCSF.  Apoptosis was measured and expressed by the fold change 
against unstimulated FBS-incubated neutrophils Within the renal active sera analysis, GMCSF 
significantly reduced apoptosis in FBS-incubated neutrophils compared to unstimulated, FBS-
incubated neutrophils (0.3 ± 0.03 vs 1.0, n=5, p=0035) (Figure 4.17). Within the control sera 
analysis, the inactive sera analysis, and the haematological active sera analysis, this reduction 
of apoptosis by GMCSF, although observed, was not statistically significant. This may be due 
to the fact that one GMCSF experimental observation had to be omitted due to operator 
error, and therefore the complete data set would have reached significance. Additionally, 
there was no reduction in apoptosis in FBS-incubated neutrophils upon any IFN subtype, 
which seems to contradict data analysed previously (Figures 4.6, 4.10, 4.15, 4.16 and 4.18; 
Section 4.5.4 and Section 4.5.6). These contradictory results may be due to the small sample 
size, and the way the results were analysed (fold change versus percentage). This was 
particularly relevant for neutrophils that were stimulated with sera from JSLE patients who 
were active in the haematological pBILAG domain, as this was the smallest sample size, due 
to a loss of one of the GMCSF stimulated FBS control samples (which did not run through the 
flow cytometer successfully and thus had to be omitted). None of the IFN subtypes nor 
GMCSF had any marked effect on neutrophil apoptosis in neutrophils that had been pre-
treated with either healthy control and JSLE patient sera. This suggests that the presence of 
heterologous serum primed neutrophils, regardless of origin of the serum (Figures 4.11-
4.18). This priming lead to abrogation of GMCSF related reduction in apoptosis (Figures 4.15-
4.18)These results compare to other experimental data seen previously (Section 4.5.4.3), in 
which priming of neutrophils with TNFα was able to abrogate the anti-apoptotic potential of 
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GMCSF (Figure 4.10). However, as none of the IFN subtypes had any effect on apoptosis in 
naïve/FBS incubated neutrophils in these experiments (contradictory to what was see in 
Section 4.5.4.3), the effect of serum on IFN apoptosis remains inconclusive (Figures 4.15-
4.18).  
 
 
 
 
 
 
 
 
 
 
146 
 
 
Figure 4.15. Apoptosis analysis of healthy adult neutrophils primed with sera from 
paediatric control patients, stimulated with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ 
or 10ng/ml IFNβ for 6hrs. Neutrophils were isolated from healthy adult donors and were left 
naïve or were primed with 10% sera from paediatric control patients for 30mins, and 
subsequently stimulated with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ 
for 6hrs. Neutrophils were stained with annexin V FITC and PI, and the percentage of 
apoptosis was measured using flow cytometry (n=4-5). 
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Figure 4.16. Apoptosis analysis of healthy adult neutrophils primed with sera from JSLE 
patients with inactive disease, stimulated with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml 
IFNγ or 10ng/ml IFNβ for 6hrs. Neutrophils were isolated from healthy adult donors and 
were left naïve or were primed with 10% sera from JSLE patients with inactive disease in all 
pBILAG domains for 30mins, and subsequently stimulated with 5ng/ml GMCSF, 10ng/ml 
IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs. Neutrophils were stained with annexin V FITC 
and PI, and the percentage of apoptosis was measured using flow cytometry (n=4-5). 
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Figure 4.17. Apoptosis analysis of healthy adult neutrophils primed with sera from JSLE 
patients with active disease in the renal domain, stimulated with 5ng/ml GMCSF, 10ng/ml 
IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs. Neutrophils were isolated from healthy adult 
donors and were left naïve or were primed with 10% sera from JSLE patients with active 
disease in the renal pBILAG domain for 30mins, and subsequently stimulated with 5ng/ml 
GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs. Neutrophils were stained with 
annexin V FITC and PI, and the percentage of apoptosis was measured using flow cytometry 
(n=5). GMCSF in FBS-incubated neutrophils significantly reduced apoptosis compared to 
unstimulated FBS-incubated neutrophils (n=5, p=0.0035).  
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Figure 4.18. Apoptosis analysis of neutrophils primed with sera from JSLE patients with 
active disease in the haematological domain, stimulated with 5ng/ml GMCSF, 10ng/ml 
IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs. Neutrophils were isolated from healthy adult 
donors and were left naïve or were primed with 10% sera from JSLE patients with active 
disease in the haematological pBILAG domain for 30mins and subsequently stimulated with 
5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs. Neutrophils were 
stained with annexin V FITC and PI, and the percentage of apoptosis was measured using flow 
cytometry (n=3). 
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4.5.8. Investigating the role of IFNs on apoptosis in paediatric control and 
JSLE patient neutrophils 
It has been shown that there is an increase in pro-apoptotic proteins within JSLE neutrophils 
(170) (Sections 1.5.3.1 and 4.1). As the cellular environment (serum effects) had already been 
investigated in part, it was important to determine whether the neutrophils from JSLE 
patients themselves responded differently to IFNs compared to neutrophils from control 
patients (83). 
4.5.8.1. The activation state of paediatric control and JSLE patient neutrophils 
Neutrophils from paediatric control and JSLE patient whole blood were isolated, stained with 
CD11b and CD62L, and the expression of these markers was analysed using flow cytometry. 
JSLE neutrophils had a higher expression of CD11b compared to paediatric control 
neutrophils (1260 ± 150, n=5, vs 814 ± 129, n=6, p=0.052). However, JSLE neutrophil 
expression of CD62L was comparable to that of paediatric control neutrophils (313 ± 37, n=5, 
vs 380 ± 66, n=6) (Figure 4.19). These data indicate that the JSLE neutrophils are activated 
compared to that of paediatric controls (as shown by the increase in CD11b).  
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Table 4.2. Clinical and demographic information of individuals providing blood for 
neutrophil activation marker experimental analysis. 
Variables JSLE (n=5) Control (n=6) 
Age (years)a 17.7 [14.5-18.9] 13.9 [8.2-15.4] 
Duration of disease 
(months)a 
40 [22-101] - 
Femaleb 5 (100) 2 (33.3) 
Total pBILAG scorec 3 [0-5] - 
Ethnicity   
 White British 5 (100) 5 (100) 
Family history    
  Autoimmune diseases 2 1 
  Other 2 1 
  None 2 3 
Medicationd   
  Steroids 2 - 
  DMARDs 5 - 
   Hydroxychloroquine 4 - 
   Mycophenolate 5 - 
C3 (g/L) 1.1 [1.05-1.47] - 
C4 (g/L) 0.19 [0.07-0.24] - 
ESR (mm/h) 4 [3-12] - 
Data are expressed as median and range [square brackets] or as total numbers with 
percentages (round brackets) 
pBILAG. Paediatric British Isles Lupus Assessment Group; C3, complement component 3; C4, 
complement component 4; DMARDs, disease-modifying anti-rheumatic drugs; ESR, 
erythrocyte sedimentation rate 
aAge and disease duration time of neutrophil isolation and analysis 
bGender of patients 
cTotal pBILAG score determined by the numeric scoring of disease classifications of the organ 
domains 
dMedication taken at time of serum sample collection 
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Figure 4.19. CD11b and CD62L expression analysis of neutrophils isolated from paediatric 
control patients and JSLE patients. Neutrophils were isolated from paediatric control patients and 
JSLE patients, were stained with CD11b and CD62L and relative expression via geometric mean was 
measured using flow cytometry. There was an increase in CD11b in JSLE neutrophils compared to 
paediatric control neutrophils, but this was not statistically significant (n=5-6).  
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4.5.8.2. The effect of IFNs on paediatric control patient neutrophil apoptosis 
Healthy paediatric control patients used in this experimental analysis (n=5) had a median age 
of 10.4 years (7.7-14.9 years) and were 40% female (2 females and 3 males) (Table 4.3). 
Control patient neutrophils were incubated for 6hrs with 5ng/ml GMCSF and 10ng/ml IFNα, 
10ng/ml IFNγ or 10ng/ml IFNβ. At 6hrs, GMCSF significantly reduced apoptosis in neutrophils 
from paediatric control patients compared to unstimulated neutrophils (5.5 ± 0.6% vs 18.1 ± 
3.5%, n=5, p=0.021) (Figure 4.20). There was a suggestion that IFNγ also reduced apoptosis 
in neutrophils from paediatric control patients (13.6 ± 3.3%, n=5). IFNα (18.3 ± 3.2%, n=5), 
and IFNβ (16.5 ± 3.0%, n=5) had no overall effect on paediatric control patient neutrophil 
apoptosis (p>0.05) (Figure 4.20). These data are reflective of the results shown in healthy 
adult control neutrophils (Section 4.5.4.1), although IFNγ seems to be less effective in 
reducing apoptosis in children than adults. 
4.5.8.3. The effect of IFNs on JSLE patient neutrophil apoptosis 
JSLE patients recruited to this experimental analysis (n=5) had a median age of 14.9 years 
(14.4-18.9 years) and were 80% female (4 females and 1 male) (Table 4.3). JSLE patient 
neutrophils were incubated for 6hrs with 5ng/ml GMCSF and 10ng/ml IFNα, 10ng/ml IFNγ 
and 10ng/ml IFNβ. At 6hrs, GMCSF significantly reduced apoptosis in JSLE neutrophils 
compared to unstimulated neutrophils (6.1 ± 0.9% vs 19.1 ± 0.9%, n=5, p=0.037) (Figure 4.20). 
IFNα (21.5 ± 2.1%, n=5) and IFNβ (22.2 ± 1.6%, n=5) had no overall effect on control patient 
apoptosis (p>0.05) (Figure 4.20). IFNγ (15.0 ± 1.2%, n-=5) had a reducing effect on apoptosis, 
but this was not statistically significant. Additionally, there were no statistically significant 
differences in naïve and stimulated neutrophil apoptosis between control and JSLE patients. 
These data do not reflect what was expected from the literature (72). The fact that no 
statistically significant differences were noted in these JSLE patients may be that when their 
samples were collected, they may have their disease well managed or have medication 
masking the effects. Many demographic and clinical factors may be affecting the rate of 
neutrophil apoptosis measured here. Table 4.3 summarises some key demographic and 
clinical data for the patients included in this part of the study. The data indicates that the 
median pBILAG (disease activity score) was 1, which indicates that the disease was generally 
inactive in these patients. All were on a range of medication, including a couple on 
corticosteroids, which again may be affecting the rate of neutrophil apoptosis and how these 
neutrophils respond to IFNs. Small sample size precluded further investigation of the specific 
effects of medication on these findings. Overall, it is likely that the patients’ neutrophils are 
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responding more similarly paediatric control neutrophils, in part due to low disease activity 
and/or the disease was well managed due to medication.  
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Table 4.3. Clinical and demographic information of individuals providing blood for 
neutrophil apoptosis experimental analysis. 
Variables JSLE (n=5) Control (n=5) 
Age (years)a 14.9 [14.4-18.5] 10.4 [7.7-14.8] 
Duration of disease 
(months)a 
41 [30-125] - 
Femaleb 4 (80) 2 (40) 
Total pBILAG scorec 1 [0-8] - 
Ethnicity   
 White British 4 (80) 5 (100) 
 Bangladeshi 1 (20) - 
Family history    
 Autoimmune diseases 2 1 
 Other 1 2 
 None 3 2 
Medicationd   
  Steroids 4 - 
  DMARDs 5 - 
   Hydroxychloroquine 5 - 
   Mycophenolate 4 - 
  Other 1 - 
   OCP 1 - 
dsDNA (IU/L)e 7 [0-202] - 
C3 (g/L)f 1.17 [1.06-1.27] - 
ESR (mm/h) 3 [1-25] - 
 
Data are expressed as median and range [square brackets] or as total numbers with 
percentages (round brackets) 
pBILAG. Paediatric British Isles Lupus Assessment Group; DMARDs, disease-modifying anti-
rheumatic drugs; dsDNA, anti-double stranded DNA antibody; C3, complement component 
3; ESR, erythrocyte sedimentation rate 
aAge and disease duration time of neutrophil isolation and analysis 
bGender of patients 
cTotal pBILAG score determined by the numeric scoring of disease classifications of the organ 
domains 
dMedication taken at time of serum sample collection 
eTwo patients had no dsDNA data at time of demographic analysis 
fOne patient had no C3 data at time of demographic analysis 
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A  
B   
Figure 4.20. Apoptosis analysis of neutrophils isolated from paediatric control patients and 
JSLE patients stimulated with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ 
for 6hrs. Neutrophils were isolated from paediatric control patients (A) or JSLE patients (B) 
and were left unstimulated or were stimulated with 5ng/ml GMCSF, 10ng/ml IFNα, 10ng/ml 
IFNγ or 10ng/ml IFNβ for 6hrs. Neutrophils were stained with annexin V FITC and PI, and the 
percentage of apoptosis was measured using flow cytometry and the percentage of apoptotic 
neutrophils was measured using flow cytometry. A significant reduction in apoptosis was 
found in GMCSF stimulated neutrophils in both control (*, n=5, p=0.021) and JSLE patients 
(*, n=5, p=0.037). 
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4.6. Discussion 
Neutrophils have been shown to undergo increased apoptosis within both SLE and JSLE, and 
this may be due to dysregulation in both extrinsic environmental factors and intrinsic 
signalling pathways (71, 72, 110, 170). Neutrophils from SLE have been shown to be 
activated, and it confirmed here that neutrophils from JSLE are also activated; this may be an 
important factor in the increased neutrophil apoptosis seen (71, 72, 83). IFNs have been 
shown to be increased in the serum of SLE and JSLE patients, and IFN gene signatures have 
been shown to be increased in both SLE and JSLE patients (41, 68, 171, 172, 174) (Section 
1.5.4.1). Importantly, high IFNα serum levels has been indicated to be a risk factor in 
developing SLE and IFN activity has be shown to be increased in patients with JSLE even 
before disease classification (190, 222) (Section 1.5.4.1). Along with the IFN gene signature 
as mentioned previously, there is also an increase in a granulocyte gene signature within 
PMBCs from JSLE patients (41). This therefore indicates an important interaction between 
neutrophils and IFNs in JSLE pathogenesis, particularly in regards to increased neutrophil 
apoptosis. 
4.6.1. IFN subtypes and their effect on apoptosis in naïve and TNFα primed 
neutrophils 
Within this study, it was it was important to initially investigate the role of IFNs on neutrophil 
apoptosis within naïve and primed neutrophils. Literature has shown that IFNs can be both 
pro- and anti-apoptotic on a variety of cells, including immune cells, although only an anti-
apoptotic role by both type 1 and 2 IFNs has been demonstrated in naïve neutrophils 
previously (138, 141, 164, 165) (Section 1.5.3.1). However, no data had been published in 
regards to any differential apoptotic effects of IFNs on naïve and primed neutrophils or the 
role of IFNs on neutrophil apoptosis within SLE or JSLE. 
It was confirmed that IFNs have a pro- and anti-apoptotic effect on neutrophils; this effect 
was dependent on concentration of IFNs and activation state of neutrophils (Section 4.5.3). 
At a high concentration, both IFNα and IFNγ reduced apoptosis in naïve neutrophils; 
however, within TNFα primed neutrophils, all three IFN subtypes increased the rate of 
apoptosis (Section 4.5.3). Following on from this, all three IFN subtypes could reduce the level 
of apoptosis in naïve using a lower concentration of IFNs, although to varying degrees, by 
which IFNγ reduced apoptosis the most. This effect was abrogated in neutrophils primed with 
TNFα (Sections 4.5.4, 4.5.6).  
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4.6.1.1. Use of TNFα-primed neutrophils to model JSLE neutrophils 
It is important to note that TNFα can be also pro- and anti-apoptotic, and therefore careful 
consideration of the effect of TNFα on apoptosis was undertaken (221). Other priming agents 
were considered, but from review of the literate, the only other possibilities were IFNγ and 
GMCSF; these were not appropriate priming agents as both were important downstream 
conditions in this investigation (86, 90, 167) (Section 1.3.5). Here, there was no observed 
overall effect of TNFα on neutrophil apoptosis downstream, and therefore its use as a 
priming agent was suitable to model the JSLE neutrophils in vitro. 
4.6.2. IFN subtypes and their effect on downstream apoptotic signalling 
proteins in naïve neutrophils 
Apoptosis signalling is complex and is mediated by many pro and anti-apoptotic factors. 
GMCSF has been shown to reduce apoptosis through the stability of MCL1, a member of the 
anti-apoptotic BCL2 family (77, 223) (Section 1.3.4). Caspase 3, however, is known as a 
apoptosis effector protein, and is cleaved by both the extrinsic and intrinsic apoptosis 
pathways (73) (Section 1.3.4). Hence, these two contrasting apoptotic proteins were 
analysed in regards to IFN signalling pathway within naïve neutrophils to start elucidating 
how IFNs inflict their effect on apoptosis. Data here has shown that IFNs reduce the cleavage 
of caspase 3, which is likely to coincide with the reduced apoptosis seen, IFNs did not have 
any influence over the stability of MCL1; these observations have not been previously 
published (Section 4.5.5). However, IFNs are known to stimulate the JAK/STAT pathway, 
whereby STAT1 is pro-apoptotic and STAT3 is anti-apoptotic (138, 141) (Section 1.5.3.1). This 
IFN/JAK/STAT pathway will be further investigated in chapter 5 in regards to the differential 
effect of IFNs on apoptosis (138, 141) (Section 5.5.3). In brief, the STATs are likely to be 
fundamental to IFN signalling and apoptosis within JSLE. An increase in the activation of the 
STAT1 pathway has been indicated in PBMCs of SLE patients, and within a mouse model of 
lupus nephritis, and therefore it is highly likely that this pro-apoptotic pathway is heightened 
in JSLE neutrophils, and therefore contribute to the increased neutrophil apoptosis seen in 
JSLE (72, 194, 196).   
4.6.3. IFN subtypes and their effect on apoptosis in patient serum primed 
neutrophils 
This study confirmed that IFNs’ differential roles on apoptosis was dependent on activation 
of neutrophils through priming with TNFα (Section 4.6.1). However, neutrophils within SLE 
and JSLE will be exposed to a variety of inflammatory factors and cytokines, and thus 
investigation of apoptosis in neutrophils exposed to paediatric control and JSLE patient sera 
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was an important next step (72, 224, 225). It was observed that patient serum induced 
neutrophil activation, as shown through increased CD11b and CD62L. However, there was no 
differences in the level of neutrophil activation upon priming with either paediatric control 
patient or JSLE patient sera, or between the different JSLE sera groups (Section 4.5.7.2). 
These observations may simply indicate that neutrophils will become activated when 
exposed to homogenous environments. As expected, the anti-apoptotic effect of IFNs was 
abrogated following neutrophil activation by patient sera, reflecting what was observed in 
the in vitro model (Sections 4.5.6 and 4.5.7.3). However, no increase in neutrophil apoptosis 
was observed in neutrophils primed with JSLE serum, contradictory to what other studies 
have shown (72, 110) (Section 4.5.7.3). Of note, contrary to the neutrophils used here, these 
studies used JSLE or paediatric control neutrophils; these neutrophils may be more 
susceptible to environmental apoptotic factors found in JSLE serum than adult neutrophils. 
Therefore, repeat of this study using paediatric control or JSLE neutrophils may be beneficial 
to fully investigate the role of IFNs in a JSLE environment.    
 4.6.4. IFN subtypes effect on apoptosis in patient neutrophils 
Neutrophils have been shown to undergo increased apoptosis in both SLE and JSLE and may 
be partly due to their increased activation state as observed by the increase in CD11b in a 
published study and as shown here (71, 72, 83) (Sections 1.3.5 and  4.5.6.1). The increase of 
IFNs in serum, the IFN and granulocyte gene signature within JSLE PBMCs, and the pro-
apoptotic effect IFNs can have on activated neutrophils indicate that IFNs may induce 
apoptosis in JSLE neutrophils (41, 68, 171, 172) (Section 1.5). 
It has been shown here that JSLE patient neutrophil had comparable rates of apoptosis to 
paediatric control patient neutrophils, both unstimulated and stimulated with IFNs, which 
does not correlate with published data (71, 72) (Sections 1.4.3 and 4.5.8). The study by 
Midgley et al. had included patients with active disease, which may contribute to the 
increased apoptosis seen (72). Therefore, clinical data was analysed, and it was concluded 
that the JSLE patients, of whom the neutrophils were isolated from, had a low pBILAG score, 
and thus had inactive disease at sampling. Their health, therefore, may be comparable to 
that of paediatric control patients as their disease was well managed, and therefore may 
explain similar neutrophil responses and apoptosis. Thus, a larger study, containing JSLE 
patients with various levels of disease activity, would test whether disease activity and 
medication at time of sampling are important contributors to the dysregulated apoptosis 
seen (71, 72).  
160 
 
4.7. Summary 
IFNs as a group can be both pro- and anti-apoptotic, and this depends on the activation state 
of the neutrophils and concentration of the IFNs. IFNs induce an anti-apoptotic effect through 
the reduced cleavage of caspase 3, but not through the stability of MCL1. Patient serum 
activated healthy adult neutrophils and abrogated the anti-apoptotic effect of IFNs. 
However, there were no observed differences between the different patient serum groups 
on neutrophil activation or apoptosis, which may be due to the complexity of human serum. 
Although result suggested JSLE neutrophils from inactive patients were slightly more 
activated than paediatric control neutrophils, there was not differences in the rate of 
apoptosis between patient groups. This may be due to the patients’ disease being inactive 
and their medication influencing neutrophil function.  
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Chapter 5: The role of IFN signalling in neutrophils 
in JSLE 
5.1. Introduction 
Cytokines signal their effect through a series of proteins on the surface of and within the cell. 
The expression of receptors and proteins within cells differ between cell types and the 
environment they are in. Thus, the effect of cytokines differs depending on cell type and 
between different states of health and disease.  
It is recognised that there is a difference in cell protein constitution within neutrophils from 
healthy individuals and individuals with JSLE (170). It has been shown that there is an increase 
in pro-apoptotic proteins and decrease in anti-apoptotic proteins within JSLE neutrophils 
compared to healthy paediatric controls (72, 170). This difference in protein constitution may 
be due to the likely activation of JSLE neutrophils (83) (Section 1.5.3.1, Section 4.5.8.1, Figure 
4.19). It has been shown that TNFα activated neutrophils have an up-regulation of proteins 
and cellular markers, such as increased activation of ERK and p38 MAPK, and increased 
surface expression of CD11b and CD66b, compared to that of healthy, naïve neutrophils (84, 
85, 95, 169) (Section 1.3.5). 
It is well established that IFNs signal through the JAK/STAT pathway within a variety of cells, 
including neutrophils (138, 141, 166) (Section 1.5.1). Although the various IFN subtypes have 
similar and overlapping effects, there are key differences in their signalling pathways. Type 1 
IFNs all signal through the IFNα receptor (IFNAR), albeit with varying potencies and effects 
(159, 160). Type 2 IFNs signal through the IFNγ receptor (IFNGR) (161, 162). 
Each IFN receptor is made up of two chains, and the expression and dimerization of these 
chains contribute to which downstream signalling pathways are activated (146, 147) (Section 
1.5.2). In summary, particular the IFNGR chains have differential expression on three immune 
cell lines, and this observed difference can contribute to either cell proliferation or apoptosis. 
(161). IFNGR1 has been shown to be consistently expressed on different immune cell lines 
(such as myeloid, B cell and T cell lines), but IFNGR2 has differential expression levels 
depending on cell type and environment (161). In particular IFNGR2 had limited expression 
on T cell line and NK cell line; however the myeloid cell line (the closest cell line to 
neutrophils) have high IFNGR2 membrane expressions (161). The environment has an 
important role to play in the expression of these receptor chains. IFNGR2 can have increased 
expression in serum-depleted T cells, and within cells that have a high IFNGR2 expression, 
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IFNγ induced apoptosis (161). Additionally, the expression of IFNGR2 on T cells extracted 
from healthy volunteers can influence whether IFNγ induces proliferation (when IFNGR2 is 
low) or apoptosis (when IFNGR2 is high) (162). This suggests that the IFN receptor chain 
expression is interchangeable, and the IFN effect on apoptosis is dependent on the relative 
expression of its receptor chains.  
As noted previously, IFNAR is understood to be important in the increased IFN signature 
found in JSLE patients (41, 187) (Section 1.5.4.1). Previous studies have shown that murine 
lupus could be induced by 2,6,10,14-Tetramethylpentadecane (TMPD), also known as 
pristine, a compound that can induce autoimmune disease, in particular SLE (187, 226). This 
drug-induced lupus model was associated with high levels of type 1 IFNs and caused an 
increase in ISGs such as IP10, Mx1 and IRF-7 in mouse PBMCs (187, 227). However, within 
the IFNAR deficient mice, these genes did not increase in expression after TMPD treatment, 
suggesting that the IFNα receptor is important in lupus-associated IFN gene signature 
expression.  
Additionally, in TMPD treated mice, there was a high level of ANAs in the sera (187). IFNAR 
knockout mice also had an increase in ANAs upon TMPD treatment, but is reduced compared 
to control mice treated with TMPD (187). A significant reduction of anti- nuclear (n)RNP/Sm, 
anti-Su, anti-chromatin, anti-dsDNA and anti-single stranded (ss)DNA is seen in the knockout 
IFNAR mice treated with TMPD compared with TMPD treated control mice (187). This shows 
that IFNAR and thus type 1 IFNs contribute to the SLE autoantibody production, that in turn 
contribute to disease pathogenesis.  
In the kidney, glomerular cellularity is increased in TMPD-control mice, however this is 
unchanged in TMPD-treated, IFNAR knockout mice (187). Proteinuria was decreased and 
immune deposits were unchanged in TMPD treated IFNAR knock out mice compared to 
TMPD treated control mice (187). This suggests that within lupus nephritis, IFNAR is required 
for increased glomerular cellularity and may be involved in the increased proteinuria seen in 
lupus patients; however, IFNAR is not involved in immune deposits in the kidney.  
IFNs signal through the phosphorylation of the different STATs; the activation of STATs can 
result in very different endpoints. In particular, it has been shown that STAT1 is considered 
to be pro-apoptotic, and STAT3 is considered to be anti-apoptotic (138, 141). The IFN 
receptor chain expressions may be important in determining which STAT is phosphorylated. 
It has been shown via EMSA that IFNγ induces phosphorylation of STAT1 in the myeloid cell 
line, and that this may be associated with the high expression of IFNGR2 in these cells (161). 
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It was shown that IFNγ was able to only slightly induce phosphorylation of  STAT1 within the 
T cell lines, and this may relate to the low expression of IFNGR2 on the membrane (161). It 
was also shown that depleting T cell line of serum lead to an increase IFNGR2 expression, 
which lead to an increase in IFNγ-induced STAT1 phosphorylation, and an increase in 
apoptosis (161). Thus, the increase in apoptosis may be due to the increase in STAT1 
phosphorylation and therefore activation, which may be reliant on the increased IFNGR2 
expression on the membrane. This part of the IFN/JAK/STAT pathway may therefore be 
important in JSLE neutrophil apoptosis. 
Within this thesis, it was shown that both type 1 and type 2 IFNs phosphorylate STAT1 and 
STAT3, and activation of neutrophils alters the level of phosphorylation (Section 5.5.3).  It has 
been shown that there is proportionally more STAT1 and phosphorylated STAT1 (pSTAT1) in 
PBMCs in adult-onset SLE compared to healthy controls, and IFNγ was able to effectively 
phosphorylate more STAT1 in SLE PBMCs than in healthy controls (194). This up-regulation 
of STAT1 in SLE PBMCs positively correlated with dsDNA levels, indicating a link between 
STAT1 and a marker of disease activity (194). Additionally, STAT1 has also been implicated in 
the mouse model of lupus nephritis, where by the expression of both STAT1 and pSTAT1 were 
higher in lupus nephritis mice compared to healthy controls (196). There is a high level of 
STAT1 in lupus nephritis mesangial cells, and both IFNγ and IFNα are able to phosphorylate 
STAT1 in these cells, albeit IFNα less so than IFNγ (196). This difference in IFN-induced pSTAT1 
may be due to receptor and potency differences mentioned previously. This indicates an 
important role of STAT1 in SLE pathogenesis.  
5.1.1. Summary 
IFNs can be both pro- and anti-apoptotic, and this function depends on the phosphorylation 
of pro-apoptotic STAT1 or phosphorylation of anti-apoptotic STAT3. This differentiation may 
depend on the activation state of the neutrophils; stressful influences can modulate the IFNγ 
receptor chains in particular, and switch IFNγ signalling from proliferative to apoptotic. The 
IFNα receptor also is paramount to contributing to the increase in the IFN signature seen in 
JSLE. Additionally, the STAT1 pathway is increased in SLE PBMCs and a mouse modal in lupus 
nephritis, and therefore is likely to be important in SLE pathogenesis. Thus, investigation into 
the IFN signalling pathway is required to determine whether IFN-induced STAT1 
phosphorylation contributes to the increase in neutrophil apoptosis seen in JSLE, and thus 
may become a potential therapeutic target. 
164 
 
5.2. Chapter hypothesis 
IFNs exert their effect through the JAK/STAT pathway. Their influence on neutrophil functions 
is dependent on the expression of IFN receptor chains and which STAT is phosphorylated, 
whereby STAT1 is considered pro-apoptotic, and STAT3 is considered anti-apoptotic. 
Therefore, it is hypothesized that within activated neutrophils, as found in JSLE, the IFN 
receptor expressions differs from that of healthy naïve neutrophils, and this drives the IFN 
subtypes to activate the STAT1, pro-apoptotic signalling pathway.  
 
5.3. Chapter aim and objectives  
Aim 3: To investigate the IFN signalling pathway in naïve and primed neutrophils and its 
relation to apoptosis.  
 Objective 1: Using flow cytometry, measure the IFN receptor expression on naïve and 
TNFα-primed healthy adult neutrophils. 
 Objective 2: Using flow cytometry, measure the IFN receptor expression on 
paediatric control and JSLE patient neutrophils. 
 Objective 3: Using Western blotting, measure the relative expression of pSTAT1 and 
pSTAT3 in naïve and TNFα-primed healthy adult neutrophils. 
 Objective 4: Using both flow cytometry and Western blotting, measure the ability of 
fludarabine phosphate and S1459 to reduce pSTAT1/β actin expression ratio (and 
therefore possibly inhibiting pSTAT1) within healthy adult neutrophils and their 
effect on the rate of neutrophil apoptosis. . 
 
5.4. Methods 
5.4.1. IFN receptor and activation marker analysis 
Neutrophils were isolated from healthy adults (Section 2.5.2). Neutrophils were treated with 
1μg/ml TNFα, 1μg/ml IFNα, 1µg/ml IFNβ or 1μg/ml of IFNγ for 30mins at 37°C, 5% CO2 in a 
96 well plate, using 1x105 neutrophils per condition. The plate was centrifuged at 1800 RPM 
for 5mins, and the supernatant was decanted. Neutrophils were washed in 100μl of PBS/0.5% 
BSA, and the plate was centrifuged at 1500 RPM for 5mins. The supernatant was decanted 
and 100μl of PBS/0.5% BSA was added. PE (eBioscience, UK) and APC isotype controls 
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(eBioscience, UK [for CD62L], Miltenyi Biotec, UK [for IFNAR2], R&D Systems [for IFNGR2]), 
and IFNAR1 (Sino Biological, China/Stratech, UK), IFNAR2 (Miltenyi Biotec, UK), IFNGR1 
(eBioscience, UK) and IFNGR2 (R&D Systems, UK) were added to neutrophils at a final 
concentration of 1μg/ml (or ~ 1μg/ml for IFNAR2 and its APC isotype). Single and dual stain 
CD11b and CD62L were added to unstimulated and TNFα/IFN stimulated neutrophils at a 
final concentration of 1μg/ml. Neutrophils were incubated at 4°C for 30mins, and the plate 
was centrifuged at 1500 RPM for 5mins. The supernatant was decanted and 200μl PBS/0.5% 
BSA was added. The neutrophils were transferred to 1.5ml/2ml microcentrifuge tubes and 
run through Guava EasyCyte, using a pre-set programme. 
5.4.2. IFN receptor and activation marker analysis on paediatric control and 
JSLE neutrophils  
Neutrophils were isolated from healthy adults (Section 2.5.2). Neutrophils were plated at 
1x105 neutrophils per condition and stained (Section 5.4.1). 
5.4.3. Analysis of phosphorylation of STAT1 and STAT3 within naïve and 
primed neutrophils 
Neutrophils were isolated from healthy adults (Section 2.5.2). Neutrophils were seeded at 
5x105 –1x106 and left untreated or treated with 1ng/ml TNFα for 30mins 37°C, 5% CO2. 
Neutrophils were stimulated 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 15mins at 
37°C, 5% CO2. Proteins were extracted and analysed for pSTAT1/β actin and pSTAT3/STAT3 
expression ratios using Western blotting (Section 2.7). 
5.4.4. STAT1 inhibition analysis 
5.4.4.1. Fludarabine phosphate dose response 
Fludarabine phosphate (Sigma-Aldrich, UK) was diluted at 1µg/µl in dimethyl sulfoxide 
(DMSO). Neutrophils were isolated from healthy adults as described in the technical methods 
chapter (section 2.5.2) and were seeded at 5x105 in a 24 well plate. Neutrophils were either 
unstimulated or treated with 25μM fludarabine phosphate, 50μM fludarabine phosphate or 
100μM fludarabine phosphate for 2hrs. Additional neutrophils were treated with an 
equivalent volume of DMSO (for 25μM fludarabine phosphate only) to check for any DMSO-
induced STAT1 phosphorylation. Neutrophils were primed with 1μg/ml TNFα for 30mins at 
37°C, 5% CO2, and stimulated with 10μg/ml IFNα for 15mins at 37°C, 5% CO2. Proteins were 
extracted and analysed for pSTAT1/β actin expression ratios using Western blotting (Section 
2.7). 
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5.4.4.2. DMSO dose response 
Since fludarabine phosphate (Section 5.4.4.1) was initially diluted at 1µg/µl DMSO, and thus 
as a control, the effect of DMSO on apoptosis was investigated alongside fludarabine 
phosphate dose response. Neutrophils were isolated from healthy adults (Section 2.5.2) and 
were seeded at 5x105 in 24 well plates. Neutrophils were either unstimulated or treated with 
4.5μl DMSO (equates to 25μM fludarabine phosphate), 9μl DMSO (equates to 50μM 
fludarabine phosphate) or 18μl DMSO (equates to 100μM fludarabine phosphate) for 2hrs at 
37°C, 5% CO2. Apoptosis was analysed (Section 2.6.2.2), and results analysed using FlowJo. 
5.4.4.3. Fludarabine phosphate time course 
Fludarabine phosphate was diluted at 10µg/µl in DMSO then diluted further to 1µg/µl with 
media. Neutrophils were isolated from healthy adults (Section 2.5.2) and were seeded at 
1x106 in a 24 well plate. Neutrophils were untreated or treated with 50μM of fludarabine 
phosphate for 30, 60 and 120mins at 37°C, 5% CO2. Neutrophils were stimulated with 
10ng/ml IFNα and 10ng/ml IFNγ for 15mins at 37°C, 5% CO2. Proteins were extracted and 
analysed for pSTAT1/β actin and pSTAT3/STAT3 expression ratios using Western blotting 
(Section 2.7). 
 5.4.4.4. The effect of S1495 on STAT1 phosphorylation in A549 cells (positive 
control) 
S1459 (Abcam, UK) was reconstituted at 10µg/µl in DMSO, and then diluted further to 1µg/µl 
with media A549 cells were grown to confluency in T75 flask in high glucose Dulbecco’s 
modified eagle’s medium (DMEM) (Sigma) with 10% heat-inactivated FBS (Life Technologies, 
UK), and 0.1% of gentamicin (Sigma) (known so forth as ‘DMEM’). DMEM was removed and 
A549 cells washed with 5ml PBS and were lifted using 1ml trypsin (Sigma). 4ml DMEM was 
added to neutralise the trypsin. The cells were centrifuged at 2000 RPM for 5mins. The 
supernatant was removed and cells were re-suspended in 5ml of DMEM. 1ml of A549 cells 
was added to two wells in a 24 well plate, and 500µl PBS was added to the surrounding wells. 
Cells were left to settle for up to 6hrs. DMEM was removed from wells and cells were washed 
with 1ml PBS. Add 1ml of serum-free DMEM with 0.1% gentamicin and 10µl of S1495 (final 
concentration 10µg/ml). The cells were incubated for 18hrs and then stimulated with 
10ng/ml IFNα and 10ng/ml IFNγ for 15mins. The cells were lysed by removing the DMEM, 
washing with 1ml PBS and adding 100µl lysis buffer. Wells were scraped with a tip, and 
supernatants containing proteins were transferred to wells, and heated/vortexed as per 
protocol (Section 2.7.1). Proteins were analysed for pSTAT1/β actin and pSTAT3/STAT3 
expression ratios using Western blotting (Section 2.7). 
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5.4.4.5. The effect of S1495 on STAT1 and STAT3 phosphorylation in neutrophils 
Neutrophils were isolated from healthy adults (Section 2.5.2). Neutrophils were seeded at 
5x105 - 1x106 in a 24 well plate and treated with either 5μg/ml or 10µg/ml S14-95 for 1hr at 
37°C, 5% CO2. Neutrophils were naïve (10μg/ml S1495 investigation) or primed with 1µg/ml 
TNFα for 30mins at 37°C, 5% CO2 (5μg/ml S1495 investigation) and subsequently stimulated 
with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml of IFNβ individually (10μg/ml S1495 
investigation), or 10ng/ml IFNα and 10ng/ml IFNγ combined (10μg/ml S1495 investigation) 
for 15mins at 37°C, 5% CO2. Proteins were extracted and analysed for pSTAT1/β actin and 
pSTAT3/STAT3 expression ratios using Western blotting (Section 2.7). 
5.4.4.6. S14-95 dose response on naïve and primed neutrophil, and priming trial 
Neutrophils were isolated from healthy adults (Section 2.5.2). Neutrophils were seeded at 
1x105 in a 96 well plate. Neutrophils were either left naïve or primed with 1µg/ml TNFα for 
30mins, and subsequently treated with a dose response 1, 5 or 10µg/ml S1495, or one dose 
of 10µg/ml S1495 alone, and incubated for 6hrs at 37°C, 5% CO2. Apoptosis was analysed 
(Section 2.6.2.2) and results analysed on FlowJo. 
5.4.4.7. S1495 effect on IFN apoptosis on TNFα-primed neutrophils 
Neutrophils were isolated from healthy adults (Section 2.5.2). Neutrophils were seeded at 
1x105 in a 96 well plate. Neutrophils were either unstimulated or treated with 5µg/ml or 
10µg/ml S1495 for 1hr at 37°C, 5% CO2. Neutrophils were also primed with 1µg/ml TNFα 
30mins at 37°C, 5% CO2, and subsequently stimulated with 10ng/ml IFNα, 10ng/ml IFNγ and 
10ng/ml IFNβ for 6hrs at 37°C, 5% CO2. Apoptosis was analysed (Section 2.6.2.2) and results 
analysed on FlowJo. 
5.4.5. Statistical analysis 
P values were analysed in GraphPad Prism 6. Friedman’s test with Dunn’s post hoc multiple 
comparison tests was conducted for analysis of the majority of data sets. One-tailed 
Wilcoxon matched-pairs signed rank test was used for analysis of activation marker 
expression. Kruskal-Wallis test with a post hoc Dunn’s multiple comparison test was 
conducted for analysis of comparing multiple comparisons between JSLE and paediatric 
control patient data sets. For detailed statistical methodology, Section 2.10. 
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5.5. Results 
5.5.1. IFN receptor expression on naïve and TNFα-primed adult neutrophils 
Each IFN subtype binds to its own receptor; IFNAR (type 1) and IFNGR (type 2). Each receptor 
is made up of a chain 1 (α chain) and chain 2 (β chain). Published data suggest that differential 
expression of these chains is commonly found between cell types, and the effect of the IFN 
signalling is dependent on the expression of the chains (159, 161, 162) (Sections 1 5.2 and 
5.1). It has also been established that signalling pathways differ not only between naïve and 
primed neutrophils, but between neutrophils from JSLE patients and paediatric control 
patients (84, 85, 170) (Sections 1.3.5 and 5.1). Therefore, receptor chains may also differ 
between naïve and primed neutrophils, and paediatric control and JSLE neutrophils. Thus, 
the first aim was to investigate how naïve and primed adult healthy neutrophils differ in their 
IFN receptor expressions. 
5.5.1.1. TNFα, but not IFNα or IFNβ, primes healthy adult control neutrophils for 
activation as measured by CD11b and CD62L expression 
Neutrophils were stimulated with 1μg/ml TNFα, 1μg/ml IFNα or 1μg/ml IFNβ for 30mins and 
measured for CD11b and CD62L. TNFα activated the neutrophils, as shown through the 
increase in CD11b (2102 ± 282 vs 1218±131, n=5, p=0.0031) and decrease in CD62L (88 ± 16 
vs 387 ± 55, n=5, p=0.023) compared to unstimulated neutrophils (Figure 5.1). However, IFNα 
and IFNβ had no overall effect on the expression of either CD11b (IFNα = 1305 ± 124, n=5; 
IFNβ = 1195 ± 201, n=3) or CD62L (IFNα = 389 ± 52, n=5; IFNβ = 382 ± 89, n=3) and thus did 
not demonstrate activation these neutrophils (Figure 5.1).  
5.5.1.2. TNFα, but not IFNγ, primes healthy adult control neutrophils for activation 
as measured by CD11b and CD62L expression 
Neutrophils were stimulated with 1μg/ml TNFα or 1μg/ml IFNγ for 30mins and measured for 
CD11b and CD62L. Again, TNFα-primed the neutrophils, as shown through the increase in 
CD11b (2227 ± 310 vs 1242 ± 107, n=5, p=0.0031) and decrease in CD62L (68 ± 6 vs 375 ± 51, 
n=5, p=0.0089) compared to unstimulated neutrophils (Figure 5.2). However, IFNγ did not 
have an overall effect on expression of either CD11b (1325 ± 120, n=5) or CD62L (368 ± 50, 
n=5) compared to unstimulated neutrophils, and thus did not prime these neutrophils for 
activation (Figure 5.2). 
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A  
B  
Figure 5.1. CD11b and CD62L expression analysis on naïve and 1µg/ml cytokine-primed 
neutrophils at 30mins. Neutrophils were isolated from healthy adult donors and were left 
naïve or were primed with 1μg/ml TNFα, 1μg/ml IFNα or 1μg/ml IFNβ for 30mins. Neutrophils 
were stained with antibodies for CD11b (A) and CD62L (B), and the relative expression via 
geometric mean was measured using flow cytometry. TNFα significantly primed neutrophils 
for activation as shown by the increase in CD11b (A) (**, n=5, p=0.0031) and decrease in 
CD62L (B) (*, n=5, p=0.023). IFNα and IFNβ had no overall effect on the expression of CD11b 
or CD62L (n=3-5).  
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Figure 5.2. CD11b and CD62L expression analysis on naïve and 1µg/ml cytokine-primed 
neutrophils at 30mins. Neutrophils were isolated from healthy adult donors and were left 
naïve or were primed with 1μg/ml TNFα or 1μg/ml IFNγ for 30mins. Neutrophils were stained 
with CD11b and CD62L antibodies, and the relative expression via geometric mean was 
measured using flow cytometry. TNFα significantly primed the neutrophils for activation as 
shown by the increase in CD11b (A) (**, n=5, p=0.0031) and decrease in CD62L (**, n=5, 
p=0.0089). IFNγ had no overall effect on the expression of CD11b or CD62L (n=5).  
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5.5.1.3. Expression of IFNAR chains 1 and 2 on naïve and primed neutrophils. 
Receptor chains IFNAR1 and IFNAR2 were measured using flow cytometry after 30mins 
stimulation with 1μg/ml TNFα, 1μg/ml IFNα or1μg/ml IFNβ. TNFα decreased the expression 
of IFNAR1 (54 ± 11 vs 133 ± 37, n=5, p=0.014) compared to unstimulated neutrophils, but 
had no overall effect on IFNAR2 (59 ± 8 vs 58±10, n=5) (Figure 5.3). Neither IFNα (IFNAR1 = 
125 ± 35; IFNAR2 60 ± 10; n=4-5) nor IFNβ (IFNAR1 = 117 ± 52; IFNAR2 54 ± 6; n=4-5) have an 
effect on either chain (Figure 5.3).  
5.5.1.4. Expression of IFNGR chains 1 and 2 on naïve and primed neutrophils 
Receptor chains IFNGR1 and IFNGR2 were measured after 30 min stimulation with 1μg/ml 
TNFα or 1μg/ml IFNγ. TNFα increased the expression of IFNGR2 (58 ± 7 vs 47 ± 3, n=5) 
compared to unstimulated neutrophils, but this was not significant. However, TNFα also had 
no overall effect on IFNGR1 (40 ± 4 vs 41 ± 2, n=5) (Figure 5.4). There was an increase in 
IFNGR2 upon IFNγ stimulation (59 ± 10 vs 47 ± 3, n=5) compared to unstimulated neutrophils, 
but this was not significant, and IFNγ had no overall effect on IFNGR1 (39 ± 4, n=5) (Figure 
5.4).  
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Figure 5.3. IFNα receptor chain analysis on naïve and 1µg/ml cytokine-primed neutrophils 
at 30mins. Neutrophils were isolated from healthy adult donors and were left naïve or were 
primed with 1μg/ml TNFα, 1μg/ml IFNα or 1μg/ml IFNβ for 30mins. Neutrophils were stained 
with IFNAR1 and IFNAR2 antibodies, and the relative expression via geometric mean was 
measured using flow cytometry for IFNAR1 (A+C) and 2 (B+D). TNFα reduced the expression 
of IFNAR1 (*, n=5, p=0.014) (A+C), but there was little effect of any of the cytokines on IFNAR2 
(n=4-5) (B+D). Representative peaks are shown, where unstained is red, isotype controls are 
light blue, unstimulated neutrophils are dark green, TNFα stimulated neutrophils are orange, 
IFNα stimulated neutrophils are dark blue and IFNβ stimulated neutrophils are purple (C+D). 
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Figure 5.4. IFNγ receptor chain analysis on naïve and 1µg/ml cytokine-primed neutrophils 
at 30mins. Neutrophils were isolated from healthy adult donors and were left naïve or were 
primed with 1μg/ml TNFα or 1μg/ml IFNγ for 30 mins. Neutrophils were stained with IFNGR1 
and IFNGR2 antibodies and the relative expression via geometric mean was measured using 
flow cytometry for IFNGR1 (A+C) and 2 (B+D). There is suggestion that TNFα and IFNγ 
increased the expression of IFNGR2 (n=5) (B+D), but there was little effect of any of the 
cytokines on IFNGR1 (n=5) (A+C). Representative peaks are shown, where unstained is red, 
isotype controls are light blue, unstimulated neutrophils are dark green, TNFα stimulated 
neutrophils are orange, IFNγ stimulated neutrophils are pink (C+D). 
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5.5.2. IFN receptor expression and activation states in neutrophils from 
JSLE patients and paediatric control patients  
Based on data presented in Section 5.5.1, the next step was to investigate whether there was 
a difference in the activation state between neutrophils from JSLE patients and paediatric 
control patients. Additionally, to determine whether differences in activation states 
influences the expression of the receptor chains. This hypothesis stems from literature that 
suggests SLE neutrophils are activated compared to control neutrophils, which may influence 
IFN receptor expression; the activation of neutrophils and any IFN receptor changes may link 
to the increase in apoptosis reported in published studies (72, 83, 161). (Sections 1.4.3, and 
1.5.2).  
JSLE neutrophils had a higher expression of CD11b compared to paediatric control 
neutrophils (1260 ± 150, n=5, vs 814 ± 129, n=6, p=0.052), although JSLE CD62L was 
comparable to that of paediatric control neutrophils (312 ± 37, n=5, vs 380 ± 66, n=6) (Figure 
5.5). This indicates that the JSLE neutrophils are activated compared to that of paediatric 
controls (as shown by the increase in CD11b), but not quite as activated as TNFα-primed 
healthy adult neutrophils (as shown by the expression of CD62L) (Figures 5.1, 5.2, and 5.5 
respectively). CD11b is an integrin that forms part of differentiation antigen Mac-1, which is 
involved in various functions such as endothelium attachment, chemotaxis and phagocytosis 
whereas CD62L, or L-Selectin is an adhesion molecule and mediates leukocyte rolling (97, 
101). Thus, TNFα-primed healthy adult neutrophils may be increasing their membrane 
antigens to respond to the surrounding environment, whilst losing their adhesive and rolling 
ability. In contrast, JSLE neutrophils may enhance their responsiveness to the environment 
through up-regulation of CD11b but retain their adhesive and rolling ability through CD62L.  
Generally, there were no significant difference between expression of the different IFN 
receptors in neutrophils from JSLE patients and paediatric control patients. IFNAR1 and 
IFNAR2 expressions were slightly higher in JSLE neutrophils compared to paediatric control 
neutrophils (IFNAR1 = 140 ± 41, n=5, vs 123 ± 23, n=6; IFNAR2 = 89 ± 16, n=5, vs 69 ± 4, n=6) 
(Figure 5.6). However, these differences were not statistically significant. IFNGR1 expression 
was similar in JSLE and paediatric control neutrophils (43 ± 2, n=5, vs 44 ± 3, n=6) (Figure 5.7). 
Again, there was a slight increase of IFNGR2 in JSLE neutrophils compared to paediatric 
control neutrophils, although this was not statistically significant (60 ± 4, n=5, vs 52 ± 5, n=6) 
(Figure 5.7). These observations, namely that there was no significant difference between 
the JSLE and paediatric control neutrophils, can be considered in light of the clinical 
characteristics of the patients at the time of sampling (see Table 5.1). The JSLE patients’ 
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disease activity status was in a state of relatively low current disease activity at the time of 
sampling, as evidenced by the low medium pBILAG score. This would be most likely due to 
the effective clinical management of their condition. The results may be affected by the 
medication that all the JSLE patients were on (Table 5.1). 
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Table 5.1. Clinical and demographic information of individuals providing blood for 
neutrophil activation marker and IFN receptor chain experimental analysis. 
Variables JSLE (n=5) Control (n=6) 
Age (years)a 17.7 [14.5-18.9] 13.9 [8.2-15.4] 
Duration of disease 
(months)a 
40 [22-101] - 
Femaleb 5 (100) 2 (33.3) 
Total pBILAG scorec 3 [0-5] - 
Ethnicity   
 White British 5 (100) 5 (100) 
Family history   
 Autoimmune diseases 2 1 
 Other 2 1 
 None 2 3 
Medicationd   
  Steroids 2 - 
  DMARDs 5 - 
   Hydroxychloroquine 4 - 
   Mycophenolate 5 - 
C3 (g/L) 1.1 [1.05-1.47] - 
C4 (g/L) 0.19 [0.07-0.24] - 
ESR (mm/h) 4 [3-12] - 
Data are expressed as median and range [square brackets] or as total numbers with 
percentages (round brackets) 
pBILAG. Paediatric British Isles Lupus Assessment Group; C3, complement component 3; C4, 
complement component 4; DMARDs, disease-modifying anti-rheumatic drugs; ESR, 
erythrocyte sedimentation rate 
aAge and disease duration time of neutrophil isolation and analysis 
bGender of patients 
cTotal pBILAG score determined by the numeric scoring of disease classifications of the organ 
domains 
dMedication taken at time of serum sample collection 
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Figure 5.5. CD11b and CD62L expression analysis of neutrophils isolated from paediatric 
control patients and JSLE patients. Neutrophils were isolated from paediatric control patients and 
JSLE patients, were stained with CD11b and CD62L and the relative expression via geometric mean was 
measured using flow cytometry. There was an increase in CD11b in JSLE neutrophils compared to 
paediatric control neutrophils (n=5-6, p=0.052). 
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Figure 5.6. IFNα receptor chain expression analysis on neutrophils from paediatric control 
patients and JSLE patients. Neutrophils were isolated form paediatric control patients and 
JSLE patients, were stained with IFNAR1 and IFNAR2 and the relative expression via 
geometric mean was measured using flow cytometry (n=5-6).  
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Figure 5.7. IFNγ receptor chain expression analysis on neutrophils from paediatric control 
patients and JSLE patients. Neutrophils were isolated form paediatric control samples and 
JSLE samples and were stained with IFNAR1 and IFNAR2 the relative expression via geometric 
mean was measured using flow cytometry (n=5-6). 
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5.5.3. Phosphorylation of STAT1 and STAT3 in naïve and TNFα-primed 
neutrophils 
The next step was to investigate the activation of the proteins immediately downstream from 
IFN receptors. This is important to investigate in the context of data observed and previously 
summarised regarding the differential effect of IFN stimulation on apoptosis. STAT1 has been 
shown to be pro-apoptotic and STAT3 has been shown to be anti-apoptotic (138, 141) 
(Section 1.5.3.1). Thus, the phosphorylation of STAT1 and STAT3 was measured in naïve and 
primed neutrophils.  
Neutrophils were primed with 1ng/ml TNFα for 30mins, and then stimulated with 10ng/ml 
IFNα, 10ng/ml IFNγ, or 10ng/ml IFNβ for 15mins. Protein was extracted, and pSTAT1/β actin 
and pSTAT3/STAT3 expression ratios were measured using Western blotting. 
It was shown that both pSTAT1 and pSTAT3 were expressed upon all IFN subtypes (Figure 
5.8, 5.9), although this effect was not always statistically significant. IFNβ significantly 
increased the pSTAT3/STAT3 ratio in naïve neutrophils compared to unstimulated naïve 
neutrophils (15.6 ± 10.2 vs 0, n=5, p=0.0018) (Figure 5.8). IFNγ significantly increased 
pSTAT1/β actin ratio in TNFα-primed neutrophils compared to unstimulated naïve and 
primed neutrophils (4.4 ± 2.5, vs 0, n=5, p=0.0014) (Figure 5.9). Importantly, TNFα alone did 
not cause any phosphorylated STAT expression, and thus any differences in phosphorylation 
state between naïve and primed neutrophils were due to activation state and not a 
compounding cytokine effect (Figure 5.8, Figure 5.9).  
There was a reduction in pSTAT3/STAT3 expression ratios in primed neutrophils compared 
to naïve neutrophils (IFNα = 1.1 ± 0.3 vs 3.3 ± 1.2; IFNγ 0.4 ± 0.1 vs 3.6 ± 2.7; IFNβ 3.1 ± 1.2 
vs 15.6 ± 10.2; n=5) (Figure 5.8). This indicates a reduction in the ability of IFNs to 
phosphorylate STAT3, and thus may reduce the IFN anti-apoptotic effect in primed 
neutrophils. There was an increase in pSTAT1/β actin expression ratio in primed neutrophils 
compared to naïve neutrophils in the presence of IFNγ (4.4 ± 2.5 vs 1.4 ± 0.5, n=5) (Figure 
5.9). This effect was not seen with IFNα (1.1 ± 0.4 vs 1.2 ± 0.4, n=5) or IFNβ (1.6 ± 0.7 vs 1.5 
± 0.6, n=5) (Figure 5.9). This indicates that, although there seems to switch to increasing 
pSTAT1/β actin expression ratio (which may be due to either increased phosphorylation of 
STAT1 or increased expression of STAT1) from pSTAT3/STAT3 expression ratio, suggesting a 
switch from the anti-apoptotic to pro-apoptotic signalling pathway, it is dependent on the 
presence of IFNγ. 
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Figure 5.8. The phosphorylation of STAT3 in naïve and TNFα-primed healthy adult 
neutrophils, stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 15mins. 
Neutrophils were isolated from healthy adult donors and were left naïve (blue) or were 
primed 1ng/ml TNFα (red) for 30mins. Neutrophils were subsequently stimulated with 
10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ. Proteins were extracted, and pSTAT3/STAT3 
expression ratios were measured using Western blotting. All IFN subtypes phosphorylated 
STAT3. However, increased pSTAT3/STAT3 expression ratios correlated more with IFNα and 
IFNβ (whereby IFNβ significantly increased the pSTAT3/STAT3 expression ratio in naïve 
neutrophils compared to unstimulated naïve neutrophils; **, n=5, p=0.0018). Priming of the 
neutrophils with TNFα reduced the pSTAT3/STAT3 in all IFNα and IFNβ-stimulated 
neutrophils, compared to naïve neutrophils stimulated with IFNα and IFNβ (n=5). 
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Figure 5.9. The phosphorylation of STAT1 in naïve and TNFα-primed healthy adult 
neutrophils, stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 15mins. 
Neutrophils were isolated from healthy adult donors and left naïve (blue) or were primed 
1ng/ml TNFα (red) for 30mins. Neutrophils were subsequently stimulated with 10ng/ml IFNα, 
10ng/ml IFNγ or 10ng/ml IFNβ. Proteins were extracted, and pSTAT1/β actin expression 
ratios were measured using Western blotting. All IFN subtypes increased the pSTAT1/β actin 
expression ratio (n=5). However, the pSTAT1/β actin expression ratio increase correlated 
more with IFNγ. IFNγ significantly increased the pSTAT1/β actin expression ratio in TNFα-
primed neutrophils, compared to naïve and TNFα-primed neutrophils without IFN 
stimulation (**, n=5, p=0.0014). This may be due to either increased phosphorylation of 
STAT1, or increased expression of STAT1. It is of note that the STAT1 antibody was not able 
to be optimised in this thesis, and therefore the STAT1 expression was not analysed.  
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5.5.4. Investigating the ability of fludarabine phosphate to inhibit STAT1  
STAT1 has a pro-apoptotic role, and its increase in primed neutrophils, (as shown in Figure 
5.9) may be important in IFN-related neutrophil apoptosis (Section 1.5.3.1). It may therefore 
be a potential therapeutic target in JSLE neutrophil apoptosis (138, 194). Therefore, the next 
specific objective was to investigate if STAT1 could be inhibited by specific inhibitors in 
neutrophils. 
5.5.4.1 Fludarabine phosphate dose and time course 
The first STAT1 inhibitor used was fludarabine phosphate. The initial experiments were to 
determine an appropriate concentration of fludarabine phosphate to use to inhibit the 
phosphorylation of STAT1. It is of note the fludarabine phosphate was dissolved at 1μg/μl in 
DMSO.  
At 2hrs, it was shown that neither TNFα, DMSO, nor fludarabine phosphate at any 
concentration tested induced any phosphorylation of STAT1. Only IFNα resulted in an 
increase in the pSTAT1/β actin expression ratio. This indicates that IFNα is needed to activate 
this pathway (Figure 5.10). It was shown that TNFα-priming increased pSTAT1/β actin 
expression ratio in neutrophils stimulated with IFNα compared to naïve neutrophils 
stimulated with IFNα (1.27 vs 0.65, n=1) (Figure 5.10). This confirms that in this assay, as 
shown previously in the data arising from experiments presented above (see Figure 5.9), IFNα 
is required to induce the JAK/STAT pathway. At 50μM, fludarabine phosphate reduced the 
amount of pSTAT1 in IFNα-stimulated, TNFα-primed neutrophils the most compared to IFNα-
stimulated, TNFα-primed neutrophils only. This indicates that this was the most appropriate 
concentration to use for subsequent experiments (no inhibitor = 1.27, 25μM = 0.99, 50μM = 
0.57, 100μM = 0.63, n=1) (Figure 5.10).  
As fludarabine phosphate was initially diluted in DMSO at 1μg/μl, it was important to test if 
there was any potential effect of DMSO on neutrophil apoptosis directly. Thus, neutrophils 
were incubated with equivalent volumes of DMSO to those used in the dose response of 
fludarabine phosphate for 2hrs (4.5μl DMSO in 500μl of neutrophils equates to 25μM of 
fludarabine phosphate, 9μl DMSO in 500μl of neutrophils equates to 50μM of fludarabine 
phosphate, and 18μl DMSO in 500μl of neutrophils equates to 100μM of fludarabine 
phosphate). The level of apoptosis was then measured. It was shown that all volumes of 
DMSO induced an increase in apoptosis compared to unstimulated neutrophils (4.5μl DMSO 
= 8.4 ± 1.1%, 9μl DMSO = 13.7 ± 2.8%, 18μl DMSO = 21.5 ± 4.6%, unstimulated = 5.3 ± 0.9%, 
n=5) with 18μg/ml becoming significant (p=0.0007) (Figure 5.11). Thus, suspending 
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fludarabine phosphate in less DMSO was required to inhibit STAT1 phosphorylation without 
DMSO-affected apoptosis. 
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Figure 5.10. Dose response of fludarabine phosphate at 2hrs on TNFα-primed healthy adult 
neutrophils, stimulated with 10µg/ml of IFNα for 15mins. Neutrophils were isolated from 
healthy adult donors and were left unstimulated or treated with 25μM, 50μM or 100μM of 
fludarabine phosphate, or 25μM equivalent (v/v) of DMSO for 2hrs. Neutrophils were 
subsequently primed with 1μg/ml TNFα for 30mins and stimulated with 10μg/ml IFNα for 
15mins. Protein was extracted and pSTAT1/β actin expression ratios was measured using 
western blotting. TNFα, DMSO, and fludarabine phosphate alone treatments did not induce 
any pSTAT1 expression. 50μM of fludarabine phosphate reduced the pSTAT1/β actin 
expression ratio in TNFα primed, IFNα treated neutrophils the most compared to the TNFα 
primed, IFNα treated neutrophil control, and subsequent experiments used this 
concentration (n=1). 
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Figure 5.11. Apoptosis analysis of healthy adult neutrophils following a 2hr dose response 
of DMSO. Neutrophils were isolated from healthy adult donors and were left unstimulated 
or treated with equivalent v/v of DMSO to fludarabine phosphate dose response used in 
Figure 5.10. Specifically, 4.5μl corresponds to 25μM of fludarabine phosphate, 9μl 
corresponds to 50μM of fludarabine phosphate, and 18μl corresponds to 100μM of 
fludarabine phosphate originally constituted at 1μg/μl. Neutrophils were incubated for 2hrs, 
and apoptosis was measured using annexin V FITC and PI. All volumes of DMSO induced 
apoptosis with 18μl DMSO being significant (***, n=5, p=0.0007) and thus fludarabine 
phosphate needs to be re-constituted in smaller amounts of DMSO.  
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The next stage in optimisation was to do a time course using 50μM of fludarabine phosphate. 
Fludarabine phosphate was re-suspended initially at 10μg/μl in DMSO, then diluted more so 
to 1μg/μl using media. This enabled dilution of the fludarabine phosphate at lower 
concentrations of DMSO which would not induce neutrophil apoptosis.  
Neutrophils were treated with 50μM of fludarabine phosphate for 30, 60 and 120mins, and 
subsequently stimulated with 10ng/ml IFNα and 10ng/ml IFNγ for 15mins. There was some 
indication of possible pSTAT1 inhibition through reduction of pSTAT1/β actin expression ratio 
at all time points by fludarabine phosphate when compared to neutrophils without 
fludarabine phosphate as fold change baseline (30mins = 0.9 ± 2 of baseline; 60mins = 0.9 ± 
0.1 of baseline; 120mins = 0.8 ± 0.2 of baseline; n=5) (Figure 5.12). There was also an 
indication of inhibition of pSTAT3 through the reduction of pSTAT3/STAT3 expression ratio, 
which was seen in particular at 120mins (30mins = 0.9 ± 0.2 of baseline; 60mins = 1.1 ± 0.3 
of baseline, 120mins = 0.7 ± 0.1; n=5) (Figure 5.13).  
Importantly, this indication of a dual inhibition of both STAT1 and STAT3 indicated that 
fludarabine phosphate is inappropriate to use as a STAT1 inhibitor. 
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Figure 5.12. Fludarabine phosphate time response in healthy adult neutrophils stimulated 
with 10ng/ml IFNα and 10ng/ml IFNγ. Neutrophils were isolated from healthy adult donors 
and were left unstimulated or treated with or without 50μM of fludarabine phosphate for 
30, 60 and 120mins, and subsequently stimulated with 10ng/ml IFNα and 10ng/ml of IFNγ 
for 15mins. Protein was extracted and pSTAT1/β actin expression ratios was measured by 
Western blotting (n=5). 
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Figure 5.13. Fludarabine phosphate time response in healthy adult neutrophils stimulated 
with 10ng/ml IFNα and 10ng/ml IFNγ for 15mins. Neutrophils were isolated from healthy 
adult donors and were left unstimulated or treated with 50μM of fludarabine phosphate for 
30, 60 and 120mins, and subsequently stimulated with 10ng/ml IFNα and 10ng/ml of IFNγ 
for 15mins. Protein was extracted and pSTAT3/STAT3 expression ratios was measured by 
Western blotting (n=5).  
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5.5.5. Inhibition of STAT1 phosphorylation by S1495 
The above experiments demonstrated that fludarabine phosphate was not an appropriate 
pSTAT1 specific inhibitor to use in these experiments, an alternative STAT1 inhibitor was 
selected. S1495 is a compound isolated from the fungus Penicillium species and was shown 
to inhibit STAT1 phosphorylation in a variety of cells (201, 202). The aim of the next set of 
experiments was to investigate the ability of S1495 to inhibit STAT1 phosphoryation. 
5.5.5.1. pSTAT1/β actin expression ratio reduction in A549 cells (positive control) 
Similar to fludarabine phosphate, S1495 requires a solvent to initially dissolve it. Following 
on from the preliminary data from fludarabine phosphate experiments outlined above, and 
DMSO apoptosis analysis (Figure 5.12), S1495 was diluted at 10µg/µl in DMSO, and 
subsequently diluted to 1µg/µl with media.  
Based on the study by Yao et al. (201), A549 cells were used as a positive control for S1495-
related STAT1 phosphorylation A549 cells were left un-treated or treated with 10µg/ml of 
S1495 for 18hrs serum-free DMEM, and stimulated with 10ng/ml IFNα and 10ng/ml IFNγ for 
15mins. Cells were lysed and the pSTAT1/β actin expression ratio was analysed. This was 
repeated for another passage of A549 cells. There was a reduction in the ratio of pSTAT1 to 
β actin upon S1495 treatment compared to untreated cells (0.3 vs 1.2 for 1st passage; 1.4 vs 
2.0 for 2nd passage) (Figure 5.14). Additionally, S1495 had little effect on pSTAT3/STAT3 
expression ratios compared to untreated cells (0.007 vs 0.06 for 1st passage; 0.07 vs 0.1 for 
2nd passage) (Figure 5.15). This indicates that the S1495 reduces the pSTAT1/β actin 
expression ratio without effecting STAT3 phosphorylation and therefore may be a suitable 
STAT1 phosphorylation specific inhibitor in neutrophils.  
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Figure 5.14. S1495 pre-treatment on STAT1 phosphorylation in IFN stimulated A549 cells. 
Based on study by Yao et al. (201), A549 cells were used as a positive control in investigation 
into the use of S1495 as a STAT1 phosphorylation inhibitor. After 18hrs pre-treatment, S1495 
was able to reduce pSTAT1/β actin expression ratio in A549 cells stimulated with 10ng/ml 
IFNα and 10ng/ml IFNγ for 15mins. This was consistent across two passages and therefore 
indicates that S1495 may be an effective STAT1 phosphorylation inhibitor.  
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Figure 5.15. S1495 pre-treatment on STAT3 phosphorylation in IFN stimulated A549 cells. 
Based on study by Yao et al. (201), A549 cells were used as a positive control in investigation 
into the use of S1495 as a STAT1 phosphorylation specific inhibitor. After 18hrs pre-
treatment, S1495 had no significant effect on pSTAT3/STAT3 expression ratio in A549 cells 
stimulated with 10ng/ml IFNα and 10ng/ml IFNγ for 15mins. This was consistent across two 
passages and therefore indicates that S1495 may be an effective STAT1 phosphorylation 
specific inhibitor.  
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5.5.5.2. Dose response of S1495 on apoptosis 
Neutrophils were treated with a dose response of S1495 for 6hrs (1µg/ml, 5µg/ml and 
10µg/ml), and apoptosis was measured. Little difference was seen between doses of S1495, 
indicating that it does not appear to affect naïve neutrophil apoptosis significantly at any of 
the doses tested (unstimulated = 12.7 ± 5.4%; 1µg/ml = 12.4 ± 5.2%; 5µg/ml = 12.6 ± 5.5%; 
10µg/ml = 15.5 ± 6.7%; n=3) (Figure 5.16). This was reassuring as it is hypothesised in this 
study that STAT1 is more likely to be activated in IFN-stimulated, TNFα-primed neutrophils. 
Thus, its effect on apoptosis may be more pronounced, and so STAT1 inhibition by S1495 may 
only affect apoptosis in these conditions. From this experiment, as there was little difference 
in effect between different concentrations used, it was initially decided pragmatically that 
10µg/ml of S1495 was an appropriate concentration for subsequent experiments, modelling 
previous published studies that used this concentration (202). 
5.5.5.3. The effect of S1495 on pSTAT1 and pSTAT3 expression 
Following on from the dose response above, the effect of S1495 on STAT1 and STAT3 
phosphorylation was investigated. Here, it was shown that the S1495 reduced the pSTAT1/β 
actin expression ratio in neutrophils from healthy adult donors, following 1hr S1495 
treatment at 10µg/ml and subsequent stimulation with 10ng/ml IFNα and 10ng/ml IFNγ, for 
15mins (0.46 ± 0.23 vs 0.78 ± 0.37; n=5) (Figure 5.17). This suggests that S1495 may be 
inhibiting STAT1 phosphorylation or reducing overall STAT1 expression. However, donor 
dependency was observed, whereby the S1495 had little inhibitory effect on IFN-related 
pSTAT1 in 2 of 5 donors (Figure 5.16). Reassuringly, there was no overall effect on the IFN-
related pSTAT3 expression (0.20 ± 0.05 vs 0.16 ± 0.05; n=5) (Figure 5.18), suggesting that, 
unlike fludarabine phosphate, S1495 is a specific STAT1 inhibitor. 
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Figure 5.16. Apoptosis analysis in neutrophils from healthy adult donors following a S1495 
dose response at 6hrs. Neutrophils were isolated from healthy adult donors and were left 
unstimulated or treated with a dose response of 1, 5 or 10µg/ml S1495 for 6hrs. Neutrophils 
were stained with annexin V FITC and PI and apoptosis was calculated as a percentage. No 
overall differences were seen between concentrations; however, 10μg/ml was used in other 
studies (n=5).  
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Figure 5.17. pSTAT1/Β actin expression ratios after 1hr S1495 treatment in healthy adult 
neutrophils stimulated with 10ng/ml of IFNα and 10ng/ml IFNγ for 15mins. Neutrophils 
were isolated from healthy adults and were left unstimulated or treated with S1495 for 1hr 
and both conditions subsequently stimulated with 10ng/ml IFNα and 10ng/ml IFNγ for 
15mins. Protein was extracted, and pSTAT1/β actin expression ratios was measured using 
Western blotting (n=5). 
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Figure 5.18. pSTAT3/STAT3 expression ratios after 1hr S1495 treatment in healthy adult 
neutrophils treated stimulated with 10ng/ml of IFNα and 10ng/ml IFNγ for 15mins. 
Neutrophils were isolated from healthy adult donors and were left unstimulated or were 
treated with S1595 for 1hr and both conditions were subsequently stimulated with 10ng/ml 
IFNα and 10ng/ml IFNγ for 15mins. Protein was extracted and pSTAT3/STAT3 expression 
ratios was measured using Western blotting (n=5). 
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5.5.5.4. The effect of S1495 on neutrophil apoptosis 
Following on from the investigations above (Section 5.5.5.3), the effect of S1495 on apoptosis 
in TNFα-primed, IFN stimulated neutrophils was investigated. As has been shown in this study 
(see above) such neutrophils have increased STAT1 phosphorylation, which may lead to the 
increase in apoptosis seen with the high concentration of IFNs. It is hypothesised that in the 
presence of STAT1 inhibition with S1495, that IFNs are forced to signal through the anti-
apoptotic STAT3 in primed neutrophils, where they may typically induce STAT3 
phosphorylation, and thus become anti-apoptotic.  
Neutrophils were pre-treated with 10µg/ml S1495, primed with 1µg/ml TNFα for 30mins and 
stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs. Initially, data 
suggested that in primed neutrophils, S1495 had an anti-apoptotic effect on neutrophils, and 
IFNs had no additional effect on this reduction in apoptosis (unstimulated = 12.3 ± 1.2% vs 
25.1 ± 2.6%; IFNα = 12.4 ± 3.3% vs 26.6 ± 3.0%; IFNγ = 15.0 ± 1.8% vs 27.3 ± 3.8%; IFNβ =12.9 
± 2.0% vs 26.6 ± 3.0% n=3) (Figure 5.19).  
Thus, an experiment was conducted to investigate whether priming neutrophils initially with 
TNFα would affect how S1495 modulates apoptosis through STAT1 inhibition. Neutrophils 
were primed with 1µg/ml TNFα for 30mins, then treated with S1495 for 6hrs. This did 
demonstrate again that the S1495 still had an overall anti-apoptotic effect on primed 
neutrophils, but not on naïve neutrophils (unstimulated = 7.7 ± 1.7% vs 10.4 ± 2.5%; TNFα 
=19.2 ± 3.7% vs 27.1 ± 9.0%; n=3) (Figure 5.20). This indicated that, contrary to what was 
hypothesised, S1495 actually reduced apoptosis when neutrophils were primed with TNFα, 
but without any IFN stimulation. Therefore, any reduction in apoptosis by S1495 is not via 
the phosphorylation of anti-apoptotic STAT3. This was regardless of whether the neutrophils 
were primed with TNFα first or stimulated with S1495 first.  
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Figure 5.19. The effect of 10μg/ml of S1495 on 10ng/ml IFN-related apoptosis in TNFα-
primed healthy adult neutrophils at 6hrs. Neutrophils were isolated from healthy adult 
donors and left unstimulated (blue) or treated with 10μg/ml S1495 (red) for 1hr. Neutrophils 
were primed with 1μg/ml TNFα and stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml 
IFNβ for 6hrs. Neutrophils were stained for annexin V FITC and PI, and the apoptosis was 
calculated as a percentage. As expected, IFNs lost their ability to reduce apoptosis primed 
neutrophils without S1495. However, S1495 had reduced apoptosis effect in primed 
neutrophils with no additional effect from the IFNs (n=3).  
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Figure 5.20. The effect of S1495 on apoptosis in naïve and primed neutrophils from healthy 
adults. Neutrophils were isolated from healthy adult donors and either left naïve or primed 
with 1μg/ml TNFα. Neutrophils were either left unstimulated (blue) or treated with 10μg/ml 
S1495 (red) for 6hrs, and neutrophils were stained with annexin V FITC and PI. Apoptosis was 
measured and presented as a percentage. Here, TNFα had an apoptotic effect at 1μg/ml, an 
effect not seen in other experiments. S1495 had no effect on unstimulated neutrophil nor 
TNFα-primed neutrophil apoptosis (n=3). 
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Thus, another dose response experiment was conducted, to see if in TNFα-primed 
neutrophils, a lower concentration of S1495 may be more appropriate in inhibiting STAT1 
without having an additional anti-apoptotic effect when IFNs are not present. Neutrophils 
were primed with 1μg/ml TNFα for 30mins, and subsequently treated with S1495 for 6hrs. It 
was shown that again, 10μg/ml of S1495 was able to reduce apoptosis in primed neutrophils 
compared to unstimulated primed neutrophils, but this was not seen at lower concentrations 
(unstimulated = 29 ± 4.6%; 1μg/ml = 29 ± 4.7%; 5μg/ml = 32 ± 5.4%; 10μg/ml = 23 ± 2.0%; 
n=3) (Figure 5.21). 
It has to be clarified that, although at 5μg/ml the inappropriate S1495 anti-apoptotic effect 
was lost, that S1495 was still able to reduce pSTAT1/β actin expression ratios at this 
concentration indicating that S1495 is possibly inhibiting STAT1 phosphorylation. Neutrophils 
were treated with 5µg/ml S1495, primed with 1µg/ml TNFα for 30mins and stimulated with 
10ng/ml IFNα, 10ng/ml IFNγ, or 10ng/ml IFNβ for 15 mins. Using Western blotting, it was 
confirmed that at 5µg/ml, S1495 was able to reduce pSTAT1/β actin expression radios in 
primed neutrophils stimulated with IFNα, IFNγ or IFNβ but again this was donor dependent 
(donor 1: unstimulated = 0 vs 0.05; IFNα = 0.24 vs 0.08; IFNγ = 0.56 vs 0.42; IFNβ = 0.57 vs 
0.47; donor 2: unstimulated = 0 vs 0.04; IFNα= 0.30 vs 0.18; IFNγ = 1.02 vs 1.23; IFNβ = 0.62 
vs 1.34) (Figure 5.22). Interestingly there was some level expression of pSTAT1 in primed 
neutrophils without S1495 or IFN stimulation, which was inhibited in the presence of S1495 
at 5µg/ml (Figure 5.22). Thus, TNFα may phosphorylate STAT1 in neutrophils but only at a 
high concentration (1µg/ml) as opposed to 1ng/ml initially used in STAT1 experiments (Figure 
5.9, Figure 5.22). 
It was now important to analyse the effect of 5µg/ml S1495 on TNFα-primed neutrophil 
apoptosis in the presence of IFNs. Neutrophils were pre-treated with 5µg/ml S1495, primed 
with 1µg/ml TNFα for 30mins and stimulated with 10ng/ml IFNα, 10ng/ml IFNγ, or 10ng/ml 
IFNβ for 6hrs. Unlike at 10µg/ml, at 5µg/ml S1495 had no effect apoptosis of primed 
neutrophils, and IFNs had no effect in the presence of S1495 at this concentration 
(unstimulated = 19.5 ± 2.2% vs 22.2 ± 2.7%; IFNα = 24.0 ± 2.8% vs 23.9 ± 3.1%; IFNγ = 23.3 ± 
3.2% vs 24.4 ± 2.1%; IFNβ =23.8 ± 3.1% vs 23.0 ± 2.2% n=3) (Figure 5.23). This was regardless 
of the concentration of neutrophils seeded. Neutrophils from one donor were seeded at 
5x104 neutrophils per 100µl per condition compared to 1x105 neutrophils per 100µl per 
condition for other donors, with no difference noted.  
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Figure 5.21. The effect of S1495 dose response on apoptosis in TNFα-primed neutrophils 
from healthy adults. Neutrophils were isolated from healthy adult donors and were primed 
with 1μg/ml TNFα for 30mins and treated with a dose response of 1, 5 or 10µg/ml S1495 for 
6hrs. Neutrophils were stained with annexin V FITC and PI and apoptosis was calculated as a 
percentage. On average, only 10μg/ml S1495 reduced apoptosis (n=3).  
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A  
B  
Figure 5.22. The effect of 5μg/ml of S1495 on STAT1 phosphorylation in primed neutrophils 
from healthy adults. Neutrophils were isolated from healthy adult donors and left 
unstimulated or treated with 5μg/ml of S1495 for 1hr. Neutrophils were primed with 1μg/ml 
TNFα and stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 15mins. Proteins 
were extracted and pSTAT1/β actin expression ratios were measured using western blotting. 
S1495 at this concentration can inhibit pSTAT1 in IFNγ and IFNβ stimulated neutrophils (B) 
but this seems to be donor dependent (n=2).  
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Figure 5.23. The effect of 5μg/ml of S1495 on IFN-related apoptosis in primed neutrophils 
from healthy adults. Neutrophils were isolated from healthy adult donors and left 
unstimulated (blue) or treated with 5μg/ml S1495 (red) for 1hr. Neutrophils were primed 
with 1μg/ml TNFα and stimulated with 10ng/ml IFNα, 10ng/ml IFNγ or 10ng/ml IFNβ for 6hrs. 
Neutrophils were stained for annexin V FITC and PI, and the apoptosis was calculated as a 
percentage. S1495 had no effect on apoptosis in TNFα-primed neutrophils (n=3). 
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5.6. Discussion 
In this chapter, it has been shown that as the IFN subtypes exert their effect through the 
JAK/STAT pathway, this may be important pathway in JSLE neutrophil apoptosis. It was 
shown that there was an up-regulation of IFNGR2 and subsequent increased phosphorylation 
of pro-apoptotic STAT1 in TNFα-primed neutrophils, and down-regulation of IFNAR1 and 
decreased phosphorylation of anti-apoptotic STAT3. This suggests that the JAK/STAT 
signalling pathway may have a role in JSLE neutrophil apoptosis and that IFNγ in may be an 
important effector of this pathway. Although efforts were made to see if STAT1 inhibition 
promotes IFN-induced anti-apoptosis via signalling through pSTAT3, this was not always 
possible using the two inhibitors investigated. However, the pathway has been shown to be 
up-regulated in SLE (194), and as it is important in neutrophil apoptosis, it still highlights a 
potential therapeutic in JSLE. 
5.6.1. IFN receptor expression and the JAK/STAT pathway 
Published data has shown that IFN receptor chain expression can influence different parts of 
the JAK/STAT pathway, and an increase in IFNGR2 is linked to increased IFNγ related pSTAT1 
and apoptosis (161, 162) (Sections 1.5.2, and 5.1).  
The data in this chapter showed that in TNFα-primed neutrophils, as confirmed by changes 
in CD11b and CD62L expression, there was a significant decrease in IFNAR1, and a trending 
increase in IFNGR2 (Section 5.5.1). IFNs had no overall effect on activation or IFN receptor 
chain expression although there was suggestion that IFNγ could increase IFNGR2 (Section 
5.5.1). Downstream, there was a reduction in pSTAT3/STAT3 expression ratio and an increase 
in pSTAT1/β actin expression ratio in these activated neutrophils (Section 5.5.3). The link 
suggests that the reduction in type 1 IFN-induced pSTAT3 is linked to the reduction in IFNAR1; 
that in activated neutrophils, the ability of IFNα and IFNβ to phosphorylate STAT3 was 
reduced (Section 5.5.3). Additionally, as published data indicated, there was an increase in 
type 2 IFN-induced pSTAT/β actin ratio (Section 5.5.3). It was shown in activated neutrophils, 
IFNγ-related  pSTAT1/β actin expression ratio is increased (although whether this increase 
was due to increase pSTAT1 expression or an increase in overall STAT1 expression was not 
concluded due to issues with the pan STAT1 antibody), and this increase may be linked to 
increased apoptosis seen in these cells. This supports the evidence that indicates this 
pathway is important in SLE and lupus nephritis pathogenesis (161, 162, 194, 196) (Section 
1.5).  
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These findings are important and supportive of the previous findings in Sections 4.5.3.2 and 
4.5.4.3 with regards to neutrophil apoptosis. It seems that there is a reduction in the anti-
apoptotic signalling pathway and an increase in the pro-apoptotic signalling pathway via 
decrease in pSTAT3/STAT3 expression ratio and increase in pSTAT1/β actin expression ratio 
(which may be due to an increase in pSTAT1 expression or overall STAT1 expression) which 
may be contributing the differential apoptotic effects of IFNs on neutrophils (138, 141) 
(Sections 1.5, and 4.5.3-4.5.7). Although apoptosis was only seen at high concentrations of 
IFNs in activated neutrophils, it still may be possible that IFNγ in particular can induce 
apoptosis in JSLE through an increase in IFNGR2 expression suggested by published studies 
on T cells and increase pSTAT1/β actin expression ratio seen here (161, 162) (Sections 1.5 
and 5.1).. Alternatively, activated neutrophils, which represent neutrophils found in SLE and 
JSLE patients have reduced IFNAR1 (83, 90). This may reduce the activation of STAT3; this 
reduction of anti-apoptotic STAT3 activation could contribute to the increase in neutrophil 
apoptosis seen in SLE and JSLE patients (71, 72, 141) (Section 1.4.3). 
5.6.2. IFN receptors in JSLE neutrophils 
This study showed that there was an increase in CD11b in freshly isolated JSLE neutrophils 
compared with paediatric control neutrophils. This indicates that the JSLE neutrophils are 
more active, most likely due to the pro-inflammatory environment in which they came from. 
However, there was no comparable reduction in CD62L in JSLE neutrophils. This reflects well 
with a published study which has already shown that neutrophils are activated in adult-onset 
SLE patients (83) (Section 1.3.5). However, although the increase in CD11b correlates well 
with activation of healthy adult neutrophils though TNFα-priming, the lack of change in 
CD62L between JSLE and paediatric control neutrophils did not reflect that of the in vitro 
model. This inconsistency may be due high concentration of TNFα used in the model; the 
concentration is higher than the range of cytokine concentrations typically found in JSLE 
serum and plasma (68, 72, 172, 225). However, the environment in which SLE and JSLE 
neutrophils are in is complex, and there is evidence to suggest both an increase and decrease 
in neutrophil priming agents with SLE and JSLE serum (72, 86, 90, 168, 171) (Sections 1.5.4 
and 4.1). A published study has shown that GMCSF, a known neutrophil priming agent that 
can induce the expression of CD11b, has been shown to be decreased in JSLE serum, 
indicating that the JSLE environment may be less likely to activate neutrophils (72, 86, 168, 
228) (Section 1.3.5). However, although not shown here, it has been suggested that IFNγ, can 
also prime neutrophils (90) (Sections 1.3.5 and 5.5.1.2). As IFNγ is increased in SLE and 
therefore likely to be increased in JSLE, it may be involved in activation of neutrophils (171). 
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However, these conflicting studies may reflect the differences in SLE and JSLE patients and 
their diseases (7) (Section 1.1). Following from this, the patients who contributed neutrophils 
to be analysed were noted to have inactive disease (Section 5.5.2); therefore, CD62L 
expression on neutrophils from these patients may not significantly differ from that of 
paediatric control neutrophils. Therefore, although these neutrophils may be activated, 
activation of neutrophils via the pro-inflammatory environment within JSLE patients with 
inactive disease may not be as extreme in comparison to TNFα-primed neutrophils in vitro or 
indeed compared to neutrophils from JSLE patients with active disease. It would therefore 
be interesting to investigate these markers on neutrophils from patients with more active 
disease to fully elucidate how disease activity affects neutrophil activation.  
Following on from this activation analysis, IFN receptor chain expressions were analysed 
(Section 5.5.2). There were no significant differences in the expression of IFNAR chains and 
IFNGR chains between JSLE and paediatric control neutrophils. The observed similarities of 
IFNGR chain expression between JSLE and paediatric control neutrophils was as expected; 
these results reflect the in vitro model mentioned above. Therefore, unlike published 
observations on T cells, IFNGR chain expression is likely to be always stable on neutrophils 
regardless of environmental factors, activation or JSLE disease, and thus any differential 
effect of IFNγ on neutrophil apoptosis (Section 4.5.3.2) is not due to the expression of IFNGR 
chains (161, 162) (Sections 1.5.2 and 5.1). The similarities in IFNAR expression between JSLE 
and paediatric control neutrophils, do not reflect the adult in vitro model. However, again 
the neutrophils analysed for IFN receptor chains were from patients who had inactive 
disease; therefore, similarities in IFN receptor chains on neutrophils from inactive JSLE 
patients and paediatric control patients may be due to the JSLE patients’ good health at time 
of sampling (Section 5.5.2). As with neutrophil activation, it would be beneficial to extend 
this study to neutrophils from JSLE patients with active disease; these neutrophils may be 
more active than those from inactive JSLE patients, and this increased activation may result 
in decreased IFNAR1. 
This observed similarity in IFN receptor chain expression in JSLE patients and healthy controls 
(and thus, allowing IFNs to phosphorylate the anti-apoptotic STAT3) may explain why there 
was not an increase in apoptosis in JSLE neutrophils seen in the previous chapter (Section 
4.5.8); the receptor chain expression is not primed to induce STAT1 related apoptosis 
(Section 5.5.2). However, sample size makes it difficult to see a difference between cases and 
controls. Additionally, JSLE patients, of whom the neutrophils were used in these 
experiments, and were found to have relatively inactive disease in general. Therefore, these 
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patients used may not fully represent the JSLE patient population as a whole. JSLE patients 
are heterogeneous through disease characteristics and medication exposure, may be other 
sub-groups of JSLE patients in whom the JAK/STAT pathway is more of a drug therapy target 
than in others. Additionally, the JSLE patients used in this study had a low medium pBILAG 
score indicating overall as a group, their disease was inactive or relatively inactive, and well 
controlled by the medication they are on. This may also contribute to the comparable IFN 
receptor chain expression between JSLE patients and healthy controls. Thus, more sampling, 
preferably from those patients that have very active disease, would be needed to fully 
investigate this signalling pathway. 
5.6.3. STAT1 inhibition 
As these data have indicated, IFNs can have a pro-apoptotic effect in neutrophils, and this is 
via the phosphorylation of STAT1 (Section 5.5.3). If STAT1 phosphorylation is inhibited, IFNs 
may not be able to have a pro-apoptotic effect in neutrophils. If they are unable to 
phosphorylate STAT1, IFNs may have to phosphorylate STAT3, and thus induce an anti-
apoptotic signalling pathway in activated neutrophils. This may then be beneficial in reducing 
the number of apoptotic neutrophils in JSLE.  
5.6.3.1. Fludarabine phosphate as a STAT1 inhibitor 
The first inhibitor of STAT1 that was investigated was fludarabine phosphate. It is a known 
chemotherapeutic medication; but was also suggested to inhibit STAT1 made it an interesting 
inhibitor as it may have had therapeutic potential in SLE (200, 229) (Section 1.5.4.3).  
This assessment of this inhibitor was associated with several experimental issues (Section 
5.5.4). The first was that it needed DMSO to dissolve it. Initial experiments showed that 
although fludarabine phosphate was effective at reducing the pSTAT1/β actin expression 
ratio at 50µM, the equivalent amount of DMSO significantly induced apoptosis. This was a 
fundamental flaw in the experimental set up; the carrier solution had an independent effect 
on neutrophils additional (and in theory opposite) to that of fludarabine phosphate. 
Fludarabine phosphate was therefore diluted in less DMSO, and a time course was 
investigated using 50µM fludarabine phosphate as the optimal concentration for reducing 
pSTAT1/β actin expression ratio and therefore probably inhibiting STAT1, either through 
reducing pan STAT1 expression, or inhibiting specifically the phosphorylation of STAT1. At 
2hrs, fludarabine phosphate had STAT1 inhibition ability shown through the reduction of the 
pSTAT1/β actin expression ratio. However, the pSTAT3/STAT3 expression ratio was also 
reduced, indicating that STAT3 was also inhibited under these conditions. Again, this 
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demonstrated another problem with using this as an inhibitor in this model. Any inhibitory 
effect fludarabine phosphate had was not STAT1 specific, and that it also influenced STAT3 
meant that it was not able to subsequently be used as a specific ‘STAT1 inhibitor’. Thus, 
further investigation into fludarabine phosphate was halted.  
5.6.3.2. S1495 as a STAT1 inhibitor 
S1495 was the second STAT1 inhibitor to be investigated (Section 5.5.5). More recent studies 
have used S1495 to inhibit IFNγ-induced pSTAT1 in J774 mouse macrophages, suggesting it 
may inhibit pSTAT1 in human neutrophils (201, 202). S1495 needed a solvent to dissolve in, 
and in this study, it was dissolved in DMSO similar to that of fludarabine phosphate (10μg/μl 
in DMSO, then diluted further to 1μg/μl in media)). However, it did not dissolve quite as well 
as fludarabine phosphate. At time of order and reconstitution, there was no suggestion from 
the company of which solvent was most suitable, and communication with technical support 
and data shown in this study on the effect of DMSO on apoptosis suggested DMSO would be 
suitable. However, recent searches have suggested methanol as solvent of choice for S1495 
reconstitution (http://www.abcam.com/s14-95-ab144515.html). Thus, this may explain why 
S1495 didn’t dissolve in DMSO quite as well as fludarabine phosphate, and methanol may be 
considered in any future S1495 studies. Additionally, the use of DMSO as a solvent for S1495, 
although diluted, may have some impact on the results shown in Section 5.5.5. 
Unlike fludarabine phosphate, S1495 at 10μg/ml was shown to inhibit IFN-induced increase 
in pSTAT1/β actin expression ratio in neutrophils after 1hr incubation without any obvious 
effect on the pSTAT3/STAT3 expression ratio. This S1495 concentration and time course was 
selected based on previous published data observed in the J774 mouse macrophage cell line 
(therefore a useful starting protocol for work in neutrophils) (202). Additionally, another 
study showed that S1495 had an inhibitory effect on STAT1 phosphorylation in immortalised 
human cell lines (albeit at a higher concentration) indicating that inhibition of STAT1 by s1495 
may be also be viable in human cells (201). These studies, however, did not show any 
comparative data on the effect of S1495 on other STATs, particularly STAT3 (201, 202). 
Therefore, here it was shown the selectivity of S1495 on STAT1 inhibition, without affecting 
STAT3, although its effect on other STATs remain to be elucidated. However, this possible 
pSTAT1 inhibition was donor dependent, and only reduced pSTAT1/β actin expression ratios 
in three out of five donors in initial experiments. This variability was deemed acceptable; 
however careful analysis on the effect S1495 on apoptosis would be needed due to the high 
probability donor-dependent variability.  
209 
 
Next, it was of interest to investigate how the STAT1 inhibition by S1495 affected apoptosis, 
a function that which was not investigated by other published studies using S1495 as a STAT1 
inhibitor (201, 202). It was shown here that S1495 had no effect on apoptosis in naïve 
neutrophils; this may be due to the fact that type 1 IFNs in particular signal through the anti-
apoptotic STAT3 more in these naïve neutrophils, exerting an anti-apoptotic effect (Section 
4.5.3 and Section 4.5.4). Therefore, as it was shown that S1495 has no effect on STAT3 
phosphorylation, it was unlikely to affect IFN signalling in naïve neutrophils in regards to 
apoptosis. However, the S1495 reduced apoptosis in TNFα-primed neutrophils, which was 
unaffected by IFN stimulation. It is likely that, within primed neutrophils treated with S1495, 
any reduction in apoptosis is not through the anti-apoptotic IFN/STAT3 pathway. This also 
correlates with the observation that S1495 had no effect on IFN-induced STAT3 
phosphorylation; there was no increased IFN-induced pSTAT3/STAT3 expression ratios when 
pSTAT1/β actin expression ratios were reduced by S1495 (Figure 5.16), and therefore no 
downstream increase in an IFN induced anti-apoptotic effect. As with IFNs, TNFα can be both 
pro- and anti-apoptotic on neutrophils (221). Here, it was shown that TNFα does not activate 
either STAT1 or STAT3. It may be possible that S1495 has another target that is part of the 
TNFα pathway; this may lead to TNFα reducing apoptosis in neutrophils in the presence of 
S1495. Thus, S1495 is not ideal to investigate how STAT1 inhibition affects the IFN pathway 
and its effect on apoptosis in TNFα-primed neutrophils in vitro. More investigation is required 
to fully investigate the IFN/STAT1 pathway in regards to neutrophil apoptosis, and whether 
inhibition of this pathway would be therapeutically beneficial in JSLE.  
 
5.7. Summary 
In this chapter, it has been shown that TNFα-primed neutrophils have dysregulated IFN 
receptor chain expressions, and this may lead to IFN-induced increase in pSTAT1/β actin 
expression ratio, decrease in pSTAT3/STAT3 expression ratios, and the dysregulation of 
apoptosis, as demonstrated also in chapter 4. However, JSLE neutrophils do not completely 
reflect the activated adult neutrophils, which may be due to a variety of reasons, including 
the fact that TNFα was used at a high concentration and JSLE neutrophils were from patients 
with inactive disease. Efforts were made to inhibit STAT1, known to be pro-apoptotic and 
increased in SLE. Important preliminary data explored potential inhibitors of STAT1 in this 
model, with progress was made in understanding a potential role of S1495 as a specific 
inhibitor. However, the S1495-mediated reduction in apoptosis in TNFα-primed neutrophils 
led us to question whether S1495 modulates the TNFα pathway, leading to a TNFα anti-
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apoptotic effect. Thus, the role of STAT1 in JSLE needs further investigation, particularly in 
regard to IFN-related neutrophil apoptosis, and whether STAT1 inhibition is potentially 
therapeutic in JSLE.  
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Chapter 6: Discussion  
6.1. Concept of study 
This study aimed to show how interactions between the different IFN subtypes and 
neutrophils might contribute to the pathogenesis of JSLE. There were many aspects to 
investigate, as the roles and functions of both neutrophils and the IFN subtypes are diverse 
and extensive, and many immune functions have been shown to be dysregulated within both 
adult-onset and JSLE (72, 110, 112, 113, 115-118, 123, 163, 170, 189, 208, 230) (Section 1.5). 
Neutrophil function is particularly impaired in SLE and with increased, dysregulated 
neutrophil apoptosis noted in both SLE and JSLE, neutrophils are thought to be a source of 
autoantigens in these conditions (19, 72, 114, 230) (Section 1.4.3). 
A detailed literature review concluded that both the IFN gene expression and serum protein 
level were increased within SLE and JSLE, and indeed that increased IFN activity may actually 
take place before the onset of clinical symptoms of SLE (41, 68, 171, 172, 174, 190) (Section 
1.5). This highlights that both type 1 and type 2 IFNs may have an important and key role in 
JSLE pathogenesis. In fact, review of the literature indicates that IFNs may be important in 
predicting SLE onset and also have a probable role in the induction of SLE pathogenesis (190). 
Therefore, the mechanism of action of type 1 and type 2 IFNs on neutrophils was investigated 
in regard to neutrophils within JSLE. 
Published data has shown that not only is there an increased type 1 IFN gene signature within 
PBMCs of JSLE patients, there is also an increased expression of granulocyte-associated genes 
(41) (Section 1.5). These data indicate that IFNα, which is increased in sera from both adult-
onset SLE and JSLE patients, could potentially, either directly or indirectly, interact with 
neutrophils to contribute to pathogenesis of JSLE (163, 231). Within adult-onset SLE, there is 
indication that IFNγ genes are also up-regulated, and that this increase correlates with both 
disease activity and with expression of type 1 IFN genes (174). IFNγ signalling pathways, via 
STAT1, have also been shown to be up-regulated within PBMCs of SLE patients (194). 
Additionally, the STAT1 pathway is up-regulated in a lupus nephritis model in MRL/lpr mice 
(196). These data suggest that not only are different IFN subtypes up-regulated in adult-onset 
SLE and JSLE, but also their signalling pathways are up-regulated and thus may be important 
in disease pathogenesis.  
Although a careful review of the literature underlined a number of important studies 
investigating the role of the different IFN subtypes and their interaction with neutrophils and 
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their impact on neutrophil function in both adult-onset SLE and JSLE, detailed investigation 
into how the specific IFN subtypes interact with neutrophils in JSLE was limited to date.  
The aim therefore of this thesis was to investigate the interaction of IFN sub-types with 
neutrophils, and how IFNs can influence neutrophil function and cell death in the context of 
JSLE. This was achieved by: a) Investigating the effect of the IFN subtypes on neutrophil 
chemotaxis, phagocytosis and NETosis; b) Investigating the role of IFN subtypes on neutrophil 
apoptosis; and c) Investigating the underlying IFN signalling pathways in naïve and TNFα-
primed neutrophils with respect to neutrophil apoptosis. 
 
6.2. IFNs and neutrophil function 
6.2.1. Chemotaxis 
The first function to be investigated was chemotaxis (Sections 1.3.1, 1.4.3, 3.1, 3.5.1 and 
3.5.2). There is contradicting published data in how neutrophil chemotaxis is altered within 
SLE and JSLE. One study suggests an increase in chemotactic activity through an increase of 
plasma chemokines (118) (Section 3.1). However, other studies have suggested a decrease 
in chemotactic activity (116, 117) (Section 3.1). Many factors can influence and/or regulate 
neutrophil chemotaxis, in both health and disease, specifically in JSLE. It has been shown that 
a younger age of disease onset, renal involvement, and increased infection incidence may be 
associated with reduced neutrophil chemotactic function (117). Ethnicity of patients may 
also affect whether, and how, the neutrophil chemotaxis is dysregulated. In a population of 
Taiwanese JSLE patients, infection, disease activity and/or medication has no influence on 
chemotaxis in JSLE, although there was some (non-statistically significant) suggestion of 
reduced chemotaxis in JSLE neutrophils (112). However, within two populations of SLE 
patients from the USA neutrophils were demonstrated to have a reduced chemotactic ability 
and a reduced chemotactic activity within SLE serum (116, 117). Additionally, in contrast to 
the USA SLE patient populations, within a Chinese population of SLE patients, there was an 
observed increase in plasma chemokine concentration, although it was not clear if this was 
associated with increased neutrophil chemotaxis (118). Consideration of patient ethnicity 
and other clinical variables such as age of onset and organ involvement may be important 
when investigating chemotaxis within JSLE patients. In addition, considering basic 
demographic and medical information, such as any recent infections of the healthy 
volunteers contributing neutrophils to the in vitro models used, may greatly influence the 
results obtained from chemotaxis assays. 
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As neutrophils within SLE and JSLE are exposed to high levels of IFNs, it may be that the 
different IFN subtypes are priming neutrophils to respond to chemokines differently, as 
opposed to acting as chemokines themselves (68, 171, 172). IFNγ in particular has been 
suggested to prime neutrophils, whilst both IFNγ and IFNβ have been indicated to have roles 
in chemotaxis (90, 177-179). The next step into investigating neutrophil chemotaxis therefore 
was to initially prime neutrophils before testing their random and directed migration. IFN 
priming of the neutrophils did not have any overall effect on either random migration or 
directed migration to fMLP and IL-8. These experiments were carried out on healthy control 
neutrophils and, as literature has suggested, IFNγ and IFNβ may have a prominent role in 
chemotaxis in other scenarios. This included influencing immune cells than other than 
neutrophils and towards chemoattractants other than IL-8 and fMLP (112, 116-118). It would 
be interesting to conduct similar experiments on JSLE neutrophils (and other immune cells) 
to see if IFNs may contribute to the dysregulated chemotaxis already proposed in SLE and 
JSLE. The lack of any significant changes of the IFN priming on chemotaxis on healthy adult 
control neutrophils demonstrated in this present study may be due to many factors. As noted 
previously, within SLE patients, age of onset, renal involvement and also infection can 
enhance the reduced chemotaxis, and ethnicity is important in whether neutrophils have 
increased or reduced chemotactic activity (112, 116-118). The chemotaxis studies presented 
in this thesis were in a healthy adult cohort, and therefore these specific factors noted in SLE 
patients that may influence chemotaxis were not relevant. So, for example, whilst infection 
may be a factor that impacts on chemotaxis, it is unlikely that this is causing any effect here 
as the volunteers were all healthy at time of sampling. This means that although these results 
have not shown any significant IFN involvement in neutrophils in a healthy, non-pathological 
state, the IFNs may still be involved in a disease setting such as lupus where they too may be 
influenced by cytokines increased during inflammation or infections.  
Additionally, other studies have investigated chemotaxis using other 
chemokines/chemoattractants in addition to those studied above (118, 177-179). It has been 
shown that chemokines are up-regulated in SLE, in which GROα, another neutrophil 
chemokine, is one; however, importantly for this published study, it was also shown that 
there was no difference in IL-8 between SLE patients and healthy controls (118). Thus, 
although this study has shown that IFNs don’t influence chemotaxis towards IL-8 and fMLP, 
IFNs may influence neutrophil migration towards other chemokines. This has been reinforced 
by another study which showed that IFNγ can up-regulate CCR1 and CCR3 on neutrophils 
which have been shown to bind chemokines such as MCP3 and RANTES (179-182). To 
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understand further the role of IFNs on chemotaxis in a disease setting, an understanding of 
chemokine expression within JSLE disease is important. IFNs and other cytokines may prime 
neutrophils to respond differently to chemokines, however, a reduction/increase in 
neutrophil chemotaxis may also be due to altered level chemokines within inflammatory 
diseases. However, due to experimental restraints, primarily due to cell number available, it 
was not feasible to investigate the influence of IFNs on neutrophil chemotaxis against a full 
range of neutrophil chemokines. These experiments were conducted using an already 
optimised chemotaxis protocol with ideal fMLP and IL-8 concentrations, which were known 
to be strong neutrophil chemokines/chemoattractants. As at time of experimental 
investigation, the role of IFNs on neutrophil chemotaxis was unknown, at least towards fMLP 
and IL-8, in hindsight, GROα, MCP3 and RANTES may have been better, and more relevant 
candidates for this investigation.  
Chemotaxis was measured using a transwell migration assay which is a standard assay for 
measuring chemotaxis, however the number of cells migrated were counted using a non-
automated system, which can have increased variability and user bias compared to an 
automated cell counter. Other chemotaxis assays include using an under-agarose cell 
migration assay. However, this still requires manual counting by the user. Analysis of the 
chemotaxis receptors using flow cytometry would have been beneficial to see how IFN 
priming is affecting chemotaxis in this way.  
Another difficulty noted was that priming of the neutrophils required extra incubations and 
centrifugation, which resulted in loss of cells. Therefore, cell yields used in the assay between 
donor repeats were varied and may have affected results. Possible assay improvements could 
include adding the IFNs into the inserts directly with the neutrophils. However, this may not 
allow the IFNs sufficient time to influence chemotaxis before the neutrophils migrate.  
6.2.2. Phagocytosis 
Neutrophils normally attack invading pathogens by phagocytosis, and subsequent ROS 
production. However, it has been shown that neutrophil phagocytosis in SLE and JSLE is 
reduced (112, 114, 115, 189) (Sections 1.3.2, 1.4.3, and 3.1). Thus, the next neutrophil 
function investigated in this present study was phagocytosis.  
In published studies, IFNs have been shown to affect phagocytosis, but it should be noted 
that this dysregulation is very dependent on a variety of factors including type of immune 
cell and specific type of bacteria (183, 184) (Sections 1.4.3 and 3.1). Previously, it has been 
shown that IFNs can up-regulate neutrophil phagocytosis of both S. aureus bacteria and 
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bioparticles (184, 185). Although there is some indication that IFNγ may have some down-
regulatory effect on macrophage phagocytosis, in general, IFNs up-regulated phagocytosis, 
particularly with regards to neutrophils (184, 185). 
It is important to note that there are various receptors involved in phagocytosis, which in 
turn relies on how bacteria are opsonised. Published data has suggested that sheep 
erythrocytes opsonised with IgG were attached and internalised by mouse peritoneal 
macrophages via the Fc receptor, whereas C3b opsonised sheep erythrocytes were 
internalised by C3b receptors (183). Both processes were up-regulated by IFNα but not IFNγ 
(183). It has been shown that IFNγ induces an up-regulation of Fc receptors on human 
monocytes, and specifically Fcγ receptors are particularly augmented (215). IFNs also 
increased IgG binding to monocytes, although IFNα and IFNβ less so than IFNγ (215). IFNγ has 
also been shown to up-regulate FcγRI in circulating neutrophils, and FcγRI, FcγRII and FcγRIII 
in circulating monocytes (185). Integrin subunits CD11a, CD11b and CD18, and the human 
leukocyte antigen (HLA) class 2 antigen, HLA- antigen D Related (DR) was also increased on 
monocytes upon IFNγ stimulation (185). Within this present study, autologous serum was 
used to opsonise the E.coli bioparticles. However, due to the complexity of serum, the 
bioparticles may have been opsonised for several pathways, and thus any effect of IFNs on 
the phagocytosis of E.coli bioparticles may be masked by other, more prominent pathways. 
Alternatively, neutrophil phagocytosis could be activated by other pathways independent of 
IFNs. Therefore, it is difficult to discriminate any effect(s) due to the influence of IFNs alone.   
This importance of selectively analysing the effect of IFNs on specific phagocytic pathways 
and not just broadly opsonising for all pathways was highlighted by a published study (185). 
The study showed that IFNγ increased neutrophil phagocytosis of S. aureus, but only when 
opsonised with complement depleted heat inactivated pooled human serum (HI-PHS) and 
not pooled human serum (185). It was thought that the increase in FcγRI on neutrophils by 
IFNγ increased FcR-mediated phagocytosis of this complement depleted opsonised S. aureus 
(185). However, whereas because complement-mediated phagocytosis of complete human 
serum opsonised S. aureus faster and is a preferable system than FcR-mediated phagocytosis, 
the complement in human serum (which may not be affected by IFNs) may mask the increase 
in FcR-mediated phagocytosis seen with complement depleted opsonised S. aureus (185). 
How bacteria are opsonised and therefore how neutrophils recognise bacteria is essential, 
and that it may be that complete serum-opsonised E.coli used in this study are phagocytosed 
by neutrophils via a receptor not influenced by IFNs, for example the complement system 
(185). CD11b/CD18 make up Mac-1, also known as complement receptor 3 or CR3 (96). This 
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complement receptor can recognise gram negative bacteria such as E.coli, and medicate the 
phagocytosis of such bacteria (232). 
These data have shown that IFNs did not affect phagocytosis of E. coli in healthy neutrophils 
(Section 3.4.3). Previous studies have shown that IFNs increase phagocytosis and phagocytic 
receptors (183-185, 215) and therefore the observed IFN signature within JSLE, and 
heightened level of IFNs within SLE and JSLE serum could indicate that IFNs would have an 
increased effect on neutrophil phagocytosis in JSLE. For this reason, it was hypothesised that 
within JSLE, the decreased neutrophil phagocytosis reported is unlikely to be due to IFNs, and 
that the decreased neutrophil phagocytosis seen is probably due to other factors, either 
through altered expression of phagocytic genes, or factors within the serum (41, 68, 112, 
113, 115, 171, 172). 
There are other methods other than flow cytometry for analysis of phagocytosis. However, 
one benefit of flow cytometry is that it generates a reliable, quantitative estimate. 
Immunocytochemistry can be used to analyse phagocytosis, via the fluorescence of the E.coli 
bioparticles and staining of the nucleus of the neutrophils via DAPI. However, again this is 
not quantitative, and requires analysis on different planes to confirm that the particle is 
indeed within the neutrophil. The phagocytosis of the bioparticles can also be analysed using 
a fluorescence detecting plate reader, akin to that of enzyme-linked immunosorbent assays 
(ELISAs). This may be beneficial for analysing multiple samples at any given time, reduce the 
number of cells needed (as each experiment is conducted using a 96 well plate) and have the 
benefit of replication of samples to improve the repeatability and reliability of the results. It 
would also be beneficial to analyse not only the phagocytic receptor expression using flow 
cytometry, but also use ELISAs to analyse immune factors within serum, such as IgG or C3b 
that may be opsonising the E.coli bioparticles for phagocytic pathways (183). This may differ 
between donors, and also give insight into which phagocytic pathways are being stimulated 
(which may or may not be affected by IFNs). This analysis may allow discrimination, and 
therefore individual investigation, of the different phagocytosis pathways being influenced 
by the serum, and analysis into how opsonising immune complexes differ between paediatric 
controls and JSLE serum. However, as JSLE is a heterogeneous disease, and both serum and 
phagocytosis signalling are so complex, this type of analysis may offer limited interpretation.  
The limitation of the phagocytosis assay used in these methods is that only opsonised E.coli 
bioparticles were analysed. There is evidence that there is a relationship between the means 
by which the bioparticles are opsonised and the effect on phagocytosis. Additionally, specific 
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bacteria type and whether bioparticles or bacteria were used in the assay may have a 
significant effect on phagocytic results achieved. Thus, further, more extensive study into 
how IFNs affect neutrophil phagocytosis is required.  
6.2.3. NETosis 
NETosis is a type of cell death, whereby neutrophils expel their contents to ‘trap’ bacterial 
products and has been shown to be up-regulated in SLE and JSLE (37, 163, 208). IFNs have 
been suggested to have a role in NETosis through priming and additionally, it has been shown 
that NETs induce the production of IFNα from dendritic cells (163, 175) (Sections 1.3.3, 1.4.3, 
and 3.1).  
The data in this thesis have shown that IFN and TNFα priming induces some NETs from adult 
healthy neutrophils (Section 3.5.4). However, this was difficult to detect and was not 
consistently seen in all images and donors. In this study, two techniques were used to 
establish the role of IFNs in NET production. Using a confocal analysis, quantification was 
attempted by three independent operators; one confocal image from each donor was 
selected per condition and used for analysis. The three operators each counted both the 
number of viable neutrophils and number of neutrophils producing NETs and calculated the 
percentage of NETs within the population. For any experimental condition, the mean was 
calculated, and inter-operator variability was graphically analysed and any inter-operator 
variability calculated and compared. Although confocal microscopy gave a visual indication 
of NET formation, multiple operators’ quantification comparisons showed that this technique 
showed high inter-operator variability within certain conditions, and therefore too subjective 
to be a quantifiable technique. Thus, quantification of DNA was also analysed as DNA is a 
constituent part of NET material (37).  
The DNA quantification analysis only correlated well with analysis of the confocal images in 
regards to PMA stimulated neutrophils. This was the only condition that substantially 
increased the DNA release that is characteristic of NETs and was consistently detected by 
both DNA quantification and confocal analysis. Although these techniques have some validity 
for NET analysis, there are some experimental issues that were highlighted; staining with 
DAPI does show some, non-significant, release of DNA from the neutrophils (and thus is likely 
to be NET material). However, unless this is stained with MPO and NE, there was uncertainty 
whether the DNA material is: a) of neutrophil origin, and b) NET material. Unfortunately, time 
became limited at the late stage of laboratory work when these experiments were 
conducted, as otherwise additional staining would have been helpful to undertake further 
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validation experiments. Additionally, the DNA assay quantification assay may not be specific 
for DNA associated with NETs and that DNA from necrotic cells may compromise specificity. 
Minimal NET formation as observed using confocal microscopy for some of the other 
conditions in this experiment may not have produced enough DNA to be detected within the 
limits of the quantification assay. Due to the potential limitations of the DNA quantification 
technique, future work should include developing a protocol that allows more rigorous 
scoring of NETs, and therefore allow more consistent and improved inter-operator 
quantification of the confocal microscopy images. Computational methods of NET detection 
and quantification have been developed, which may be beneficial to analyse the data in this 
thesis, although this was not possible within the time frame of studies (216, 217).  
Here, it was shown that the IFNs did prime neutrophils to induce NET formation as measured 
by confocal microscopy. However, this was not observed in all images and donors, and thus 
remains inconclusive as to whether IFN priming has a definitive role on NETs. However, 
another study has shown that IFNs prime neutrophils to undergo NETosis upon stimulation 
with C5a (using DNA staining of neutrophils and confocal microscopy); C5a was not used here 
(175). It has to be of note that Martinelli et al., did quantify NETs by quantifying DNA release 
and MPO release using fluorescence and spectrometry quantification techniques 
respectively. Therefore, a wider investigation into the role of IFN priming on NETs, using a 
more extensive staining for confocal microscopy, variety of potential NETosis stimulants 
(such as C5a and HMGB1), and quantification of components such as MPO alongside DNA 
already used, may be necessary to conclude this IFN function (66, 175). 
Contextually, however, NETs are important in inducing IFNα release from pDCs; within JSLE, 
this interaction could heighten the level of IFNα within the serum (163). As NETs are not 
disassembled effectively within SLE, chronic activation of pDCs and IFNα release (163, 208) 
prime neutrophils to undergo NETosis, but only in the presence of other stimuli, creating a 
feedback loop (68, 171, 172, 175). Additionally, although NET formation seen in this present 
study is minimal, this could be important as neutrophils are so large in number in the disease 
state, even a small percentage of NETs could be biologically relevant in the damage of joints 
or kidney within JSLE. 
NETosis assays are traditionally analysed using confocal images, although a more extensive 
staining is typically used. MPO and NE staining can also be used in conjugation with DAPI to 
confirm the release of DNA is from NETs. Alongside this, ROS production analysis (ROS is 
linked to the induction of NETosis) can be conducted (63). It may be that although IFNs do 
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not induce NETosis, their priming function for NETosis may be due to alteration in ROS 
production. This may be another way to quantify the rate of NET induction.  
The limitations of the assays used in these studies include confocal images with ‘clumps’ of 
cells. This made it difficult to differentiate between what was a viable cell and what was a 
NETing cell, and to discriminate between a large single NET, multiple smaller ones, or a 
combination. Confocal microscopy can be a very subjective method of NET quantification, 
and thus quantifying the NETs on these images has limitations. The DNA quantification assay, 
although superior for quantification than the confocal images, was not set up to detect 
specifically DNA from NET material and can detect any DNA present in the supernatant. Also, 
besides PMA, there was no indication of DNA in any of the experimental condition above that 
of unstimulated cells despite confocal images showing minimal NETs. Thus, the DNA assay 
may not be sensitive enough to detect small amounts of DNA released in these conditions.  
 
6.3. IFNs and apoptosis 
The involvement of the IFN subtypes in apoptosis is well established, and literature has 
indicated IFNs can have dual, opposing roles in influencing neutrophil apoptosis, which is very 
dependent on the phosphorylation state of pro-apoptotic STAT1 or anti-apoptotic STAT3 
(138, 164, 165, 219, 233) (Sections 1.3.4, 1.4.3, 1.5.3.1, and 4.1). Neutrophils in JSLE undergo 
increased apoptosis, and this can be related to up-regulated extrinsic apoptotic factors in the 
serum, such as TRAIL and FasL, through which the serum can additively increase JSLE 
neutrophil apoptosis in vitro (72, 170). In JSLE, there can be changes in the balance of pro- 
and anti-apoptotic proteins within the neutrophil themselves (170). For example, JSLE 
neutrophils can demonstrate an increase in caspase 7, 8 and 9 mRNA, and decrease in IAP1, 
IAP2 and xIAP mRNA in JSLE neutrophils (170). This indicates that signalling pathways within 
JSLE neutrophils lean towards pro-apoptosis, and thus are likely to be an important 
contributor to the increased neutrophil apoptosis seen in JSLE (72, 170). 
 GMCSF has been shown to delay neutrophil apoptosis, and in particular has been shown to 
delay JSLE serum-induced neutrophil apoptosis via the stability of MCL1 (77, 110) (Section 
1.3.4). Thus, GMCSF via the stability of MCL1 was used as an anti-apoptotic control in 
investigating the effect of IFNs on apoptosis. GMCSF was shown to significantly delay 
neutrophil apoptosis within this study, correlating well with other studies and was an 
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effective control for apoptosis assays, particularly in regards to investigating the anti-
apoptotic effect of IFNs (77, 110, 141). 
Neutrophils in SLE are activated, and it is likely that JSLE neutrophils are activated, which has 
been shown in this study via the increase in CD11b (83) (Sections 1.3.5, 4.5.8.1 and 5.5.2). In 
in vitro studies, priming of neutrophils with cytokines such as GMCSF, TNFα and IFNγ, 
changes the way neutrophils respond, with certain functions such as respiratory burst 
becoming enhanced (81, 90). Additionally, cell membrane and intracellular proteins can be 
up-regulated or activated upon priming, and these changes in protein constitution on and 
within primed neutrophils alter how other cytokines inflict their effect to naïve neutrophils 
(81, 85, 86, 95, 169). Activation of both SLE neutrophils and JSLE neutrophils may therefore 
alter the constitution of proteins on and within the neutrophils (81, 83, 85, 86, 95, 169). This 
may include the alteration of intrinsic apoptotic pathways within JSLE neutrophils described 
above (170). This may influence how IFNs effect apoptosis within JSLE neutrophils compared 
to that of healthy naïve neutrophils.  
TNFα is a potent priming agent for neutrophils and was chosen over GMCSF and IFNγ as it 
was not an experimental condition used in this study downstream from priming (85, 90, 167) 
(Section 1.3.5). TNFα was used to prime neutrophils in order to try and model better the 
activated state neutrophils have been shown to be in SLE. The neutrophils in this present 
study were confirmed to be activated neutrophils through the up-regulation of CD11b (83) 
(Section 4.5.8.1 and 5.5.2). TNFα has also shown to be elevated in both the mesangial cells 
and plasma of patients with lupus nephritis and is associated with increased disease activity 
(67, 234). Therefore, TNFα is a physiologically relevant priming agent for the in vitro model, 
due to indication of its role in lupus nephritis and SLE (67, 234). It was therefore subsequently 
used to analyse IFN responses on neutrophils in an activating/inflammatory environment. 
 Initially, TNFα was used to prime neutrophils in vitro to model the activated neutrophils 
found in SLE and JSLE (83). These primed neutrophils were subsequently saturated with a 
high concentration of IFNs. Compared to naïve neutrophils, where a high concentration of 
IFNs reduced apoptosis, priming of neutrophils led to IFNs increasing the rate of apoptosis 
compared to unstimulated neutrophils This is an important consolidation of previous 
literature as this in vitro model suggests that a high level of IFNs in SLE and JSLE serum is not 
enough to induce apoptosis in JSLE neutrophils, and there is a need for other factors within 
the JSLE environment to activate the neutrophils for IFNs to induce apoptosis (138, 164, 165, 
219, 233).  
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The concentration of IFNs used (1-10µg/ml) for above experiments is likely to be a supra-
physiological concentration, thus a lower concentration was used for subsequent 
experiments (Section 4.5). Although 10ng/ml was still higher than that detected in JSLE serum 
(a range of 13.8 – 22.5 pg/ml of IFNα was detected in two observational studies), it is 
comparable to standard experimental concentrations of cytokines used in vitro (68, 77, 110, 
172). Additionally, within JSLE serum levels of IFNs may be lower, and therefore not 
reflective, of IFN levels in areas of active disease or inflammation within organs (235). In these 
assays, IFNs again reduced naïve neutrophil apoptosis, and although IFNs reduced the 
amount of cleaved caspase 3, showing that they are, indeed, delaying apoptosis, it is not 
through MCL1. The anti-apoptotic STAT3 is likely involved in this delay in apoptosis and may 
up-regulate such anti-apoptotic proteins such as B-cell lymphoma extra-large (Bcl-XL) and the 
IAPs (233, 236, 237). GCSF, STAT3 and cIAP2 have all been indicated to contribute anti-
apoptosis in neutrophils and overexpression of cIAP2 contributes to neutrophilia in chronic 
neutrophilic leukaemia (78). Both type 1 and type 2 IFNs can delay neutrophil apoptosis via 
the activation of STAT3 and subsequent up-regulation of cIAP2 protein and mRNA transcripts 
(233). The pro-apoptotic STAT1 was also phosphorylated in these neutrophils (141). Thus, a 
fine balance between the activation of STAT1 and STAT3 may be important in how 
neutrophils respond to IFNs in regards to apoptosis, and thus needed more investigation 
within this study (138, 233).  
Although this confirmation of the type 1 and 2 IFN role in reduced apoptosis, and elucidation 
of the pathway the IFNs may be signalling through to reduce apoptosis is important, this role 
in apoptosis was in naïve neutrophils. It was therefore also important to demonstrate the 
role of IFNs in activated or primed neutrophils; which may reflect better the status of 
neutrophils in inflammatory conditions such as JSLE (83). The investigation using the lower 
concentration of IFNs was repeated on TNFα-primed neutrophils; these primed neutrophils 
were used to model the activated JSLE neutrophils in vitro. Within this thesis, it was shown 
that the delay in apoptosis using 10ng/ml was abrogated in TNFα-primed neutrophils, which 
could potentially enable other factors, such as TRAIL and FasL (that have been shown to be 
elevated in JSLE serum) to induce apoptosis (72) (Section 4.5).  
Cytokines rarely function alone, and as noted above, cytokines other than IFNs can have a 
priming effect that can influence the effect of IFNs on apoptosis. Importantly as stated above, 
the serum of JSLE patients has increased apoptotic factors, such as TRAIL and FasL amongst 
other pro-inflammatory factors which may also influence the effect of IFNs on apoptosis (72). 
As JSLE serum has been shown to increase neutrophil apoptosis (110) and that GMCSF can 
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reduce the level of apoptosis induced by JSLE serum (110), it was important to also 
investigate the effect IFNs may have on neutrophil apoptosis in the presence of other factors 
within JSLE serum.  
Healthy control, inactive JSLE and two types of disease active JSLE serum (renal active and 
haematological active) were used to pre-treat adult healthy neutrophils before incubation 
with IFNs (Section 4.5.7). The rationale of the different types of JSLE serum was that in 
inactive patients, their disease is under control and least likely to induce neutrophil apoptosis 
compared to paediatric control serum. Within sera from patients with activity in the 
haematological domain, one of the clinical characteristics is a decreased white blood count, 
which includes a decreased level of neutrophils – these levels may reflect what is happening 
systematically and is an environment that would directly modulate the neutrophils, which 
are a primary interest of this thesis. Additionally, sera may contain increased factors, such as 
FasL and TRAIL, that lead to the increased neutrophil apoptosis that has been investigated 
greatly within this thesis (72). Patients with active renal manifestations was used as, although 
this was more localised to one organ, lupus nephritis is a major complication seen in JSLE, 
which occurs more frequently and more severely than on adult onset SLE patients, and may 
be more reflective of overall active JSLE disease than activity in the haematological domain 
(1, 238). Additionally, renal involvement in JSLE is a particular research interest of the UK JSLE 
cohort (239, 240). Given the complexity of JSLE, whereby classification of active disease can 
be organ domain specific, it was of interest to investigate how sera from inactive JSLE patients 
and JSLE patients with two different classifications of disease activity influences a) neutrophil 
activation, b) neutrophil apoptosis and c) the effect of the different subtypes of IFNs on 
apoptosis.  
All patient sera groups were able to activate healthy adult control neutrophils. This 
observation did not differ between paediatric control sera and JSLE sera, or between the JSLE 
sera subtypes. The increase in adult neutrophil activation by the patient sera was a result of 
exposure to a foreign environment rather than a specific serum profile. Overall the serum 
did not significantly induce apoptosis, and neither IFNs nor GMCSF had any significant effect 
on this, in contrast with other published findings (72, 110). However, this study used adult 
healthy neutrophils, which may be less responsive to paediatric serum in regards to 
apoptosis, and in particular compared to JSLE neutrophils.  
Future experiments investigating the compounded effect of serum and IFNs should include 
incubation of paediatric or JSLE neutrophils with paediatric control or JSLE serum. Unlike the 
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adult neutrophils here, published observations that both paediatric control neutrophils and 
JSLE have been shown to undergo increased apoptosis in response to JSLE serum (72, 110). 
These published studies could be expanded to investigate how JSLE sera of different disease 
states and organ involvement could affect paediatric control and JSLE neutrophil activation 
and subsequently how IFNs influence downstream apoptosis. These experiments would 
expand on published observations and the observations depicted in this thesis, and give a 
thorough overview on the effect of apoptosis on neutrophils from a variety of patient groups 
and environments which would reflect the complexity of JSLE 
Within paediatric control neutrophils and JSLE neutrophils, GMCSF was able to delay 
apoptosis and this was consistent with previous data and literature (72, 110) (Sections 1.3.4, 
4.1 and 4.5.8). Additionally, IFNγ was able to delay apoptosis in JSLE neutrophils, but not in 
control neutrophils. This is of interest as not only were control neutrophils more varied in 
response to cytokines, but there was also no overall difference in apoptosis between 
paediatric control and JSLE neutrophils. In the adult neutrophil model, the IFNs do induce 
apoptosis, but only at a very high IFN concentration (1-10μg/ml). Therefore, it would be of 
interest to expose JSLE neutrophils to higher concentrations of IFNs, with a particular focus 
on neutrophils from individuals with active JSLE disease. These neutrophils are likely to be 
more activated than the patient neutrophils used in this study and may be more likely to 
undergo IFN-induced apoptosis.  
JSLE neutrophils have a more active intrinsic pro-apoptotic signalling pathway, via the up-
regulation of caspase mRNA and the down-regulation of IAP mRNA (170). Thus, in theory, 
IFNs should be pro-apoptotic towards JSLE neutrophils if the neutrophils are already ‘primed’ 
for this effect. However, the data in this thesis shows that this is not necessarily the case and 
that neutrophils may need the pro-apoptotic environment found in JSLE and may have a 
‘healthier’ response in in vitro conditions (such as in 10% FBS). The neutrophils used in these 
experiments were from JSLE patients with tight disease control and had a lower overall 
pBILAG score compared to other cohorts investigated in the literature, which may contribute 
to this response observed (72, 110). Additionally, although they have the apoptotic potential 
through the up-regulation of caspases, this seems to be insufficient for IFNs to induce 
apoptosis, and further investigation into the signalling pathway of IFNs was needed. 
 Neutrophil apoptosis involves the loss of the FcγRIII (an immunoglobulin receptor found on 
the surface of neutrophils) (241, 242). This loss of FcγRIII in neutrophil apoptosis also 
associates with annexin V binding sites, and therefore is possibly an important step in the 
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early stages of apoptosis (242). Importantly, a published study showed that there is an 
association between different aspects of SLE and polymorphic variants of FcγRIII genes (243). 
In particular, polymorphisms of the FcγRIIIa gene are particularly associated with lupus 
nephritis (243). The FcγRIIIa gene polymorphisms may dysregulate, in part, the FcγRIII protein 
in some SLE patients (and by association some JSLE patients) which may be contributing to 
increased SLE and JSLE neutrophil apoptosis (72, 230). It would be of interest to investigate 
whether any of the polymorphic variants and protein expression changes of FcγRIII, associate 
with the increased neutrophil apoptosis seen in JSLE, and how these changes influence any 
effect of IFNs on neutrophil apoptosis (72).  
IFNγ signalling can be inhibited by immune complexes, and this inhibition is dependent on 
FcγRIII (244). Pre-incubation of macrophages with intravenous immunoglobulin (IVIG) for 16-
24 hours abolished IFNγ-stimulated STAT1 phosphorylation (244). Downstream, IFNγ 
stimulated monokine induced by γ IFN (MIG), IP10 and IRF1 mRNAs were suppressed 
following IVIG pre-treatment, (244). Additionally, IVIG was able to down regulate the 
expression of IFNGR2 but not IFNGR1, , confirming that the IFNγ signalling pathway is 
supressed by the IgG immune complex (244). Within NK cells, that only express FcγRIII and 
no other Fcγ receptors, IVIG inhibited IFNγ signalling, but this was not seen in B cells that 
express only FcγRIIb, indicating FcγRIII is involved in IFNγ signalling (244). Additionally, within 
murine macrophages deficient in FcγRIII, IVIG did not supress IFNγ signalling (244). Therefore, 
it would be of interest in future work to investigate how IFNγ signalling and the FcγRIII are 
linked in regards to neutrophil apoptosis, and additionally if FcγRIII has a similar effect on 
type 1 IFN signalling.  
 Further analysis of the effect of IFNs on neutrophil apoptosis could involve the analysis of 
different apoptotic proteins or genes. For example, membrane associated apoptotic proteins 
such as Fas can be analysed via flow cytometry. Intracellular proteins such as caspase 8 and 
9 can be analysed by Western blotting. Apoptotic genes such as IAPs can be analysed via 
qPCR. These analyses could be measured at baseline within all neutrophil types (adult 
healthy, paediatric control and JSLE) and upon TNFα-priming and IFN stimulation. The 
analysis of caspases would confirm which apoptotic pathway (extrinsic or intrinsic) the IFNs 
may influence. It would also be of interest to use the analysis described above to investigate 
how priming of neutrophils affects the composition of apoptotic proteins within neutrophils, 
and how these compare to JSLE and paediatric control neutrophils. The rationale of this 
analysis is that it is known that there are intrinsic differences of apoptotic proteins between 
paediatric control and JSLE neutrophils, and an appreciation of how this arises would 
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contribute to the knowledge base of the apoptotic process and highlight any potential 
therapeutic targets (170). It would also be of interest in how the IFNs, and their signalling 
pathways, influence apoptotic genes in regards to priming, and in both healthy and JSLE 
neutrophils. Additionally, the UK JSLE Study Group has shown a dysregulation of pro- and 
anti-apoptotic factors within JSLE serum, and thus it may be important to analyse the 
expression of the neutrophil receptors and subsequent signalling pathways for these factors 
in JSLE neutrophils and understand how these other factors may influence the IFN effect on 
apoptosis (72, 170).  
Methods other than flow cytometry can be used to measure apoptosis. These include: (1) 
light microscopy, which can be used to analyse trypan blue stained, non-viable cells, which 
can be distinguished from other, viable cells. However, although a cheap way to analyse 
viability, this requires counting manually and introduces operator variability. (2) Western 
blotting, which can be used to measure the level of expression of apoptotic proteins. 
Although good for intracellular protein analysis, Western blots are only semi-quantitative, 
and the multiple steps need optimisation and allow for increased technical errors. They are 
also time-consuming compared to other techniques, and not as sensitive as techniques such 
as ELISAs. (3) Immunohistochemistry can also be used to visually analyse different apoptotic 
proteins within and on the cell. Immunohistochemistry is not quantifiable and can introduce 
operator subjectivity. However, this thesis used the annexin V/PI flow cytometry analysis, as 
this was consistently accurate, quantifiable assay that could distinguish viable cells from cells 
that are undergoing early and late apoptosis, and those cells undergoing necrosis (245). Dye 
based assays can be used to measure the number of viable cells. 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay involves reducing the water soluble MTT 
compound to an insoluble formazan compound in the presence of viable cells. The colour 
goes from yellow to purple, and this colour change can be read and quantified using a plate 
reader. However this method would not necessarily differentiate cells in different stages of 
apoptosis or distinguish different types of cell death, which was an important analysis within 
this thesis (5). DNA fragmentation analysis could also be used to quantify apoptotic cell death 
by analysing DNA breaks that are characteristic of apoptosis. Terminal deoxynucleotidyl 
transferase (TUNEL) can catalyse the addition of 2´-deoxyuridine, 5´-triphosphate (dUTP) 
nucleotides to the free 3' ends of fragmented DNA. These dUTPs can contain fluorescent 
labels that can be detected by either microscopy or quantified using flow cytometry. 
In regard to the analysis of MCL1 and caspase 3, Western blots are routinely used for 
intracellular protein analysis due to their reduced expense in comparison to other techniques 
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and the ability to analyse several proteins on the same blot, saving time, precious samples 
and additional expense. However, due to their limitations (see above), other techniques 
could be used to analyse these proteins, where some are fully quantitative. Flow cytometry 
can be used to analyse intracellular proteins and would require less time and less cells than 
Western blots, and also give a quantitative result. However, fixing of cells that would be 
required for flow cytometry can cause stable protein/protein interactions that prevent 
antibodies from binding, and thus skew results. This is not an issue in regards to Western 
blotting; the reducing and denaturing effect of the lysis buffer, with addition of the boil prep 
disrupts any protein/protein interactions and allows antibodies full access to the protein 
structures. ELISA can also give a fully quantitative analysis of intracellular proteins; however, 
they can be expensive. Immunocytochemistry can also be used to give a visual analysis of 
intracellular proteins; however, this is not necessarily quantifiable and signal can degrade if 
the slides are not punctually analysed 
6.4. IFN signalling 
IFNs bind to specific receptors (type 1 IFNs bind IFNAR and type 2 IFNs bind IFNGR) on the 
cell surface and downstream signalling is via the JAK/STAT pathway. IFNs phosphorylate 
STATs, whereby STAT1 is pro-apoptotic and STAT3 is anti-apoptotic (138, 141) (Sections 
1.5.3.1 and 5.1). This has highlighted an important pathway to investigate in regards to IFNs 
and apoptosis within JSLE neutrophils. 
The differences in signalling pathway, and thus how the different IFN subtypes influence 
apoptosis, may be dependent on whether neutrophils are activated. Here, it was investigated 
how activation of neutrophils influences the IFN signalling pathway (Section 5.5). 
Data in this thesis showed that within TNFα-primed adult control neutrophils, there is a 
significant reduction of the IFNAR1 chain expression compared to naïve neutrophils, and 
there was indication that the IFNGR2 chain increased, although not significant (Section 5.5.1). 
This decrease in IFNAR1 expression correlates particularly well with the reduction in 
pSTAT3/STAT3 expression ratio also observed, indicating that activation of the STAT3 
pathway is dependent on IFNAR1 expression (Section 5.5.3). It should be of note that blocking 
the IFNAR1 chain has been shown to be a beneficial therapeutic target for SLE patients 
(Section 6.7.2), and thus this pathway may need to be further investigation within JSLE (246). 
IFNGR2 was up-regulated (although the increase was not statistically significant) upon TNFα 
or IFNγ stimulation; however, no differences were seen in either chain of the IFNγ receptor 
between JSLE and paediatric control neutrophils (Sections 5.5.1 and 5.5.2). It has been shown 
227 
 
that IFNGR2 expression can influence whether IFNγ induces proliferation in T cells (when 
IFNGR2 expression is low) or apoptosis (when IFNGR2 expression is high) (162) (Sections 1.5.2 
and 5.1). In immune cell lines the up-regulation of IFNGR2 on T cells, through serum 
starvation, can lead to apoptosis (161). However, this observation was not seen in the 
myeloid cell line (which was the closest cell line to neutrophils studied),  which had a 
constitutionally high expression of the IFNGR2, as well as the constitutionally expressed 
IFNGR1 (161) (Sections 1.5.2 and 5.1). This may explain why no significant changes were 
observed within the activated neutrophil model or within patient neutrophils.  
It has to also be noted that the activation state of the JSLE neutrophils was only shown 
through a non- significant increase in CD11b, and there was no difference in CD62L between 
JSLE and paediatric control neutrophils (Sections 4.5.8.1 and 5.5.2). This indicates that 
compared to the in vitro model, the JSLE neutrophils weren’t as activated as the TNFα-primed 
neutrophils. However similar observations have been seen in SLE neutrophils (83). Thus, it 
may be that JSLE neutrophils need to be significantly activated for the IFN receptor 
expression to change (as shown with the TNFα-primed in vitro model), and affect 
downstream signalling, including apoptosis, as seen in a published study (161). Again, 
neutrophils used in this analysis were from JSLE patients whose disease was well managed. 
It would be of interest for future experiments to include JSLE patients with a more active 
disease and analyse receptor expression on JSLE neutrophils that may be more activated than 
the ones used here.  
Experiments were conducted to investigate the balance of STAT1 and STAT3 phosphorylation 
between naïve and TNFα-primed neutrophils, and how this relates to the expression of the 
IFN receptor chains. Through Western blots, the study showed that the pSTAT3/STST3 
expression ratio was increased more by type 1 IFNs than type 2 IFNs; whereas pSTAT1/β actin 
expression ratio was increased more by type 2 IFN, particularly in TNFα-primed neutrophils 
(Section 5.5.3). Within this thesis, it was also shown that pSTAT3/STAT3 expression ratios 
were reduced in primed neutrophils compared to naïve neutrophils, and pSTAT1/β actin 
expression ratios were increased in TNFα-primed neutrophils Section 5.5.3). It should be of 
note that a lower concentration (1ng/ml) of TNFα was used to prime neutrophils for STAT 
analysis. Different concentrations of TNFα can affect neutrophil responses and downstream 
protein signalling (221). In this context, data shown in this thesis suggest that STAT 
phosphorylation is more acutely influenced by TNFα priming than maybe that of apoptosis, 
and that the higher concentration of TNFα used in other assays may amplify the differences 
in phosphorylation of STAT1 and 3 between naïve and TNFα-primed neutrophils. It has been 
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shown that phosphorylation of the tyrosine within the protein structures in neutrophils is 
amplified dramatically by TNFα priming, and this amplification increases upon increasing 
doses of TNFα (247). In another study, priming of neutrophils with 10ng/ml TNFα for 1-2 
minutes resulted in a varied increase in apoptosis upon subsequent stimulation by a variety 
of cytokines (248). An increase in apoptosis in TNFα-primed neutrophils stimulated with IFNγ 
compared to naïve neutrophils was observed, however this was not significant or as dramatic 
as the phosphorylation of tyrosine (247, 248). This small increase in apoptosis by TNFα 
priming was not consistently shown for all cytokines; apoptosis significantly increased in 
TNFα- primed neutrophils upon stimulation with factors such as PMA and fMLP (248). 
Therefore, the hypothesis is that intracellular signalling is more sensitive to the priming 
effects of TNFα than that of more generalised neutrophil functions, such as apoptosis, which 
may require a higher concentration of TNFα to be affected.  
This difference in STAT phosphorylation seen in the in vitro model may be true of JSLE 
neutrophils. Literature has shown that in SLE, STAT1 is more highly expressed and pSTAT1 is 
up-regulated within PBMCs, and it was observed that the STAT1 pathway was activated in a 
mouse model of lupus nephritis, and thus it is likely that the pro-apoptotic STAT1 pathway 
may be heightened in JSLE neutrophils, contributing to the increased apoptosis seen in these 
cells (194, 196). Again, this may be due to the fact that SLE and JSLE neutrophils are activated, 
as activation can causes dysregulation of proteins, markers and functions (83, 85, 86, 90). It 
should be noted that in this study, the JSLE neutrophils were activated compared to 
paediatric control neutrophils, but not as significantly so as TNFα-primed adult neutrophils 
compared to naïve neutrophils. If JSLE neutrophils are investigated for STAT1 
phosphorylation, the difference observed may not be as significant compared to that shown 
by the TNFα-primed models. Additionally, neutrophils from active JSLE patients may be more 
important to investigate the signalling pathways as they may be more activated and thus akin 
to the TNFα-primed neutrophils. 
These data as well as previous studies suggest that STAT1 is important in IFN-related 
apoptosis, and possibly in SLE and JSLE pathogenesis (138, 194, 196). If IFNs are causing the 
observed increase in neutrophil apoptosis in JSLE, it is probably via STAT1, which has been 
suggested to be activated in SLE (72, 138, 194, 196). Thus, it was investigated whether 
inhibiting pSTAT1 may delay IFN-related pro-apoptosis and increase IFN-related anti-
apoptosis through up-regulation of pSTAT3 in TNFα-primed neutrophils.  
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The initial STAT1 inhibitor used was fludarabine phosphate (Section 5.5.4). Fludarabine 
phosphate was selected as its mechanism of STAT1 inhibition has been described. 
Fludarabine phosphate functions through binding to the SH2 domain of STAT1 and 
preventing STAT1 phosphorylation of the tyrosine residues and subsequent dimerization of 
STAT1 with other STAT proteins (249). It had a promising function in delaying neutrophil 
apoptosis through STAT1 inhibition, as published data showed that fludarabine phosphate 
can inhibit STAT1 in PBMCs, which were still viable after fludarabine phosphate incubation 
(200). At the time of inhibitor selection, fludarabine phosphate was the only viable option, 
and it was already used as a chemotherapy agent with a known safety profile (200, 229). 
However, another report suggests that it has no effect on STAT1 (250). Data in this thesis 
additionally saw that although it did reduce pSTAT1/β actin expression ratios, indicated a 
possible inhibition of pSTAT1, fludarabine phosphate also reduced pSTAT3/STAT3 expression 
ratios, showing inhibition of STAT3 phosphorylation (Section 5.5.4). Thus, fludarabine 
phosphate was not deemed appropriate to investigate further.  
S1495 was subsequently used as an STAT1 inhibitor (Section 5.5.5). S1495 was shown to 
reduce pSTAT1/β actin expression ratios, indicated a possible inhibition of pSTAT1, with no 
effect on pSTAT3/STAT3 expression ratios (Section 5.5.5). However, this inhibition was 
variable which in part maybe donor dependent, or due to problems with the solubility of 
S1495 in DMSO and its possible impact on inter-experimental variability in the final s1495 
concentration (see Chapter 5). Interestingly S1495 had a consistently anti-apoptotic effect in 
TNFα-primed neutrophils, with IFNs having no additional effect, and additionally S1495 had 
no effect on naïve neutrophils (Section 5.5.5). From these observations, it was hypothesised 
that, although an increase in pSTAT1/β actin expression ratio in TNFα-primed neutrophils 
was not observed, TNFα may have some influence on the STAT1 pathway. TNFα has been 
previously shown to have an effect on STAT1, in in cell lines such as HeLa, A431 and 2fTGH, 
however this is inconsistent with the data in this thesis which did not show that TNFα had 
any effect on pSTAT1 expression in neutrophils, and thus it remains inconclusive (251, 252). 
To establish whether S1495 could be used as an inhibitor of STAT1 phosphorylation more 
investigation is required. However, due to its anti-apoptotic effect on TNFα-primed 
neutrophils, without IFN stimulation, and the fact that its inhibition of STAT1 was donor 
dependent, it may not be appropriate to fully investigate STAT1 role in JSLE neutrophil 
apoptosis. 
Western blot analysis was used to measure the activation of STATs by measuring the 
expression of pSTATs. Additionally, due to issues with the pan STAT1 antibody (which did not 
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detect the protein even after multiple optimisation trials) changes in pSTAT1 relative to β 
actin were reported here. Flow cytometry again would give a more quantifiable analysis of 
the expression of STATs within the cell. However, again fixing of cells that would be required 
for flow cytometry can cause stable protein/protein interactions that prevent antibodies 
from binding, and thus skew results. Lysing of proteins for Western blot preparation disrupts 
protein/protein interactions and allows antibodies full access to the protein structures. A 
Luminex multiplex kit was investigated to analyse all STATs simultaneously, which would 
have increased reliability, consistency and given a more quantifiable result. However, at time 
of investigation, analysing both pan and phosphorylated STAT1 in the same sample was not 
possible, and the kits are very expensive compared to other techniques.  
Although it was attempted, with some success, to inhibit STAT1 phosphorylation (although it 
remains inconclusive if this supposed decrease in pSTAT1 was due to a reduction in overall 
pan STAT1, or specifically pSTAT1), it was not consistently effective. Thus, other techniques 
that can be used to specifically inhibit STAT1 include use of small interfering RNA (siRNA) to 
inhibit the STAT1 at the gene transcription level. This would prevent protein translation and 
therefore expression of STAT1. However, published data have shown reduction of the STAT1 
protein in DCs following 2-3 days incubation of the siRNA, and thus this may not be 
appropriate to use in neutrophils, which have a shorter life span (253, 254).                                            
Within this section of the study, the experiments were limited mainly in how to rigorously 
analyse the STAT1 and STAT3 proteins, in that the Western blot could not be optimised for 
the pan-STAT1 antibody. Additionally, the specific inhibition of STAT1 was problematic, and 
thus limited the conclusions that could be made based on the limited results obtained. 
Western blots, in regards to the pan STAT1 antibody and new techniques in regards to STAT1 
inhibition (as described above) would hopefully allow for a more in-depth investigation in the 
future.  
 
6.5. Limitations 
A limitation in this study was the access to JSLE patient samples in different disease states. 
JSLE patient numbers required for biosamples for the study are limited, and specifically the 
frequency of samples and the paediatric blood volume collected restrict the experiments that 
could be conducted. Analysis using flow cytometry is usually possible, due to a small yield of 
neutrophils required compared to the yields required for Western blotting. However, due to 
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the small volume of JSLE patient blood samples, and that the final neutrophil yield was 
frequently low, an appropriate yield of JSLE neutrophils to extract protein to analyse STAT1 
and 3 phosphorylation states was not frequently possible. Consideration of the effect of 
treatment for clinical symptoms, whereby all patients are on to maintain their disease, on 
neutrophil protein expression is required. Possible approaches to address this consideration 
may include incubating neutrophils with common medication such as hydroxychloroquine 
and mycophenolate, or protein analysis of neutrophils from patients with a variety of 
medications.  
Previous studies investigating neutrophil phagocytosis and chemotaxis had suggested a wide 
scope of signalling which IFNs may be affecting in these functions, such as affecting 
chemotactic receptors CCR1 and CCR3, and phagocytic receptor FcγRI (177-179, 183-185, 
215). Although some of these may have been addressed, time and resources meant that this 
study was limited in what could be investigated. Therefore, in regards to phagocytosis and 
chemotaxis, analysis was conducted using an already optimised protocol, and conditions 
were chosen based on association with other experiments within this thesis (i.e. IFN priming) 
and also have been indicated to be functionally important in regards to neutrophils (such as 
IL-8). Chemotaxis and phagocytosis have also been indicated to be dysregulated in SLE and 
JSLE, and therefore were important to investigate. However, IFNs role in chemotaxis and 
phagocytosis could not be comprehensively concluded in this study due to only a snapshot 
of these functions being investigated. Therefore, it would be of importance to fully 
investigate these complex and diverse neutrophil functions outside the context of this thesis.  
6.6. Future work 
This study has highlighted new avenues for future work. From data obtained in this thesis, 
new questions have arisen through the investigation of the interaction of IFNs and 
neutrophils in JSLE. These are discussed below. 
6.6.1. Neutrophil function 
For phagocytosis assays, only opsonised E.coli phagocytosis were investigated. Although IFNs 
can affect phagocytosis, this is dependent on many factors including cell type, 
bacteria/pathogen type, and whether the bacteria or pathogen are opsonised (183-185, 
215). However, literature on the role of IFNs in phagocytosis in general, (whereby generally 
IFNs increase phagocytosis) and phagocytosis in SLE and JSLE (in which neutrophil and 
immune cell phagocytosis is reduced) is unequivocal (112-115, 183-185, 189, 215). In this 
regard, it is important to consider any effect of disease-related medication on neutrophil 
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phagocytosis in JSLE. Thus, it would be important to investigate through flow cytometry: a) 
how IFNs influence neutrophil phagocytosis of other non-opsonised and specific opsonised 
pathogens and b) whether IFNs save the phagocytic function of JSLE neutrophils or reduce 
neutrophil phagocytosis function further.  
Data in this thesis that IFNs do not induce any significant NET formation, although priming 
with TNFα or IFNs with additional stimulus minimally increased NETs, is in keeping with 
previously data (175). These published data showed that priming with IFNα, IFNγ or GMCSF, 
and subsequent stimulation with C5a-induced the formation of fibres, similar to NETs, in 
mature but not immature neutrophils (175). These immature neutrophils could be LDGs. 
These granulocytes have been detected within PBMC fractions of isolated blood, and Kaplan 
et al. have isolated these cells from patients with SLE using negative selection, and 
additionally have been shown to be increased in JSLE patients (40, 119). Phenotypically, 
LDGs, additionally known as low density neutrophils (LDNs), neutrophil markers; however 
CD15, CD11b and CD66b were higher on LDNs than on high density neutrophils (HDNs) (255). 
These LDGs have an enhanced ability to produce type 1 and type 2 IFNs (40, 256). However, 
Kaplan et al. have suggested that LDGs have an increased ability to undergo NETosis, and 
thus LDGs are unlikely to be the immature neutrophils investigated by Martinelli et al. (40, 
175). It was shown the extracellular fibres contained DNA and MPO, confirming that IFN 
priming plus C5a stimulation resulted in NET formation (175). However, stimulation with 
IFNs, GMCSF or C5a alone did not induce NETs (175). Thus, it is likely that any role that IFNs 
have on NETosis, at least in healthy neutrophils, is purely through priming. These findings are 
important when considering IFNs role in JSLE neutrophil NETosis. Although IFNs probably do 
have an important priming role they may not be the most important mediator of NETosis 
induction, and thus it may be more important to investigate what is causing the IFN-primed 
neutrophils to NET. These mediators may include that of C5a and HMGB1 (66, 175). 
Confocal microscopy methods used in this thesis to investigate induction of NETosis did not 
result in reliable data that always correlated well with DNA quantification data. The 
reliability, and therefore the validity, of the confocal image data interpretation would 
therefore need to be addressed before any solid conclusion can be made. Additional staining, 
through the staining of MPO and NE, may be beneficial to improve visual data outcome of 
these experiments. Additionally, conducting these experiments in JSLE neutrophils would 
add another important dimension; a combination of IFNs would replicate what JSLE 
neutrophils experience in vivo and would be of interest as cytokines rarely function alone. 
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6.6.2. Apoptosis 
This study has shown that the IFNs can be both pro- and anti-apoptotic for neutrophils and 
this is dependent on whether the neutrophils are activated or naïve. However, cytokines 
rarely function alone, and observing the effects on neutrophil apoptosis of combinations of 
IFNs and in the presence of other pro and anti-apoptotic cytokines, such as FasL and GMCSF, 
would be paramount. FasL in particular has been shown to be increased in JSLE serum, and 
therefore is likely to not only have an effect on neutrophil apoptosis itself, but IFNs and FasL 
may influence each other’s effect on apoptosis (72). If IFNs are acting as pro-apoptotic 
factors, a combination of FasL and IFNs may result in accelerated neutrophil apoptosis 
compared to the rate of neutrophil apoptosis seen with incubation of each cytokine alone. 
Alternatively, if IFNs lose their anti-apoptotic ability on JSLE or activated neutrophils, this may 
increase FasL-related apoptosis due to the IFNs inability to counteract this effect. In regards 
to GMCSF, it has been indicated that this cytokine is reduced in JSLE serum (72). it has also 
been demonstrated that GMCSF reduces JSLE serum-induced neutrophil apoptosis (110) If 
IFNs are acting as pro-apoptotic factors, GMCSF may counteract this effect and reduce the 
JSLE neutrophil apoptosis that may be comparable to healthy control neutrophils. 
Alternatively, if IFNs lose their anti-apoptotic ability on JSLE or activated neutrophils, GMCSF 
may not only be able to induce the anti-apoptotic effect in place of IFNs, it would most likely 
have a stronger anti-apoptotic effect and again reduce the JSLE neutrophil apoptosis to be 
comparable to healthy control neutrophils. 
JSLE serum activates neutrophils and prevents IFNs from delaying apoptosis; however, it does 
not increase apoptosis as observed is some studies (72, 110). As paediatric control serum 
also had this effect, the results seen in this thesis may be due to healthy adult control 
neutrophils responding to homologous serum which is not specific to JSLE. It has been shown 
that both paediatric control neutrophils and JSLE neutrophils undergo increased apoptosis 
when primed with JSLE serum. However, the rate of increased apoptosis was greater in JSLE 
neutrophils than paediatric control neutrophils (72, 110). From this, it would be of interest 
to incubate paediatric control and JSLE neutrophils with IFNs in the presence of JSLE serum 
to see how IFNs might affect this increase in apoptosis (72, 110). Additionally, analysis of 
cytokines within sera, with a particular focus on IFNs may be beneficial; IFN expression within 
sera of healthy patients and volunteers may be increased if the patient/volunteer was 
recently exposed to a virus. Therefore, these IFN levels within the sera, along with other 
inflammatory cytokines, may affect neutrophil activation and apoptosis compared to sera 
with normal levels of IFNs and cytokines.  
234 
 
Additionally, data showed that there was no difference in baseline or cytokine influenced 
apoptosis between paediatric control and JSLE neutrophil apoptosis at 6hr, which does not 
correlate with previous literature (71, 72). However, the JSLE patients used had their disease 
well managed at time of blood sampling and this may be due to their steroid and disease-
modifying anti-rheumatic drug (DMARD) medication. This may dampen any dysregulated 
neutrophil response, including increased apoptosis (72). It would be of interest to include 
patients who are flaring/have very active disease at time of sampling. This may show the 
increased apoptosis seen in other literature and show how IFNs affect this (71, 72).  
6.6.3. IFN signalling 
There are differences in the IFN/JAK/STAT signalling pathway between naïve and TNFα-
primed neutrophils. Specifically, there is a down-regulation of STAT3 and an up-regulation of 
STAT1 phosphorylation within TNFα-primed neutrophils, and this may be due to the 
dysregulation of IFN receptor chains and may lead to the increase in apoptosis seen. 
Although there was some indication of activation of JSLE neutrophils, the receptor analysis 
did not reflect the TNFα-primed, adult neutrophil in vitro model used in this thesis. This may 
be because the TNFα-primed adult neutrophils were more activated, or that again these 
patients’ disease was inactive and well managed by medication. Thus, further experiments, 
that may include neutrophils from JSLE patients with active disease, may contribute to a 
better understanding of data, specifically in regards to IFN receptors. Additionally, full 
analysis of the sensitivity of IFN receptors, that go beyond the initial downstream signalling 
analysis conducted in this thesis (through STAT phosphorylation) may also be beneficial and 
add scope to the importance of altered expression levels seen.  
The role of STATs in IFN signalling is complex, and additional investigations within JSLE and 
paediatric control neutrophils are needed to fully define their roles. It would be of interest 
to see if these data reflect that of naïve and TNFα-primed adult neutrophils, and whether 
inactive and active JSLE neutrophils have different pan and phosphorylated STAT expressions. 
Additionally, IFN/JAK/STAT-induced genes may confirm which STAT is more active within JSLE 
neutrophils and confirm how the IFNs affect the neutrophils and JSLE pathogenesis.  
The experimental conditions used in this thesis were unable to provide confirmatory data on 
STAT1 inhibition to see if this prevents IFN-induced apoptosis, these experiments were not 
successful. S1495 may have potential if its dissolvability is improved; however, the ability of 
S1495 to delay apoptosis highlights a major issue that may not be resolved. Other options for 
inhibition of STAT1 in experimental cell models that could be investigated are siRNAs towards 
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the STAT1 gene. Alternatively, a STAT1 knock out mouse model could be used to investigate 
IFN-related effects on neutrophils and the immune system. These STAT1 knock out mice 
could also have lupus induced by pristine to see how the STAT1 knock out effects the 
development of SLE in regards to IFN signalling pathways, gene signatures, and neutrophil 
apoptosis. 
6.6.4. LDGs 
As described in the literature review, LDGs are a subset of granulocytes that are found in the 
PBMC layer of fractioned blood (39, 40). LDGs have been observed to be increased in SLE and 
JSLE blood compared to healthy controls and this increase correlates with active disease (42, 
119). LDG NETosis has been indicated to contribute to inflammation and organ damage; in 
particular lupus nephritis (40). Additionally, LDGs have an increased ability to produce IFNα 
(40). Therefore, LDGs may be contributing to SLE and JSLE pathogenesis through directly 
causing organ damage, and contributing to the pro inflammatory environment by producing 
cytokines such as TNFα and IFNα.  
Previous literature had stated that LDGs had decreased phagocytosis and increased NETosis 
compared to normal density LDGs which may contribute to decreased neutrophil 
phagocytosis and increased NETosis seen in SLE and JSLE (40). Within this study, there was 
no observed significant differences in neutrophil phagocytosis or with NETosis upon either 
IFN priming or IFN stimulation. Although as already discussed, there are other implications 
that may have resulted in lack of observed results, it may be that if IFNs are indeed affecting 
phagocytosis or NETosis, the affect may be on LDGs and not neutrophils. It would be 
therefore of interest to investigate the role of IFNs on LDG phagocytosis and NETosis, and 
how this reflect that of these functions in SLE and JSLE pathogenesis.  
 
6.7. Therapies 
6.7.1. IFN therapies and the induction of lupus-like symptoms 
The importance of IFNs in SLE pathogenesis has been highlighted by the fact that IFN 
therapies are capable of inducing a lupus-like disease. IFNα has been shown to induce SLE in 
a patient treated for cryoglobulinaemic vasculitis associated with hepatitis C with IFNα 
therapy (257). SLE or lupus-like syndromes seems to be a common complication of IFNα 
treatment of hepatitis C (258-260). SLE or lupus like symptoms such as arthritis, arthralgia, 
leukopenia, fever and erythematosus maculopapular rash are also induced by IFNα 
treatment of malignancies and SLE like markers antibodies such as dsDNA and ANA were 
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increased (261, 262). These studies show the role of IFNα in clinical manifestations and 
symptoms that mirror that of SLE, and thus it is possible that IFNα is important in SLE 
pathogenesis. 
6.7.2. Blocking IFNα as a potential therapeutic target in SLE 
As the IFN subtypes, particularly IFNα, have been implicated to be involved in SLE and JSLE 
pathogenesis, a key step is to investigate whether blocking IFNα, and thus its signalling 
pathway, would be therapeutically beneficial to SLE patients (41, 68, 163, 171, 172, 174, 190). 
There are monoclonal antibodies (administered as biologic drugs) that target IFNα and its 
signalling pathways. Some of these are now being trialled in adults within phase 1 and 2 
clinical trials in the treatment of SLE (246, 263-267). For example, two block the IFNα protein 
itself (sifalimumab and rontalizumab) and another blocks the IFNAR (anifrolumab) (246, 263-
267). 
A fully human IgG1κ monoclonal antibody has been developed that binds to the majority of 
IFNα subtypes, and by this can inhibit IFN signalling within a phase 1 clinical trial (263). 21 
genes that form part of the type 1 IFN gene signature were investigated in a phase 1a clinical 
trial as pharmacodynamics biomarkers to determine if the antibody effectively blocks IFNα 
activity (263). It was shown that there was a dose dependent increase in the neutralisation 
of IFN gene signature within whole blood by using the monoclonal antibody in SLE patients 
(263). It was also shown that the increased type 1 gene signature within skin lesions and 
associated proteins could also be neutralised by the antibody (263). 
This human IgG1κ monoclonal antibody, re-marketed as sifalimumab, which can bind to IFNα 
with high affinity and prevents IFNα binding to the IFNAR, has been tested in other clinical 
trials (264). One study, looking at sifalimumab in a phase 1a clinical trial, showed that most 
adverse effects (AEs) in this study were mild or moderate, incidence of infection was similar 
between sifalimumab and placebo populations and no patients developed antibodies 
towards sifalimumab (264). Within the sifalimumab group, patients had a dose dependent 
inhibition of the type 1 IFN signature in whole blood, and two type 1 IFN inducible proteins, 
ubiquitin specific peptidase 18 (USP18) and epithelial stromal interaction 1 (ESI1) were 
reduced in paired skin biopsies upon 10ng/kg administration of sifalimumab (264). Disease 
activity also decreased in patients administered sifalimumab compared to placebo, defined 
by SLEDAI score, SLEDAI flare and BILAG flare (264).  
Another phase 1b clinical trial of use of sifalimumab in SLE, suggested that multiple doses of 
sifalimumab were safe and tolerable, and similar rates of AEs were found in placebo and 
237 
 
treatment groups (265). It was shown that SLE flares decreased when higher sifalimumab 
doses were administered (265). Multiple-dose pharmacokinetics (PK) of sifalimumab was 
linear and proportional to the dose administered, and had a long half-like of 20-29 days, and 
therefore the antibody was long lasting and was not systematically cleared quickly (265). On 
initial inspection, the effect of sifalimumab on disease activity, through analysis of Safety of 
Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus 
Disease Activity Index (SELENA-SLEDAI) and BILAG scores, was no different than that of the 
placebo group (265). However, post hoc analysis indicated a positive trend in the sifalimumab 
group as a whole and the subgroup of SLE patients with a high IFN gene signature treated 
with sifalimumab (265). Additionally, sifalimumab had a normalising effect on C3 and C4 
complement levels in those patients with low levels of C3 and C4 at baseline (265). This 
suggests that the sifalimumab, through IFN signalling blockade, had a positive benefit on 
important immunological factors that correlate with SLE, and thus is a good potential 
therapeutic for SLE patients with a high IFN gene score. However, a subset of JSLE patients 
with a low IFN gene signature may not respond well or at all to IFN therapy. Therefore, 
personalised therapies, based on IFN gene signatures, may be particularly useful for JSLE 
patients.  
Another antibody has been tested as a therapeutic agent in SLE. Rontalizumab is a humanised 
IgG1 monoclonal antibody, which, unlike sifalimumab, can bind all subtypes of IFNα (266). 
Within a phase 1 clinical trial, it was shown that rontalizumab was well tolerated and most 
AEs were mild or moderate (266). There was some reporting of more severe adverse effects 
(SAE) in the rontalizumab group compared with placebo. However, there was no definitive 
rontalizumab dose versus AE demonstrated (266). The majority of infections were deemed 
mild or moderate, and their frequency did not differ between groups (266). Similar to 
sifalimumab, the PK of rontalizumab was proportional to dose, and had a long half-life 18.8 
days (266). It was shown that at 3 and 10mg/kg of intravenous (IV) rontalizumab reduced 
interferon regulatory genes, at both a single dose and repeated dose, and in particular this 
gene expression was maintained at this low level for more than 100 days after 10mg/kg IV 
dose (266). However, rontalizumab did not change the protein expression level of IFN 
inducible genes such as 1P10, MCP1 or BAFF in whole blood, or any autoantibodies such as 
anti-dsDNA, anti-RNP or anti-Ro/Sjögren's syndrome type A (SSA) in patients deemed to have 
a high interferon signature matrix (ISM) (266).  
In the phase 2 trial of rontalizumab it was shown that although disease activity did not differ 
between patients with a high ISM and patients with a low ISM, according to SELENA-SLEDAI 
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or BILAG, high ISM patients were more likely to have increased anti-dsDNA antibodies, and 
low C3 and C4 levels (267). It was shown that there was no differences in improvement in 
BILAG score between treatment and placebo, or any differences between ISM high and ISM 
low patients (267). It was shown that the SLE response index (SRI)-4 was also not different 
between pooled placebo or pooled rontalizumab treated patients, or comparing placebo vs 
rontalizumab in the ISM high SLE sub group (267). However, it was shown that ISM low 
patients did have a low SRI-4 score upon rontalizumab administration compared to placebo 
(267). It was shown that there were fewer flares in the rontalizumab treated patient group 
compared to placebo, which were predominantly seen in the ISM low patients (267). AEs 
were comparable between placebo and rontalizumab treated groups (267). Thus, 
rontalizumab may have some benefit in patients with a low IFN gene score whereby patients 
with a high IFN gene score received little benefit from the antibody. Thus, it may be beneficial 
only as a supplementary treatment in patients with a low IFN gene score. The fact that 
rontalizumab binds to all IFNα subtypes and sifalimumab doesn’t may contribute to their 
different effects on IFN high and IFN low patients.  
Anifrolumab is a human, IgG1κ monoclonal antibody that can bind to the IFNAR1 and thus 
inhibits the receptor and signalling by type 1 IFNs (268). Within a phase 2b study, it was 
shown that the SRI-4 (defined as sustained reduced oral corticosteroids at week 24) was 
more frequently obtained in the group taking anifrolumab than the placebo, and within the 
treatment group, the (genetically) IFN-high sub-population reached this SRI-4 more 
frequently than the IFN-low sub-population (246). Anifrolumab reduced the SLEDAI-2K and 
BILAG score more than placebo group, indicating disease activity improved (246). Organ 
disease specific disease measurements were also improved with anifrolumab (246). 
Anifrolumab also reduced anti-dsDNA and increased complement C3 levels, and neutralised 
the type 1 IFN gene signature (246). AEs were similar across all treatment groups, although 
upper respiratory infections occurred more frequently in patients treated with anifrolumab 
(246).  
From these studies, it is evident that there is some clinical, demonstrable benefit from using 
IFNα blocking antibodies. This is both by blocking IFNα itself and blocking the receptors. 
Clinical trials have shown significant changes in the type 1 IFN signature, proteins associate 
with type 1 IFNs were reduced, and improvement in disease activity seen. However, the IFNα 
blocking antibodies weren’t always effective. The antibodies did not consistently reduce 
every aspect of the IFN signalling (e.g. no differences seen in protein expression of IFN 
inducible genes with rontalizumab treatment) and disease activity did not always improve. 
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Additionally, sifalimumab did not improve disease activity in those patients with a low IFN 
gene score. Thus, alternative treatments must be investigated. Anifrolumab had the most 
benefits, with the most improvement in disease activity observed in the clinical trials 
discussed here.  
However, IFNα is not the only IFN involved in SLE and JSLE pathogenesis, and the role of IFNγ 
has been demonstrated in the published literature and this present study to be important in 
SLE and JSLE (171, 174, 190). Its role is particularly related to the up-regulation of the STAT1 
pathway, and its involvement in apoptosis, where both functions are indicated to be 
important in SLE, with apoptosis important in JSLE (71, 72, 138, 194). Thus, it would be 
important to investigate how an IFNγ monoclonal antibody works as a therapeutic. There is 
a distinct type 2 IFN genetic signature found in SLE patients, indicating a strong IFNγ signalling 
pathway in SLE, and so an antibody specific for IFNα may not always be effective in these 
patients (174). Additionally, as mentioned below (6.8), IFNλ is also increased and therefore 
likely to be involved in SLE (and thus JSLE) pathogenesis and can up-regulate a subset of type 
1 IFN-induced genes, and thus can induce a type 1 IFN like response (269-272). Thus, it would 
be of interest to investigate the role how an IFNλ monoclonal antibody may work as a 
potential therapeutic, and how a combination of these treatments may be beneficial to those 
patients that may have a genetic signature induced by a combination of type 1, type 2 and 
type 3 IFNs, and thus have a multitude of IFN signalling pathways that do not respond to just 
one treatment. 
6.7.3. Neutrophils as therapeutic targets 
Neutrophils themselves may be an important cell of the immune system to target 
therapeutically in JSLE. This is reflected in their increased apoptosis and that they can be a 
potential source of autoantigens (72). RP3 is a monoclonal antibody found to deplete 
neutrophils (273). Rats with adjuvant arthritis were shown to have increased leukocyte 
numbers, in particular with neutrophils (274). RP3 was found to significantly reduce the 
number of neutrophils within rats with arthritis to that of normal levels (274). RP3 treatment, 
and subsequent neutrophil depletion, decreased adjuvant arthritis, including reduced joint 
swelling and reduced synovial fluid cell influx (274).  
Neutrophils have been implicated in chronic obstructive pulmonary diseases (COPD), in 
particular, the increase in neutrophil inflammation, and have been shown to be involved in 
the significant lung tissue damage within COPD (275). Neutrophil targeted nanoparticles have 
been developed for COPD (276). A published study used polyethylene glycol (PEG)ylated 
240 
 
immune-conjugated Polylactide-coglycolide (PLGA) nanoparticle (PINP), loaded with 
ibuprofen (IBF) and the anti-neutrophil antibody NIMP-R14 (PINPNIMP-IBF) to investigate how 
neutrophil targeted therapies could help chronic obstructive lung diseases (276). Within wild 
type mice, LPS induced inflammatory lung disease. Additionally, the PINPNIMP-IBF decreased 
MPO levels and NFκB activity in bronchoalveolar lavage fluid (BALF) neutrophils, and 
decreased LPS-induced Fas expression compared to LPS treated mice (276). It was also shown 
that PINPNIMP-IBF decreased NFκB expression, neutrophil infiltration and Fas expression in mice 
exposed to chronic smoke and thus used as an emphysema model (276).  
It was investigated whether targeting neutrophils, through the inhibition of STAT1, may 
prevent possible IFN related apoptosis, which may reduce the production of autoantigens 
within JSLE, and thus may act as a therapeutic. Although not successful here, other studies 
shown here that it is possible to target neutrophils as a therapeutic target, resulting in clinical 
and aetiological benefits. Although this approach did not produce any unequivocal 
conclusions, the concept, along with other literature, does still stand in that neutrophil 
targeted therapeutics may be of benefit to JSLE patients, particularly via the inhibition of 
neutrophil apoptosis and thus production of the autoantigens that is characteristic of JSLE 
pathogenesis.  
 
6.8. IFNλ 
IFNλ has been more recently characterised alongside other known IFNs and is deemed the 
only subtype 3 IFN (121, 277). Specifically, there are 3 types of IFNλ; IFNλ1, IFNλ2 and IFNλ3, 
previously known as IL29, IL28A and IL28B respectively (120). IFNλ is secreted by pDCs upon 
viral infection such as influenza (278). IFNλ has a role in modulating Th1/Th2 responses and 
functions through a distinct receptor and the initiation of the JAK/STAT pathway, 
phosphorylating STAT1, STAT2 and STAT3, which can induce antiviral responses (120, 122, 
269). IFNλ also can induce a type 1 IFN like response via the activation of the JAK/STAT 
pathway (via STAT1 and STAT2) and MAPKs (269). It is important to note that IFNλ increased 
a subset of the type 1 IFN-induced gene profile, albeit more weakly than IFNα, and thus there 
is not a unique IFNλ gene profile (269). 
A published study developed a colorectal adenocarcinoma p53 deficient HT29 cell line with 
a FLAG (aspartic acid-tyrosine-lysine-aspartic acid-aspartic  acid-lysine [DYKDDDDK] epitope)-
IL-10 receptor 1 (FLIL10R1)/ λ receptor 1 (λR1) chimeric receptor, as they have found that 
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HT29 cells transfected with a FLAG epitope-tagged IFNλR1 did not express any detectable 
level of the receptor (120, 279). As IL-10 and IFNλ share this receptor, and IL-10 could induce 
an IFNλ signalling pathway in HT29 cells with this chimeric receptor, this was subsequently 
used to characterise the effect of IFNλ signalling on apoptosis, through IL-10 stimulation of 
the FLIL10R1/λR1 chimeric receptor (120, 279). IFNλ signal induction through the IL-10 
stimulation of the chimeric receptor lead to the externalisation of PS (through detection with 
annexin V) and DNA fragmentation (through detection with terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) assay) (279). The signalling also induced cleavage 
of caspase 8, 9 and 3, confirming that IFNλ signalling induces apoptosis in these HT29 cells 
(279). Thus, it may be, like with type 1 and 2 IFNs, IFNλ may have a role in apoptosis in other 
cells, and would be interesting to see its effect on neutrophil apoptosis.  
Research has also shown that IFNλ is possibly involved in SLE pathogenesis. IFNλ1 mRNA and 
its serum protein levels were elevated in SLE patients compared to healthy controls and were 
shown to be higher in active SLE patients compared to inactive SLE patients (270). It was also 
shown that IFNλ1 serum protein levels positively correlated with SLEDAI scores and 
laboratory markers such as dsDNA, and negatively correlated with C3 levels (270) IFNλ1 
protein was also shown to be higher in patients with renal disease and arthritis (270). IFNλ1 
also induced chemokine production from PBMCs, such as IP10 and MIG, with more secretion 
from SLE PBMCs compared to healthy control PBMCs (270). Interestingly IFNλ1 reduced IL-8 
secretion from SLE PBMCs compared to control PBMCs, which can relate back to the reduced 
neutrophil chemotaxis seen in other studies (116, 117, 270).  
IFNλ3 was particularly shown to be increased in the serum of SLE patients compared to 
healthy controls, but not IFNλ1 or IFNλ2 (272). Additionally, IFNλ3 was shown to be affected 
by medication, whereby patients on glucocorticoids had 3 times higher IFNλ3 serum levels 
than those patients not on glucocorticoids (272). Prednisone also affected IFNλ3, with those 
patients on a high dose of prednisone having the highest serum level of IFNλ3 (272). High 
IFNλ3 levels also correlated with patients with serositis and cutaneous involvement, 
positively correlated with Ro/SSA and ds-DNA antibodies and negatively correlated with C3 
and C4 levels (272).  
It has been shown that IFNλ is increased in serum of SLE patients with active nephritis at 
baseline compared to healthy controls, which did not change at follow up (271). IFNλ was 
found to be more detectable in biopsies from patients with membranous nephritis than in 
patients with proliferative nephritis (271). In particular staining of IFNλ in these biopsies was 
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more prominent in the glomeruli with cellular crescent formations, in inflammatory 
infiltrates of CD3+ T cells and in tubular cells (271).  
These studies confirm that IFNλ functions like type 1 and 2 IFNs in regard to anti-viral action, 
and there are crucial similarities in the downstream signalling, whereby genes are activated 
by both IFNα and IFNλ. It may be that IFNλ may have a dual role in apoptosis that is akin to 
other IFNs, and this may be important in regards to the increased neutrophil apoptosis seen 
in JSLE. Studies have also shown that IFNλ has a possible important in lupus nephritis 
pathogenesis, which suggests that it may be important in JSLE (270-272). To date, there was 
no published literature investigating the role of IFNλ in JSLE. However, based on findings with 
IFNα and IFNγ within literature and within this thesis, it would be of interest to investigate 
whether the increase in IFNλ mRNA expression and serum protein concentration present 
within adult SLE patients is also true of JSLE patients. Furthermore, it the potential role of 
IFNλ in SLE and JSLE pathogenesis should be investigated to see if it compares or contrasts 
with the roles of the type 1 and 2 IFNs. From this, it would be important to analyse the genetic 
signature and serum levels of IFNλ within JSLE and investigate its functional role in JSLE 
pathogenesis in relation to type 1 and 2 IFNs, particularly in regard to any potential 
interaction with neutrophils.  
 
6.9. Conclusion 
In this study, and in previous literature, it was shown that IFNs may have a potential priming 
role in NETosis, however it was not conclusively shown here. Additionally, evidence from the 
literature indicates that the IFN subtypes can have roles in neutrophil phagocytosis and 
chemotaxis (albeit not demonstrated clearly here), and these may also be important in JSLE 
pathogenesis. IFNs have shown both a pro- and anti-apoptotic effect on neutrophils; 
however, this is dependent on the activation of neutrophils and the subsequent IFN 
concentration. These findings may be relevant in particularly JSLE patients with active 
disease. It was also shown that the pro-apoptotic STAT1 has increased phosphorylation in 
type 2 IFN-stimulated TNFα-primed neutrophils compared to naïve neutrophils, and the anti-
apoptotic STAT3 has decreased phosphorylation in type 1 IFN-stimulated, TNFα-primed 
neutrophils compared to naïve neutrophils, which may relate to differences in the IFN 
receptor chain expression. These findings may link to the differential effect of IFNs on 
apoptosis, and thus again may be important in the increased apoptosis found in JSLE 
neutrophils. However, it is important to note that a reduction of IFNAR1 was only found in 
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the in vitro model and did not extrapolate to JSLE neutrophils. Additionally, an antibody 
which blocks IFNAR has recently been shown in published studies to have therapeutic benefit 
in SLE, correlating with the observation that the IFNAR chains are well expressed on JSLE 
neutrophils. It was investigated whether STAT1 inhibition delays any potential IFN-induced 
apoptosis, and although here, it did not have consistent or appropriate inhibitory results, it 
still remains a potential therapeutic target in preventing neutrophil apoptosis within JSLE. 
Neutrophil therapeutic targets have been shown to be beneficial in other diseases, and thus 
neutrophils as a target for therapy may be beneficial in JSLE, due to neutrophil apoptosis 
being a potential source of autoantigens. Lastly, results from this study have also provided 
the foundation for further studies that may wish to investigate the effects of other IFN 
subtypes such as IFNλ.  
In conclusion, it was demonstrated that type 1 and type 2 IFNs do have an important role in 
modulating neutrophil function. In particular, this was demonstrated through dual, opposing 
apoptotic effects on neutrophil apoptosis via the JAK/STAT pathway. IFNs may be involved in 
the increased neutrophil apoptosis seen in JSLE; IFNs may have a direct, pro-apoptotic effect 
on neutrophils or that the pro-inflammatory environment, and subsequent activation of JSLE 
neutrophils, may abrogate the anti-apoptotic IFN effect on neutrophils. In the latter scenario, 
neutrophil apoptosis may be induced by other pro-inflammatory factors that are increased 
in the JSLE serum. Additionally, the JAK/STAT pathway was shown to be altered when 
neutrophils are primed to be activated, through the dysregulation of IFNAR in particular, an 
increase in IFNγ-related STAT1 phosphorylation, and decrease in IFNα/β related STAT3 
phosphorylation. This may be true of JSLE neutrophils and highlights a potential therapeutic 
target. Inhibiting the pro-apoptotic STAT1 may lead to increase in IFN-induced up-regulation 
of anti-apoptotic STAT3, which may reduce the neutrophil apoptosis which in turn may 
contribute to the increased autoantigens that are fundamental to JSLE pathogenesis.  
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Appendix B. Clinical and consent forms 
B1. JSLE clinical and BILAG forms 
B1.1. JSLE annual assessment form 
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B1.2. JSLE ACR and SLICC form 
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B.1.3 JSLE pBILAG form 
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B2: Demographic forms 
B2.1. JSLE patient demographic form 
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B2.2. Paediatric control patient demographic form 
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B3: Consent forms and information sheets 
B3.1. JSLE patient/parent information sheet  
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B3.2. JSLE patient/parent consent form 
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B3.3. JSLE patient information sheets 
B3.3.1. JSLE patient information sheet for under 6  
 
B3.3.2. JSLE patient information sheet for 6-12 
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B3.3.3. JSLE patient information sheet for 13-15 
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B3.3.4. JSLE patient information sheet for 16 and over  
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B3.4. JSLE patient assent form 
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B3.5 JSLE patient consent form 
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B3.6 Paediatric control patient/parent information sheet  
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B3.7. Paediatric control patient/parental consent form  
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B3.8. Paediatric control patient information sheet  
B3.8.1. Paediatric control patient information sheet for under 6  
 
B3.8.2.Paediatric control patients’ information sheet for 6 -12 
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B3.8.3 Paediatric control patient information sheet for 13-15 
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B3.8.4. Paediatric control patient information sheet for 16 and over  
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B3.9. Paediatric control patient assent form 
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B3.10. Paediatric control patient consent form 
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B.11. Adult volunteer information sheet 
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B3.12. Adult volunteer consent form 
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Appendix C. Reagents and equipment 
C1. Reagents 
1640 RPMI media with L-glutamine Lonza, Switzerland/SLS, UK  
Acetic acid P&R lab supplies, UK 
Ammonium chloride Sigma-Aldrich, UK 
Annexin V FITC Sigma-Aldrich, UK 
Anti – Β actin mouse polyclonal antibody 
(pAB) 
Abcam, UK 
Anti – caspase 3 rabbit pAB Cell Signalling, USA - New England Biolabs, 
UK 
Anti - human CD11b (ICRF44) PE mouse 
IgG1κ monoclonal antibody (mAB) 
eBioscience, UK 
Anti-human CD62L (DREG56) APC mouse 
IgG1κ mAB 
eBioscience, UK 
Anti-human IFNAR1 PE mouse IgG1 
antibody (AB) 
Sino Biological, China – Stratech, UK 
Anti-human IFNAR2 (REA124) APC human 
mAB 
Miltenyi Biotec, UK 
Anti-human IFNGR1 (GIR208) PE mouse 
IgG1 mAB 
eBioscience, UK 
Anti-human IFNGR2 APC goat IgG pAB R&D systems, UK 
Anti-pSTAT1 (Y701) (58D6) rabbit mAB Cell Signalling - New England Biolabs, UK 
Anti-pSTAT3 (Y705) (3E2) mouse mAB Cell Signalling - New England Biolabs, UK 
Anti – STAT3 (79D7) rabbit mAB Cell Signalling - New England Biolabs, UK 
APC isotype control, mouse IgG1 AB Beckman Coulter, UK 
APC isotype control, mouse IgG1κ AB 
(p3.6.2.8.1) 
eBioscience, UK 
APC isotype control, REA control (S) 
(REA293) human IgG1 mAB 
Miltenyi Biotech, UK 
APC isotype control, goat IgG pAB R&D systems, UK 
Bromophenol blue Sigma-Aldrich, UK 
Calcium chloride Sigma-Aldrich, UK 
Crystal violet Sigma-Aldrich, UK 
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DMEM Sigma-Aldrich, UK 
DTT Sigma-Aldrich, UK 
DMSO Sigma-Aldrich, UK 
Ethanol Chemistry Department, University of 
Liverpool, UK 
EDTA Fisher, UK 
FBS Life Technologies, UK 
fMLP Sigma-Aldrich, UK 
Formaldehyde 
Gentamicin  
Sigma-Aldrich, UK 
Sigma-Aldrich, UK 
Glycerol BDH, UK 
Glycine Fisher, UK 
Goat anti-mouse IgG HRP conjugated pAB R&D systems, UK 
Goat anti-Rabbit IgG HRP conjugated pAB R&D systems, UK 
Fludarabine phosphate  Sigma-Aldrich, UK 
Hanks’ balanced salt solution (HBSS) 
Heat-inactivated FBS 
Sigma-Aldrich, UK 
Life Technologies, UK 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Sigma-Aldrich, UK 
HetaSep StemCell, UK 
Histopaque 1077 Sigma-Aldrich, UK 
Hydrogen chloride BDH, UK 
Ionic detergent compatibility reagent for 
Pierce™ 660nm protein assay  
ThermoFisherScientific, UK 
LPS Sigma-Aldrich, UK 
Marvel semi-skimmed milk Sainsbury’s, UK 
12% mini-PROTEAN® TGX™ precast protein 
gels, 12-well, 20 µl 
BioRAD, UK 
fMLP Sigma-Aldrich, UK 
PBS Sigma-Aldrich, UK Fisher, UK 
PE isotype control, IgG1 AB Beckman Coulter, UK 
PE isotype control, anti-mouse Rat mIgG1 
AB (M1-14D12) 
eBioscience, UK 
Pierce™ 660nm protein assay reagent Life Technologies, UK 
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pHrodo red E.coli bioparticles conjugate for 
phagocytosis  
Life Technologies, UK 
PI Sigma-Aldrich, UK 
PMA Sigma-Aldrich, UK 
Poly(HEMA) Sigma-Aldrich, UK 
Polymorph prep Axis Shield, Norway - Alere Ltd, UK 
Potassium bicarbonate Sigma-Aldrich, UK 
Precision plus protein western c standards BioRAD, UK 
Precision protein streptactin HRP conjugate BioRAD, UK 
Prolong gold antifade reagent with DAPI Molecular Probes by Life Technologies, UK 
100x protease and phosphatase inhibitor 
cocktail 
ThermoFisherScientific, UK 
Quant-iT™ PicoGreen™ dsDNA assay kit Invitrogen - ThermoFisherScientific, UK 
Recombinant human GMCSF R&D systems, UK 
Recombinant human IFNα  PeproTech, UK 
Recombinant human IFNβ  PeproTech, UK 
Recombinant human IFNγ PeproTech, UK 
Recombinant human IL-8 PeproTech, UK 
Recombinant human TNFα  PeproTech, UK 
Sodium azide Sigma-Aldrich, UK 
Sodium chloride Sigma-Aldrich, UK 
Sodium dodecyl (lauryl) sulphate BioRAD, UK 
Sodium hydroxide BDH, UK 
Trans-Blot® Turbo™ mini PVDF transfer 
packs 
BioRAD, UK 
Tris base 
Trypsin 
Fisher, UK 
Sigma-Aldrich, UK 
Tween 20 Fisher, UK 
WesternSure® PREMIUM chemiluminescent 
substrate 
LI-COR, UK 
C2. Equipment  
C-DiGit® blot Scanner LI-COR, UK 
DM2500 confocal microscope Leica, UK 
Evos microscope w/camera ThermoFisherScientific, UK 
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Flow cytometer F500 Beckman Coulter, UK 
Guava EasyCyte Merck Millipore, UK 
Light microscope Leica, UK 
TECAN GENios Plus plate reader Tecan, UK 
Western blot electrophoresis tank BioRAD, UK 
Western blot transfer blot BioRAD, UK 
Varioskan flash plate reader ThermoFisherScientific, UK 
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Appendix D. Extended patient demographics 
tables  
Appendix D, Table 1. Extended clinical and demographic information at time of blood 
collection and serum isolation, whereby serum was used in experimental apoptosis 
analysis (for shortened table, see Table 4.1, Chapter 4) 
 
Data are expressed as median and interquartile range [square brackets] or as total numbers with percentages (round brackets). 
pBILAG. Paediatric British Isles Lupus Assessment Group; DMARDs, disease-modifying anti-rheumatic drugs; dsDNA, anti-double 
stranded DNA antibody; C3, complement component 3; ESR, erythrocyte sedimentation rate. 
aClassification of patients into active disease in haematological domain (scored A/B), active disease in the renal domain (scored 
A/B) and inactive disease in all domains (D/E) was determined using the pBILAG. 
bAge and disease duration at time of serum sample collection.  
cGender of patients. 
dTotal pBILAG score determined by the numeric scoring of disease classifications of the organ domains. 
eMedication taken at time of serum sample collection.
 
Variable Active Haematological pBILAG (n=3) Active Renal pBILAGa (n=5) Inactive pBILAGa (n=5) Control (n=5) 
Age (years)b 13.60 [13.12-15.32] 16.59 [11.85-17.97] 15.52 [12.22-17.98] 15.00 [14.78 – 
15.36] 
Duration of disease (months)b 25 [4-109] 13 [0-24] 18 [7-43] - 
Femalec 2 (66.6) 5 (100) 4 (80) 4 (80) 
Total pBILAG scored 9 [7-10] 9 [8-13] 0 - 
Ethnicity     
  White British - 3 (60) 4 (80) 4 (80) 
  Any other White background - 1 (20) - - 
  Bangladeshi 1 (20) - - - 
  Pakistani 1 (20) - 1 (20) - 
  Chinese - 1 (20) - - 
  Latin American - - - 1 (20) 
  Other 1 (20) - - - 
Family history     
  Autoimmune diseases - 3 3 - 
    Hemophagocytic 
Lymphohistiocytosis 
- 1 - - 
    Psoriasis/psoriatic arthritis - 1 - - 
    Rheumatoid Arthritis - - 3 - 
    Type 1 Diabetes - - 1 - 
    Vitiligo - 1 - - 
    Wegner’s   Granulomatosis - 1 - - 
  Other 1 1 1 2 
    Arthritis (undefined) - - - 2 
    Synthetic Aortic Valve - 1 - - 
    Thyroid Problems (undefined) 1 - 1 - 
  None 2 2 1 3 
Medicatione     
  Steroids 2 5 2 - 
    Prednisolone 2 5 2 - 
  DMARDs 3 5 5 - 
    Hydroxichloriquine 3 4 5 - 
    Mycophenolate 1 3 3 - 
    Infliximab 1 - - - 
    Azathioprine 1 1 - - 
    Rituximab 1 1 1 - 
  Other 2 4 2 1 
    Omeprazole - 2 - - 
    Diclofenic - 1 - - 
    Aspirin 2 - - - 
    Bisphosphonate - 1 - - 
    OCP - - 1 - 
    Sunsence  2 2 1 - 
    Antihistamine - - - 1 
    Cotrimox 1 - - - 
    Ranitidine 1 - - - 
    Statin - - 1 - 
    Sunblock - 1 - - 
    Novorapid - 1 - - 
dsDNA (IU/L) 0  0  0 [0-7] - 
C3 (g/L) 1.13 [0.95-1.36] 1.07 [0.65-1.32] 1.11 [1.03-1.33] - 
ESR (mm/h) 1 [1-4] 2 [1-23] 8 [2-16] - 
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Appendix D, Table 2. Extended clinical and demographic information of individuals 
providing blood for neutrophil activation and IFN receptor experimental analysis (for 
shortened table, see Table 4.2, Chapter 4, and Table 5.1, Chapter 5). 
Variable JSLE (n=5) Control (n=6) 
Age (years)a 17.65 [14.50-
18.91] 
13.87 [8.21-
15.42] 
Duration of disease 
(months)a 
40 [22-101] - 
Femaleb 5 (100) 2 (33.3) 
Total pBILAG scorec 3 [0-5] - 
Ethnicity   
 White British 5 (100) 5 (100) 
Family history   
 Autoimmune diseases 2 1 
   Hemophagocytic 
Lymphohistiocytosis 
1 - 
   JSLE 1 - 
   Psoriasis - 1 
 Other 2 1 
   Kidney problems 
(undefined) 
- 1 
   Raynaud’s 1 - 
   Thyroid problems 
(undefined) 
1 - 
  None 2 3 
Medicationd   
  Corticosteroids 2 - 
    Prednisolone 2 - 
  DMARDs 5 - 
   Hydroxychloroquine 4 - 
   Mycophenolate Mofetil 5 - 
C3 (g/L) 1.1 [1.05-1.47] - 
C4 (g/L) 0.19 [0.07-0.24] - 
ESR (mm/h) 4 [3-12] - 
Data are expressed as median and interquartile range [square brackets] or as total numbers 
with percentages (round brackets). 
pBILAG. Paediatric British Isles Lupus Assessment Group; C3, complement component 3; C4, 
complement component 4; DMARDs, disease-modifying anti-rheumatic drugs; ESR, 
erythrocyte sedimentation rate. 
aAge and disease duration time of neutrophil isolation and analysis. 
bGender of patients. 
cTotal pBILAG score determined by the numeric scoring of disease classifications of the organ 
domains. 
dMedication taken at time of serum sample collection. 
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Appendix D, Table 3. Extended clinical and demographic information of individuals 
providing blood for neutrophil apoptosis experimental analysis. (For shortened table, see 
Table 4.3, chapter 4) 
Variable JSLE (n=5) Control (n=5) 
Age (years)a 14.88 [14.24-
18.45] 
10.35 [7.74-
14.77] 
Duration of disease 
(months)a 
41 [30-125] - 
Femaleb 4 (80) 2 (40) 
Total pBILAG scorec 1 [0-8] - 
Ethnicity   
 White British 4 (80) 5 (100) 
 Bangladeshi 1 (20) - 
Family history   
  Autoimmune diseases 2 1 
  Hemophagocytic 
Lymphohistiocytosis 
1 - 
   JSLE 1 - 
  Rheumatoid Arthritis - 1 
 Other 1 2 
  Arthritis (undefined) - 2 
  Raynaud’s 1 - 
  Thyroid problems 
(undefined) 
- 1 
  Type 2 Diabetes - 1 
 None 3 2 
Medicationd   
  Corticosteroids 4 - 
   Prednisolone 4 - 
  DMARDs 5 - 
   Hydroxychloroquine 5 - 
   Mycophenolate 4 - 
  Other 1 - 
   OCP 1 - 
dsDNA (IU/L) 7 [0-202] - 
C3 (g/L) 1.17 [1.06-1.27] - 
ESR (mm/h) 3 [1-25] - 
Data are expressed as median and interquartile range [square brackets] or as total numbers 
with percentages (round brackets). 
pBILAG. Paediatric British Isles Lupus Assessment Group; DMARDs, disease-modifying anti-
rheumatic drugs; dsDNA, anti-double stranded DNA antibody; C3, complement component 
3; ESR, erythrocyte sedimentation rate. 
aAge and disease duration time of neutrophil isolation and analysis. 
bGender of patients. 
cTotal pBILAG score determined by the numeric scoring of disease classifications of the organ 
domains. 
dMedication taken at time of serum sample collection. 
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Appendix E. All confocal microscopy images 
obtained for NETosis analysis (chapter 3) 
 
 
Appendix E, Figure 1. Unstimulated neutrophils stained with DAPI, and NETosis was 
visualised. Neutrophils were isolated from healthy adult donors (n=5) and were left to settle 
on cover slips for 4hrs. Neutrophils were subsequently fixed and stained with DAPI within 
mounting media. 5 images were taken per donor. 
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Appendix E, Figure 2. Neutrophils were stimulated with PMA stained with DAPI, and 
NETosis was visualised. Neutrophils were isolated from healthy adult donors (n=5) and were 
left to settle on cover slips for 1hr. Neutrophils were treated with 320nM PMA for 3hrs, and 
subsequently fixed and stained with DAPI within mounting media. 5 images were taken per 
donor. 
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Appendix E, Figure 3. Neutrophils were stimulated with IFNα stained with DAPI, and 
NETosis was visualised. Neutrophils were isolated from healthy adult donors (n=5) and were 
left to settle on cover slips for 1hr. Neutrophils were treated with 10ng/ml IFNα for 3hrs, and 
subsequently fixed and stained with DAPI within mounting media. 5-6 images were taken per 
donor. 
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Appendix E, Figure 4. Neutrophils were stimulated with IFNγ and stained with DAPI, and 
NETosis was visualised. Neutrophils were isolated from healthy adult donors (n=5) and were 
left to settle on cover slips for 1hr. Neutrophils were treated with 10ng/ml IFNγ for 3hrs, and 
subsequently fixed and stained with DAPI within mounting media. 5 images were taken per 
donor. 
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Appendix E, Figure 5. Neutrophils were stimulated with IFNβ and stained with DAPI, and 
NETosis was visualised. Neutrophils were isolated from healthy adult donors (n=5) and were 
left to settle on cover slips for 1hr. Neutrophils were treated with 10ng/ml IFNβ for 3hrs, and 
subsequently fixed and stained with DAPI within mounting media. 5-6 images were taken per 
donor. 
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Appendix E, Figure 6. Neutrophils were primed with TNFα, stained with DAPI, and NETosis 
was visualised. Neutrophils were isolated from healthy adult donors (n=5) and were left to 
settle on cover slips for 30mins. Neutrophils were primed with 1µg/ml TNFα for 30mins and 
left unstimulated for 3hrs. Neutrophils were subsequently fixed and stained with DAPI within 
mounting media. 5 images were taken per donor. 
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Appendix E, Figure 7. Neutrophils were primed with TNFα, stimulated with IFNα and 
stained with DAPI, and NETosis was visualised. Neutrophils were isolated from healthy adult 
donors (n=5) and were left to settle on cover slips for 30mins. Neutrophils were primed with 
1µg/ml TNFα for 30mins, and stimulated with 10ng/ml IFNα for 3hrs. Neutrophils were 
subsequently fixed and stained with DAPI within mounting media. 5 images were taken per 
donor. 
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Appendix E, Figure 8. Neutrophils were primed with TNFα-primed, stimulated with IFNγ, 
stained with DAPI and NETosis was visualised. Neutrophils were isolated from healthy adult 
donors (n=5) and were left to settle on cover slips for 30mins. Neutrophils were primed with 
1µg/ml TNFα for 30mins, and stimulated with 10ng/ml IFNγ for 3hrs. Neutrophils were 
subsequently fixed and stained with DAPI within mounting media. 5-6 images were taken per 
donor. 
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Appendix E, Figure 9. Neutrophils were primed with TNFα, stimulated with IFNβ and 
stained with DAPI and NETosis was visualised. Neutrophils were isolated from healthy adult 
donors (n=5) and were left to settle on cover slips for 30mins. Neutrophils were primed with 
1µg/ml TNFα for 30mins, and stimulated with 10ng/ml IFNβ for 3hrs. They were subsequently 
fixed and stained with DAPI within mounting media. 5-6 images were taken per donor. 
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Appendix E, Figure 10. Naïve neutrophils were stimulated with LPS stained with DAPI 
staining and NETosis was visualised. Neutrophils were isolated from healthy adult donors 
(n=5) and were left to settle on cover slips for 1hr. Neutrophils were stimulated with 1µg/ml 
LPS for 3hrs. They were subsequently fixed and stained with DAPI within mounting media. 5 
images were taken per donor. 
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Appendix E, Figure 11. Neutrophils were primed with IFNα, stimulated with LPS, stained 
with DAPI and NETosis was visualised. Neutrophils were isolated from healthy adult donors 
(n=5) and were left to settle on cover slips for 30mins. Neutrophils were primed with 10ng/ml 
IFNα for 30mins and stimulated with 1µg/ml LPS for 3hrs. They were subsequently fixed and 
stained with DAPI within mounting media. 5 images were taken per donor. 
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Appendix E. Figure 12. Neutrophils were primed with IFNγ stimulated with LPS, stained 
with DAPI and NETosis was visualised. Neutrophils were isolated from healthy adult donors 
(n=5) and were left to settle on cover slips for 30 mins. Neutrophils were primed with 
10ng/ml IFNγ for 30mins and stimulated with 1µg/ml LPS for 3hrs. They were subsequently 
fixed and stained with DAPI within mounting media. 5-6 images were taken per donor. 
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Appendix E, Figure 13. Neutrophils were primed with IFNβ, stimulated with LPS, stained 
with DAPI and NETosis was visualised. Neutrophils were isolated from healthy adult donors 
(n=5) and were left to settle on cover slips for 30 mins. Neutrophils were primed with 
10ng/ml IFNβ for 30mins and stimulated with 1µg/ml LPS for 3hrs. They were subsequently 
fixed and stained with DAPI within mounting media. 5-6 images were taken per donor (n=5). 
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